[{"title01":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","title02":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288891. Online ahead of print","author":"Boussi L, Bewersdorf JP, Liu Y, Shallis RM, Aguirre LE, Bystrom RP, Zucenka A, Garciaz S, DeAngelo DJ, Stone RM, Luskin MR, Garcia JS, Winer ES, Chen EC, Wadleigh M, Berton G, Ling K, Zeidan AM, Stein EM, Shimony S, Goldberg AD, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609030"},{"title01":"Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide.","title02":"Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288855. Online ahead of print","author":"Najar W, Barette L, Penther D, Maarek O, Stamatoullas A, Penichoux J, Veresezan EL, Daliphard S, Buchonnet G, Bobee V, Jardin F, De Botton S, Fenaux P, Camus V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609063"},{"title01":"Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes.","title02":"Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes.","journal":"Br J Haematol","issue":"2026 January 20. doi: 10.1111\/bjh.70330. Online ahead of print","author":"Pedraza A, Castano S, Pereira A, Nomdedeu M, Ruiz C, Esteva M, Diaz-Beya M, Sanz C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41560464"},{"title01":"Faulty antibody editing permits antiplatelet B cells in ITP.","title02":"Faulty antibody editing permits antiplatelet B cells in ITP.","journal":"Blood","issue":"2026 January 22; 147(4):323-325. doi: 10.1182\/blood.2025031605","author":"Bednarski JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569624"},{"title01":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","title02":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","journal":"Blood advances","issue":"2026 January 27; 10(2):494-504. doi: 10.1182\/bloodadvances.2025017035","author":"Sebert M, Thepot S, Cluzeau T, Duployez N, Lefebvre T, Chaffaut C, Orvain C, Loschi M, Peterlin P, Chevallier P, D'Aveni M, Rubio MT, Rauzy O, Huynh A, Charbonnier A, Sapena R, Chermat F, Ceballos P, Fossard G, Nguyen S, Park S, Ades L, Peffault de Latour R, Preudhomme C, Fenaux P, Chevret S, Robin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061188"},{"title01":"Pregnancy after Haematopoietic Stem Cell Transplant: an international multicentre study.","title02":"Pregnancy after Haematopoietic Stem Cell Transplant: an international multicentre study.","journal":"Blood advances","issue":"2026 January 28. doi: 10.1182\/bloodadvances.2025016977. Online ahead of print","author":"Salooja N, Eikema DJ, Michonneau D, Tichelli AA, Apperley JF, Akhtar S, Bourhis JH, Maertens JA, Maghfoor I, Massarotti C, Collin M, Mielke S, Raiola AM, Schaap M, Sedlacek P, Socie G, van der Werf S, Aljurf M, Kalwak K, Basak GW, Peric Z, Penack O, Schoemans HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604618"},{"title01":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","title02":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","journal":"Blood advances","issue":"2026 January 27. doi: 10.1182\/bloodadvances.2025017360. Online ahead of print","author":"Holtan SG, Grover P, Walton K, El Jurdi N, Quinones V, Maakaron JE, Juckett MB, Bachanova V, Hou JH, Terezakis SA, Myers TJ, Paradiso LJ, DeFor TE, Cao Q, Betts BC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592279"},{"title01":"Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time.","title02":"Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025017559. Online ahead of print","author":"Lu B, Troyer J, Krause KJ, Lapite A, Aviles MM, Della-Moretta S, Dobson D, Farrokhi K, Hasanali ZS, Pillai PM, Taborda C, Villagomez L, Vo P, Wangondu R, Yui JC, Weyand AC, Fingrut WB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587417"},{"title01":"HCT Pre-App Program: A Telemedicine-based Prehabilitation for Allogeneic Hematopoietic Cell Transplant candidates.","title02":"HCT Pre-App Program: A Telemedicine-based Prehabilitation for Allogeneic Hematopoietic Cell Transplant candidates.","journal":"Blood advances","issue":"2026 January 16. doi: 10.1182\/bloodadvances.2025018378. Online ahead of print","author":"Salinas Gonzalez R, Guardia L, Sole B, Moreno C, de Llobet N, Cascos E, Martinez-Sanchez J, Diaz-Ricart M, Carreras E, Antonio M, Suarez-Lledo M, Rosinol L, Closa C, Sebio R, Martinez C, Fernandez-Aviles F, Rovira M, Salas MQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544211"},{"title01":"Acquired non-permissive BM microenvironment impairs HSCs proliferation and maintenance and B-cell development post-HSCT.","title02":"Acquired non-permissive BM microenvironment impairs HSCs proliferation and maintenance and B-cell development post-HSCT.","journal":"Blood advances","issue":"2026 January 16. doi: 10.1182\/bloodadvances.2025015915. Online ahead of print","author":"de Gier M, Korzhenevich J, Schmidt F, Janowska I, van Ostaijen-Ten Dam MM, Pico-Knijnenburg I, Cats D, Keller F, Hadlova P, Kunze M, Markfeld-Erol F, Mei H, Reising K, Bredius RG, Lankester AC, van der Burg M, Rizzi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544216"},{"title01":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","title02":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","journal":"Blood advances","issue":"2026 January 20. doi: 10.1182\/bloodadvances.2025016780. Online ahead of print","author":"Fan C, Hayase T, Chang CC, Glover IK, Flores II, McDaniel LK, Ortega MR, Sanchez CA, El-Himri RK, Brown AN, Karmouch JL, Jamal MA, Ahmed SS, Halsey TM, Jin Y, Tsai WB, Prasad R, Enkhbayar A, Mohammed A, Schmiester M, Damania AV, Ajami NJ, Wargo JA, Peterson CB, Rondon G, Al-Juhaishi T, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Martens E, Arias CA, Jenq RR, Hayase E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558030"},{"title01":"Anti-CD4 Antibody-modulated Transplants for GVHD Prevention in Hematopoietic Cell Transplantation.","title02":"Anti-CD4 Antibody-modulated Transplants for GVHD Prevention in Hematopoietic Cell Transplantation.","journal":"Blood","issue":"2026 January 26. doi: 10.1182\/blood.2025031370. Online ahead of print","author":"Roth K, Loeffler D, Blumert C, Scholz A, Reiche K, Bauer M, Wickenhauser C, Schiefer D, Hilger N, Blaudszun AR, Thees J, Walter J, Tretbar S, Koehl U, Fricke S, Blache U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587074"},{"title01":"Dynamic rRNA methylation regulates translation in the hematopoietic system and is essential for stem cell fitness.","title02":"Dynamic rRNA methylation regulates translation in the hematopoietic system and is essential for stem cell fitness.","journal":"Blood","issue":"2026 January 29; 147(5):520-533. doi: 10.1182\/blood.2024028300","author":"Rabany O, Ben Dror S, Arafat M, Aharoni Levitanus H, Halperin Y, Marchand V, Romanovski N, Ussishkin N, Livneh Golany M, Reches A, Wexler J, Mayorek N, Monderer-Rothkoff G, Shifman S, Bouhou WM, VanInsberghe M, Pauli C, Muller-Tidow C, Karmi O, Livneh Y, van Oudenaarden A, Motorin Y, Nachmani D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191530"},{"title01":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","title02":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","journal":"Blood","issue":"2026 January 29; 147(5):584-601. doi: 10.1182\/blood.2025029712","author":"Fetsch V, Schwobel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, Kohler N, Kuban M, Metzger E, Rummelt C, Duyster J, Boerries M, Hofmann M, Farber J, Braun LM, Zahringer A, Lubbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, Kuhn MWM, Timmers HTM, Wertheimer T, Perner F, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144759"},{"title01":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","title02":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","journal":"Blood","issue":"2026 January 22; 147(4):357-368. doi: 10.1182\/blood.2024026512","author":"Chalandon Y, Simonetta F, Masouridi-Levrat S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40354577"},{"title01":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","title02":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","journal":"Leukemia","issue":"2026 January 22. doi: 10.1038\/s41375-026-02860-2. Online ahead of print","author":"Barosi G, De Silvestri A, Gale RP, Rosti V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571769"},{"title01":"Selective lymphodepletion underlies the efficacy of horse anti-thymocyte globulin-based immunosuppressive therapy in aplastic anemia.","title02":"Selective lymphodepletion underlies the efficacy of horse anti-thymocyte globulin-based immunosuppressive therapy in aplastic anemia.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.300002. Online ahead of print","author":"Pool ES, Pothast CR, Gennesse SM, Van Egmond EHM, Giezen JM, Veld SAJ, Toes REM, Koning F, Halkes CJM, Heemskerk MHM, Moes DJAR, Tjon JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609027"},{"title01":"Functional impact of a deep intronic variant in the RPS19 gene detected in a case of Diamond-Blackfan anemia syndrome.","title02":"Functional impact of a deep intronic variant in the RPS19 gene detected in a case of Diamond-Blackfan anemia syndrome.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300131. Online ahead of print","author":"Kanezaki R, Toki T, Okuse R, Kobayashi A, Sato M, Kimura S, Kudo K, Sato T, Tanaka T, Yoshida K, Kawai Y, Tokunaga K, Takita J, Ogawa S, Terui K, Ito E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568468"},{"title01":"Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.","title02":"Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288956. Online ahead of print","author":"Sekeres MA, Zeidan AM, Santini V, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcarcel D, Regnault A, Creel K, Sun L, Wan Y, Navada S, Berry T, Feller F, Platzbecker U, Diez-Campelo M, Oliva EN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568521"},{"title01":"Thrombophilia screening in patients with autoimmune hemolytic anemia: a single-center analysis.","title02":"Thrombophilia screening in patients with autoimmune hemolytic anemia: a single-center analysis.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288981. Online ahead of print","author":"Fattizzo B, Abbatista M, Cecchi N, Novembrino C, Boscolo-Anzoletti M, Pedone GL, Bortolotti M, Artoni A, Giannotta JA, Peyvandi F, Passamonti F, Barcellini W, Capecchi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568533"},{"title01":"Suboptimal screening and correction of maternal iron deficiency anaemia in the general population and in inherited bleeding disorders: A population-based cohort study.","title02":"Suboptimal screening and correction of maternal iron deficiency anaemia in the general population and in inherited bleeding disorders: A population-based cohort study.","journal":"Br J Haematol","issue":"2026 January 27. doi: 10.1111\/bjh.70348. Online ahead of print","author":"Alam AU, Kaul P, Jain V, Wu C, Sun HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41589617"},{"title01":"Medical haematology: Repositioning haematology at the centre of medicine.","title02":"Medical haematology: Repositioning haematology at the centre of medicine.","journal":"Br J Haematol","issue":"2026 January 20. doi: 10.1111\/bjh.70340. Online ahead of print","author":"Toh CH, Bates I, Pavord S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41556724"},{"title01":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.","title02":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.","journal":"Blood advances","issue":"2026 January 28. doi: 10.1182\/bloodadvances.2025017519. Online ahead of print","author":"Gotlib J, Reiter A, Radia DH, Alvarez-Twose I, Deininger MW, George TI, Panse JP, Mital A, Pettit KM, Vannucchi AM, Platzbecker U, Hermine O, Elshoury A, Livideanu C, Mesa RA, Ustun C, Triggiani M, Dybedal I, Jurcic JG, Zanotti R, Oh ST, Yacoub A, Hexner EO, Bose P, Lee SG, Sperr WR, Griffiths EA, Butler M, Lubke J, Bidollari I, Lin HM, Rylova SN, Dimitrijevic S, Munoz-Gonzalez JI, DeAngelo DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604606"},{"title01":"Cold clues in pediatric autoimmune hemolytic anemia.","title02":"Cold clues in pediatric autoimmune hemolytic anemia.","journal":"Blood advances","issue":"2026 January 27; 10(2):531-532. doi: 10.1182\/bloodadvances.2025018452","author":"Jacobs JW, Bloch EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41591772"},{"title01":"Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations.","title02":"Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations.","journal":"Blood advances","issue":"2026 January 27; 10(2):418-427. doi: 10.1182\/bloodadvances.2025017254","author":"Power-Hays A, McElhinney KE, Williams TN, Mochamah G, Olupot-Olupot P, Paasi G, Reid ME, Rankine-Mullings AE, Opoka RO, John CC, McGann PT, Quinn CT, Punt NC, Smart LR, Stuber SE, Latham TS, Vinks AA, Ware RE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026975"},{"title01":"Lipid Metabolism Transcriptomic Signature of Defective Erythropoiesis in Diamond Blackfan Anemia syndrome.","title02":"Lipid Metabolism Transcriptomic Signature of Defective Erythropoiesis in Diamond Blackfan Anemia syndrome.","journal":"Blood advances","issue":"2026 January 23. doi: 10.1182\/bloodadvances.2025017318. Online ahead of print","author":"Deng K, Wang Y, Min JC, Liu X, Ueharu H, Myers G, Yu L, Hammoud SB, Adam A, Saba R, Natogi V, Drysdale C, Chen B, Yee JL, Kitzman J, Lyssiotis CA, Mishina Y, Jones MA, Kaartinen V, Guan Y, Khoriaty R, Engel JD, Singh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41576344"},{"title01":"Childhood isolated C3d-positive AIHA: favorable prognosis but rare relapse or associated immunodeficiency.","title02":"Childhood isolated C3d-positive AIHA: favorable prognosis but rare relapse or associated immunodeficiency.","journal":"Blood advances","issue":"2026 January 27; 10(2):521-530. doi: 10.1182\/bloodadvances.2025017309","author":"Blachez M, Aladjidi N, Modot T, Fernandes H, Garnier N, Chastagner P, Bayart S, Armari-Alla C, Piguet C, Pasquet M, Paillard C, Pluchart C, Guitton C, Thomas C, Barlogis V, Pellier I, Stephan JL, Benadiba J, Jeziorski E, Deparis M, Carausu L, Cheikh N, Li-Thiao Te V, Lejeune J, Marie-Cardine A, Millot F, Abou Chahla W, Gay S, Alimi A, Petit A, Castelle M, Moshous D, Picard C, Rieux-Laucat F, Leblanc T, Ducassou S, Leverger G, Fahd M, Heritier S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41118608"},{"title01":"Atrial fibrillation prevalence and its management in aging transfusion-dependent thalassemia patients: the FATHAL study.","title02":"Atrial fibrillation prevalence and its management in aging transfusion-dependent thalassemia patients: the FATHAL study.","journal":"Blood advances","issue":"2026 January 22. doi: 10.1182\/bloodadvances.2025017577. Online ahead of print","author":"Di Stefano V, Gianesin B, Orecchia V, Longo F, Susanna B, Barone A, Culcasi M, Denotti AR, Costantini S, Ferrara F, Foggetti I, Gigante A, Manca MR, Mazzi F, Pasanisi A, Pisaniello M, Ricchi P, Serra M, Origa R, Bertini M, Motta I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569798"},{"title01":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","title02":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","journal":"Blood advances","issue":"2026 January 20. doi: 10.1182\/bloodadvances.2025018285. Online ahead of print","author":"Andresen F, Yoshimi A, Bader P, Bierings MB, Bodova I, Bordon V, Buechner J, Burkhardt B, Dworzak MN, Erlacher M, Kallay KM, Labarque V, Locatelli F, Malone A, Masmas TN, Muller I, Nollke P, Schmugge M, Pawelec KM, Sedlacek P, Sevilla J, Smith O Professor, Stary J, Niemeyer CM, Strahm B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558034"},{"title01":"Hematologic malignancies in pediatric patients with RUNX1-Familial Platelet Disorder with Associated Myeloid Malignancy.","title02":"Hematologic malignancies in pediatric patients with RUNX1-Familial Platelet Disorder with Associated Myeloid Malignancy.","journal":"Blood advances","issue":"2026 January 30. doi: 10.1182\/bloodadvances.2025017808. Online ahead of print","author":"Kajdic A, Deuitch NT, Bresciani E, Chong SN, Craft KM, Davis J, Bashtawi R, McReynolds LJ, Giri N, Young DJ, Liu PP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41616279"},{"title01":"GATA1 N-terminus coordinates metabolic reprogramming in erythropoiesis.","title02":"GATA1 N-terminus coordinates metabolic reprogramming in erythropoiesis.","journal":"Blood","issue":"2026 January 26. doi: 10.1182\/blood.2025030464. Online ahead of print","author":"Ling T, Bezavada L, Mehmood R, Zhang K, Cotton A, Crawford JC, Jin H, Sona S, Li L, Ju Y, Han L, Liu N, Tran T, Vu H, Jin Y, Zhai J, Pruett-Miller SM, Bhoopalan SV, Xu J, Ni M, Crispino JD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587073"},{"title01":"A Retrospective, Real-World Study of IV Iron Use to Treat Iron deficiency Anemia During Acute Infection.","title02":"A Retrospective, Real-World Study of IV Iron Use to Treat Iron deficiency Anemia During Acute Infection.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025031965. Online ahead of print","author":"Sohail H, Collins JE, Chan KH, Alamgir MA, Kamran AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592284"},{"title01":"Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.","title02":"Characteristics and prognostic significance of myelodysplasia-related features in VEXAS syndrome.","journal":"Leukemia","issue":"2026 January 16. doi: 10.1038\/s41375-025-02858-2. Online ahead of print","author":"Zhao LP, Kosmider O, Heiblig M, Moulinet T, Lacombe V, Comont T, Lobbes H, Karam JD, Terriou L, Ardois S, Le Guenno G, Jachiet V, Wolff L, Vertenoeil G, Hadjadj J, Bouaziz JD, Lemaire P, Fain O, Terrier B, Georgin-Lavialle S, Larcher L, Clappier E, Sebert M, Ades L, Mekinian A, Fenaux P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545701"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 January 30. doi: 10.1016\/S2352-3026(25)00359-X. Online ahead of print","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.","title02":"Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288956. Online ahead of print","author":"Sekeres MA, Zeidan AM, Santini V, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcarcel D, Regnault A, Creel K, Sun L, Wan Y, Navada S, Berry T, Feller F, Platzbecker U, Diez-Campelo M, Oliva EN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568521"},{"title01":"Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall.","title02":"Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300405. Online ahead of print","author":"Oster H, Mittelman M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568531"},{"title01":"Diabetes mellitus and diabetes-related complications are common in patients with myelodysplastic syndromes but Hemoglobin A1C is an inadequate marker.","title02":"Diabetes mellitus and diabetes-related complications are common in patients with myelodysplastic syndromes but Hemoglobin A1C is an inadequate marker.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.300022. Online ahead of print","author":"Israel A, Gat R, Oster H, Moshe Y, Raz I, Mittelman M, Merzon E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609028"},{"title01":"Improvement in survival of patients with higher risk but not lower risk myelodysplastic syndromes over 20 years: A retrospective study from Nagasaki, Japan.","title02":"Improvement in survival of patients with higher risk but not lower risk myelodysplastic syndromes over 20 years: A retrospective study from Nagasaki, Japan.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70345. Online ahead of print","author":"Furumoto T, Ando K, Toriyama E, Hata T, Sakamoto H, Chiwata M, Kitanosono H, Nakashima J, Kato T, Taguchi M, Horai M, Itonaga H, Sato S, Sawayama Y, Imanishi D, Imaizumi Y, Jo T, Yoshida S, Moriuchi Y, Miyazaki Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582419"},{"title01":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","title02":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","journal":"Blood advances","issue":"2026 January 27; 10(2):494-504. doi: 10.1182\/bloodadvances.2025017035","author":"Sebert M, Thepot S, Cluzeau T, Duployez N, Lefebvre T, Chaffaut C, Orvain C, Loschi M, Peterlin P, Chevallier P, D'Aveni M, Rubio MT, Rauzy O, Huynh A, Charbonnier A, Sapena R, Chermat F, Ceballos P, Fossard G, Nguyen S, Park S, Ades L, Peffault de Latour R, Preudhomme C, Fenaux P, Chevret S, Robin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061188"},{"title01":"Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.","title02":"Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018431. Online ahead of print","author":"Aguirre LE, Kim HT, Elmariah H, Frumm SM, Kelkar AH, Ho VT, Gooptu M, Koreth J, Shapiro RM, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Shimony S, Luskin MR, Garcia JS, Chen EC, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Al-Ali N, Sallman DA, Kuykendall AT, Sweet KL, Lancet JE, Padron E, Chan O, Xie Z, Cutler CS, Komrokji RS, Stahl MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587470"},{"title01":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","title02":"Prognostic value of anemia plus thrombocytopenia in primary myelofibrosis.","journal":"Leukemia","issue":"2026 January 22. doi: 10.1038\/s41375-026-02860-2. Online ahead of print","author":"Barosi G, De Silvestri A, Gale RP, Rosti V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571769"},{"title01":"Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.","title02":"Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288948. Online ahead of print","author":"Yang X, Lee S, Masarik K, Ahmed T, Zheng L, Zhan H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568522"},{"title01":"Myeloproliferative neoplasm subtypes have distinct impact on risk of incident osteoporosis and osteoporotic fractures.","title02":"Myeloproliferative neoplasm subtypes have distinct impact on risk of incident osteoporosis and osteoporotic fractures.","journal":"Blood advances","issue":"2026 January 27; 10(2):315-319. doi: 10.1182\/bloodadvances.2025017168","author":"Lee MH, Wang Y, Cronin A, Tramontano AC, Weeks LD, Hobbs GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056521"},{"title01":"Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.","title02":"Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera.","journal":"Blood advances","issue":"2026 January 27; 10(2):507-510. doi: 10.1182\/bloodadvances.2025017938","author":"Suo S, Fu R, Qin A, Shao Z, Bai J, Zhou H, Xu N, Chen S, Zuo X, Du X, Duan M, Wang L, Li P, Zhang X, Zhang S, Wu D, Zhang J, Xiao Z, Zhang L, Jin J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41172233"},{"title01":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant MPN patients.","title02":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant MPN patients.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018811. Online ahead of print","author":"Tashi T, Shih LY, Yo YT, Sullivan A, Chueh HY, Kuo MC, Smith A, Kim SJ, Parsegov B, Reeves BN, Song J, Prchal JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587484"},{"title01":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","title02":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","journal":"Blood","issue":"2026 January 22; 147(4):390-401. doi: 10.1182\/blood.2025029916","author":"Neven Q, Arfeuille C, Caye-Eude A, Durand P, Lainey E, Fenneteau O, Nelken B, Nolla M, Sterin A, Grain A, Khouri C, Simonin M, Dourthe ME, Fahd M, Millot F, Neven B, Petit A, Chevret S, Dalle JH, Baruchel A, Cave H, Strullu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971523"},{"title01":"BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia.","title02":"BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia.","journal":"Lancet","issue":"2026 January 31; 407(10527):489-491. doi: 10.1016\/S0140-6736(25)02515-2","author":"Duque-Afonso J, Rummelt C, Forster K, Zeiser R, Mougiakakos D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587555"},{"title01":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","title02":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288558. Online ahead of print","author":"Ao Y, Zheng H, Huang Y, Kang S, Zhang Q, Huang C, Wu X, Zeng Y, Zhou D, Fang J, Fu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609024"},{"title01":"Long-term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia.","title02":"Long-term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia.","journal":"Br J Haematol","issue":"2026 January 19. doi: 10.1111\/bjh.70309. Online ahead of print","author":"Wang JH, Yang Q, Duan SQ, Yang L, Zhou Y, Fang CL, Xiao ZG, Yang CH, Xiong YC, Tian X, Huang TL, Zhang XW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41554292"},{"title01":"Immune repertoire profiling in immune thrombocytopenia: A path towards biomarkers, for The British Journal of Haematology.","title02":"Immune repertoire profiling in immune thrombocytopenia: A path towards biomarkers, for The British Journal of Haematology.","journal":"Br J Haematol","issue":"2026 January 21. doi: 10.1111\/bjh.70341. Online ahead of print","author":"Malik A, Hart A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41560569"},{"title01":"A single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia.","title02":"A single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia.","journal":"Blood","issue":"2026 January 22; 147(4):416-430. doi: 10.1182\/blood.2025028960","author":"Sheng Z, Jiang N, Gao Y, Zhang Y, Zhang X, Li N, Feng Q, Zhang Y, Wang L, Semple JW, Wang S, Li S, Peng J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032749"},{"title01":"Immune biomarkers of increased infection risk in multiple myeloma.","title02":"Immune biomarkers of increased infection risk in multiple myeloma.","journal":"Blood","issue":"2026 January 29. doi: 10.1182\/blood.2025031744. Online ahead of print","author":"Zabaleta A, Tamariz-Amador LE, Kostopoulos IV, Sklavenitis Pistofidis R, Smits F, Rodriguez-Otero P, Roncal C, Aranha MP, Zihala D, Machu M, Tsakirakis N, Bakouros P, Tsitsilonis O, Solia I, Moreno C, Maia C, Martin-Sanchez E, Perez JJ Sr, Encinas C, Rios-Tamayo R, Oriol A, Blanchard MJ, de Arriba F, Gonzalez-Garcia E, Lakhwani S, Sureda A, Cabanas V, Escalante F, Carrillo-Cruz E, Perez-Montana A, Ocio EMM, Bargay J, Orfao A, Jelinek T, Ghobrial IM, Mutis T, Zweegman S, Terpos E, Kastritis E, Martinez-Lopez J, Lahuerta JJ, Fernandez de Larrea C, Rosinol L, Blade J, Mateos MV, San-Miguel JF, Cedena MT, Puig N, Paiva B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610428"},{"title01":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","title02":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","journal":"J Clin Oncol","issue":"2026 January 21; JCO2502130. doi: 10.1200\/JCO-25-02130. Online ahead of print","author":"Kelkar AH, Abel GA, Cutler CS, Lee SJ, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564387"},{"title01":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","title02":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288891. Online ahead of print","author":"Boussi L, Bewersdorf JP, Liu Y, Shallis RM, Aguirre LE, Bystrom RP, Zucenka A, Garciaz S, DeAngelo DJ, Stone RM, Luskin MR, Garcia JS, Winer ES, Chen EC, Wadleigh M, Berton G, Ling K, Zeidan AM, Stein EM, Shimony S, Goldberg AD, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609030"},{"title01":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","title02":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288770. Online ahead of print","author":"Stolzel F, Stelljes M, Beelen DW, Markiewicz M, Remenyi P, Luft T, Ciceri F, Wagner-Drouet EM, Junghanss C, Scheid C, Patriarca F, Socie G, Hilgendorf I, Rambaldi A, Schaefer-Eckart K, Russo D, Wulf G, Glass B, Labussiere-Wallet H, Stuhler G, Bieniaszewska M, Casper J, Holler E, Benedetti F, Iori AP, Kunadt D, Mihajlovic J, Schild B, Khan I, Li X, Bethge W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609025"},{"title01":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","title02":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300184. Online ahead of print","author":"Amit O, Fridberg G, Moshe Y, Ospovat I, Sherf Y, Tshernichovsky D, Karni C, Avivi I, Ram R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568537"},{"title01":"Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide.","title02":"Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.289266. Online ahead of print","author":"Canto PA, Montoro J, Balaguer-Rosello A, Villalba M, Chorao P, Louro A, Granados P, Eiris J, Bataller A, Gomez-Segui I, Solves P, Leon G, Lamas B, Eritzpokhoff L, Vallejo N, Hervas A, Hurtado M, Lopez J, Mansilla-Polo M, Reig JP, Valero MGG, De la Rubia M, Satorres C, De la Rubia J, Sanz MA, Sanz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568541"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70350. Online ahead of print","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.","title02":"Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018431. Online ahead of print","author":"Aguirre LE, Kim HT, Elmariah H, Frumm SM, Kelkar AH, Ho VT, Gooptu M, Koreth J, Shapiro RM, Romee R, Nikiforow S, Antin JH, Soiffer RJ, Shimony S, Luskin MR, Garcia JS, Chen EC, Wadleigh M, Winer ES, Stone RM, DeAngelo DJ, Al-Ali N, Sallman DA, Kuykendall AT, Sweet KL, Lancet JE, Padron E, Chan O, Xie Z, Cutler CS, Komrokji RS, Stahl MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587470"},{"title01":"Pediatric-Inspired Regimens &#038; HSCT for Adolescents &#038; Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","title02":"Pediatric-Inspired Regimens &#038; HSCT for Adolescents &#038; Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","journal":"Blood advances","issue":"2026 January 29. doi: 10.1182\/bloodadvances.2025018736. Online ahead of print","author":"Sereda Y, Mai HJ, Kanaan G, Melson JW, Terasawa T, Cheung MC, Stock WA, Wolfson JA, Saldanha IJ, Balk EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610329"},{"title01":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","title02":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","journal":"Blood advances","issue":"2026 January 20. doi: 10.1182\/bloodadvances.2025018285. Online ahead of print","author":"Andresen F, Yoshimi A, Bader P, Bierings MB, Bodova I, Bordon V, Buechner J, Burkhardt B, Dworzak MN, Erlacher M, Kallay KM, Labarque V, Locatelli F, Malone A, Masmas TN, Muller I, Nollke P, Schmugge M, Pawelec KM, Sedlacek P, Sevilla J, Smith O Professor, Stary J, Niemeyer CM, Strahm B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558034"},{"title01":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","title02":"Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.","journal":"Blood advances","issue":"2026 January 20. doi: 10.1182\/bloodadvances.2025016780. Online ahead of print","author":"Fan C, Hayase T, Chang CC, Glover IK, Flores II, McDaniel LK, Ortega MR, Sanchez CA, El-Himri RK, Brown AN, Karmouch JL, Jamal MA, Ahmed SS, Halsey TM, Jin Y, Tsai WB, Prasad R, Enkhbayar A, Mohammed A, Schmiester M, Damania AV, Ajami NJ, Wargo JA, Peterson CB, Rondon G, Al-Juhaishi T, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Martens E, Arias CA, Jenq RR, Hayase E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558030"},{"title01":"A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.","title02":"A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 27; 10(2):479-491. doi: 10.1182\/bloodadvances.2025017127","author":"Haydu JE, Redd RA, Lei MM, Hochberg EP, Barnes JA, Armand P, Soumerai JD, Eichler AF, Jacobsen ED, Jordan JT, Jacobson CA, LaCasce AS, Arrillaga-Romany I, McFaline-Figueroa JR, Plotkin SR, Takvorian RW, Chukwueke UN, Crombie JL, Johnson PC, Karschnia P, Dietrich J, Nayak L, Abramson JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170917"},{"title01":"Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling.","title02":"Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling.","journal":"Blood advances","issue":"2026 January 27; 10(2):379-391. doi: 10.1182\/bloodadvances.2025017980","author":"Diaz-Gonzalez A, Mora E, Garrote M, Carreno-Tarragona G, Salido M, Pastor-Galan I, Stuckey R, Cisneros A, Domingo-Monfort JA, Uresandi-Iruin N, Argoitia-Ituarte N, Avetisyan G, Garcia-Ruiz C, Torres-Hernandez N, Furio S, Arellano-Rodrigo E, Alvarez N, Velez P, Villamon E, Segura-Diaz A, Ayala R, Espinet B, Alvarez-Larran A, Hernandez-Boluda JC, Such E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41150842"},{"title01":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","title02":"Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.","journal":"Blood advances","issue":"2026 January 27; 10(2):494-504. doi: 10.1182\/bloodadvances.2025017035","author":"Sebert M, Thepot S, Cluzeau T, Duployez N, Lefebvre T, Chaffaut C, Orvain C, Loschi M, Peterlin P, Chevallier P, D'Aveni M, Rubio MT, Rauzy O, Huynh A, Charbonnier A, Sapena R, Chermat F, Ceballos P, Fossard G, Nguyen S, Park S, Ades L, Peffault de Latour R, Preudhomme C, Fenaux P, Chevret S, Robin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061188"},{"title01":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","title02":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","journal":"Blood","issue":"2026 January 22; 147(4):390-401. doi: 10.1182\/blood.2025029916","author":"Neven Q, Arfeuille C, Caye-Eude A, Durand P, Lainey E, Fenneteau O, Nelken B, Nolla M, Sterin A, Grain A, Khouri C, Simonin M, Dourthe ME, Fahd M, Millot F, Neven B, Petit A, Chevret S, Dalle JH, Baruchel A, Cave H, Strullu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971523"},{"title01":"Anti-CD4 Antibody-modulated Transplants for GVHD Prevention in Hematopoietic Cell Transplantation.","title02":"Anti-CD4 Antibody-modulated Transplants for GVHD Prevention in Hematopoietic Cell Transplantation.","journal":"Blood","issue":"2026 January 26. doi: 10.1182\/blood.2025031370. Online ahead of print","author":"Roth K, Loeffler D, Blumert C, Scholz A, Reiche K, Bauer M, Wickenhauser C, Schiefer D, Hilger N, Blaudszun AR, Thees J, Walter J, Tretbar S, Koehl U, Fricke S, Blache U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587074"},{"title01":"How I treat advanced phases of CML.","title02":"How I treat advanced phases of CML.","journal":"Blood","issue":"2026 January 22; 147(4):369-378. doi: 10.1182\/blood.2024026510","author":"Mauro MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329950"},{"title01":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","title02":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025031952. Online ahead of print","author":"Bal S, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria B, Giri S, Godby K, Silbermann R, Mikhail FM, Huls F, Reddy V, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592281"},{"title01":"Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.","title02":"Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025032347. Online ahead of print","author":"Blumenberg V, Birocchi F, Shih A, Escobar G, Mucci A, Armstrong A, Cirstea DD, Harris DL, Bozym DJ, Puliafito BR, Newcomb RA, Dhawale TM, Johnson PC, El-Jawahri A, Jeffrey R 3rd, Barselau A, Li A, Emmanuel-Alejandro E, Cook D, Lindell KA, Luk SO, Chaffee R, Yee AJ, Branagan AR, Raje NS, Graham C, Hammond SP, Bushman FD, Roche AM, Reddy S, McFarland AG, Chen YB, Choi BD, Mount CW, Dougan M, Nardi V, Sohani A, Gallagher KME, Maus MV, Frigault MJ, Leick MB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592291"},{"title01":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","title02":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","journal":"Blood","issue":"2026 January 29; 147(5):584-601. doi: 10.1182\/blood.2025029712","author":"Fetsch V, Schwobel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, Kohler N, Kuban M, Metzger E, Rummelt C, Duyster J, Boerries M, Hofmann M, Farber J, Braun LM, Zahringer A, Lubbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, Kuhn MWM, Timmers HTM, Wertheimer T, Perner F, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144759"},{"title01":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","title02":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","journal":"Blood","issue":"2026 January 29; 147(5):485-496. doi: 10.1182\/blood.2025029011","author":"Thakur RK, Karlsson G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105914"},{"title01":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","title02":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","journal":"Blood","issue":"2026 January 22; 147(4):357-368. doi: 10.1182\/blood.2024026512","author":"Chalandon Y, Simonetta F, Masouridi-Levrat S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40354577"},{"title01":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","title02":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","journal":"Leukemia","issue":"2026 January 26. doi: 10.1038\/s41375-025-02828-8. Online ahead of print","author":"Guo Y, Sui P, Yang H, Zhu G, Li Y, Chen S, Zhao Y, Ge G, Eisa YA, Delma CR, Medina EA, Zhang P, Lee J, Xu M, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588055"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 January 30. doi: 10.1016\/S2352-3026(25)00359-X. Online ahead of print","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","title02":"Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?","journal":"J Clin Oncol","issue":"2026 January 21; JCO2502130. doi: 10.1200\/JCO-25-02130. Online ahead of print","author":"Kelkar AH, Abel GA, Cutler CS, Lee SJ, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564387"},{"title01":"Clonal hematopoiesis driver mutations: molecular mechanisms and clinical implications &#8211; inclusive fitness of pre-leukemic hematopoietic stem and progenitor cells through pro-inflammatory features of their progeny.","title02":"Clonal hematopoiesis driver mutations: molecular mechanisms and clinical implications &#8211; inclusive fitness of pre-leukemic hematopoietic stem and progenitor cells through pro-inflammatory features of their progeny.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.287480. Online ahead of print","author":"Bachrach T, Duek A, Shlush LI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609026"},{"title01":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","title02":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288770. Online ahead of print","author":"Stolzel F, Stelljes M, Beelen DW, Markiewicz M, Remenyi P, Luft T, Ciceri F, Wagner-Drouet EM, Junghanss C, Scheid C, Patriarca F, Socie G, Hilgendorf I, Rambaldi A, Schaefer-Eckart K, Russo D, Wulf G, Glass B, Labussiere-Wallet H, Stuhler G, Bieniaszewska M, Casper J, Holler E, Benedetti F, Iori AP, Kunadt D, Mihajlovic J, Schild B, Khan I, Li X, Bethge W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609025"},{"title01":"Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide.","title02":"Chronic graft-versus-host disease in the era of post-transplant cyclophosphamide.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.289266. Online ahead of print","author":"Canto PA, Montoro J, Balaguer-Rosello A, Villalba M, Chorao P, Louro A, Granados P, Eiris J, Bataller A, Gomez-Segui I, Solves P, Leon G, Lamas B, Eritzpokhoff L, Vallejo N, Hervas A, Hurtado M, Lopez J, Mansilla-Polo M, Reig JP, Valero MGG, De la Rubia M, Satorres C, De la Rubia J, Sanz MA, Sanz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568541"},{"title01":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","title02":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300184. Online ahead of print","author":"Amit O, Fridberg G, Moshe Y, Ospovat I, Sherf Y, Tshernichovsky D, Karni C, Avivi I, Ram R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568537"},{"title01":"Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.","title02":"Immunomodulatory role of megakaryocytes in the hematopoietic niche of myeloproliferative neoplasms.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288948. Online ahead of print","author":"Yang X, Lee S, Masarik K, Ahmed T, Zheng L, Zhan H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568522"},{"title01":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","title02":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.287609. Online ahead of print","author":"Chen N, Yang L, Chen F, Zeng H, Zhong X, Liu Y, Chen Z, Yao M, Lu Y, Shen M, Chen M, Xu Y, Wang S, Zhang X, Wang J, Hu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568470"},{"title01":"Ligature-induced periodontitis promotes Dnmt3a R878H-driven clonal hematopoiesis.","title02":"Ligature-induced periodontitis promotes Dnmt3a R878H-driven clonal hematopoiesis.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288827. Online ahead of print","author":"Yuan Q, Liao M, Zhuang Z, Huang C, Chen R, Song Y, Wu Y, Zou P, Li L, Nie H, Zhang M, Song S, Li Y, Yan F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568536"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70350. Online ahead of print","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","title02":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","journal":"Br J Haematol","issue":"2026 January 21. doi: 10.1111\/bjh.70292. Online ahead of print","author":"Bagnoli F, Calabrese De Feo J, Ricci F, Corrado F, Mannina D, Rahal D, Bonometti A, Rodari M, Giordano L, Bramanti S, Carlo-Stella C, Santoro A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41566789"},{"title01":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","title02":"Comparable outcomes of HSCT upfront and after failure of IST in pediatric aplastic anemia in recent years.","journal":"Blood advances","issue":"2026 January 20. doi: 10.1182\/bloodadvances.2025018285. Online ahead of print","author":"Andresen F, Yoshimi A, Bader P, Bierings MB, Bodova I, Bordon V, Buechner J, Burkhardt B, Dworzak MN, Erlacher M, Kallay KM, Labarque V, Locatelli F, Malone A, Masmas TN, Muller I, Nollke P, Schmugge M, Pawelec KM, Sedlacek P, Sevilla J, Smith O Professor, Stary J, Niemeyer CM, Strahm B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41558034"},{"title01":"Pediatric-Inspired Regimens &#038; HSCT for Adolescents &#038; Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","title02":"Pediatric-Inspired Regimens &#038; HSCT for Adolescents &#038; Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","journal":"Blood advances","issue":"2026 January 29. doi: 10.1182\/bloodadvances.2025018736. Online ahead of print","author":"Sereda Y, Mai HJ, Kanaan G, Melson JW, Terasawa T, Cheung MC, Stock WA, Wolfson JA, Saldanha IJ, Balk EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610329"},{"title01":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","title02":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","journal":"Blood","issue":"2026 January 22; 147(4):390-401. doi: 10.1182\/blood.2025029916","author":"Neven Q, Arfeuille C, Caye-Eude A, Durand P, Lainey E, Fenneteau O, Nelken B, Nolla M, Sterin A, Grain A, Khouri C, Simonin M, Dourthe ME, Fahd M, Millot F, Neven B, Petit A, Chevret S, Dalle JH, Baruchel A, Cave H, Strullu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971523"},{"title01":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","title02":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","journal":"Blood","issue":"2026 January 29; 147(5):485-496. doi: 10.1182\/blood.2025029011","author":"Thakur RK, Karlsson G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105914"},{"title01":"Ribosomal RNA methylation in HSCs: it&#8217;s so &#8220;good for you&#8221;.","title02":"Ribosomal RNA methylation in HSCs: it&#8217;s so &#8220;good for you&#8221;.","journal":"Blood","issue":"2026 January 29; 147(5):476-478. doi: 10.1182\/blood.2025032073","author":"Lopez J, Tzelepis K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609808"},{"title01":"Remodelling of the bone marrow vasculature induced by venetoclax and azacitidine damage.","title02":"Remodelling of the bone marrow vasculature induced by venetoclax and azacitidine damage.","journal":"Blood","issue":"2026 January 29. doi: 10.1182\/blood.2025030055. Online ahead of print","author":"Ngo S, D'Agostino GA, Papazoglou D, Mohamad Nor F, Finsterbusch K, Habel K, Ferrelli A, Anjos-Afonso F, Bonnet D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610429"},{"title01":"Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.","title02":"Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.","journal":"Blood advances","issue":"2026 January 27; 10(2):392-401. doi: 10.1182\/bloodadvances.2025016727","author":"Erbella F, Bachy E, Cartron G, Gat E, Manson G, Morschhauser F, Gros FX, Roulin L, Tessoulin B, Bories P, Tournilhac O, Ricard L, Guidez S, Choquet S, Casasnovas RO, Brisou G, Campidelli A, Castilla-Llorente C, Jardin F, Gyan E, Guffroy B, Abraham J, Decroocq J, Chauchet A, Joris M, Claves F, Carras S, Guillerm G, Loschi M, Hermine O, Taguy-Schimidt A, Le Gouill S, Houot R, Di Blasi R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124667"},{"title01":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","title02":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","journal":"Blood","issue":"2026 January 21. doi: 10.1182\/blood.2025031287. Online ahead of print","author":"Davidson-Swinton HR, Iyer S, Kolchinski A, Salem JA, DeBoy EA, Kilada AG, Hwang JS, Jain T, Keel SB, Gocke CD, Zou YS, Schratz KE, Armanios M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564438"},{"title01":"DC-SIGN Binding to the Surface Ig Oligomannose-type Glycans Promotes Follicular Lymphoma Cell Adhesion and Survival.","title02":"DC-SIGN Binding to the Surface Ig Oligomannose-type Glycans Promotes Follicular Lymphoma Cell Adhesion and Survival.","journal":"Blood","issue":"2026 January 20. doi: 10.1182\/blood.2025030049. Online ahead of print","author":"Chiodin G, Tatterton DJ, Rock PJ, Del Rio L, Snook E, James S, Duriez PJ, Di Re M, Verdoes M, Lanham S, Hodson DJ, Burack R, Forconi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557914"},{"title01":"Primary colonic T-cell lymphoma with a TFH phenotype, favoring extranodal TFH lymphoma, angioimmunoblastic type.","title02":"Primary colonic T-cell lymphoma with a TFH phenotype, favoring extranodal TFH lymphoma, angioimmunoblastic type.","journal":"Blood","issue":"2026 January 29; 147(5):602. doi: 10.1182\/blood.2025031040","author":"Urano Y, Satou A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609805"},{"title01":"Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed\/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.","title02":"Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed\/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):164-175. doi: 10.1200\/JCO-25-00924","author":"Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, Kapoor P, Katodritou E, Kortum KM, Ling S, Nagarajan C, Suzuki K, Qiu L, Onishi M, Ku G, Dail M, Mukherjee N, Ross JA, Badawi MA, Fusco MJ, Dobkowska E, Arriola E, Bueno OF, Bahlis NJ, Iida S, Moreau P, Valent J, Mateos MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370738"},{"title01":"Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis.","title02":"Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis.","journal":"J Clin Oncol","issue":"2026 January 27; JCO2501713. doi: 10.1200\/JCO-25-01713. Online ahead of print","author":"Banerjee R, King T, Faiman B, Harding S, Rosenberg AS, Sanchorawala V, Mikhael JR, Cowan AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592262"},{"title01":"Genomics Define Malignant Transformation in Myeloma Precursor Conditions.","title02":"Genomics Define Malignant Transformation in Myeloma Precursor Conditions.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):188-199. doi: 10.1200\/JCO-25-01733","author":"Maura F, Bergsagel PL, Ziccheddu B, Kumar S, Maclachlan K, Derkach A, Garces JJ, Firestone R, Braggio E, Asmann Y, Durante M, Diamond BT, Papadimitriou M, Hultcrantz M, Marella A, Castellano G, Maeda A, Lionetti M, Matera A, Pioggia S, Da Via MC, de Magistris C, Leongamornlert D, DeAvila D, Sudalagunta PR, Canevarolo RR, Siegel EM, Agius P, Teer J, McPherson A, Yamashita Y, Silva AS, Blaney P, Baz R, Patel KK, Campbell P, Morgan G, Fonseca R, Landgren O, Orlowski RZ, Shain KH, Bolli N, Usmani S, Rajkumar SV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061199"},{"title01":"Tumultuous Development of Venetoclax in t(11;14) Multiple Myeloma.","title02":"Tumultuous Development of Venetoclax in t(11;14) Multiple Myeloma.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):139-142. doi: 10.1200\/JCO-25-01088","author":"Kaiser MF, Cliff ERS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40929614"},{"title01":"Morphologic and immunophenotypic characterization of lymphocytosis following BCMAtargeted CAR-T cell therapy in relapsed\/refractory multiple myeloma.","title02":"Morphologic and immunophenotypic characterization of lymphocytosis following BCMAtargeted CAR-T cell therapy in relapsed\/refractory multiple myeloma.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.289079. Online ahead of print","author":"Chai JN, Simonson PD, Gulgar K, Costanzo F, Jayabalan DS, Bustoros M, Inghirami GG, Geyer JT, Saldarriaga MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609029"},{"title01":"Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed\/refractory multiple myeloma treated in Europe.","title02":"Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed\/refractory multiple myeloma treated in Europe.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.289034. Online ahead of print","author":"Cavo M, Schjesvold F, Dimopoulos M, Delforge M, Escalante F, Kleinman D, Lee HC, Vij R, Greil R, Melchardt T, Antonioli E, Lysen A, Camadoo-O'Byrne L, Bitetti J, D'Estrube T, Fry M, Byrne J, Vossen CY, Sapra S, Benson VS, Mouro J, Hultcrantz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568469"},{"title01":"Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study.","title02":"Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.289200. Online ahead of print","author":"Roman E, Bagguley T, Crouch S, Smith A, Painter D, Howell D, Patmore R, Tooze R, Cargo C, De Tute R, Rawstron A, Cook G, Parrish C, Seymour F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609031"},{"title01":"Metabolic syndrome and risk of monoclonal gammopathy of undetermined significance: a large Korean cohort study.","title02":"Metabolic syndrome and risk of monoclonal gammopathy of undetermined significance: a large Korean cohort study.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.300043. Online ahead of print","author":"Lee JY, Jung EJ, Kwon S, Kim SA, Lee JO, Han K, Bang SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609060"},{"title01":"Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.","title02":"Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity.","journal":"Blood advances","issue":"2026 January 21. doi: 10.1182\/bloodadvances.2025018951. Online ahead of print","author":"Oswald LB, Li X, Ferraris CE, DeAvila G, Scheiber-Camoretti D, Gudenkauf LM, Small BJ, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Crowder SL, Parker N, Carson TL, Vinci CE, Baz RC, Shain KH, Blue BJ, Grajales-Cruz AF, Matte K, Kale B, Kaldas D, Perna F, Alsina M, Freeman CL, Castaneda Puglianini OA, Nishihori T, Liu HD, Locke FL, Jim HS, Hansen DK, Peres LC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564433"},{"title01":"Efficacy and Safety of Selinexor Combined with VRD in Newly Diagnosed Multiple Myeloma with EMD: A Phase 2 Trial.","title02":"Efficacy and Safety of Selinexor Combined with VRD in Newly Diagnosed Multiple Myeloma with EMD: A Phase 2 Trial.","journal":"Blood advances","issue":"2026 January 21. doi: 10.1182\/bloodadvances.2025018945. Online ahead of print","author":"Jin Y, Cheng X, Zhang X, Shi Q, Zhu Y, Li J, Fan L, Chen L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564431"},{"title01":"Impact of body mass index on the prognosis of patients with newly diagnosed multiple myeloma.","title02":"Impact of body mass index on the prognosis of patients with newly diagnosed multiple myeloma.","journal":"Blood advances","issue":"2026 January 27; 10(2):439-451. doi: 10.1182\/bloodadvances.2025018024","author":"Arnold KD, Ong KL, Ravi G, Wessel MC, Davies FE, Costa LJ, Deshpande A, Morgan GJ, Birmann BM, Brown EE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41150833"},{"title01":"Vaccination during bispecific antibody treatment for myeloma.","title02":"Vaccination during bispecific antibody treatment for myeloma.","journal":"Blood advances","issue":"2026 January 27; 10(2):519-520. doi: 10.1182\/bloodadvances.2025018225","author":"Banerjee R, Raje NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061155"},{"title01":"Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma.","title02":"Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma.","journal":"Blood advances","issue":"2026 January 28. doi: 10.1182\/bloodadvances.2025017889. Online ahead of print","author":"Mersi J, Burow L, Zhou X, Eisele F, Fante M, Riedhammer C, Stich A, Isberner N, Afrin N, Duell J, Topp MS, Einsele H, Waldschmidt JM, Kortum KM, Rasche L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610311"},{"title01":"Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.","title02":"Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.","journal":"Blood advances","issue":"2026 January 27; 10(2):343-355. doi: 10.1182\/bloodadvances.2025017296","author":"Dyer MR, Zheleznyak A, Teubner EN, Prior JL, Manion B, Jing Z, Sharma AK, Du J, Tang R, Fiala MA, DiPersio JF, Veis D, O'Neal J, Berezin MY, Shokeen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056513"},{"title01":"Long-term follow-up of zevor-cel in patients with relapsed\/refractory multiple myeloma.","title02":"Long-term follow-up of zevor-cel in patients with relapsed\/refractory multiple myeloma.","journal":"Blood advances","issue":"2026 January 27; 10(2):468-478. doi: 10.1182\/bloodadvances.2025017365","author":"Fu C, Chen W, Cai Z, Yan L, Wang H, Shang J, Wu Y, Yan S, Gao W, Shi X, Han X, Tang F, Zheng G, Wen Y, Meng X, Yuan D, Wang H, Li Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160798"},{"title01":"Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.","title02":"Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory Diarrhea.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025032347. Online ahead of print","author":"Blumenberg V, Birocchi F, Shih A, Escobar G, Mucci A, Armstrong A, Cirstea DD, Harris DL, Bozym DJ, Puliafito BR, Newcomb RA, Dhawale TM, Johnson PC, El-Jawahri A, Jeffrey R 3rd, Barselau A, Li A, Emmanuel-Alejandro E, Cook D, Lindell KA, Luk SO, Chaffee R, Yee AJ, Branagan AR, Raje NS, Graham C, Hammond SP, Bushman FD, Roche AM, Reddy S, McFarland AG, Chen YB, Choi BD, Mount CW, Dougan M, Nardi V, Sohani A, Gallagher KME, Maus MV, Frigault MJ, Leick MB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592291"},{"title01":"A myeloma identity crisis yields daratumumab resistance.","title02":"A myeloma identity crisis yields daratumumab resistance.","journal":"Blood","issue":"2026 January 29; 147(5):473-474. doi: 10.1182\/blood.2025031281","author":"Pandey A, Diamond B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609806"},{"title01":"The post-BCMA playbook: RD118 GPRC5D CAR T cells for myeloma.","title02":"The post-BCMA playbook: RD118 GPRC5D CAR T cells for myeloma.","journal":"Blood","issue":"2026 January 29; 147(5):474-476. doi: 10.1182\/blood.2025031961","author":"Al Hadidi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609812"},{"title01":"Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.","title02":"Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.","journal":"Blood","issue":"2026 January 29. doi: 10.1182\/blood.2025032536. Online ahead of print","author":"van de Donk NWCJ, Sonneveld P, Einsele H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610427"},{"title01":"Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens.","title02":"Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens.","journal":"Blood","issue":"2026 January 29; 147(5):534-546. doi: 10.1182\/blood.2024027616","author":"Rieger L, Irlinger K, Fuchsl F, Tietje M, Purcarea A, Barbian N, Faber M, Vogelsang C, Pfeuffer L, Stotz S, Karpiuk O, Schulze T, Augsburger A, Glaisner N, Konetzki V, Friedel S, Besse A, Besse L, Driessen C, Buchner M, Schwamborn K, Steiger K, Giansanti P, Theurich S, Waldschmidt J, Kortum KM, Hudecek M, Einsele H, Hogner M, Kuster B, Krackhardt AM, Hecker JS, Bassermann F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40638685"},{"title01":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","title02":"Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025031952. Online ahead of print","author":"Bal S, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria B, Giri S, Godby K, Silbermann R, Mikhail FM, Huls F, Reddy V, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592281"},{"title01":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","title02":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","journal":"Blood","issue":"2026 January 21. doi: 10.1182\/blood.2025031287. Online ahead of print","author":"Davidson-Swinton HR, Iyer S, Kolchinski A, Salem JA, DeBoy EA, Kilada AG, Hwang JS, Jain T, Keel SB, Gocke CD, Zou YS, Schratz KE, Armanios M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564438"},{"title01":"Time to Revise Myeloma Diagnostic Criteria? A Decade of Accumulated Evidence on Serum Free Light Chain Ratio >\/=100.","title02":"Time to Revise Myeloma Diagnostic Criteria? A Decade of Accumulated Evidence on Serum Free Light Chain Ratio >\/=100.","journal":"Blood","issue":"2026 January 20. doi: 10.1182\/blood.2025031907. Online ahead of print","author":"Chakraborty R, Mohyuddin GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557896"},{"title01":"The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed\/refractory multiple myeloma.","title02":"The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed\/refractory multiple myeloma.","journal":"Blood","issue":"2026 January 29; 147(5):513-519. doi: 10.1182\/blood.2025030559","author":"Pan M, Wang D, Xu J, Jin S, Wang Y, Tao Y, Liu Y, Ouyang W, Weng X, Yi H, Huang Y, Cao X, Li S, Zhang F, Zhang W, Li C, Mi JQ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41118600"},{"title01":"Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.","title02":"Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.","journal":"Blood","issue":"2026 January 22; 147(4):431-442. doi: 10.1182\/blood.2025030113","author":"Bertamini L, Fokkema C, Rodriguez-Otero P, van Duin M, Terpos E, D'Agostino M, van der Velden VHJ, van de Donk NWCJ, Delforge M, Driessen C, Hajek R, Einsele H, Vangsted A, Vieyra D, Attar R, Sitthi-Amorn A, Carson R, Schjesvold F, Robak P, Beksac M, Spencer A, Broijl A, Cupedo T, Moreau P, Boccadoro M, Sonneveld P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060326"},{"title01":"Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.","title02":"Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.","journal":"Blood","issue":"2026 January 29; 147(5):497-512. doi: 10.1182\/blood.2025029921","author":"Meads MB, Zhao X, Noyes D, Sudalagunta PR, Achille A, Zhang C, Canevarolo RR, Silva M, Magaletti D, DeAvila D, Toska S, Oates A, Lastorino D, Idiaquez DW, Song J, Sansil SS, Yoder SJ, Grajales-Cruz AF, Blue B, Freeman CL, Kim J, Alsina M, Brayer J, Silva AS, Song X, Shain KH, Baz R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983035"},{"title01":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","title02":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70347. Online ahead of print","author":"Aleid M, Fakih RE, Hanbali A, Alfraih F, Alothaimeen H, Elhassan T, Alahmari A, Rasheed W, Almohareb F, Chaudhri N, Alotaibi S, Alsharif F, Shaheen M, Alhayli S, Alkhaldi H, Alyamany R, Alshaibani A, Alotaibi AS, Alamer A, Albabtain AA, Ahmed SO, Alzahrani H, Aljurf M, Saad A, Alfayez M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582435"},{"title01":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","title02":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","journal":"Br J Haematol","issue":"2026 January 21. doi: 10.1111\/bjh.70292. Online ahead of print","author":"Bagnoli F, Calabrese De Feo J, Ricci F, Corrado F, Mannina D, Rahal D, Bonometti A, Rodari M, Giordano L, Bramanti S, Carlo-Stella C, Santoro A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41566789"},{"title01":"Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBI.","title02":"Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBI.","journal":"Blood advances","issue":"2026 January 22. doi: 10.1182\/bloodadvances.2025017413. Online ahead of print","author":"Goldenberg M, Varadhan R, Gamper CJ, Cooke KR, Ambinder AJ, Symons HJ, Pecker LH, Jones RJ, Brodsky RA, Bolanos-Meade J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569644"},{"title01":"Ravulizumab for Treatment of Paroxysmal Nocturnal Hemoglobinuria During Pregnancy.","title02":"Ravulizumab for Treatment of Paroxysmal Nocturnal Hemoglobinuria During Pregnancy.","journal":"Blood advances","issue":"2026 January 29. doi: 10.1182\/bloodadvances.2025019253. Online ahead of print","author":"Hochsmann B, Gerber GF, Leopold W, Patel BJ, Gavriilaki E, Hefter A, Kalhammer U, Opitz SA, Marx-Hoffmann A, Knight DB, Brodsky RA, Marvaki A, Lalayanni C, Korper S, Babushok DV, Schrezenmeier H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610317"},{"title01":"Pregnancy after Haematopoietic Stem Cell Transplant: an international multicentre study.","title02":"Pregnancy after Haematopoietic Stem Cell Transplant: an international multicentre study.","journal":"Blood advances","issue":"2026 January 28. doi: 10.1182\/bloodadvances.2025016977. Online ahead of print","author":"Salooja N, Eikema DJ, Michonneau D, Tichelli AA, Apperley JF, Akhtar S, Bourhis JH, Maertens JA, Maghfoor I, Massarotti C, Collin M, Mielke S, Raiola AM, Schaap M, Sedlacek P, Socie G, van der Werf S, Aljurf M, Kalwak K, Basak GW, Peric Z, Penack O, Schoemans HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604618"},{"title01":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","title02":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","journal":"Blood advances","issue":"2026 January 27. doi: 10.1182\/bloodadvances.2025017360. Online ahead of print","author":"Holtan SG, Grover P, Walton K, El Jurdi N, Quinones V, Maakaron JE, Juckett MB, Bachanova V, Hou JH, Terezakis SA, Myers TJ, Paradiso LJ, DeFor TE, Cao Q, Betts BC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592279"},{"title01":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant MPN patients.","title02":"Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant MPN patients.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018811. Online ahead of print","author":"Tashi T, Shih LY, Yo YT, Sullivan A, Chueh HY, Kuo MC, Smith A, Kim SJ, Parsegov B, Reeves BN, Song J, Prchal JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587484"},{"title01":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","title02":"How I approach hematopoietic stem cell transplantation for CML in a TKI world.","journal":"Blood","issue":"2026 January 22; 147(4):357-368. doi: 10.1182\/blood.2024026512","author":"Chalandon Y, Simonetta F, Masouridi-Levrat S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40354577"},{"title01":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","title02":"Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.","journal":"Blood","issue":"2026 January 29; 147(5):584-601. doi: 10.1182\/blood.2025029712","author":"Fetsch V, Schwobel L, Ozyerli-Goknar E, Stell AV, Punta M, Plenge T, Klaus T, Gupta MK, Andrieux G, Shoumariyeh K, Pfeiffer S, Corrales E, Schlenke L, Baniadam H, Brandl SM, Andreis M, Remen M, Hartmann A, Grueter K, Zwick M, Kohler N, Kuban M, Metzger E, Rummelt C, Duyster J, Boerries M, Hofmann M, Farber J, Braun LM, Zahringer A, Lubbert M, Toffalori C, Vago L, Heidel FH, Minguet S, Apostolova P, Feuchtinger T, Maas-Bauer K, Blaeschke F, Kuhn MWM, Timmers HTM, Wertheimer T, Perner F, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144759"},{"title01":"How I treat advanced phases of CML.","title02":"How I treat advanced phases of CML.","journal":"Blood","issue":"2026 January 22; 147(4):369-378. doi: 10.1182\/blood.2024026510","author":"Mauro MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329950"},{"title01":"Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia.","title02":"Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia.","journal":"Blood","issue":"2026 January 29; 147(5):547-556. doi: 10.1182\/blood.2025030498","author":"Azevedo RS, Jabbour E, Kantarjian HM, Lavu S, Loghavi S, Jain N, Sasaki K, Garris RS, Takahashi K, Ravandi F, Short NJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41335402"},{"title01":"The proteostasis network is a therapeutic target in acute myeloid leukemia.","title02":"The proteostasis network is a therapeutic target in acute myeloid leukemia.","journal":"Blood","issue":"2026 January 29; 147(5):557-572. doi: 10.1182\/blood.2024026749","author":"Lam K, Kim YJ, Tan EL, Ong CM, Liu AZ, Zhou FJ, Sunshine MJ, Chua BA, Vicenzi S, Chen K, Yu H, Ford PW, Zhou JH, Hong Y, Bennett EJ, Crews LA, Ball ED, Signer RAJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41111393"},{"title01":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","title02":"Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.","journal":"Blood","issue":"2026 January 29; 147(5):485-496. doi: 10.1182\/blood.2025029011","author":"Thakur RK, Karlsson G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105914"},{"title01":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","title02":"The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.","journal":"Blood","issue":"2026 January 22; 147(4):390-401. doi: 10.1182\/blood.2025029916","author":"Neven Q, Arfeuille C, Caye-Eude A, Durand P, Lainey E, Fenneteau O, Nelken B, Nolla M, Sterin A, Grain A, Khouri C, Simonin M, Dourthe ME, Fahd M, Millot F, Neven B, Petit A, Chevret S, Dalle JH, Baruchel A, Cave H, Strullu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971523"},{"title01":"GATA1 N-terminus coordinates metabolic reprogramming in erythropoiesis.","title02":"GATA1 N-terminus coordinates metabolic reprogramming in erythropoiesis.","journal":"Blood","issue":"2026 January 26. doi: 10.1182\/blood.2025030464. Online ahead of print","author":"Ling T, Bezavada L, Mehmood R, Zhang K, Cotton A, Crawford JC, Jin H, Sona S, Li L, Ju Y, Han L, Liu N, Tran T, Vu H, Jin Y, Zhai J, Pruett-Miller SM, Bhoopalan SV, Xu J, Ni M, Crispino JD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587073"},{"title01":"Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.","title02":"Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.","journal":"Blood","issue":"2026 January 26. doi: 10.1182\/blood.2025029972. Online ahead of print","author":"Sekrecki M, Sekrecka A, Lattupally RR, Le K, Jin X, Mozes C, Dwyer BG, Zhuang Z, Romero BA, Pineda JMB, Cao X, Nguyen L, Chen VW, Zhou C, Wallace JA, Tanaka KL, Tiwari C, Gabel A, Kim WJ, Stanley RF, Benbarche S, Thind J, Muruganandham A, Zhang TYY, Greenberg PL, Gotlib J, Mannis GN, Shomali W, Salmasi GG, Kuo CJ, Shanafelt TD, Singh I, Inoue D, Hansen FK, Gray NS, Van Rechem C, Fakhri B, Zhang X, Lu SX","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587094"},{"title01":"How I treat chronic myeloid leukemia in children and adolescents.","title02":"How I treat chronic myeloid leukemia in children and adolescents.","journal":"Blood","issue":"2026 January 22; 147(4):379-389. doi: 10.1182\/blood.2024026514","author":"Chen J, Suttorp M, Hijiya N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40132166"},{"title01":"Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model.","title02":"Establishment and characterization of a CCND1-rearranged non-mantle cell lymphoma cell line and patient-derived xenograft model.","journal":"Leukemia","issue":"2026 January 26. doi: 10.1038\/s41375-025-02849-3. Online ahead of print","author":"Graf CM, Reese M, Vicente-Luque A, Monig N, Bruzeau C, Nadeu F, Latacz M, Bihler J, Meinel J, Cartolano M, Peifer M, Bea S, Campo E, Thelen M, Brockelmann PJ, Jachimowicz RD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588054"},{"title01":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 January 16. doi: 10.1038\/s41375-025-02844-8. Online ahead of print","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545700"},{"title01":"Transforming mantle cell lymphoma: the journey across eras.","title02":"Transforming mantle cell lymphoma: the journey across eras.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.300275. Online ahead of print","author":"Castonguay M, Seymour JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609054"},{"title01":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","title02":"Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.","journal":"Br J Haematol","issue":"2026 January 21. doi: 10.1111\/bjh.70292. Online ahead of print","author":"Bagnoli F, Calabrese De Feo J, Ricci F, Corrado F, Mannina D, Rahal D, Bonometti A, Rodari M, Giordano L, Bramanti S, Carlo-Stella C, Santoro A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41566789"},{"title01":"A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL): Results from the phase 3 study BRUIN CLL-321.","title02":"A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL): Results from the phase 3 study BRUIN CLL-321.","journal":"Br J Haematol","issue":"2026 January 22. doi: 10.1111\/bjh.70334. Online ahead of print","author":"Yi S, Cao J, Feng R, Zhou K, Qiu L, Li F, Yang HY, Zhou H, Hui W, Cui J, Huang H, Zhu J, Ye X, Sharman J, Qiu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571607"},{"title01":"Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.","title02":"Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.","journal":"Br J Haematol","issue":"2026 January 29. doi: 10.1111\/bjh.70344. Online ahead of print","author":"Fleischmann M, Hansen O, Voigtlander D, Bechwar J, Schwietzer LJ, Bahr S, Schnetzke U, Fischer M, Heidel FH, Schnoder TM, Muller JP, Hochhaus A, Scholl S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608989"},{"title01":"How I manage mycosis fungoides and Sezary syndrome: Current controversies and unmet needs.","title02":"How I manage mycosis fungoides and Sezary syndrome: Current controversies and unmet needs.","journal":"Br J Haematol","issue":"2026 January 19. doi: 10.1111\/bjh.70308. Online ahead of print","author":"Stadler R, Quaglino P, Roccuzzo G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41555738"},{"title01":"Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.","title02":"Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.","journal":"Br J Haematol","issue":"2026 January 20. doi: 10.1111\/bjh.70298. Online ahead of print","author":"Angel S, Marc B, Victor N, Patricia LP, David Q, Juan-Manuel S, Adolfo S, Ana JU, Carlos CJ, Raul C, Maria C, la Cruz Beatriz D, Samuel R, Ainara F, Tomas G, Teresa V, Andrea R, Sofia V, Paola V, Carmen H, Miguel C, Miguel A, Alejandro MG, Javier M, Cristina G, Ana MN, Gloria I, Francesc B, Pau A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41560431"},{"title01":"Zanubrutinib, lenalidomide, rituximab, temozolomide +\/- methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.","title02":"Zanubrutinib, lenalidomide, rituximab, temozolomide +\/- methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.","journal":"Br J Haematol","issue":"2026 January 26. doi: 10.1111\/bjh.70335. Online ahead of print","author":"Song J, Jiang H, Ding K, Liu H, Wang Y, Gao S, Ren Y, Liu Z, Zhuo J, Li B, Wang G, Jiao Z, Gao D, Fu R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582824"},{"title01":"Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.","title02":"Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.","journal":"Blood advances","issue":"2026 January 27. doi: 10.1182\/bloodadvances.2025018719. Online ahead of print","author":"Heger JM, Mattlener J, Herhaus P, Meissner J, Trautmann-Grill K, Voltin CA, Schneider J, Schleifenbaum JK, Heidenreich SJ, Kobe C, Kaul H, Klapper W, von Tresckow B, Borchmann P, Brockelmann PJ, Borchmann S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592288"},{"title01":"An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL.","title02":"An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018536. Online ahead of print","author":"Shadman M, Tam CS, Brander DM, Lefebure M, Yang K, Xu S, Tian T, Kuptsova-Clarkson N, Williams R, Hirata J, Munir T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587482"},{"title01":"Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.","title02":"Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018491. Online ahead of print","author":"Gong IY, Kuruvilla J, Prica A, Olney HJ, Fraser GA, Buckstein RJ, Skrabek P, Keating MM, Hay AE, Shepherd L, Chen BE, Crump M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587423"},{"title01":"Treatment and Survival Outcomes in Follicular Lymphoma Patients with POD24: A Systematic Review and Meta-Analysis.","title02":"Treatment and Survival Outcomes in Follicular Lymphoma Patients with POD24: A Systematic Review and Meta-Analysis.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018474. Online ahead of print","author":"Shen J, Zhang J, Zhu Z, Ma H, Zhang J, Zhou F, Tian H, Liu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587420"},{"title01":"Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.","title02":"Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.","journal":"Blood advances","issue":"2026 January 27; 10(2):358-366. doi: 10.1182\/bloodadvances.2025017248","author":"Montagne A, Bertho G, Papastergiou T, Chartier L, Ricci R, Jardin F, Ghesquieres H, Rossi C, Morschhauser F, Haioun C, Ribrag V, Feugier P, Brisou G, Oberic L, Gaulard P, Giraud N, Bennani Y, Thieblemont C, Baud V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056515"},{"title01":"Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.","title02":"Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.","journal":"Blood advances","issue":"2026 January 22. doi: 10.1182\/bloodadvances.2025016925. Online ahead of print","author":"Schmeing S, Nassiri S, Leclercq-Cohen G, Yanguez E, Husser T, Alberti Servera L, Schlenker R, Sam J, Klein C, Umana P, Herter S, Bottos A, Bacac M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569641"},{"title01":"Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC\/BCL2 rearrangements, DLBCL morphology.","title02":"Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC\/BCL2 rearrangements, DLBCL morphology.","journal":"Blood advances","issue":"2026 January 27; 10(2):320-333. doi: 10.1182\/bloodadvances.2025017282","author":"Alduaij W, Sehn LH, Champagne JN, Collinge B, Ben-Neriah S, Jiang A, Hilton LK, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Savage KJ, Villa D, Gerrie AS, Freeman CL, Mungall AJ, Steidl C, Scott DW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071951"},{"title01":"Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma.","title02":"Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma.","journal":"Blood advances","issue":"2026 January 21. doi: 10.1182\/bloodadvances.2025017682. Online ahead of print","author":"Qin Y, Xia PH, Huang YH, Cheng S, Liu JY, Gao X, Cai MC, Wang C, Qiu YR, Hu S, Shi Q, Yang HX, Zhao JY, Wang L, Xiong J, Zhao WL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564436"},{"title01":"Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.","title02":"Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.","journal":"Blood advances","issue":"2026 January 16. doi: 10.1182\/bloodadvances.2025017049. Online ahead of print","author":"Yim J, Lee S, Kim S, Han B, Lim S, Song YK, Youk J, Bae JM, Koh J, Lee C, Kim YA, Paik JH, Kim TMM, Yun H, Jeon YK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544233"},{"title01":"Improved survival and healthcare utilization with CAR-T vs historical care in relapsed-refractory large B-cell lymphoma.","title02":"Improved survival and healthcare utilization with CAR-T vs historical care in relapsed-refractory large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 16. doi: 10.1182\/bloodadvances.2025017401. Online ahead of print","author":"Kordbacheh T, Chan KK, Crump M, Ante Z, Liu N, Aminilari M, Gong IY, Bhella S, Vijenthira A, Kuruvilla J, Kridel R, Chen C, Kukreti V, Yang C, Hodgson D, Prica A, Rodin D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544221"},{"title01":"Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R\/R Marginal Zone Lymphoma: Phase 1\/2 BRUIN Study.","title02":"Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R\/R Marginal Zone Lymphoma: Phase 1\/2 BRUIN Study.","journal":"Blood advances","issue":"2026 January 16. doi: 10.1182\/bloodadvances.2025017489. Online ahead of print","author":"Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani CS, Hoffmann MS, Cheah CY, Munir T, Lewis DJ, Scarfo L, Eyre TA, Alencar AJ, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada PB, Balbas M, Zinzani PLL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41544219"},{"title01":"A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.","title02":"A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 27; 10(2):479-491. doi: 10.1182\/bloodadvances.2025017127","author":"Haydu JE, Redd RA, Lei MM, Hochberg EP, Barnes JA, Armand P, Soumerai JD, Eichler AF, Jacobsen ED, Jordan JT, Jacobson CA, LaCasce AS, Arrillaga-Romany I, McFaline-Figueroa JR, Plotkin SR, Takvorian RW, Chukwueke UN, Crombie JL, Johnson PC, Karschnia P, Dietrich J, Nayak L, Abramson JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41170917"},{"title01":"Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model.","title02":"Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model.","journal":"Blood advances","issue":"2026 January 27; 10(2):289-300. doi: 10.1182\/bloodadvances.2025017321","author":"Butt H, Sathish S, London E, Le A, Li Q, Gudmundsdottir B, Lee DY, Burke EV, Yates BP, Liu DR, Hsieh M, Leonard A, Eaton WA, Uchida N, Pierciey FJ Jr, Newby GA, Tisdale JF, Demirci S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41150843"},{"title01":"Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics.","title02":"Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):135-138. doi: 10.1200\/JCO-25-02305","author":"Saldarriaga MM, Bellman P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385751"},{"title01":"National-level dietary patterns and acute myeloid leukemia: a global ecological analysis.","title02":"National-level dietary patterns and acute myeloid leukemia: a global ecological analysis.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288955. Online ahead of print","author":"Wen D, Peng Z, Deng J, National-Level Dietary Patterns And Acute Myeloid Leukemia A Global Ecological, Analysis NNSFOCN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609059"},{"title01":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","title02":"Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288558. Online ahead of print","author":"Ao Y, Zheng H, Huang Y, Kang S, Zhang Q, Huang C, Wu X, Zeng Y, Zhou D, Fang J, Fu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609024"},{"title01":"Exploring the synergy between telomere length and genomic complexity in CLL.","title02":"Exploring the synergy between telomere length and genomic complexity in CLL.","journal":"Br J Haematol","issue":"2026 January 23. doi: 10.1111\/bjh.70317. Online ahead of print","author":"Ramos-Campoy S, Puiggros A, Kamaso J, Parker H, Rigolin GM, Haferlach C, Larrayoz MJ, Collado R, Salgado R, Calasanz MJ, Etter L, Valiente A, Abrisqueta P, Bosch F, Gimeno E, Cuneo A, Nguyen-Khac F, Schoumans J, Strefford JC, Espinet B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41574981"},{"title01":"Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study.","title02":"Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study.","journal":"Br J Haematol","issue":"2026 January 29. doi: 10.1111\/bjh.70353. Online ahead of print","author":"Lee YW, Chiang CJ, Lin YC, Tzeng HE, Chuang YT, Yang YW, Lee WC, Wu SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608915"},{"title01":"The impact of scaRNA12 deregulation on p53-mediated cellular stress response in B-cell precursor acute lymphoblastic leukaemia.","title02":"The impact of scaRNA12 deregulation on p53-mediated cellular stress response in B-cell precursor acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 January 19. doi: 10.1111\/bjh.70336. Online ahead of print","author":"Verbeek MWC, Sanders MA, Grashof DGB, Hoogenboezem RM, van Zuijen I, Bos A, van Gulck T, Olsman R, Mukhopadhyay R, Bindels EMJ, Valk PJM, van de Werken HJG, van der Velden VHJ, Erkeland SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41550039"},{"title01":"An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL.","title02":"An Indirect Comparison of Zanubrutinib vs Acalabrutinib Plus Venetoclax in Patients With Treatment-Naive CLL.","journal":"Blood advances","issue":"2026 January 26. doi: 10.1182\/bloodadvances.2025018536. Online ahead of print","author":"Shadman M, Tam CS, Brander DM, Lefebure M, Yang K, Xu S, Tian T, Kuptsova-Clarkson N, Williams R, Hirata J, Munir T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41587482"},{"title01":"Hypertension Impacts Survival and Treatment in Chronic Lymphocytic Leukemia.","title02":"Hypertension Impacts Survival and Treatment in Chronic Lymphocytic Leukemia.","journal":"Blood advances","issue":"2026 January 28. doi: 10.1182\/bloodadvances.2025018771. Online ahead of print","author":"Vainer N, Brieghel C, Rostgaard K, Davidsson OB, Dietz JB, Frederiksen CM, da Cunha-Bang C, Hjalgrim H, Niemann CU, Curovic Rotbain E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41604617"},{"title01":"Advancing Precision Therapy in Pediatric Acute Myeloid Leukemia Through PDX Models and Mitochondrial Targeting.","title02":"Advancing Precision Therapy in Pediatric Acute Myeloid Leukemia Through PDX Models and Mitochondrial Targeting.","journal":"Blood advances","issue":"2026 January 23. doi: 10.1182\/bloodadvances.2025018002. Online ahead of print","author":"Da Ros A, Peloso A, Longo G, Benetton M, Indio V, Cairo S, Sandri M, Buldini B, Bresolin S, Rosato A, Pession A, Tregnago C, Locatelli F, Pigazzi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41576348"},{"title01":"Ectopic expression of BEX genes in T-cell acute lymphoblastic leukemia.","title02":"Ectopic expression of BEX genes in T-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 January 27; 10(2):452-465. doi: 10.1182\/bloodadvances.2024015174","author":"Quessada J, Nozais M, Grosjean C, Savey C, Pankaew S, Allelova S, Potier D, Loosveld M, Payet-Bornet D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811813"},{"title01":"Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.","title02":"Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.","journal":"Blood advances","issue":"2026 January 29. doi: 10.1182\/bloodadvances.2025018369. Online ahead of print","author":"Baeten JT, Agashe S, Tabet I, Wooldridge JT, Carter A, Butler JN, Miller CA, Helton NM, Quinet A, Johansson KB, Yang Y, Uy GL, Vindigni A, Link DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610325"},{"title01":"Pediatric-Inspired Regimens &#038; HSCT for Adolescents &#038; Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","title02":"Pediatric-Inspired Regimens &#038; HSCT for Adolescents &#038; Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews.","journal":"Blood advances","issue":"2026 January 29. doi: 10.1182\/bloodadvances.2025018736. Online ahead of print","author":"Sereda Y, Mai HJ, Kanaan G, Melson JW, Terasawa T, Cheung MC, Stock WA, Wolfson JA, Saldanha IJ, Balk EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610329"},{"title01":"Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model.","title02":"Comparative analysis of CRISPR-Cas9, lentiviral transduction, and base editing for sickle cell disease in a murine model.","journal":"Blood advances","issue":"2026 January 27; 10(2):289-300. doi: 10.1182\/bloodadvances.2025017321","author":"Butt H, Sathish S, London E, Le A, Li Q, Gudmundsdottir B, Lee DY, Burke EV, Yates BP, Liu DR, Hsieh M, Leonard A, Eaton WA, Uchida N, Pierciey FJ Jr, Newby GA, Tisdale JF, Demirci S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41150843"},{"title01":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","title02":"Targeting Aurora Kinase A to Prevent GVHD and Relapse after Myeloablative Allogeneic Hematopoietic Cell Transplantation.","journal":"Blood advances","issue":"2026 January 27. doi: 10.1182\/bloodadvances.2025017360. Online ahead of print","author":"Holtan SG, Grover P, Walton K, El Jurdi N, Quinones V, Maakaron JE, Juckett MB, Bachanova V, Hou JH, Terezakis SA, Myers TJ, Paradiso LJ, DeFor TE, Cao Q, Betts BC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592279"},{"title01":"High-Dimensional Spatiotemporal Single-Cell Atlas and 3D imaging of Bone Marrow Microenvironment during CML Progression.","title02":"High-Dimensional Spatiotemporal Single-Cell Atlas and 3D imaging of Bone Marrow Microenvironment during CML Progression.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025029824. Online ahead of print","author":"Li L, Rottmann I, Saeed BR, Ivison G, Wei H, Schroeder JC, Dunkel G, Greif K, Zhang Y, Makky A, Ochsenbein AF, Riether C, Goltsev Y, Nolan G, Mayer AT, Weigelin B, Schurch CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592325"},{"title01":"Menin inhibitors: a 2-in-1 defense versus AML immune evasion.","title02":"Menin inhibitors: a 2-in-1 defense versus AML immune evasion.","journal":"Blood","issue":"2026 January 29; 147(5):482-483. doi: 10.1182\/blood.2025031975","author":"Chakraverty R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609810"},{"title01":"Targeting proteostasis addiction in AML.","title02":"Targeting proteostasis addiction in AML.","journal":"Blood","issue":"2026 January 29; 147(5):479-480. doi: 10.1182\/blood.2025031546","author":"Clarke ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609811"},{"title01":"Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.","title02":"Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.","journal":"Blood","issue":"2026 January 29. doi: 10.1182\/blood.2025031266. Online ahead of print","author":"Ranasinghe D, Lin WY, Fordham SE, Alharbi AA, Sunter NJ, Elstob C, Nahari MH, Xu Y, Park C, Hungate E, Quante A, Strauch K, Gieger C, Skol AD, Rahman T, Sucheston-Campbell L, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Enshaei A, Gunasinghe D, Hawking ZL, Heslop HS, Nandana D, Di B, Plokhuta A, Brown IT, Allsup DJ, Houlston RS, Collins A, Milne P, Norden J, Dickinson AM, Lendrem BC, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhauser M, Rollig C, Altmann H, Ruhnke L, Kunadt D, Wagenfuhr L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gomez-Segui I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Dombret H, Cheok MH, Preudhomme C, Gale RE, Linch DC, Weisinger J, Masszi A, Nowak D, Hofmann WK, Gilkes AF, Porkka K, Milosevic Feenstra JD, Kralovics R, Wang J, Meggendorfer M, Haferlach T, Krizsan S, Bodor C, Parkin BL, Malek SN, Stolzel F, Onel K, Allan JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610418"},{"title01":"circPCMTD1: A protein-coding circular RNA that regulates DNA damage response in BCR\/ABL1-positive leukemias.","title02":"circPCMTD1: A protein-coding circular RNA that regulates DNA damage response in BCR\/ABL1-positive leukemias.","journal":"Blood","issue":"2026 January 29. doi: 10.1182\/blood.2025031129. Online ahead of print","author":"Papaioannou D, Urs AP, Buisson R, Petri A, Liu M, Woodward L, Kulkarni R, Weislamle X, Ivashkiv O, Nicolet D, Goda C, Paraskevopoulou V, Bustos Y, Mrozek K, Eisfeld AK, Chandrasekharan MB, Behbehani GK, Kauppinen S, Aifantis I, Singh G, Dorrance AM, Garzon R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41610425"},{"title01":"Homeodomain-driven oncogenic diversion to a TCRgammadelta phenotype in T-cell Acute Lymphoblastic Leukemia.","title02":"Homeodomain-driven oncogenic diversion to a TCRgammadelta phenotype in T-cell Acute Lymphoblastic Leukemia.","journal":"Blood","issue":"2026 January 27. doi: 10.1182\/blood.2025030626. Online ahead of print","author":"Pinton A, Courtois L, Delafoy M, Bonnet MF, Cieslak A, Lhermitte L, Simonin M, Dourthe ME, Touzart A, Andrieu GP, Dombret H, Baruchel A, Spicuglia S, Payet-Bornet D, Boissel N, Macintyre EA, Asnafi V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41592282"},{"title01":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","title02":"Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome.","journal":"Blood","issue":"2026 January 21. doi: 10.1182\/blood.2025031287. Online ahead of print","author":"Davidson-Swinton HR, Iyer S, Kolchinski A, Salem JA, DeBoy EA, Kilada AG, Hwang JS, Jain T, Keel SB, Gocke CD, Zou YS, Schratz KE, Armanios M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41564438"},{"title01":"Introduction to a How I Treat series on chronic myeloid leukemia.","title02":"Introduction to a How I Treat series on chronic myeloid leukemia.","journal":"Blood","issue":"2026 January 22; 147(4):319-320. doi: 10.1182\/blood.2025031933","author":"Gotlib J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569619"},{"title01":"TP53-mutated AML with salmon-colored globules, a single Auer rod, pseudo-Chediak-Higashi granules, and micronuclei.","title02":"TP53-mutated AML with salmon-colored globules, a single Auer rod, pseudo-Chediak-Higashi granules, and micronuclei.","journal":"Blood","issue":"2026 January 22; 147(4):471. doi: 10.1182\/blood.2025031282","author":"Xu Z, Medvedev N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41569620"},{"title01":"How I individualize frontline treatment for chronic-phase CML.","title02":"How I individualize frontline treatment for chronic-phase CML.","journal":"Blood","issue":"2026 January 22; 147(4):329-336. doi: 10.1182\/blood.2024026508","author":"Leyte-Vidal A, Shah NP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40239150"},{"title01":"How I manage chronic myeloid leukemia during pregnancy.","title02":"How I manage chronic myeloid leukemia during pregnancy.","journal":"Blood","issue":"2026 January 22; 147(4):347-356. doi: 10.1182\/blood.2024026513","author":"Abruzzese E, Chelysheva E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40758938"},{"title01":"DHODH as a Targetable Metabolic Achilles&#8217; Heel for chemo-resistant B-ALL.","title02":"DHODH as a Targetable Metabolic Achilles&#8217; Heel for chemo-resistant B-ALL.","journal":"Blood","issue":"2026 January 23. doi: 10.1182\/blood.2025029264. Online ahead of print","author":"Liu Y, Jiang H, Liu J, Stuani L, Merchant MJ, Jager A, Koladiya A, Chang TC, Domizi P, Sarno J, Wang A, Keyes T, Jedoui D, Meng J, Hartmann F, Hou R, Fries C, Pirillo C, Gao Q, Iacobucci I, Bendall SC, Huang M, Lacayo NJ, Sakamoto KM, Mullighan CG, Loh ML, Yu J, Yang JJ, Ye J, Davis KL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41576347"},{"title01":"How I evaluate and treat resistance and relapse in CML.","title02":"How I evaluate and treat resistance and relapse in CML.","journal":"Blood","issue":"2026 January 22; 147(4):337-346. doi: 10.1182\/blood.2024026511","author":"Soverini S, Castagnetti F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40373278"},{"title01":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","title02":"Phf6 truncating mutation drives leukemogenesis via disrupted epigenetic regulation in mice.","journal":"Leukemia","issue":"2026 January 26. doi: 10.1038\/s41375-025-02828-8. Online ahead of print","author":"Guo Y, Sui P, Yang H, Zhu G, Li Y, Chen S, Zhao Y, Ge G, Eisa YA, Delma CR, Medina EA, Zhang P, Lee J, Xu M, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41588055"},{"title01":"Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.","title02":"Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.","journal":"Leukemia","issue":"2026 January 23. doi: 10.1038\/s41375-025-02852-8. Online ahead of print","author":"Oehler VG, Sala-Torra O, Gilderman N, Beppu L, Woolston DW, Namaganda P, Rynning J, Gonzalez IG, Towlerton A, Voutsinas J, Wu Q, Yeung CCS, Radich JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41577999"},{"title01":"Metabolic profiling of measurable residual disease (MRD) in APL: Do MRD cells retain PML::RARalpha-mediated long-chain fatty acid (LCFA) dependency?","title02":"Metabolic profiling of measurable residual disease (MRD) in APL: Do MRD cells retain PML::RARalpha-mediated long-chain fatty acid (LCFA) dependency?","journal":"Leukemia","issue":"2026 January 22. doi: 10.1038\/s41375-025-02837-7. Online ahead of print","author":"Zheng Y, Dong F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571770"},{"title01":"Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells.","title02":"Distal enhancer RNAs regulate alternative promoter usage of MYB and drug resistance in human leukemia cells.","journal":"Leukemia","issue":"2026 January 22. doi: 10.1038\/s41375-026-02862-0. Online ahead of print","author":"Wang Y, Wang X, Li M, Song H, Liu C, Shi M, Tao X, Shen S, Li X, Fang H, Zhou Z, Zhang J, Han B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571768"},{"title01":"Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.","title02":"Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.","journal":"Leukemia","issue":"2026 January 19. doi: 10.1038\/s41375-025-02847-5. Online ahead of print","author":"Rea D, Kyrcz-Krzemien S, Sportoletti P, Mayer J, Illes A, Angona Figueras A, Kiani A, Charbonnier A, Marinakis T, Stenke L, Steegmann JL, Saglio G, Hellmann A, Niederwieser D, Schuld P, Rosti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41555010"},{"title01":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","title02":"Strong constitutive NF-kappaB signaling in B cells drives SLL\/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.","journal":"Leukemia","issue":"2026 January 16. doi: 10.1038\/s41375-025-02844-8. Online ahead of print","author":"Soberon V, Osswald L, Moore A, Sosnowska D, Swinerd G, Chen J, Baygun S, Diehl C, Seyhan G, Kraus L, Golling V, Trapp R, O'Neill TJ, Bortoluzzi S, Kovacs D, Ammon T, Singroul P, Hubarzhevska Y, Ollinger R, Mueller S, Baranov O, Giansanti P, Gillhuber F, Grath S, Weigert O, Rosenwald A, Sasaki Y, Rajewsky K, Steiger K, Bassermann F, Rad R, Krappmann D, Ringshausen I, Schmidt-Supprian M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545700"},{"title01":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","title02":"Myelodysplastic syndromes versus acute myeloid leukaemia: biology or blasts-what truly defines the disease and does it matter?","journal":"Lancet Haematol","issue":"2026 January 30. doi: 10.1016\/S2352-3026(25)00359-X. Online ahead of print","author":"Duarte FB, Gurnari C, McLornan DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41628632"},{"title01":"Bridging the Gap: Pirtobrutinib for Treatment-Naive Chronic Lymphatic Leukemia.","title02":"Bridging the Gap: Pirtobrutinib for Treatment-Naive Chronic Lymphatic Leukemia.","journal":"J Clin Oncol","issue":"2026 January 20; JCO2502879. doi: 10.1200\/JCO-25-02879. Online ahead of print","author":"Braunstein MJ, Williams ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41557975"},{"title01":"Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","title02":"Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):254-256. doi: 10.1200\/JCO-25-01695","author":"Cliff ERS, Lew TE, Simon F, Hilal T, Anderson MA, Thompson PA, Seymour JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41270246"},{"title01":"Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","title02":"Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","journal":"J Clin Oncol","issue":"2026 January 20; 44(3):256-257. doi: 10.1200\/JCO-25-02231","author":"Sharman JP, Liu B, Wang DY, Leow CC, Barr PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41270260"},{"title01":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","title02":"Sequential therapy with allogeneic HCT in patients aged >\/=70 years with active AML: a singlecenter retrospective analysis.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300184. Online ahead of print","author":"Amit O, Fridberg G, Moshe Y, Ospovat I, Sherf Y, Tshernichovsky D, Karni C, Avivi I, Ram R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568537"},{"title01":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","title02":"GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288770. Online ahead of print","author":"Stolzel F, Stelljes M, Beelen DW, Markiewicz M, Remenyi P, Luft T, Ciceri F, Wagner-Drouet EM, Junghanss C, Scheid C, Patriarca F, Socie G, Hilgendorf I, Rambaldi A, Schaefer-Eckart K, Russo D, Wulf G, Glass B, Labussiere-Wallet H, Stuhler G, Bieniaszewska M, Casper J, Holler E, Benedetti F, Iori AP, Kunadt D, Mihajlovic J, Schild B, Khan I, Li X, Bethge W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609025"},{"title01":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","title02":"Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.288891. Online ahead of print","author":"Boussi L, Bewersdorf JP, Liu Y, Shallis RM, Aguirre LE, Bystrom RP, Zucenka A, Garciaz S, DeAngelo DJ, Stone RM, Luskin MR, Garcia JS, Winer ES, Chen EC, Wadleigh M, Berton G, Ling K, Zeidan AM, Stein EM, Shimony S, Goldberg AD, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609030"},{"title01":"Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: real-world efficacy and risks of early ponatinib dose reduction.","title02":"Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: real-world efficacy and risks of early ponatinib dose reduction.","journal":"Haematologica","issue":"2026 January 29. doi: 10.3324\/haematol.2025.300099. Online ahead of print","author":"Yoon JH, Min KI, Kwag D, Min GJ, Park SS, Park S, Lee SE, Cho BS, Eom KS, Kim YJ, Kim HJ, Min CK, Cho SG, Lee S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41609055"},{"title01":"Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children&#8217;s Oncology Group AALL1331 trial.","title02":"Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children&#8217;s Oncology Group AALL1331 trial.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300390. Online ahead of print","author":"Hochberg J, Cairo MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568543"},{"title01":"Incidence and outcomes of treatment-associated hepatotoxicity during pediatric acute lymphoblastic leukemia induction therapy: a Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium report.","title02":"Incidence and outcomes of treatment-associated hepatotoxicity during pediatric acute lymphoblastic leukemia induction therapy: a Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium report.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.288274. Online ahead of print","author":"Chavana AN, Mason EJ, Woodhouse JP, Taylor OA, Gramatges MM, Yi JS, Pruitt S, Bernhardt BM, Ludwig K, Klesse L, Heym K, Griffin T, Roberts M, Erana R, Bernini JC, Zhu H, Lupo PJ, Rabin KR, Scheurer ME, Mittelman SD, Huynh V, Orgel E, Brown AL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568528"},{"title01":"Optimal management of elderly\/old Ph+ acute lymphoblastic leukemia patients.","title02":"Optimal management of elderly\/old Ph+ acute lymphoblastic leukemia patients.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.300060. Online ahead of print","author":"Foa R, Chiaretti S, Ferrara F, Pizzolo G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568523"},{"title01":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","title02":"Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential.","journal":"Haematologica","issue":"2026 January 22. doi: 10.3324\/haematol.2025.287609. Online ahead of print","author":"Chen N, Yang L, Chen F, Zeng H, Zhong X, Liu Y, Chen Z, Yao M, Lu Y, Shen M, Chen M, Xu Y, Wang S, Zhang X, Wang J, Hu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41568470"},{"title01":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","title02":"Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70350. Online ahead of print","author":"Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582414"},{"title01":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","title02":"Transplant outcomes in adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2026 January 25. doi: 10.1111\/bjh.70347. Online ahead of print","author":"Aleid M, Fakih RE, Hanbali A, Alfraih F, Alothaimeen H, Elhassan T, Alahmari A, Rasheed W, Almohareb F, Chaudhri N, Alotaibi S, Alsharif F, Shaheen M, Alhayli S, Alkhaldi H, Alyamany R, Alshaibani A, Alotaibi AS, Alamer A, Albabtain AA, Ahmed SO, Alzahrani H, Aljurf M, Saad A, Alfayez M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41582435"},{"title01":"DHCR7 drives AML development through the IL6\/JAK2\/STAT3 signalling pathway.","title02":"DHCR7 drives AML development through the IL6\/JAK2\/STAT3 signalling pathway.","journal":"Br J Haematol","issue":"2026 January 29. doi: 10.1111\/bjh.70346. Online ahead of print","author":"Dai X, Wu Z, Zhang W, Chen S, Zhao X, Lu Y, Ma Y, Zheng W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608869"},{"title01":"Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.","title02":"Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2026 January 28. doi: 10.1111\/bjh.70339. Online ahead of print","author":"Crespo-Garcia E, Quero-Dotor C, Noguera-Castells A, Sancho-Vila L, Martinez-Verbo L, Esteller M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41606290"},{"title01":"A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL): Results from the phase 3 study BRUIN CLL-321.","title02":"A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL): Results from the phase 3 study BRUIN CLL-321.","journal":"Br J Haematol","issue":"2026 January 22. doi: 10.1111\/bjh.70334. Online ahead of print","author":"Yi S, Cao J, Feng R, Zhou K, Qiu L, Li F, Yang HY, Zhou H, Hui W, Cui J, Huang H, Zhu J, Ye X, Sharman J, Qiu L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571607"},{"title01":"Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.","title02":"Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.","journal":"Br J Haematol","issue":"2026 January 29. doi: 10.1111\/bjh.70344. Online ahead of print","author":"Fleischmann M, Hansen O, Voigtlander D, Bechwar J, Schwietzer LJ, Bahr S, Schnetzke U, Fischer M, Heidel FH, Schnoder TM, Muller JP, Hochhaus A, Scholl S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41608989"},{"title01":"Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes.","title02":"Red blood cell immunization as an independent predictor of survival in the myelodysplastic syndromes.","journal":"Br J Haematol","issue":"2026 January 20. doi: 10.1111\/bjh.70330. Online ahead of print","author":"Pedraza A, Castano S, Pereira A, Nomdedeu M, Ruiz C, Esteva M, Diaz-Beya M, Sanz C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41560464"},{"title01":"Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.","title02":"Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.","journal":"Blood advances","issue":"2026 January 27; 10(2):428-438. doi: 10.1182\/bloodadvances.2025017755","author":"Chatzikonstantinou T, Mikhaleva M, Brieghel C, Papangelou C, Minga E, Arrais-Rodrigues C, Besikli-Dimou S, Cerutti A, Doubek M, Enggaard L, Espinet B, Ferrer-Lores B, Garcia Vela JA, Gentile M, Vazquez EG, Gutwein O, Herishanu Y, Jablonowska-Babij P, Jaksic O, Josefsson P, Kalicinska E, Kislova M, Lista E, Kotsianidis I, Marquet J, Martino EA, McAuley C, Mela Osorio MJ, Moia R, Mosquera C, Nikitin E, Pavlovsky MA, Pfister V, Savas EM, Scarfo L, Sever M, Shvidel L, Simkovic M, Stavroyianni N, Talimtzi P, Tranidou A, Visentin A, Vrachiolias G, Wasik-Szczepanek E, Wrobel T, Yagci M, Cellini A, Chatzidimitriou A, Gaidano G, Anderson MA, Davids MS, Brown JR, Niemann CU, Stamatopoulos K, Ghia P, Ahn IE, Koren-Michowitz M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135013"},{"title01":"Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.","title02":"Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2026 January 22. doi: 10.1038\/s41375-025-02855-5. Online ahead of print","author":"Ansuinelli M, Peragine N, De Propris MS, Puzzolo MC, Di Trani M, Elia L, Skert C, Cairoli R, Sica S, Rambaldi A, Tucci A, Cerrano M, Vallisa D, Cardinali V, Mule A, Chiaretti S, Guarini A, Foa R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41571767"},{"title01":"CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.","title02":"CSF1R marks a subset of foetal haematopoietic multipotent progenitor cells with acute myeloid leukaemia propagation properties.","journal":"Leukemia","issue":"2026 January 16. doi: 10.1038\/s41375-025-02856-4. Online ahead of print","author":"Camiolo G, Gonzalez Silvera D, Leah T, Schwaller J, Ottersbach K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41545699"},{"title01":"Correspondence to &#8220;Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis&#8221;.","title02":"Correspondence to &#8220;Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis&#8221;.","journal":"Leukemia","issue":"2026 January; 40(1):245-246. doi: 10.1038\/s41375-025-02812-2","author":"Zheng H, Zhang L, Li L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41225181"},{"title01":"Correction: Correspondence to &#8220;A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development&#8221;.","title02":"Correction: Correspondence to &#8220;A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development&#8221;.","journal":"Leukemia","issue":"2026 January; 40(1):260. doi: 10.1038\/s41375-025-02813-1","author":"Wang X, Yao H, Chen J, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41272183"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","journal":"Haematologica","issue":"2026 January 1; 111(1):168-176. doi: 10.3324\/haematol.2024.287205","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kroger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP, Anemia Working Party ESA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"Erratum to: &#8220;Optimizing CRISPR methodology for precise gene editing in the erythroid cell line BEL-A with high efficiency generation of a sickle cell anemia model&#8221;.","title02":"Erratum to: &#8220;Optimizing CRISPR methodology for precise gene editing in the erythroid cell line BEL-A with high efficiency generation of a sickle cell anemia model&#8221;.","journal":"Haematologica","issue":"2026 January 1; 111(1):436. doi: 10.3324\/haematol.2025.288211","author":"Daniels DE, Hawksworth J, El Hoss S, Oyawoye FO, Ferrer-Vicens I, Wilson MC, Frayne J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41496706"},{"title01":"The landmark contribution by Erik von Willebrand.","title02":"The landmark contribution by Erik von Willebrand.","journal":"Haematologica","issue":"2026 January 1; 111(1):1-9. doi: 10.3324\/haematol.2024.286012","author":"Lassila R, Berntorp E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41496698"},{"title01":"Early detection and management of extracranial arteriopathy reduces the incidence of silent cerebral infarcts in sickle cell anemia: a long-term prospective cohort study.","title02":"Early detection and management of extracranial arteriopathy reduces the incidence of silent cerebral infarcts in sickle cell anemia: a long-term prospective cohort study.","journal":"Haematologica","issue":"2026 January 1; 111(1):314-328. doi: 10.3324\/haematol.2025.287720","author":"Bernaudin F, Arnaud C, Kamdem A, Youn J, Vasile M, Hau I, Madhi F, Malterre A, Delestrain C, Epaud R, Jung C, Verlhac S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568713"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","journal":"Haematologica","issue":"2026 January 1; 111(1):168-176. doi: 10.3324\/haematol.2024.287205","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kroger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP, Anemia Working Party ESA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","title02":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","journal":"Haematologica","issue":"2026 January 1; 111(1):149-157. doi: 10.3324\/haematol.2025.287628","author":"Oran B, Thall P, Alousi A, Al-Atrash G, Mehta R, Marin D, Kebriaei P, Popat U, Bassett R, Bashir Q, Im J, Olson A, Jewell J, Smallbone P, Shpall E, Champlin R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702903"},{"title01":"Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes.","title02":"Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.289268. Online ahead of print","author":"Aldapt M, Wang YH, Shah KJ, El Kettani M, Foran J, Kharfan-Dabaja M, Murthy H, Al-Kali A, Shah MV, Alkhateeb H, Saliba AN, Hogan W, Yi CA, Sproat L, Punwani N, Khera N, Palmer J, Litzow M, Tefferi A, Gangat N, Patnaik MM, Badar T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504247"},{"title01":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","title02":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","journal":"Br J Haematol","issue":"2026 January 4. doi: 10.1111\/bjh.70307. Online ahead of print","author":"Nakamura F, Ishiyama K, Suzuki R, Maruyama H, Onishi Y, Usuki K, Koh H, Takenaka K, Saiki R, Ogawa S, Matsumoto K, Takahashi T, Hosomichi K, Zaimoku Y, Yoshimura K, Matsumura I, Akashi K, Nakao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41485764"},{"title01":"Hypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review.","title02":"Hypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review.","journal":"Br J Haematol","issue":"2026 January 14. doi: 10.1111\/bjh.70302. Online ahead of print","author":"Hoff FW, Trikha R, Groarke EM, Patel BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41531276"},{"title01":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","title02":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","journal":"Blood advances","issue":"2026 January 13; 10(1):233-245. doi: 10.1182\/bloodadvances.2025017194","author":"Modi D, Aljawai YM, DeFor TE, Bupp C, Al Malki MM, Bolanos-Meade J, Gooptu M, Jimenez Jimenez AM, Liu H, Mensah FA, Mielcarek M, Shaffer BC, Shaw BE, Spellman SR, Stefanski HE, Auletta JJ, Devine SM, Khimani F, Abboud R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052403"},{"title01":"Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies.","title02":"Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies.","journal":"Blood advances","issue":"2026 January 13; 10(1):262-272. doi: 10.1182\/bloodadvances.2025017601","author":"Yokoyama H, Fukuhara N, Ando K, Iida H, Yamauchi T, Fukuhara S, Izutsu K, Tanoue Y, Yamamoto M, Tozaki H, Takahara E, Shoji S, Mizutani A, Morishita D, Oda R, Miyake H, Yamamoto N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056522"},{"title01":"More than CLK bait? Rogocekib for MDS and AML.","title02":"More than CLK bait? Rogocekib for MDS and AML.","journal":"Blood advances","issue":"2026 January 13; 10(1):260-261. doi: 10.1182\/bloodadvances.2025018552","author":"Chen EC, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41528737"},{"title01":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","title02":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2025018408. Online ahead of print","author":"Boertjes EL, Grob T, Al Hinai ASA, Beverloo BH, Versluis J, Kavelaars FG, Rijken M, Compagne KG, Erpelinck-Verschueren CAJ, Sanders MA, Stoetman ECG, Hanekamp D, Gradowska P, Ossenkoppele GJ, Biemond BJ, Manz MG, Pabst T, Jongen-Lavrencic M, Lowenberg B, Valk PJM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529224"},{"title01":"Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.","title02":"Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.","journal":"Blood","issue":"2026 January 8; 147(2):197-208. doi: 10.1182\/blood.2025028644","author":"Guarnera L, Wahida A, Gurnari C, Hutter S, Stainczyk SA, Williams ND, Durmaz A, Kubota Y, Bravo-Perez C, Kawashima N, Orland M, Pagliuca S, Huang Y, LaFramboise T, Visconte V, Walter W, Meggendorfer M, Kern W, Westermann F, Feuerbach L, Haferlach T, Maciejewski JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983034"},{"title01":"PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression.","title02":"PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression.","journal":"Blood","issue":"2026 January 15. doi: 10.1182\/blood.2025030760. Online ahead of print","author":"Vallelonga V, Gandolfi F, Zampini M, Riva E, Maggioni G, Ventura D, Saba E, Termanini A, Polletti S, Prosperini E, Crisafulli L, Campagna A, Ferrari I, Pinocchio N Jr, Todisco G, Pedretti S, Calvi M, Di Vito C, Mavilio D, Mitro N, Ficara F, Della Porta MG, Ghisletti SML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538708"},{"title01":"TGF-beta-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.","title02":"TGF-beta-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.","journal":"Leukemia","issue":"2026 January; 40(1):224-229. doi: 10.1038\/s41375-025-02798-x","author":"Lisle TL, Holmstrom MO, Penco MP, Ruders JH, Riley CH, Grauslund JH, Jensen EB, Sorensen AL, Skov V, Kjaer L, Hasselbalch H, Andersen MH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214139"},{"title01":"MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.","title02":"MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018682. Online ahead of print","author":"Ouellet M, Rizzolo A, Venne C, Moussa H, Bilodeau K, Mollica L, Chabot-Roy G, Huynh-Trudeau G, Lesage S, Harnois M, Busque L, Sirhan S, Szuber N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499761"},{"title01":"Impact of Statin Use on Cardiovascular and Hematologic Outcomes Among Patients with Myeloproliferative Neoplasms.","title02":"Impact of Statin Use on Cardiovascular and Hematologic Outcomes Among Patients with Myeloproliferative Neoplasms.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018724. Online ahead of print","author":"Leiva O, Soo S, Liu OC, You V, Palmer AS, Kahla JA, Murtaza Y, Odenike O, Patel AA, DeCara J, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499780"},{"title01":"Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity.","title02":"Ultraprecision Therapy for Type 1 vs Type 2 CALR+ MPN by Dual Epitope Targeting that Restores Ruxolitinib Sensitivity.","journal":"Blood","issue":"2026 January 2. doi: 10.1182\/blood.2024027897. Online ahead of print","author":"Thompson-Peach CA, Thomas D, Dottore M, Lim K, Stomski F, Panagopoulos R, Fosselteder J, Reinisch A, Chandrakanthan V, Jenkner S, Bland L, Paton S, Gronthos S, Hercus T, Wardill H, Kan WL, Kamel M, Moretti PA, Pitson SM, Burbury K, Ross DM, Nair P, Lopez AF, Tvorogov D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481383"},{"title01":"Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms.","title02":"Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms.","journal":"Blood","issue":"2026 January 9. doi: 10.1182\/blood.2025028645. Online ahead of print","author":"Constantinescu SN, Vainchenker W, Pecquet C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511882"},{"title01":"Elevated serum erythropoietin level in JAK2+ polycythemia vera with small vessel Budd-Chiari syndrome.","title02":"Elevated serum erythropoietin level in JAK2+ polycythemia vera with small vessel Budd-Chiari syndrome.","journal":"Blood","issue":"2026 January 15; 147(3):316. doi: 10.1182\/blood.2025031930","author":"Gummadi YK, Trottier AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538207"},{"title01":"Combining an immunomodulatory drug with a TPO-RA to treat multirefractory ITP patients: The Spanish ITP Group experience.","title02":"Combining an immunomodulatory drug with a TPO-RA to treat multirefractory ITP patients: The Spanish ITP Group experience.","journal":"Br J Haematol","issue":"2026 January 2. doi: 10.1111\/bjh.70306. Online ahead of print","author":"Mingot-Castellano ME, Alcalde-Mellado P, Entrena-Urena L, Pascual-Izquierdo C, Zafra-Torres D, Canaro Hirnyk M, Bastida JM, Bernat-Pablo S, Martinez-Carballeira D, Caparros-Miranda IS, Cuesta-Garcia A, Lakhwani S, Sanchez-Gonzalez B, Canet-Maldonado M, Gomez-Del-Castillo-Solano MD, Garcia-Culebras M, Chiclana-Rodriguez B, Fernandez-Villalobos M, Sanchez-Llorca P, Piquer-Monsonis D, Puerta-Vazquez C, Perez-Montes R, Garcia-Pallarols F, Poza-Santaella M, Pedrote-Amador B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41480972"},{"title01":"High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia to the British Journal of Haematology.","title02":"High pretreatment peripheral blood T-cell receptor clonality as a predictor of prolonged response in immune thrombocytopenia to the British Journal of Haematology.","journal":"Br J Haematol","issue":"2026 January 4. doi: 10.1111\/bjh.70310. Online ahead of print","author":"Schmidt-Barbo P, Schultheiss C, Jauch AJ, Simnica D, Silling G, Hanel M, Chromik J, Stauch T, Trautmann-Grill K, Repp R, Schulte C, Fleischmann B, Welslau M, Stauch M, Quiering C, Richter F, Tesanovic T, Jahn S, Holbro A, Passweg JR, Matzdorff A, Rummel M, Meyer O, Nimmerjahn F, Binder M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41486630"},{"title01":"Safety and efficacy of spleen tyrosine kinase (Syk) inhibitors in the treatment of adults with persistent and chronic immune thrombocytopenia (ITP): A systematic review and meta-analysis of randomised clinical trials.","title02":"Safety and efficacy of spleen tyrosine kinase (Syk) inhibitors in the treatment of adults with persistent and chronic immune thrombocytopenia (ITP): A systematic review and meta-analysis of randomised clinical trials.","journal":"Br J Haematol","issue":"2026 January 4. doi: 10.1111\/bjh.70316. Online ahead of print","author":"Mustafa MT, Abushanab AK, Mousa MT, Ismaeel R, Alshamasneh F, Khalaileh Y, Alkhalaileh RM, Zaina RFA, Sa'ed A, Mahfouz EA, Sitta ZAA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41486786"},{"title01":"Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia for the British Journal of Haematology.","title02":"Efficacy and safety of eltrombopag in combination with dexamethasone as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia for the British Journal of Haematology.","journal":"Br J Haematol","issue":"2026 January 6. doi: 10.1111\/bjh.70312. Online ahead of print","author":"Jauch AJ, Schmidt-Barbo P, Schultheiss C, Silling G, Hanel M, Chromik J, Stauch T, Trautmann-Grill K, Repp R, Schulte C, Fleischmann B, Welslau M, Stauch M, Quiering C, Richter F, Tesanovic T, Jahn S, Bignucolo O, Holbro A, Passweg JR, Matzdorff A, Rummel M, Meyer O, Nimmerjahn F, Binder M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41496604"},{"title01":"Safety and efficacy of daratumumab in immune thrombocytopenia.","title02":"Safety and efficacy of daratumumab in immune thrombocytopenia.","journal":"Blood advances","issue":"2026 January 13; 10(1):143-154. doi: 10.1182\/bloodadvances.2025017279","author":"Tsykunova G, Holme PA, Tran HTT, Frederiksen H, Tjonnfjord E, Munthe LA, Drivet E, Kared H, Sorvoll IH, Ahlen MT, Mahevas M, Michel M, Bussel J, Kuter DJ, Anderson Tvedt TH, Ghanima W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763272"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02848-4. Online ahead of print","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.","title02":"VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.","journal":"Lancet","issue":"2026 January 8. doi: 10.1016\/S0140-6736(25)02164-6. Online ahead of print","author":"Groarke EM, Turturice B, Patel BA, Quinn KA, Fike A, Grayson PC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41520673"},{"title01":"Performance of commonly used risk triage tools in predicting clinical deterioration among hospitalized hematopoietic stem cell transplant recipients.","title02":"Performance of commonly used risk triage tools in predicting clinical deterioration among hospitalized hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288892. Online ahead of print","author":"Park-Egan B, Hough CL, Lyons PG, Newell LF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537342"},{"title01":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","title02":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288371. Online ahead of print","author":"Sora' F, Bacigalupo A, Giammarco S, Metafuni E, Frioni F, Galli E, Limongiello MA, Sica S, Chiusolo P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537336"},{"title01":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","title02":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","journal":"Haematologica","issue":"2026 January 1; 111(1):122-134. doi: 10.3324\/haematol.2025.287456","author":"Balduzzi A, Glogova E, Peters C, Sedlacek P, Dalle JH, Locatelli F, Meisel R, Burkhardt B, Buechner J, Wachowiak J, Bierings M, Staciuk R, Graphakos S, Gungor T, Yesilipek A, Svec P, Palma J, Krivan G, Diaz-de-Heredia C, Limido F, Ansari M, Kalwak K, Bader P, Ifversen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820816"},{"title01":"The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.","title02":"The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.","journal":"Haematologica","issue":"2026 January 1; 111(1):286-299. doi: 10.3324\/haematol.2025.288041","author":"Mizuno S, Gras L, Baaij LGA, Koster L, D'Souza A, Hari PN, Estrada-Merly N, Saber W, Cowan AJ, Iida M, Okamoto S, Takamatsu H, Kawamura K, Kodera Y, Hamad N, Ko BS, Liam C, Ho KW, Goh AS, Keat TS, Elhaddad AM, Bazarbachi A, Chaudhry BQUN, Alfar R, Bekadja MA, Benakli M, Ortiz CAF, Riva E, Verburgh E, Galeano S, Bass F, Mian H, McCurdy A, Wang FR, Neumann D, Koh MBC, Snowden JA, Schonland S, McLornan DP, Hayden PJ, Balari AMS, Greinix HT, Aljurf M, Atsuta Y, Rondelli D, Niederwieser DW, Garderet L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820767"},{"title01":"Single-cell RNA sequencing reveals heterogeneity of mucosaassociated invariant T cells in donor grafts and its diagnostic relevance in gastrointestinal graft-versus-host disease.","title02":"Single-cell RNA sequencing reveals heterogeneity of mucosaassociated invariant T cells in donor grafts and its diagnostic relevance in gastrointestinal graft-versus-host disease.","journal":"Haematologica","issue":"2026 January 1; 111(1):230-244. doi: 10.3324\/haematol.2024.287114","author":"Gao M, Zhang K, Li S, Guo H, Sun Y, Kong J, Han T, Chang Y, Huang X, Zhao X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820727"},{"title01":"Aging-declined RNA exportation impairs hematopoietic stem cells by inducing R-loop.","title02":"Aging-declined RNA exportation impairs hematopoietic stem cells by inducing R-loop.","journal":"Haematologica","issue":"2026 January 1; 111(1):245-258. doi: 10.3324\/haematol.2025.287765","author":"Chen R, Dong Q, Zhou L, He H, Du Y, Sun Q, Suda T, Cheng T, Wang J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605703"},{"title01":"Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care.","title02":"Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care.","journal":"Blood advances","issue":"2026 January 13; 10(1):111-120. doi: 10.1182\/bloodadvances.2025017540","author":"Matsui H, Arai Y, Kanda J, Kondo T, Schoettler ML, Mohty M, Perales MA, Duarte RF, Rambaldi A, Takaori-Kondo A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071950"},{"title01":"MicroRNA-223-3p is a determinant of platelet procoagulant activity.","title02":"MicroRNA-223-3p is a determinant of platelet procoagulant activity.","journal":"Blood advances","issue":"2026 January 13; 10(1):83-94. doi: 10.1182\/bloodadvances.2024015290","author":"Charlon-Gay J, Nolli S, Dunoyer-Geindre S, Ciepla P, Reny JL, Fontana P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056510"},{"title01":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","title02":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","journal":"Blood advances","issue":"2026 January 13; 10(1):233-245. doi: 10.1182\/bloodadvances.2025017194","author":"Modi D, Aljawai YM, DeFor TE, Bupp C, Al Malki MM, Bolanos-Meade J, Gooptu M, Jimenez Jimenez AM, Liu H, Mensah FA, Mielcarek M, Shaffer BC, Shaw BE, Spellman SR, Stefanski HE, Auletta JJ, Devine SM, Khimani F, Abboud R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052403"},{"title01":"Risk biomarkers of chronic GVHD in children aged 10 years or younger and children\/adults older than 10 years.","title02":"Risk biomarkers of chronic GVHD in children aged 10 years or younger and children\/adults older than 10 years.","journal":"Blood advances","issue":"2026 January 13; 10(1):168-180. doi: 10.1182\/bloodadvances.2025016624","author":"Ferreira AC, Dutta D, Rowan CM, Renbarger J, Cooke KR, Carpenter PA, Krance R, Duncan C, Cruz CRY, Jacobsohn D, Bollard CM, Hill E, Paczesny S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966416"},{"title01":"Induction of moderate DNA damage enhances megakaryopoiesis and platelet production.","title02":"Induction of moderate DNA damage enhances megakaryopoiesis and platelet production.","journal":"Blood advances","issue":"2026 January 13; 10(1):155-167. doi: 10.1182\/bloodadvances.2025017375","author":"Camacho V, Bekendam RH, Stone AP, Barrachina MN, Branfield S, Carminita E, Becker IC, Lee DH, Walsey E, Payne C, Kaplan J, Tilburg J, Pal S, Batista LFZ, Italiano JE Jr, Machlus KR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40938731"},{"title01":"BK virus kinetics and associated cystitis\/urethritis symptoms after PTCy-based allogeneic hematopoietic cell transplant.","title02":"BK virus kinetics and associated cystitis\/urethritis symptoms after PTCy-based allogeneic hematopoietic cell transplant.","journal":"Blood advances","issue":"2026 January 13; 10(1):1-13. doi: 10.1182\/bloodadvances.2025016589","author":"Dimitrova D, Xue E, Hyder MA, Choo-Wosoba H, Rechache K, Flomerfelt FA, Das S, McKeown C, Cusmano A, Sabina R, Kanakry JA, Kanakry CG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864202"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018626. Online ahead of print","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Toubai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","title02":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025032277. Online ahead of print","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","title02":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","journal":"Blood","issue":"2026 January 9. doi: 10.1182\/blood.2025031080. Online ahead of print","author":"Gawron J, Czech M, Ruckert T, Holzmuller V, Andreev G, Burk AC, Hartmann A, Chatterjee S, Andrieux G, Marquard FE, Baur AS, Stell AV, Krausz M, Braun LM, Osswald N, Melchinger W, Wertheimer T, Proano-Vasco AI, Maas-Bauer K, Schmitt-Graeff A, Boerries M, Kohler N, Ayuk FA, Schell C, Quante M, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511880"},{"title01":"Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment.","title02":"Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment.","journal":"Blood","issue":"2026 January 2. doi: 10.1182\/blood.2025028762. Online ahead of print","author":"Verkamp B, Jordan MB, Allen CE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481377"},{"title01":"Compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/- mediated clonal hematopoiesis.","title02":"Compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/- mediated clonal hematopoiesis.","journal":"Blood","issue":"2026 January 12. doi: 10.1182\/blood.2024028031. Online ahead of print","author":"Lee K, Hong CL, Dissanayake W, Kulzhanova G, Pfeffer AN, Li H, Sivakumar S, Yin Z, Quarato ER, Benoodt L, Bajaj J, Cao C, Wu CL, Calvi LM, Yeh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41525451"},{"title01":"Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine.","title02":"Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine.","journal":"Blood","issue":"2026 January 2. doi: 10.1182\/blood.2024028063. Online ahead of print","author":"Castiglioni C, Piussi R, Ditadi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481376"},{"title01":"Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation.","title02":"Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation.","journal":"Blood","issue":"2026 January 15; 147(3):241-253. doi: 10.1182\/blood.2025028625","author":"Ng B, Harris AC, Abdossamadi S, Aubert G, Bajwa R, Bhatia M, Bittencourt H, Buxbaum NP, Caywood EH, Chaudhury S, Chewning JH, Choi SW, Chopek A, Chu J, Coulter D, Gadalla SM, Hogg RT, Jacobsohn DA, Johnson AK, Joyce M, Kasow KA, Kent M, Kitko CL, Lau D, Lawitschka A, Lewis VA, Li AM, McLaughlin L, Mitchell D, Nemecek ER, Parthasarathy V, Pawlowska AB, Pirsl F, Pulsipher MA, Qayed M, Rozmus J, Savasan S, Schechter T, Shenoy S, Suleimenova A, Zheng DJ, Ostroumov E, Gilman A, Klein Geltink RI, Wolff D, Cuvelier GDE, Schultz KR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060324"},{"title01":"A Notch trans-activation to cis-inhibition switch underlies hematopoietic stem cell aging.","title02":"A Notch trans-activation to cis-inhibition switch underlies hematopoietic stem cell aging.","journal":"Blood","issue":"2026 January 8; 147(2):164-179. doi: 10.1182\/blood.2024026505","author":"Matteini F, Thambyrajah R, Montserrat-Vazquez S, Jung S, Ferrer-Perez A, Herrero Molinero P, El Jaramany D, Lozano-Bartolome J, Mejia-Ramirez E, Gonzalez J, Del Sol A, Bigas A, Florian MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056036"},{"title01":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study.","title02":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study.","journal":"Blood","issue":"2026 January 8; 147(2):138-163. doi: 10.1182\/blood.2025029640","author":"Herrmann US, Felber M, Worth A, Haskologlu S, Dogu F, Lewis VA, Strahm B, Groll A, Gennery AR, Hauck F, Wynn R, Coussons M, Meyts I, Lindemans C, Bordon V, Bredius RGM, Kuhl JS, Voller M, Zirngibl F, Zaidman I, Laberko A, Zeilhofer U, Hauri-Hohl M, Lankester A, Ikinciogullari A, Guilcher GMT, Hackenberg A, Yesilipek A, Davies G, Rao K, Hershfield MS, Parikh SH, Gilbert P, Bettoni da Cunha Riehm C, Albert MH, Schulz AS, Honig M, Neven B, Gungor T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983033"},{"title01":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.","title02":"CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.","journal":"N Engl J Med","issue":"2026 January 15; 394(3):253-267. doi: 10.1056\/NEJMoa2509820","author":"Li R, Pan H, Zhang L, Ma J, Li W, Gao Z, Fang L, Tian L, Shen Y, Yang F, Zhao J, Nie N, Li J, Wang W, Pan X, Lian Y, Li X, Peng G, Li L, Yu X, Xu C, Liu Y, Kuang Z, Huang J, Zhao X, Ge M, Liu L, Chen S, Feng Y, Chang AH, Deng B, Dai M, Huang L, Lv L, Zheng Y, Luo Y, Xiong H, Shi J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41534043"},{"title01":"Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.","title02":"Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial.","journal":"Lancet Oncol","issue":"2026 January; 27(1):103-115. doi: 10.1016\/S1470-2045(25)00401-2","author":"Hsu CH, Lu Z, Gao S, Wang J, Sun JM, Liu T, Fan Q, Cai J, Ge F, Li S, Zhang L, Cha E, Allen S, Shen L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41449142"},{"title01":"Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.","title02":"Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e41-e48. doi: 10.1016\/S2352-3026(25)00291-1","author":"Mahe I, Chapelle C, Girard P, Carrier M, Palomares LJ, Samama CM, Helfer H, Gerotziafas G, Laporte S, Vicaut E, Mismetti P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41365312"},{"title01":"Management of transfusion-dependent beta-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources.","title02":"Management of transfusion-dependent beta-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e49-e54. doi: 10.1016\/S2352-3026(25)00320-5","author":"Musallam KM, Sheth S, Cappellini MD, Shah F, Rivella S, Sankaran VG, Kuo KHM, Viprakasit V, Eleftheriou A, Angastiniotis M, Locatelli F, Taher AT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41482447"},{"title01":"Uterine atony and anaemia in postpartum haemorrhage.","title02":"Uterine atony and anaemia in postpartum haemorrhage.","journal":"Lancet","issue":"2026 January 3; 407(10523):29. doi: 10.1016\/S0140-6736(25)02050-1","author":"Roberts I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41483908"},{"title01":"Uterine atony and anaemia in postpartum haemorrhage.","title02":"Uterine atony and anaemia in postpartum haemorrhage.","journal":"Lancet","issue":"2026 January 3; 407(10523):28-29. doi: 10.1016\/S0140-6736(25)02051-3","author":"Mansukhani R, Chaudhri R, Bello FA, Muganyizi P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41483905"},{"title01":"Uterine atony and anaemia in postpartum haemorrhage &#8211; Authors&#8217; reply.","title02":"Uterine atony and anaemia in postpartum haemorrhage &#8211; Authors&#8217; reply.","journal":"Lancet","issue":"2026 January 3; 407(10523):29-30. doi: 10.1016\/S0140-6736(25)02262-7","author":"Yunas I, Devall A, Coomarasamy A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41483907"},{"title01":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","title02":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","journal":"Br J Haematol","issue":"2026 January 4. doi: 10.1111\/bjh.70307. Online ahead of print","author":"Nakamura F, Ishiyama K, Suzuki R, Maruyama H, Onishi Y, Usuki K, Koh H, Takenaka K, Saiki R, Ogawa S, Matsumoto K, Takahashi T, Hosomichi K, Zaimoku Y, Yoshimura K, Matsumura I, Akashi K, Nakao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41485764"},{"title01":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","title02":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","journal":"Br J Haematol","issue":"2026 January 12. doi: 10.1111\/bjh.70328. Online ahead of print","author":"Meena SK, Kancharla A, Mohamed AI, James B, Ewins AM, Chaudhury S, Roberts W, Furtado Silva JM, Chiesa R, Amrolia PJ, Height S, Hadzic N, Rao K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41527175"},{"title01":"Warm autoimmune haemolytic anaemia: Clinical considerations.","title02":"Warm autoimmune haemolytic anaemia: Clinical considerations.","journal":"Br J Haematol","issue":"2026 January 13. doi: 10.1111\/bjh.70331. Online ahead of print","author":"Murakhovskaya I, Yazdanbakhsh K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41531134"},{"title01":"Short- and long-term effects of transfusion in beta-thalassemia: a longitudinal study of transfusion efficiency factors.","title02":"Short- and long-term effects of transfusion in beta-thalassemia: a longitudinal study of transfusion efficiency factors.","journal":"Blood advances","issue":"2026 January 13; 10(1):192-207. doi: 10.1182\/bloodadvances.2025017090","author":"Theocharaki K, Barla I, Delicou S, Anastasiadi AT, Tzounakas VL, Rouvela S, Tzafa G, Stylianaki EA, Koufogeorgou EI, Gousdovas T, Pavlou E, Kostopoulos IV, Simantiris N, Vassilaki N, Moraki M, Stamoulis K, Voskaridou E, Nomikou E, Tsitsilonis O, Thomaidis N, Gikas E, Politou M, Komninaka V, Antonelou MH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41115240"},{"title01":"Effect of obexelimab on the production of anti-RBC antibodies and cytokines in patients with warm autoimmune hemolytic anemia.","title02":"Effect of obexelimab on the production of anti-RBC antibodies and cytokines in patients with warm autoimmune hemolytic anemia.","journal":"Blood advances","issue":"2026 January 13; 10(1):124-131. doi: 10.1182\/bloodadvances.2025017722","author":"Fattizzo B, Zaninoni A, Pedone GL, Bortolotti M, Passamonti F, Barcellini W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061187"},{"title01":"Cost-Effectiveness of First-Line IV Versus Oral Iron for Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding.","title02":"Cost-Effectiveness of First-Line IV Versus Oral Iron for Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding.","journal":"Blood advances","issue":"2026 January 8. doi: 10.1182\/bloodadvances.2025018315. Online ahead of print","author":"Wang D, Sra MS, Ito S, Ng DQ, Glaeser-Khan S, Wang DY, Hirniak S, Lee AI, Cuker A, Goshua G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504430"},{"title01":"Pomalidomide for Hereditary Hemorrhagic Telangiectasia: After Trial Longitudinal Assessment Study (PATH-HHT ATLAS).","title02":"Pomalidomide for Hereditary Hemorrhagic Telangiectasia: After Trial Longitudinal Assessment Study (PATH-HHT ATLAS).","journal":"Blood advances","issue":"2026 January 9. doi: 10.1182\/bloodadvances.2025018382. Online ahead of print","author":"Zhang E, Kasthuri RS, Parambil J, Prasad V, Iyer V, Whitehead K, Hodges PG, Pishko A, Conrad M, Phelan D, Rodriguez-Lopez J, McCrae KR, Al-Samkari H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512167"},{"title01":"Ferroportin Inhibition Attenuates Pulmonary Hypertension in Hypoxic Sickle Cell Disease Mice.","title02":"Ferroportin Inhibition Attenuates Pulmonary Hypertension in Hypoxic Sickle Cell Disease Mice.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018680. Online ahead of print","author":"Lucero MJ, Setua S, Thangaraju K, Khan A, Lamb DR, Lisk C, Swindle D, Cendali FI, Dzieciatkowska M, Stephenson D, Pak DI, Tolson R, Zaeske S, Rana NK, Khan S, Westover N, Davizon-Castillio P, George G, Hassell KL, Nuss R, D'Alessandro A, Manolova V, Irwin DC, Buehler PW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538305"},{"title01":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.","title02":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.","journal":"Leukemia","issue":"2026 January; 40(1):63-71. doi: 10.1038\/s41375-025-02781-6","author":"Bill M, Eckardt JN, Dohner K, Rohnert MA, Rausch C, Metzeler KH, Spiekermann K, Stasik S, Wurm AA, Sauer T, Scholl S, Schnetzke U, Hochhaus A, Crysandt M, Brummendorf TH, Krug U, Wormann B, Einsele H, Hiddemann W, Gorlich D, Sauerland C, Steffen B, Neubauer A, Burchert A, Schafer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hanel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Schetelig J, Middeke JM, Bullinger L, Heuser M, Thol F, Serve H, Baldus CD, Platzbecker U, Muller-Tidow C, Valka J, Sramek J, Weinbergerova B, Mayer J, Dumas PY, Bertoli S, Delabesse E, Recher C, Pigneux A, Herold T, Ganser A, Dohner H, Bornhauser M, Thiede C, Rollig C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145671"},{"title01":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","title02":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","journal":"Leukemia","issue":"2026 January; 40(1):178-187. doi: 10.1038\/s41375-025-02814-0","author":"Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho G, Gondek L, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Versino F, Montoro MJ, Torres-Esquius S, Jerez Cayuela A, Lopez-Esteban M, Martinez-Laperche C, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski JP, Ogawa S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41339477"},{"title01":"Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.","title02":"Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.","journal":"Leukemia","issue":"2026 January 12. doi: 10.1038\/s41375-025-02831-z. Online ahead of print","author":"Santini V, Zeidan AM, Van Eygen K, Fenaux P, Germing U, Madanat YF, Raza A, Savona MR, Sekeres MA, Thepot S, Raddi MG, Boyer T, Sun L, Wan Y, Berry T, Xia Q, Huang F, Dougherty S, Navada S, Feller F, Komrokji RS, Platzbecker U","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526614"},{"title01":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21.","title02":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21.","journal":"Haematologica","issue":"2026 January 1; 111(1):329-334. doi: 10.3324\/haematol.2024.286719","author":"Sakaguchi H, Sakaguchi K, Kato I, Noma H, Hiramatsu H, Ishida H, Yabe H, Goto H, Kawahara Y, Yamashita YI, Sanada M, Deguchi T, Takahashi Y, Saito AM, Takagi M, Okuno K, Taga T, Horibe K, Okamoto Y, Koh K, Manabe A, Umeda K, Of Japanese Children's Cancer Group TTACTC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637726"},{"title01":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","title02":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","journal":"Blood advances","issue":"2026 January 13; 10(1):233-245. doi: 10.1182\/bloodadvances.2025017194","author":"Modi D, Aljawai YM, DeFor TE, Bupp C, Al Malki MM, Bolanos-Meade J, Gooptu M, Jimenez Jimenez AM, Liu H, Mensah FA, Mielcarek M, Shaffer BC, Shaw BE, Spellman SR, Stefanski HE, Auletta JJ, Devine SM, Khimani F, Abboud R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052403"},{"title01":"Risk biomarkers of chronic GVHD in children aged 10 years or younger and children\/adults older than 10 years.","title02":"Risk biomarkers of chronic GVHD in children aged 10 years or younger and children\/adults older than 10 years.","journal":"Blood advances","issue":"2026 January 13; 10(1):168-180. doi: 10.1182\/bloodadvances.2025016624","author":"Ferreira AC, Dutta D, Rowan CM, Renbarger J, Cooke KR, Carpenter PA, Krance R, Duncan C, Cruz CRY, Jacobsohn D, Bollard CM, Hill E, Paczesny S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966416"},{"title01":"Hematopoietic transplantation for PNP deficiency: it&#8217;s time.","title02":"Hematopoietic transplantation for PNP deficiency: it&#8217;s time.","journal":"Blood","issue":"2026 January 8; 147(2):97-98. doi: 10.1182\/blood.2025031143","author":"Grunebaum E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41505148"},{"title01":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","title02":"Gastrin for the treatment of acute graft-versus-host disease of the stomach.","journal":"Blood","issue":"2026 January 9. doi: 10.1182\/blood.2025031080. Online ahead of print","author":"Gawron J, Czech M, Ruckert T, Holzmuller V, Andreev G, Burk AC, Hartmann A, Chatterjee S, Andrieux G, Marquard FE, Baur AS, Stell AV, Krausz M, Braun LM, Osswald N, Melchinger W, Wertheimer T, Proano-Vasco AI, Maas-Bauer K, Schmitt-Graeff A, Boerries M, Kohler N, Ayuk FA, Schell C, Quante M, Zeiser R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511880"},{"title01":"Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms.","title02":"Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms.","journal":"Blood","issue":"2026 January 9. doi: 10.1182\/blood.2025028645. Online ahead of print","author":"Constantinescu SN, Vainchenker W, Pecquet C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41511882"},{"title01":"Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.","title02":"Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025031455. Online ahead of print","author":"Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin IA, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu SS, Wagner-Johnston ND, Ollila TA, Grover NS, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov AV, Tun HW, Munoz J, Narkhede MS, Rhodes JM, Prica A, Kuhnl A, Maraj AM, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Firas FB, Monick S, Trutzer IM, Can J, Ayers AA, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490516"},{"title01":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","title02":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","journal":"Blood","issue":"2026 January 15; 147(3):312-315. doi: 10.1182\/blood.2025031426","author":"Banerjee R, Khouderchah C, Akhtar OS, Liang EC, Gauthier J, Dhodapkar MV, Portuguese AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41284631"},{"title01":"Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation.","title02":"Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation.","journal":"Blood","issue":"2026 January 15; 147(3):241-253. doi: 10.1182\/blood.2025028625","author":"Ng B, Harris AC, Abdossamadi S, Aubert G, Bajwa R, Bhatia M, Bittencourt H, Buxbaum NP, Caywood EH, Chaudhury S, Chewning JH, Choi SW, Chopek A, Chu J, Coulter D, Gadalla SM, Hogg RT, Jacobsohn DA, Johnson AK, Joyce M, Kasow KA, Kent M, Kitko CL, Lau D, Lawitschka A, Lewis VA, Li AM, McLaughlin L, Mitchell D, Nemecek ER, Parthasarathy V, Pawlowska AB, Pirsl F, Pulsipher MA, Qayed M, Rozmus J, Savasan S, Schechter T, Shenoy S, Suleimenova A, Zheng DJ, Ostroumov E, Gilman A, Klein Geltink RI, Wolff D, Cuvelier GDE, Schultz KR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060324"},{"title01":"Mechanisms of immune escape and extramedullary tropism in leukemia cutis.","title02":"Mechanisms of immune escape and extramedullary tropism in leukemia cutis.","journal":"Blood","issue":"2026 January 1; 147(1):35-47. doi: 10.1182\/blood.2025029121","author":"Penter L, Maurer K, Cieri N, Lu WS, Lyu H, Selig M, Joosten M, Ihlow J, Li S, Livak KJ, Bullinger L, Ritz J, Bachireddy P, Davids MS, Garcia JS, Soiffer RJ, Wu CJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026928"},{"title01":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study.","title02":"Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study.","journal":"Blood","issue":"2026 January 8; 147(2):138-163. doi: 10.1182\/blood.2025029640","author":"Herrmann US, Felber M, Worth A, Haskologlu S, Dogu F, Lewis VA, Strahm B, Groll A, Gennery AR, Hauck F, Wynn R, Coussons M, Meyts I, Lindemans C, Bordon V, Bredius RGM, Kuhl JS, Voller M, Zirngibl F, Zaidman I, Laberko A, Zeilhofer U, Hauri-Hohl M, Lankester A, Ikinciogullari A, Guilcher GMT, Hackenberg A, Yesilipek A, Davies G, Rao K, Hershfield MS, Parikh SH, Gilbert P, Bettoni da Cunha Riehm C, Albert MH, Schulz AS, Honig M, Neven B, Gungor T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983033"},{"title01":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.","title02":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.","journal":"Blood","issue":"2026 January 8; 147(2):180-196. doi: 10.1182\/blood.2025029302","author":"Ren H, Elliott N, Lye B, Sharif Shohan MU, Cross JW, Field L, Ponnusamy K, Rice S, Jackson T, Leontari I, El Ouazzani N, Thomas R, Inglott S, Bartram J, Smith O, Bond J, Roberts IAG, Halsey C, Bashford-Rogers R, Milne TA, Roy A, Karadimitris A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40898981"},{"title01":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","title02":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025032277. Online ahead of print","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2026 January 8; 394(2):152-165. doi: 10.1056\/NEJMoa2505478","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia &#8211; a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia &#8211; a HARMONY study.","journal":"Leukemia","issue":"2026 January 14. doi: 10.1038\/s41375-025-02851-9. Online ahead of print","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis.","title02":"Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis.","journal":"Leukemia","issue":"2026 January 12. doi: 10.1038\/s41375-025-02857-3. Online ahead of print","author":"Mehta RS, Aljawai YM, Kebriaei P, Rondon G, Fingrut W, Smallbone P, Oran B, Olson A, Champlin RE, Shpall EJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526616"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02854-6. Online ahead of print","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells.","title02":"CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells.","journal":"Leukemia","issue":"2026 January 12. doi: 10.1038\/s41375-025-02850-w. Online ahead of print","author":"Zhou J, Hu T, Li D, Li S, Li M, Shi X, Nakada D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526615"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","journal":"Haematologica","issue":"2026 January 1; 111(1):168-176. doi: 10.3324\/haematol.2024.287205","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kroger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP, Anemia Working Party ESA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.","title02":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.","journal":"Haematologica","issue":"2026 January 1; 111(1):177-183. doi: 10.3324\/haematol.2025.287457","author":"Maahs L, Avila AM, Koshy M, Sweiss K, Ahn KH, Chen Z, Uzoka C, Galvez C, Sanchez M, Rubinstein P, Quigley J, Zucchetti E, Mahmud N, Aydogan B, Patel P, Rondelli D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534485"},{"title01":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","title02":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","journal":"Br J Haematol","issue":"2026 January 14. doi: 10.1111\/bjh.70327. Online ahead of print","author":"Jiang X, Xu Z, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41536163"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","journal":"Br J Haematol","issue":"2026 January 7. doi: 10.1111\/bjh.70324. Online ahead of print","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","title02":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","journal":"Br J Haematol","issue":"2026 January 12. doi: 10.1111\/bjh.70328. Online ahead of print","author":"Meena SK, Kancharla A, Mohamed AI, James B, Ewins AM, Chaudhury S, Roberts W, Furtado Silva JM, Chiesa R, Amrolia PJ, Height S, Hadzic N, Rao K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41527175"},{"title01":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","title02":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 January 8. doi: 10.1111\/bjh.70318. Online ahead of print","author":"Madkhali MM, Mitchell A, Wright C, Pearce K, Aku S, Pagan S, Duncan L, Lam J, Macdonald J, Milne P, Publicover A, Hurst E, Bigley V, Hale G, Collin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41508744"},{"title01":"Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 Criteria.","title02":"Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 Criteria.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018032. Online ahead of print","author":"Shimony S, Wang Y, Cronin AM, Walsh TP, Charles A, Slopen N, Cho HL, Stahl MF, Bystrom RP, Luskin MR, Abel GA, DeAngelo DJ, Stone RM, Lindsley RC, Hantel A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538295"},{"title01":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","title02":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025017621. Online ahead of print","author":"Tan JLC, Khong T, Kim YJ, Reynolds J, Barmanray RD, Gardiner BJ, Morrissey CO, Mithraprabhu S, Spencer A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538294"},{"title01":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","title02":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2025018152. Online ahead of print","author":"Pena M, Losi G, Navarro V, Qualls DA, Crombie JL, Mariotti J, Bramanti S, Fabbri N, Serna A, Serroukh YI, Balaguer-Rosello A, van der Poel MW, Hsu YT, Jimenez-Ubieto A, McKinnely C, Lopez-Corral L, Panizo C, Perez-Simon JA, Rovira M, Saldana R, Kwon M, Solano C, Valcarcel D, Pascual-Cascon MJ, Noriega V, Sanz J, Sanchez-Salinas A, Jurado M, Calbacho M, Bento L, Albo Lopez C, Perera M, Heras I, Guerreiro M, Balsalobre P, Armand P, Sureda A, Mussetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529227"},{"title01":"Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.","title02":"Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018031. Online ahead of print","author":"Badar T, Marando L, Latorre-Crespo E, Lasho TL, Oliva FD, Lin C, McCormick BJ, El Kettani M, Shah K, Kusne YN, Jamy O, Diebold K, Coltoff A, Finke CM, Foran JM, Kharfan-Dabaja MA, Fan YS, Jiang L, He R, Thomas M, Patel AA, Viswanatha DS, Shah MV, Saliba AN, Mangaonkar AA, Kirschner K, Al-Kali A, Gangat N, Litzow MR, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499760"},{"title01":"FOXM1 down-regulation is a trigger of isatuximab-induced direct cell death in multiple myeloma cells with 1q.","title02":"FOXM1 down-regulation is a trigger of isatuximab-induced direct cell death in multiple myeloma cells with 1q.","journal":"Haematologica","issue":"2026 January 1; 111(1):385-391. doi: 10.3324\/haematol.2025.287904","author":"Kikuchi J, Osada N, Matsuoka S, Ohta T, Kazama H, Shirai H, Meloni M, Chiron M, Yasui H, Nakasone H, Furukawa Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820736"},{"title01":"Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review.","title02":"Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review.","journal":"Br J Haematol","issue":"2026 January 2. doi: 10.1111\/bjh.70323. Online ahead of print","author":"Neupane K, Singstock M, Shah D, Dahal R, Mian H, Smith F, Chakraborty R, Al Hadidi S, Mainou M, Grajales-Cruz A, Naqvi SMH, Shain KH, Goodman A, Costa LJ, Qazilbash M, Mohyuddin GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41482478"},{"title01":"Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.","title02":"Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.","journal":"Blood advances","issue":"2026 January 13; 10(1):95-105. doi: 10.1182\/bloodadvances.2025017721","author":"Sudha P, Pham P, Niu W, Liu E, Wang L, Truong G, Ligocki C, Al-Azzawi R, Surapenini M, Bray SM, Vetrini F, Czader M, Tayeh MK, Lee K, Abonour R, Suvannasankha A, Walker BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092482"},{"title01":"A Nested Case-Control Study of Monoclonal Gammopathy of Undetermined Significance in the Multiethnic Cohort Study.","title02":"A Nested Case-Control Study of Monoclonal Gammopathy of Undetermined Significance in the Multiethnic Cohort Study.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2024015266. Online ahead of print","author":"Salehi M, Wilkens LR, Wan JY, Cortessis VK, Stram D, Conti DV, Aparicio J, Lam E, Bernstein MP, Desai P, Bertrand KA, Rosenberg AS, Lee L, Le Marchand L, Haiman CA, Emerson J, Cozen W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529215"},{"title01":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","title02":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","journal":"Blood","issue":"2026 January 15; 147(3):312-315. doi: 10.1182\/blood.2025031426","author":"Banerjee R, Khouderchah C, Akhtar OS, Liang EC, Gauthier J, Dhodapkar MV, Portuguese AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41284631"},{"title01":"High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.","title02":"High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.","journal":"Blood","issue":"2026 January 15; 147(3):266-275. doi: 10.1182\/blood.2025029999","author":"Schavgoulidze A, Perrot A, Leleu X, Cazaubiel T, Chretien ML, Feugier P, Belhadj K, Manier S, Roussel M, Brechignac S, Orsini-Piocelle F, Mohty M, Schiano de Collela JM, Macro M, Adiko D, Dib M, Fontan J, Luttiau-Motard C, Bouscary D, Pascal L, Roland V, Lifermann F, Bakala J, Montes L, Kennel C, Rey P, Richez V, Keddar F, Frenzel L, Calmettes C, Chaleteix C, Plantier I, Chalayer E, Schmitt A, Roul C, Demarquette H, Cerutti C, Pavageau L, Derrier L, Avet-Loiseau H, Corre J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991836"},{"title01":"Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma.","title02":"Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma.","journal":"Blood","issue":"2026 January 1; 147(1):48-60. doi: 10.1182\/blood.2025029950","author":"Yan Z, Han Z, Wang Y, Beus M, Zhang Y, Picado A, Wells CI, Wu J, Weidenhammer LB, Pires KM, Leibold EA, Liu L, Gooden DM, Spasojevic I, Soderblom EJ, Kang Y, Boise LH, Willson TM, Nikiforov MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40953235"},{"title01":"Targeting STK17B: unlocking ferroptosis in myeloma.","title02":"Targeting STK17B: unlocking ferroptosis in myeloma.","journal":"Blood","issue":"2026 January 1; 147(1):6-7. doi: 10.1182\/blood.2025031316","author":"Liu B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41477748"},{"title01":"Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).","title02":"Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).","journal":"Blood","issue":"2026 January 2. doi: 10.1182\/blood.2025029996. Online ahead of print","author":"Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S, Tang H, Owens RW, Sevcikova T, Fonseca R, Durante MA, Diamond BT, Zhao L, Zhu YX, Shi CX, Matulis SM, Mitsiades CS, Landgren CO, Usmani SZ, Hajek R, Chesi M, Bergsagel PL, Braggio E, Boise LH, Fonseca R, Kumar SK, Maura F, Baughn LB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41481388"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02854-6. Online ahead of print","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"Performance of commonly used risk triage tools in predicting clinical deterioration among hospitalized hematopoietic stem cell transplant recipients.","title02":"Performance of commonly used risk triage tools in predicting clinical deterioration among hospitalized hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288892. Online ahead of print","author":"Park-Egan B, Hough CL, Lyons PG, Newell LF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537342"},{"title01":"Hepatic response criteria in light chain amyloidosis: a multicenter validation study.","title02":"Hepatic response criteria in light chain amyloidosis: a multicenter validation study.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.289218. Online ahead of print","author":"Muchtar E, Palladini G, Schonland S, Geyer S, Dooley KE, Dispenzieri A, Wisniowski B, Merlini G, Milani P, Hegenbart U, Dittrich T, Kastritis E, Dimopoulos MA, Sanchorawala V, Szalat R, Liedtke M, Gupta M, Landau H, Lentzsch S, Hughes MS, Cibeira MT, Blade J, Kumar SK, Wechalekar A, Gertz MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537335"},{"title01":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","title02":"Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288371. Online ahead of print","author":"Sora' F, Bacigalupo A, Giammarco S, Metafuni E, Frioni F, Galli E, Limongiello MA, Sica S, Chiusolo P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537336"},{"title01":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.","title02":"Intensified conditioning with high-dose total marrow irradiation and myeloablative chemotherapy reduces risk of relapse without increasing toxicity in allogeneic hematopoietic stem cell transplant for high-risk myeloid malignancies: a phase II study.","journal":"Haematologica","issue":"2026 January 1; 111(1):177-183. doi: 10.3324\/haematol.2025.287457","author":"Maahs L, Avila AM, Koshy M, Sweiss K, Ahn KH, Chen Z, Uzoka C, Galvez C, Sanchez M, Rubinstein P, Quigley J, Zucchetti E, Mahmud N, Aydogan B, Patel P, Rondelli D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534485"},{"title01":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","title02":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","journal":"Haematologica","issue":"2026 January 1; 111(1):122-134. doi: 10.3324\/haematol.2025.287456","author":"Balduzzi A, Glogova E, Peters C, Sedlacek P, Dalle JH, Locatelli F, Meisel R, Burkhardt B, Buechner J, Wachowiak J, Bierings M, Staciuk R, Graphakos S, Gungor T, Yesilipek A, Svec P, Palma J, Krivan G, Diaz-de-Heredia C, Limido F, Ansari M, Kalwak K, Bader P, Ifversen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820816"},{"title01":"Single-cell RNA sequencing reveals heterogeneity of mucosaassociated invariant T cells in donor grafts and its diagnostic relevance in gastrointestinal graft-versus-host disease.","title02":"Single-cell RNA sequencing reveals heterogeneity of mucosaassociated invariant T cells in donor grafts and its diagnostic relevance in gastrointestinal graft-versus-host disease.","journal":"Haematologica","issue":"2026 January 1; 111(1):230-244. doi: 10.3324\/haematol.2024.287114","author":"Gao M, Zhang K, Li S, Guo H, Sun Y, Kong J, Han T, Chang Y, Huang X, Zhao X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820727"},{"title01":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","title02":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","journal":"Haematologica","issue":"2026 January 1; 111(1):149-157. doi: 10.3324\/haematol.2025.287628","author":"Oran B, Thall P, Alousi A, Al-Atrash G, Mehta R, Marin D, Kebriaei P, Popat U, Bassett R, Bashir Q, Im J, Olson A, Jewell J, Smallbone P, Shpall E, Champlin R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702903"},{"title01":"The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia.","title02":"The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):135-148. doi: 10.3324\/haematol.2024.286228","author":"Zhao HG, Cruz-Rodriguez N, Johnson KC, Pomicter AD, Bates B, Bateman B, Haferlach T, Gu T, Ahmann J, Yan D, Lee GS, Zhu W, Bishop J, Odelberg SJ, Deininger MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637748"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","journal":"Haematologica","issue":"2026 January 1; 111(1):168-176. doi: 10.3324\/haematol.2024.287205","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kroger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP, Anemia Working Party ESA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review.","title02":"Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review.","journal":"Br J Haematol","issue":"2026 January 2. doi: 10.1111\/bjh.70323. Online ahead of print","author":"Neupane K, Singstock M, Shah D, Dahal R, Mian H, Smith F, Chakraborty R, Al Hadidi S, Mainou M, Grajales-Cruz A, Naqvi SMH, Shain KH, Goodman A, Costa LJ, Qazilbash M, Mohyuddin GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41482478"},{"title01":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","title02":"Precision immune-guided management of cytomegalovirus (CMV) after allogeneic haematopoietic stem cell transplantation in the letermovir era: A pragmatic framework.","journal":"Br J Haematol","issue":"2026 January 14. doi: 10.1111\/bjh.70327. Online ahead of print","author":"Jiang X, Xu Z, Wang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41536163"},{"title01":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","title02":"Excellent outcomes in children after haematopoietic stem cell transplantation for hepatitis-associated aplastic anaemia following liver transplantation.","journal":"Br J Haematol","issue":"2026 January 12. doi: 10.1111\/bjh.70328. Online ahead of print","author":"Meena SK, Kancharla A, Mohamed AI, James B, Ewins AM, Chaudhury S, Roberts W, Furtado Silva JM, Chiesa R, Amrolia PJ, Height S, Hadzic N, Rao K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41527175"},{"title01":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","title02":"Dose de-escalation of alemtuzumab in matched unrelated donor haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2026 January 8. doi: 10.1111\/bjh.70318. Online ahead of print","author":"Madkhali MM, Mitchell A, Wright C, Pearce K, Aku S, Pagan S, Duncan L, Lam J, Macdonald J, Milne P, Publicover A, Hurst E, Bigley V, Hale G, Collin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41508744"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","journal":"Br J Haematol","issue":"2026 January 7. doi: 10.1111\/bjh.70324. Online ahead of print","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","title02":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2025018152. Online ahead of print","author":"Pena M, Losi G, Navarro V, Qualls DA, Crombie JL, Mariotti J, Bramanti S, Fabbri N, Serna A, Serroukh YI, Balaguer-Rosello A, van der Poel MW, Hsu YT, Jimenez-Ubieto A, McKinnely C, Lopez-Corral L, Panizo C, Perez-Simon JA, Rovira M, Saldana R, Kwon M, Solano C, Valcarcel D, Pascual-Cascon MJ, Noriega V, Sanz J, Sanchez-Salinas A, Jurado M, Calbacho M, Bento L, Albo Lopez C, Perera M, Heras I, Guerreiro M, Balsalobre P, Armand P, Sureda A, Mussetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529227"},{"title01":"Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.","title02":"Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 9. doi: 10.1182\/bloodadvances.2025018057. Online ahead of print","author":"Charton E, Anota A, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Dulery R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas RO, Brisou G, Cheminant M, Bay JO, Llamas Gutierrez F, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F, Houot R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512176"},{"title01":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","title02":"A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025017621. Online ahead of print","author":"Tan JLC, Khong T, Kim YJ, Reynolds J, Barmanray RD, Gardiner BJ, Morrissey CO, Mithraprabhu S, Spencer A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538294"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018626. Online ahead of print","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Toubai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care.","title02":"Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care.","journal":"Blood advances","issue":"2026 January 13; 10(1):111-120. doi: 10.1182\/bloodadvances.2025017540","author":"Matsui H, Arai Y, Kanda J, Kondo T, Schoettler ML, Mohty M, Perales MA, Duarte RF, Rambaldi A, Takaori-Kondo A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41071950"},{"title01":"Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.","title02":"Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.","journal":"Blood advances","issue":"2026 January 13; 10(1):75-82. doi: 10.1182\/bloodadvances.2025017234","author":"Aymard M, Cheminant M, Houot R, Cuozzo A, Gat E, Thieblemont C, Ricard L, Roulin L, Bouabdallah K, Safar V, Guidez S, Fayard A, Brisou G, Ysebaert L, Hermine O, Tessoulin B, Herbaux C, Le Gouill S, Sarkozy C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026973"},{"title01":"PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.","title02":"PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.","journal":"Blood","issue":"2026 January 15; 147(3):254-265. doi: 10.1182\/blood.2025028848","author":"Thompson C, Trneny M, Morschhauser F, Salles G, Reagan PM, Hertzberg M, Zhang H, Thieblemont C, Hu B, Fonseca G, Kim WS, Martelli M, Mehta A, Singh A, Yan M, Hirata J, Sugidono M, Lee C, Sharman JP, Mehta-Shah N, Flowers CR, Tilly H, Chua N, Casasnovas RO, Miall F, Kim TM, Tsai XC, Nasta S, Lee ST, Friedberg JW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40997297"},{"title01":"The treatment of marginal zone lymphoma.","title02":"The treatment of marginal zone lymphoma.","journal":"Blood","issue":"2026 January 8; 147(2):115-126. doi: 10.1182\/blood.2024028269","author":"Alderuccio JP, Noy A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40663786"},{"title01":"Dose-dense chemotherapy enables elimination of RT for majority of low-risk pediatric Hodgkin lymphoma: PHC study HOD08.","title02":"Dose-dense chemotherapy enables elimination of RT for majority of low-risk pediatric Hodgkin lymphoma: PHC study HOD08.","journal":"Blood","issue":"2026 January 13. doi: 10.1182\/blood.2025029535. Online ahead of print","author":"Flerlage JE, Feraco AM MD, MMSc, Zhou Y, Zheng Y MS, Liang J, Lucas JT Jr, Friedmann AM, Weinstein HJ, Yock TI, Shulkin BL, Kaste SC, Marks LJ, Ehrhardt MJ, Dixon SB, Howard S, de Alarcon P, Luna-Fineman S, Geddis AE, Larsen EC, Marcus KJ, Billett A, Donaldson SS, Hudson MM, Metzger ML, Krasin MJ, Link MP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529162"},{"title01":"The biology of marginal zone lymphoma subtypes: challenge and relevance of classification.","title02":"The biology of marginal zone lymphoma subtypes: challenge and relevance of classification.","journal":"Blood","issue":"2026 January 8; 147(2):105-114. doi: 10.1182\/blood.2024028268","author":"Laurent C, Bertoni F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026919"},{"title01":"Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.","title02":"Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025031455. Online ahead of print","author":"Alderuccio JP, Baggio D, Han S, Ghione P, Nizamuddin IA, Khwaja J, Saha A, Dong N, Wang Y, Cherng HJ, Tolu SS, Wagner-Johnston ND, Ollila TA, Grover NS, Koff JL, Desai A, Ramakrishnan Geethakumari P, Moyo TK, Sandoval-Sus J, Epperla N, Wallace DS, Kamdar M, Tavarozzi R, Danilov AV, Tun HW, Munoz J, Narkhede MS, Rhodes JM, Prica A, Kuhnl A, Maraj AM, Okosun J, Smith J, Osborne W, Calvert V, El-Sharkawi D, Hilali A, Collins GP, Linton K, Elmusharaf N, Santarsieri A, Karim F, Firas FB, Monick S, Trutzer IM, Can J, Ayers AA, Calabrese De Feo J, Sharp J, Ghosh N, Treitman R, Kallam A, Okcu I, Abeyakoon C, Hann W, Barrett A, Deshani V, Kahl BS, Chavez JC, Olszewski AJ, Cwynarski K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490516"},{"title01":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.","title02":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.","journal":"Blood","issue":"2026 January 15; 147(3):276-289. doi: 10.1182\/blood.2025030558","author":"Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Batingana AR, D'Souza J, Pikman Y, Cheng ML, Logan AC, Huang BJ, Stieglitz E, Smith CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144772"},{"title01":"Drug development in MZL: caring for the forgotten child.","title02":"Drug development in MZL: caring for the forgotten child.","journal":"Blood","issue":"2026 January 8; 147(2):127-137. doi: 10.1182\/blood.2024028270","author":"Thieblemont C, Carras S, Bommier C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961241"},{"title01":"High-grade\/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition.","title02":"High-grade\/large B-cell lymphoma-11q has a very good prognosis in children and young people without a predisposition.","journal":"Blood","issue":"2026 January 8; 147(2):209-214. doi: 10.1182\/blood.2025031086","author":"Ronceray L, Huibers MHW, Reutter K, Abla O, Andres M, Balague O, Csoka M, Gilad G, Hagleitner MM, Hori D, Hjalgrim LL, Jazbec J, Klapper W, Nakazawa A, Verdu-Amoros J, von Mersi H, Wossmann W, Xavier AC, Burkhardt B, Salaverria I, Attarbaschi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160801"},{"title01":"Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.","title02":"Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.","journal":"N Engl J Med","issue":"2026 January 1; 394(1):51-61. doi: 10.1056\/NEJMoa2514752","author":"Kumar S, Mateos MV, Ye JC, Atrash S, Magen H, Quach H, Chu MP, Trudel S, Richter J, Rodriguez-Otero P, Chuah H, Gatt M, Medvedova E, Raza S, Yoon DH, Ishida T, Matous JV, Rosinol L, Onodera K, Scott E, Heuck C, Zhang J, Henninger T, O'Rourke L, Thakkar P, Festa M, Huang L, Zhou J, Takamoto M, Pei L, Lu J, Au N, Krevvata M, Usmani SZ, Cohen YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358582"},{"title01":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.","title02":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.","journal":"Lancet Oncol","issue":"2026 January 7. doi: 10.1016\/S1470-2045(25)00653-9. Online ahead of print","author":"Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW, Sidana S, Oriol A, Cohen YC, Harrison SJ, Mateos MV, Martinez-Lopez J, Corradini P, Karlin L, Chen D, Li Q, Yeh TM, Li K, Plaks V, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Schecter JM, Lendvai N, Koneru M, Patel N, Florendo E, Ho PJ, Popat R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41519141"},{"title01":"Measurable residual disease assessment in multiple myeloma.","title02":"Measurable residual disease assessment in multiple myeloma.","journal":"Leukemia","issue":"2026 January; 40(1):25-28. doi: 10.1038\/s41375-025-02830-0","author":"Zanwar S, Rajkumar SV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41350429"},{"title01":"Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.","title02":"Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.","journal":"Leukemia","issue":"2026 January; 40(1):235-240. doi: 10.1038\/s41375-025-02802-4","author":"Pertesi M, Demangel D, Niroula A, Perrial E, Mahecha Escobar ML, Vallee M, Liacos C, Samur MK, Sperling AS, Munshi NC, Kastritis E, Dimopoulos MA, McKay JD, Mellqvist UH, Hansson M, Dumontet C, Nilsson B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41254116"},{"title01":"Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.","title02":"Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02841-x. Online ahead of print","author":"Bar N, Martin T, Hofmeister CC, Mateos MV, Hansson M, Paris L, Namburi S, Ribas P, Santoro A, Rodriguez-Otero P, Creignou M, Chen J, Cao C, Kiesel B, Gaudy A, Thompson EG, Shen Y, Zarif S, Hsu K, Shelat SG, Burgess MR, Godwin C, Costa LJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501501"},{"title01":"Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.","title02":"Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e30-e40. doi: 10.1016\/S2352-3026(25)00298-4","author":"Korst CLBM, Plattel W, de Kort EA, Smits F, Croockewit AJ, Levin MD, Westerman M, de Weerdt O, Nijhof IS, Wegman J, Smit N, Verkleij CPM, Mutis T, Nasserinejad K, Kerstiens R, van der Klift M, Franssen LE, de Ruijter MEM, Groen K, van der Spek E, Roeloffzen WWH, Zweegman S, van de Donk NWCJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41482445"},{"title01":"Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.","title02":"Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.","journal":"J Clin Oncol","issue":"2026 January 6; JCO2502587. doi: 10.1200\/JCO-25-02587. Online ahead of print","author":"Hicks LK, Messersmith HJ, Al Hadidi S, Banerjee R, Derman BA, Kumar S, Wildes TM, Bal S, Bhella S, Chmielewski C, Costello C, Dabney R, Hartley-Brown M, Langerak A, Lipe B, Martin T, McCurdy A, Mian H, Riva E, Seth R, Subramanian L, Mikhael J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41494138"},{"title01":"Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.","title02":"Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myeloma.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.289162. Online ahead of print","author":"Han S, Munawar U, Truger M, Gerhard-Hartmann E, Verbruggen C, Pfeiffer L, Hainold AS, Kurian S, Nerreter S, Besant E, Vogt C, Rein N, Koppel M, Lehmann J, Schmitt F, Tamamushi Y, Zhou X, Steinbrunn T, Haferlach C, Rosenwald A, Einsele H, Rasche L, Waldschmidt JM, Kortum MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504227"},{"title01":"Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma.","title02":"Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma.","journal":"Haematologica","issue":"2026 January 1; 111(1):184-195. doi: 10.3324\/haematol.2025.287783","author":"Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen DK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637727"},{"title01":"Macrophages promote aberrant DNA repair in multiple myeloma via the CXCL5\/8-CXCR2 axis.","title02":"Macrophages promote aberrant DNA repair in multiple myeloma via the CXCL5\/8-CXCR2 axis.","journal":"Haematologica","issue":"2026 January 1; 111(1):271-285. doi: 10.3324\/haematol.2025.287312","author":"Dong M, He D, Zhang J, Yan H, Chen H, Zhang E, Feng Y, He J, Huang X, Chen G, Sun X, Cheng F, Gu H, Wang H, Xie A, Cai Z, Lab C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568729"},{"title01":"Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma.","title02":"Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma.","journal":"Haematologica","issue":"2026 January 1; 111(1):431-435. doi: 10.3324\/haematol.2025.288521","author":"Siegel A, Reci S, Grossman L, Gleason C, Crary J, Song L, Park J, Verina D, Desai S, Kappes K, Stillman I, LaBaer J, Aleman A, Jagannath S, Parekh S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41063705"},{"title01":"After CAR-T therapy for myeloma: challenge of persistent cytopenias and infections.","title02":"After CAR-T therapy for myeloma: challenge of persistent cytopenias and infections.","journal":"Haematologica","issue":"2026 January 1; 111(1):86-88. doi: 10.3324\/haematol.2025.288539","author":"Beyar-Katz O, Stern A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40836786"},{"title01":"Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study.","title02":"Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study.","journal":"Haematologica","issue":"2026 January 1; 111(1):379-384. doi: 10.3324\/haematol.2025.287889","author":"Lee JY, Jung S, Choi S, Park SS, Kim JS, Lee JJ, Park SK, Kim HJ, Lee GW, Park YH, Eom HS, Kim JA, Kim MK, Kim Y, Shin HJ, Lee HS, Kwon J, Min CK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820811"},{"title01":"Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial.","title02":"Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial.","journal":"Haematologica","issue":"2026 January 1; 111(1):361-367. doi: 10.3324\/haematol.2025.287510","author":"Bringhen S, Cani L, Giuliani N, Mangiacavalli S, Benevolo G, Antonioli E, Zambello R, Ria R, Vincelli ID, Ronconi S, More S, Falcone AP, Allegra A, D'Agostino M, Evangelista A, Capra A, Sciorsci E, Curci P, Tosi P, Liberati AM, Cafro AM, Belotti A, Patriarca F, Mannina D, Mancuso K, Cattel F, Ciccone G, Bruno B, Boccadoro M, Larocca A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820797"},{"title01":"The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.","title02":"The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.","journal":"Haematologica","issue":"2026 January 1; 111(1):286-299. doi: 10.3324\/haematol.2025.288041","author":"Mizuno S, Gras L, Baaij LGA, Koster L, D'Souza A, Hari PN, Estrada-Merly N, Saber W, Cowan AJ, Iida M, Okamoto S, Takamatsu H, Kawamura K, Kodera Y, Hamad N, Ko BS, Liam C, Ho KW, Goh AS, Keat TS, Elhaddad AM, Bazarbachi A, Chaudhry BQUN, Alfar R, Bekadja MA, Benakli M, Ortiz CAF, Riva E, Verburgh E, Galeano S, Bass F, Mian H, McCurdy A, Wang FR, Neumann D, Koh MBC, Snowden JA, Schonland S, McLornan DP, Hayden PJ, Balari AMS, Greinix HT, Aljurf M, Atsuta Y, Rondelli D, Niederwieser DW, Garderet L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820767"},{"title01":"Time to say adieu to FISH in myeloma diagnostics.","title02":"Time to say adieu to FISH in myeloma diagnostics.","journal":"Blood","issue":"2026 January 15; 147(3):221-222. doi: 10.1182\/blood.2025031255","author":"Garces JJ, Maura F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538211"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2026 January 8; 394(2):152-165. doi: 10.1056\/NEJMoa2505478","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02848-4. Online ahead of print","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.","title02":"Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):130-137. doi: 10.1038\/s41375-025-02764-7","author":"Greiner J, Schuler PJ, Schrezenmeier H, Weiss J, Bulach C, Goetz M, Guinn BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145674"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia &#8211; a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia &#8211; a HARMONY study.","journal":"Leukemia","issue":"2026 January 14. doi: 10.1038\/s41375-025-02851-9. Online ahead of print","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Early detection and management of extracranial arteriopathy reduces the incidence of silent cerebral infarcts in sickle cell anemia: a long-term prospective cohort study.","title02":"Early detection and management of extracranial arteriopathy reduces the incidence of silent cerebral infarcts in sickle cell anemia: a long-term prospective cohort study.","journal":"Haematologica","issue":"2026 January 1; 111(1):314-328. doi: 10.3324\/haematol.2025.287720","author":"Bernaudin F, Arnaud C, Kamdem A, Youn J, Vasile M, Hau I, Madhi F, Malterre A, Delestrain C, Epaud R, Jung C, Verlhac S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568713"},{"title01":"Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children&#8217;s Oncology Group AALL0434.","title02":"Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children&#8217;s Oncology Group AALL0434.","journal":"J Clin Oncol","issue":"2026 January 5; JCO2502779. doi: 10.1200\/JCO-25-02779. Online ahead of print","author":"Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490480"},{"title01":"Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.","title02":"Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.","journal":"J Clin Oncol","issue":"2026 January 9; JCO2500203. doi: 10.1200\/JCO-25-00203. Online ahead of print","author":"Castellino SM, Li H, Herrera AF, LeBlanc M, Parsons SK, Unger JM, Punnett A, Hodgson D, Keller FG, Drachtman RA, Lamble A, Forlenza CJ, Doan A, Rutherford SC, Evens AM, Little RF, Smith MA, Hoppe BS, Song JY, Smith SM, Friedberg JW, Kelly KM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512237"},{"title01":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed\/Refractory Large B-Cell Lymphoma.","title02":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed\/Refractory Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 January 10; 44(2):86-91. doi: 10.1200\/JCO-25-00507","author":"Maziarz RT, Bishop MR, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu J, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Ma W, Han X, Nuortti M, Awasthi R, Mundt KE, Majdan M, Maier HJ, Jegerlehner A, Salles G, Schuster SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41252666"},{"title01":"Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","title02":"Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2026 January; 44(1):71. doi: 10.1200\/JCO-25-02667","author":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trneny M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Lee Batlevi C, Tilly H, Flowers CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264903"},{"title01":"FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.","title02":"FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.","journal":"J Clin Oncol","issue":"2026 January 10; 44(2):117-128. doi: 10.1200\/JCO-25-00892","author":"Maurer MJ, Prochazka VK, El-Galaly TC, Flowers CR, Villa D, Bachy E, Cahn EJ, Fournier M, Larson MC, Dietrich CE, Jakobsen LH, Ghesquieres H, Kridel R, Gandhi MK, Cheah CY, Hawkes EA, Seymour JF, Freeman CL, Clausen MR, Wahlin BE, Friedberg JW, Casulo C, Habermann TM, Wang Y, Nastoupil LJ, de Nully Brown P, Belada D, Janikova A, Mocikova H, Furst T, Feugier P, Tilly H, Haioun C, Davies AJ, Cartron G, Burack R, Chihara D, Martin P, Cohen JB, Lossos IS, Kahl BS, Sehn LH, Smedby KE, Salles G, Trneny M, Link BK, Morschhauser F, Cerhan JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329901"},{"title01":"Improving the predictive value of end-of-treatment PET\/CT in diffuse large B-cell lymphoma.","title02":"Improving the predictive value of end-of-treatment PET\/CT in diffuse large B-cell lymphoma.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.288821. Online ahead of print","author":"Bes AL, Zwezerijnen GJC, Heymans MW, Duhrsen U, Eertink JJ, Wiegers SE, Lugtenburg PJ, Huttmann A, Kurch L, Hanoun C, Mikhaeel GN, Ceriani L, Zucca E, Czibor S, Gyorke T, Chamuleau MED, Fanti S, Lee ST, Hoekstra OS, Zijlstra JM, Barrington SF, Boellaard R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504226"},{"title01":"Older patients with lymphoma: navigating a landscape of clinical controversies and barriers to innovation.","title02":"Older patients with lymphoma: navigating a landscape of clinical controversies and barriers to innovation.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288700. Online ahead of print","author":"Simonsen MR, Eyre TA, Hawkes EA, El-Galaly TC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537332"},{"title01":"Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter&#8217;s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.","title02":"Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter&#8217;s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.","journal":"Haematologica","issue":"2026 January 1; 111(1):259-270. doi: 10.3324\/haematol.2024.286945","author":"Shouse G, Chen C, Muir A, Popplewell L, Siddiqi T, Zain J, Herrera AF, Danilova O, Roleder C, Wang L, Spurgeon SEF, Kittai AS, Chen L, Xia Z, Davids MS, Danilov AV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605718"},{"title01":"Long non-coding RNA LINC00926 is a biomarker for naive B-cells with prognostic value in advanced stage classic Hodgkin lymphoma.","title02":"Long non-coding RNA LINC00926 is a biomarker for naive B-cells with prognostic value in advanced stage classic Hodgkin lymphoma.","journal":"Haematologica","issue":"2026 January 1; 111(1):368-372. doi: 10.3324\/haematol.2025.287524","author":"Iaccarino I, Beder T, Reinke S, Borchmann P, Von Tresckow B, Altenbuchinger M, Klapper W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671505"},{"title01":"Two decades of single-institution data reveal rare longterm survivors of relapsed\/refractory Burkitt lymphoma.","title02":"Two decades of single-institution data reveal rare longterm survivors of relapsed\/refractory Burkitt lymphoma.","journal":"Haematologica","issue":"2026 January 1; 111(1):345-349. doi: 10.3324\/haematol.2024.287165","author":"Molla R, Bantilan K, Berman E, Caron P, Falchi L, Hamlin P, Horwitz S, Intlekofer A, Kumar A, Lue J, Moskowitz A, Owens C, Palomba ML, Dahi PB, Salles G, Vardhana S, Shah G, Zelenetz A, Johnson W, Noy A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820818"},{"title01":"Clinical features and incidence of central nervous system involvement in patients with adult T-cell leukaemia\/lymphoma.","title02":"Clinical features and incidence of central nervous system involvement in patients with adult T-cell leukaemia\/lymphoma.","journal":"Br J Haematol","issue":"2026 January 5. doi: 10.1111\/bjh.70301. Online ahead of print","author":"Ueno T, Yoshimitsu M, Sameshima M, Nagano T, Akahoshi R, Takeshita Y, Shodai A, Shima K, Arima N, Kamada Y, Nakamura D, Ishitsuka K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41491883"},{"title01":"Prognostic role of PET\/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group.","title02":"Prognostic role of PET\/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group.","journal":"Br J Haematol","issue":"2026 January 14. doi: 10.1111\/bjh.70329. Online ahead of print","author":"Gowdy SC, Flerlage JE, Seelisch J, Palese M, Bradshaw T, Castellino SM, Cho S, Dieckmann K, Hoppe BS, Howard S, Kelly KM, Kurch L, Lai HA, Lopci E, Lucas JT Jr, Mauz-Korholz C, McCarten KM, Pandit-Taskar N, Schoder H, Steglich J, Stoevesandt D, Voss SD, Milgrom SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535222"},{"title01":"Clinical trial access after CAR T-cell therapy failure in relapsed\/refractory large B-cell lymphoma.","title02":"Clinical trial access after CAR T-cell therapy failure in relapsed\/refractory large B-cell lymphoma.","journal":"Br J Haematol","issue":"2026 January 11. doi: 10.1111\/bjh.70325. Online ahead of print","author":"Kim K, Shah R, Ayers A, Ahmed S, Claret L, Strati P, Nair R, Nze C, Ramdial J, Torres J, Shpall EJ, Fayad LE, Nastoupil LJ, Westin JR, Flowers CR, Neelapu SS, Chihara D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41521615"},{"title01":"Lymph node biopsy indications: Challenges in determining the &#8216;when&#8217;.","title02":"Lymph node biopsy indications: Challenges in determining the &#8216;when&#8217;.","journal":"Br J Haematol","issue":"2026 January 11. doi: 10.1111\/bjh.70322. Online ahead of print","author":"Matos DM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41521584"},{"title01":"POD24 is a Novel Determinant of Prognosis in Patients with Waldenstrom Macroglobulinemia.","title02":"POD24 is a Novel Determinant of Prognosis in Patients with Waldenstrom Macroglobulinemia.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025017751. Online ahead of print","author":"Zanwar S, Abeykoon JP, D'Sa S, Roos-Weil D, Larson DR, Colby CL, Durot E, Kastritis E, Uppal E, Tomkins O, Morel P, Mondello P, Montes L, Paludo J, Ailawadhi S, Sarosiek S, Ogunbiyi O, Cornillet-Lefebvre P, Rajkumar SV, Quinquenel A, Dispenzieri A, Fonseca R, Gertz MA, Kumar SK, Dimopoulos MA, Ansell SM, Treon SP, Castillo JJ, Kapoor P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499755"},{"title01":"Infections Following Bispecific Antibodies in B-cell Lymphomas.","title02":"Infections Following Bispecific Antibodies in B-cell Lymphomas.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025017366. Online ahead of print","author":"Kim DH, Lee N, Koh Y, Jo HJ, Kang CK, Choe PG, Park WB, Lee CM, Byun JM, Kim NJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538299"},{"title01":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","title02":"Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC Study.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2025018152. Online ahead of print","author":"Pena M, Losi G, Navarro V, Qualls DA, Crombie JL, Mariotti J, Bramanti S, Fabbri N, Serna A, Serroukh YI, Balaguer-Rosello A, van der Poel MW, Hsu YT, Jimenez-Ubieto A, McKinnely C, Lopez-Corral L, Panizo C, Perez-Simon JA, Rovira M, Saldana R, Kwon M, Solano C, Valcarcel D, Pascual-Cascon MJ, Noriega V, Sanz J, Sanchez-Salinas A, Jurado M, Calbacho M, Bento L, Albo Lopez C, Perera M, Heras I, Guerreiro M, Balsalobre P, Armand P, Sureda A, Mussetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529227"},{"title01":"New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.","title02":"New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 13; 10(1):217-227. doi: 10.1182\/bloodadvances.2024015599","author":"Greenbaum U, Hashmi H, Elsawy M, Kim S, Moskop A, Oloyede T, Awan FT, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Farooq U, Foglesong J, Ganguly S, Hematti P, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, McGuirk JP, Mead E, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Geethakumari PR, Riedell PA, Saber W, Shouval R, Shpall EJ, Magalhaes-Silverman M, Strouse C, Turtle CJ, Vallurupalli A, Wudhikarn K, Pasquini MC, Ahmed S, Sorror M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811818"},{"title01":"Zamtocabtagene Autoleucel in Relapsed\/refractory B-NHL: 5-year Follow Up of a CD20\/19 tandem CAR T Cell Phase 1 Trial.","title02":"Zamtocabtagene Autoleucel in Relapsed\/refractory B-NHL: 5-year Follow Up of a CD20\/19 tandem CAR T Cell Phase 1 Trial.","journal":"Blood advances","issue":"2026 January 9. doi: 10.1182\/bloodadvances.2025018073. Online ahead of print","author":"Balke-Want H, Godel P, Schmid C, Ayuk FA, Friedrichs B, van Heteren P, Holtkamp S, Zadoyan G, Brillant C, Costa J, Hanssens L, Holzer T, Wohle C, Biedermann S, Burger I, Orentas RJ, Overstijns T, Scheid C, Holtick U, Miltenyi S, Hallek MJ, Borchmann P, Kutsch N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512222"},{"title01":"Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.","title02":"Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.","journal":"Blood advances","issue":"2026 January 9. doi: 10.1182\/bloodadvances.2025018057. Online ahead of print","author":"Charton E, Anota A, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Dulery R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas RO, Brisou G, Cheminant M, Bay JO, Llamas Gutierrez F, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F, Houot R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41512176"},{"title01":"Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq.","title02":"Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq.","journal":"Blood advances","issue":"2026 January 13; 10(1):29-38. doi: 10.1182\/bloodadvances.2025017107","author":"Yin Y, Rai S, Jiang A, Xu A, O'Brien L, Telenius A, Delabie J, Chong L, Hung S, Merchant A, Scott DW, Savage KJ, Aoki T, Steidl C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924921"},{"title01":"Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed\/Refractory Follicular Lymphoma.","title02":"Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed\/Refractory Follicular Lymphoma.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018546. Online ahead of print","author":"Iacoboni G, Kyvsgaard E, Navarro V, Russler-Germain DA, Lewis KL, Martin Garcia-Sancho A, Carro I, Thompson PA, Therwhanger D, Quintela Vilchez D, Ku M, Gomez-Prieto P, Valencia-Espinoza E, Vega G, Jimenez-Ubieto A, Bastos Oreiro MB, Serna A, Husby S, de la Cruz Benito B, Luan J, Camarillas S, Medina L, Cabero Martinez A, Cordoba R, Canales MA, Sancho JM, Bosch F, Sureda A, Schuster SJ, Cheah CY, Hutchings M, Barba P, Abrisqueta P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499758"},{"title01":"Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.","title02":"Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025016953. Online ahead of print","author":"Agrusa JE, Abdel Fattah E, Lin H, Velazquez J, Salinas SA, Abhyankar HA, Scull BP, Fleischmann R, Elghetany MT, Marcogliese AN, Curry CV, Punia JN, Ozuah NW, Eckstein OS, El-Mallawany NK, Gulati N, Lubega J, Horton TM, Kamdar KY, McClain KL, Man TK, Allen CE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538304"},{"title01":"Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.","title02":"Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.","journal":"Blood advances","issue":"2026 January 13; 10(1):183-191. doi: 10.1182\/bloodadvances.2025016797","author":"Toner K, Renfro LA, Dave H, Pezzella G, Pei Q, Giulino-Roth L, Horton T, Keller FG, Kelly KM, Castellino SM, Bollard CM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40990939"},{"title01":"Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.","title02":"Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.","journal":"Blood advances","issue":"2026 January 13; 10(1):228-232. doi: 10.1182\/bloodadvances.2025016968","author":"Melody M, Grover N, Franco S, Romancik J, Cortese M, Moyo TK, Bhansali RS, Ollila T, Kenkre V, Fitzgerald L, Hess B, Matasar M, Shouse G, Annunzio K, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Ma S, Winter JN, Lin A, Danilov A, Roy I, Barta SK, Gordon LI, Stephens D, Cohen JB, Epperla N, Karmali R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124653"},{"title01":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.","title02":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 January 13; 10(1):276-288. doi: 10.1182\/bloodadvances.2025017526","author":"Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Odstrcil Bobillo S, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052404"},{"title01":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","title02":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025031409. Online ahead of print","author":"Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee AE, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang AG, Barsouk A, Cho JH, Shaw CE, Singh EB, Ugwuanyi O, Paruzzo L, Stella F MD, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey AD Jr, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490267"},{"title01":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","title02":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025032277. Online ahead of print","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Introduction to a review series on marginal zone lymphoma: reclaiming the afterthought.","title02":"Introduction to a review series on marginal zone lymphoma: reclaiming the afterthought.","journal":"Blood","issue":"2026 January 8; 147(2):95. doi: 10.1182\/blood.2025031752","author":"Armand P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41505146"},{"title01":"Clonal Hematopoiesis and Lymphoma-Associated Mutations in Hematopoietic Progenitors in B-Cell Non-Hodgkin Lymphoma.","title02":"Clonal Hematopoiesis and Lymphoma-Associated Mutations in Hematopoietic Progenitors in B-Cell Non-Hodgkin Lymphoma.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025030489. Online ahead of print","author":"Wiegand L, Silva P, Noerenberg D, Christen F, Kopp K, Locher BN, Lowe P, Tilgner M, Altwasser R, Storzer V, Stein CM, Briest F, Arends CM, Frick M, Ihlow J, Dolnik A, Ishaque N, Keller U, Na IK, Penter L, Bullinger L, Hablesreiter R, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490454"},{"title01":"PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression.","title02":"PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression.","journal":"Blood","issue":"2026 January 15. doi: 10.1182\/blood.2025030760. Online ahead of print","author":"Vallelonga V, Gandolfi F, Zampini M, Riva E, Maggioni G, Ventura D, Saba E, Termanini A, Polletti S, Prosperini E, Crisafulli L, Campagna A, Ferrari I, Pinocchio N Jr, Todisco G, Pedretti S, Calvi M, Di Vito C, Mavilio D, Mitro N, Ficara F, Della Porta MG, Ghisletti SML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538708"},{"title01":"Genomic determinants of response and resistance to pirtobrutinib in relapsed\/refractory chronic lymphocytic leukemia.","title02":"Genomic determinants of response and resistance to pirtobrutinib in relapsed\/refractory chronic lymphocytic leukemia.","journal":"Blood","issue":"2026 January 1; 147(1):24-34. doi: 10.1182\/blood.2024027009","author":"Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Botelho SC, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair B, Abada P, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41055698"},{"title01":"Acute promyelocytic leukemia diagnosed on soft tissue biopsy: a rare extramedullary presentation.","title02":"Acute promyelocytic leukemia diagnosed on soft tissue biopsy: a rare extramedullary presentation.","journal":"Blood","issue":"2026 January 8; 147(2):215. doi: 10.1182\/blood.2025031138","author":"Sharpe-Davidson WF, Wan YO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41505145"},{"title01":"Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3.","title02":"Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3.","journal":"Blood","issue":"2026 January 1; 147(1):61-72. doi: 10.1182\/blood.2025029686","author":"Mendoza-Castrejon J, Yang W, Denby E, Wang HC, Casey EB, Muthukumar R, Patel RM, Yoon J, Li Y, White JM, Chen R, Batista LFZ, Magee JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41032751"},{"title01":"Measurable residual disease intervention in AML: a new therapeutic horizon.","title02":"Measurable residual disease intervention in AML: a new therapeutic horizon.","journal":"Blood","issue":"2026 January 1; 147(1):13-23. doi: 10.1182\/blood.2025029010","author":"Wei AH, Iland HJ, DiNardo CD, Reynolds J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41105915"},{"title01":"CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.","title02":"CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.","journal":"Blood","issue":"2026 January 15; 147(3):229-240. doi: 10.1182\/blood.2025030775","author":"Laszig S, Diederichs A, Salzmann-Manrique E, Schuschel K, Goncalves-Dias J, Issa H, Miladinovic M, Rettinger E, Wehner S, Kreyenberg H, Bremm M, Hunecke S, Kerp H, Waack-Buchholz K, Thol F, Goemans BF, De Moerloose B, Boztug H, Scheidegger N, Pawinska-Wasikowska K, Reinhardt D, Klusmann JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41118594"},{"title01":"Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.","title02":"Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025030722. Online ahead of print","author":"Dohner H, Spath D, Saadati M, Fiedler W, Gotze KS, Koller E, Westermann J, Vogel W, Heuser M, Lubbert M, Tischler HJ, Germing U, Teichmann LL, Fransecky L, Wolfler A, Nachbaur D, Hertenstein B, Schroers R, Martens UM, von Harsdorf S, Radsak MP, Aschauer G, Weisshaar S, Corbacioglu A, Schrade A, Gaidzik VI, Thol FR, Paschka P, Bullinger L, Benner A, Dohner K, Ganser A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490515"},{"title01":"Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas.","title02":"Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas.","journal":"N Engl J Med","issue":"2026 January 1; 394(1):93-96. doi: 10.1056\/NEJMc2513023","author":"Merli M, Genuardi E, Zibellini S, Rattotti S, Spina M, Roti G, Motta M, Piazza F, Boccomini C, Ferreri AJM, Perbellini O, Brociner M, Dodero A, Vallisa D, Pulsoni A, Santoro A, Del Giudice I, Zuccaro V, Chimienti E, Russo S, Varraso C, Rizzo E, Bosi A, Cappello E, Favrin G, Marcheselli L, Visco C, Luminari S, Passamonti F, Ferrero S, Arcaini L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41467657"},{"title01":"Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","title02":"Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","journal":"Leukemia","issue":"2026 January; 40(1):106-119. doi: 10.1038\/s41375-025-02777-2","author":"Vallois D, Missiaglia E, Veloza L, Fischer A, Cavalieri D, Rattina V, Bisig B, Roh V, Wiehle L, Sarkis R, Bachy E, Bonnet C, Bruneau J, Cairoli A, De Wind R, Drieux F, Dubois R, Emile JF, Fataccioli V, Laribi K, Ledoux-Pilon A, Lemonnier F, Llamas-Gutierrez F, Morel P, Parrens M, Poullot E, Quintanilla-Martinez L, Sandrini J, Somja J, Xerri L, Tournilhac O, Gaulard P, Siebert R, de Leval L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41057685"},{"title01":"Key regulatory roles of PRDM1 in human NK-cell differentiation and activation.","title02":"Key regulatory roles of PRDM1 in human NK-cell differentiation and activation.","journal":"Leukemia","issue":"2026 January; 40(1):199-210. doi: 10.1038\/s41375-025-02815-z","author":"Liu X, Shi Y, Zhang J, Shetty K, Chew K, Kucuk C, Gong Q, Esmeray E, Li H, Chen R, Pan S, Dabrowska K, Moore RE, Garcia-Mansfield K, Pirrotte P, Wang J, Li Y, Dong G, Lee L, McKeithan TW, Iqbal J, Chan WC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41366532"},{"title01":"Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","title02":"Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","journal":"Leukemia","issue":"2026 January; 40(1):252-259. doi: 10.1038\/s41375-025-02808-y","author":"Vallois D, Missiaglia E, Veloza L, Fischer A, Cavalieri D, Rattina V, Bisig B, Roh V, Wiehle L, Sarkis R, Bachy E, Bonnet C, Bruneau J, Cairoli A, De Wind R, Drieux F, Dubois R, Emile JF, Fataccioli V, Laribi K, Ledoux-Pilon A, Lemonnier F, Llamas-Gutierrez F, Morel P, Parrens M, Poullot E, Quintanilla-Martinez L, Sandrini J, Somja J, Xerri L, Tournilhac O, Gaulard P, Siebert R, de Leval L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41266881"},{"title01":"The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.","title02":"The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.","journal":"Leukemia","issue":"2026 January; 40(1):152-165. doi: 10.1038\/s41375-025-02809-x","author":"Wei W, Song Z, Wang Y, Li S, Tan L, Lee J, Cai KQ, Nejati R, Kadin ME, Campbell KS, Nakagawa M, Yang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41225182"},{"title01":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.","title02":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.","journal":"Leukemia","issue":"2026 January; 40(1):219-223. doi: 10.1038\/s41375-025-02795-0","author":"Moia R, Ragaini S, Cascione L, Rinaldi A, Genuardi E, Talotta D, Almasri M, Bruscaggin A, Zaccaria GM, Evangelista A, Civita AM, Di Rocco A, Petrucci L, Cavallo F, Celli M, Luppi M, Stelitano C, Stefani PM, Visco C, Billio A, Casaroli I, Castellino C, Pavone E, Galimberti S, Plenteda C, Merli F, Mahmoud AM, Rossi D, Gaidano G, Ladetto M, Bertoni F, Ferrero S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41204002"},{"title01":"Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.","title02":"Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.","journal":"Leukemia","issue":"2026 January; 40(1):95-105. doi: 10.1038\/s41375-025-02787-0","author":"Khouja M, Genuardi E, Ferrero S, Laqua A, Alessandria B, Verhagen OJHM, Homburg CHE, Sanz RG, Medina Herrera A, van der Velden VHJ, da Silva MG, Gameiro P, Doorduijn J, Gine E, Visco C, Bruggemann M, Baldus CD, Ladetto M, Schmidt C, Dreyling M, Jiang L, Hoster E, Darzentas N, Pal K, Chitadze G, Stewart JP, Gonzalez D, Pott C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41184633"},{"title01":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","title02":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","journal":"Leukemia","issue":"2026 January; 40(1):55-62. doi: 10.1038\/s41375-025-02820-2","author":"Truger M, Meggendorfer M, Walter W, Hutter S, Alsdorf W, Massenkeil G, Martens UM, Kern W, Horst K, Kuhn C, Reiter A, Hochhaus A, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419605"},{"title01":"ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +\/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.","title02":"ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +\/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.","journal":"Leukemia","issue":"2026 January; 40(1):87-94. doi: 10.1038\/s41375-025-02759-4","author":"Khouja M, Kehden B, Blair D, Kuffer C, Wagner S, Versteegen T, Nakov P, Bruggemann M, Baldus C, Belada D, Nowakowski GS, Schilhabel A, Darzentas N, Pott C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145670"},{"title01":"Lymphoma in the BiTE era.","title02":"Lymphoma in the BiTE era.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e1. doi: 10.1016\/S2352-3026(25)00344-8","author":"The Lancet Haematology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41482441"},{"title01":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","title02":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e8-e21. doi: 10.1016\/S2352-3026(25)00327-8","author":"Kater AP, Janssens A, Eradat H, Offner F, Sandoval-Sus JD, Shadman M, Poulsen CB, Christensen JH, Thompson MC, Guan M, Steele AJ, Rios M, Holst Morch M, Oki T, Valentin R, Bellido M, Eichhorst B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380698"},{"title01":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.","title02":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.","journal":"Lancet","issue":"2026 January 10; 407(10524):133-146. doi: 10.1016\/S0140-6736(25)01778-7","author":"Sehn LH, Hubel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jimenez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41360064"},{"title01":"A step forward in the treatment of relapsed or refractory follicular lymphoma.","title02":"A step forward in the treatment of relapsed or refractory follicular lymphoma.","journal":"Lancet","issue":"2026 January 10; 407(10524):110-112. doi: 10.1016\/S0140-6736(25)02436-5","author":"Magnano L, Rivero A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41371239"},{"title01":"A new standard for relapsed or refractory follicular lymphoma.","title02":"A new standard for relapsed or refractory follicular lymphoma.","journal":"Lancet","issue":"2026 January 10; 407(10524):108-109. doi: 10.1016\/S0140-6736(25)01965-8","author":"Harel R, Cohen JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41360063"},{"title01":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.","title02":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.","journal":"Lancet","issue":"2026 January 10; 407(10524):161-173. doi: 10.1016\/S0140-6736(25)02360-8","author":"Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jimenez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41371238"},{"title01":"Action for first-line PD-1 inhibitors in paediatric Hodgkin lymphoma.","title02":"Action for first-line PD-1 inhibitors in paediatric Hodgkin lymphoma.","journal":"Lancet","issue":"2026 January 10; 407(10524):126-127. doi: 10.1016\/S0140-6736(25)02386-4","author":"Ceppi F, Veening M, Mascarin M, Balwierz W, Mauz-Koerholz C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41519588"},{"title01":"Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity.","title02":"Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity.","journal":"J Clin Oncol","issue":"2026 January 10; 44(2):76-80. doi: 10.1200\/JCO-25-02323","author":"Pophali PA, Kenkre VP, Hayes CA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370745"},{"title01":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","title02":"GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018626. Online ahead of print","author":"Yamasaki S, Yanada M, Mizuno S, Shimomura Y, Toubai T, Harada K, Uchida N, Tanaka M, Wake A, Onizuka M, Eto T, Uehara Y, Takahashi S, Izumi T, Doki N, Tokunaga M, Kawakita T, Nishida T, Sakata-Yanagimoto M, Ishimaru F, Kanda J, Atsuta Y, Konuma T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538306"},{"title01":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","title02":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.","journal":"Blood advances","issue":"2026 January 13; 10(1):233-245. doi: 10.1182\/bloodadvances.2025017194","author":"Modi D, Aljawai YM, DeFor TE, Bupp C, Al Malki MM, Bolanos-Meade J, Gooptu M, Jimenez Jimenez AM, Liu H, Mensah FA, Mielcarek M, Shaffer BC, Shaw BE, Spellman SR, Stefanski HE, Auletta JJ, Devine SM, Khimani F, Abboud R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052403"},{"title01":"Impact of Statin Use on Cardiovascular and Hematologic Outcomes Among Patients with Myeloproliferative Neoplasms.","title02":"Impact of Statin Use on Cardiovascular and Hematologic Outcomes Among Patients with Myeloproliferative Neoplasms.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018724. Online ahead of print","author":"Leiva O, Soo S, Liu OC, You V, Palmer AS, Kahla JA, Murtaza Y, Odenike O, Patel AA, DeCara J, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499780"},{"title01":"MRD assessment by flow cytometry in B-ALL made easier.","title02":"MRD assessment by flow cytometry in B-ALL made easier.","journal":"Blood advances","issue":"2026 January 13; 10(1):121-123. doi: 10.1182\/bloodadvances.2025018222","author":"DiGiuseppe J, Cherian S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41474522"},{"title01":"Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies.","title02":"Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies.","journal":"Blood advances","issue":"2026 January 13; 10(1):262-272. doi: 10.1182\/bloodadvances.2025017601","author":"Yokoyama H, Fukuhara N, Ando K, Iida H, Yamauchi T, Fukuhara S, Izutsu K, Tanoue Y, Yamamoto M, Tozaki H, Takahara E, Shoji S, Mizutani A, Morishita D, Oda R, Miyake H, Yamamoto N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056522"},{"title01":"Liberalizing hospital proximity requirements for children\/young adults with low-burden B-ALL receiving tisagenlecleucel.","title02":"Liberalizing hospital proximity requirements for children\/young adults with low-burden B-ALL receiving tisagenlecleucel.","journal":"Blood advances","issue":"2026 January 13; 10(1):106-110. doi: 10.1182\/bloodadvances.2025017012","author":"Appell LE, Baggott C, Nguyen K, Prabhu S, Pacenta H, John S, Fabrizio VA, Phillips CL, Rossoff J, Talano JA, Moskop A, Phelan R, Baumeister SHC, Verneris MR, Hall EM, Myers GD, Karras NA, Cooper SL, Qayed M, Raikar SS, Winestone L, Hermiston M, Satwani P, Krupski C, Keating AK, Friedman DN, Curran KJ, Hoover A, MacMillan ML, Ebens CL, Ramgopal A, Rahrig AL, Mackall CL, Laetsch TW, McNerney K, Schultz LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026960"},{"title01":"Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1.","title02":"Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1.","journal":"Blood advances","issue":"2026 January 13; 10(1):70-74. doi: 10.1182\/bloodadvances.2025017013","author":"Faulk KE, Kairalla JA, Hibbitts E, Long-Boyle J, Devidas M, August A, Gore L, Raetz E, Hunger SP, Loh ML, Teachey DT, Brown P, Breese EH, Kotecha RS, Guest E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991382"},{"title01":"Mini-hyper-CVD plus venetoclax and navitoclax for relapsed\/refractory acute lymphoblastic leukemia.","title02":"Mini-hyper-CVD plus venetoclax and navitoclax for relapsed\/refractory acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 January 13; 10(1):25-28. doi: 10.1182\/bloodadvances.2025016565","author":"Short NJ, Kantarjian H, Jain N, Kadia TM, Senapati J, Haddad FG, Maroun MM, Sasaki K, Xiao L, Huang X, Karrar O, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Jabbour E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763277"},{"title01":"Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry.","title02":"Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry.","journal":"Blood advances","issue":"2026 January 13; 10(1):58-69. doi: 10.1182\/bloodadvances.2025016126","author":"Seheult JN, Otteson GE, Timm MM, Weybright MJ, Shi M, Olteanu H, Jevremovic D, Chen C, Chiu A, Horna P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966417"},{"title01":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.","title02":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2026 January 13; 10(1):276-288. doi: 10.1182\/bloodadvances.2025017526","author":"Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Odstrcil Bobillo S, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41052404"},{"title01":"Shifting clones: CLL evolution under pirtobrutinib treatment.","title02":"Shifting clones: CLL evolution under pirtobrutinib treatment.","journal":"Blood","issue":"2026 January 1; 147(1):3-4. doi: 10.1182\/blood.2025031598","author":"Jebaraj BMC, Stilgenbauer S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41477751"},{"title01":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.","title02":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.","journal":"Blood","issue":"2026 January 15; 147(3):276-289. doi: 10.1182\/blood.2025030558","author":"Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Batingana AR, D'Souza J, Pikman Y, Cheng ML, Logan AC, Huang BJ, Stieglitz E, Smith CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41144772"},{"title01":"Resistance is not futile: RAS inhibition resensitizes AML.","title02":"Resistance is not futile: RAS inhibition resensitizes AML.","journal":"Blood","issue":"2026 January 15; 147(3):222-224. doi: 10.1182\/blood.2025031932","author":"Collins C, Majeti R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538212"},{"title01":"Fetal defense against leukemia: a developmental shield.","title02":"Fetal defense against leukemia: a developmental shield.","journal":"Blood","issue":"2026 January 1; 147(1):7-8. doi: 10.1182\/blood.2025031544","author":"Keeshan K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41477746"},{"title01":"Mechanisms of immune escape and extramedullary tropism in leukemia cutis.","title02":"Mechanisms of immune escape and extramedullary tropism in leukemia cutis.","journal":"Blood","issue":"2026 January 1; 147(1):35-47. doi: 10.1182\/blood.2025029121","author":"Penter L, Maurer K, Cieri N, Lu WS, Lyu H, Selig M, Joosten M, Ihlow J, Li S, Livak KJ, Bullinger L, Ritz J, Bachireddy P, Davids MS, Garcia JS, Soiffer RJ, Wu CJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026928"},{"title01":"Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.","title02":"Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.","journal":"Blood","issue":"2026 January 8; 147(2):197-208. doi: 10.1182\/blood.2025028644","author":"Guarnera L, Wahida A, Gurnari C, Hutter S, Stainczyk SA, Williams ND, Durmaz A, Kubota Y, Bravo-Perez C, Kawashima N, Orland M, Pagliuca S, Huang Y, LaFramboise T, Visconte V, Walter W, Meggendorfer M, Kern W, Westermann F, Feuerbach L, Haferlach T, Maciejewski JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983034"},{"title01":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","title02":"Chronic Active Epstein-Barr Virus Disease: Molecular Pathogenesis, Evolving Concepts, and Emerging Therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025032277. Online ahead of print","author":"Kimura H, Cohen JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490284"},{"title01":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.","title02":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.","journal":"Blood","issue":"2026 January 8; 147(2):180-196. doi: 10.1182\/blood.2025029302","author":"Ren H, Elliott N, Lye B, Sharif Shohan MU, Cross JW, Field L, Ponnusamy K, Rice S, Jackson T, Leontari I, El Ouazzani N, Thomas R, Inglott S, Bartram J, Smith O, Bond J, Roberts IAG, Halsey C, Bashford-Rogers R, Milne TA, Roy A, Karadimitris A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40898981"},{"title01":"Compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/- mediated clonal hematopoiesis.","title02":"Compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+\/- mediated clonal hematopoiesis.","journal":"Blood","issue":"2026 January 12. doi: 10.1182\/blood.2024028031. Online ahead of print","author":"Lee K, Hong CL, Dissanayake W, Kulzhanova G, Pfeffer AN, Li H, Sivakumar S, Yin Z, Quarato ER, Benoodt L, Bajaj J, Cao C, Wu CL, Calvi LM, Yeh SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41525451"},{"title01":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","title02":"Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025031409. Online ahead of print","author":"Carturan A, Angelos MG, Guruprasad P, Patel RP, Pajarillo R, Lee AE, Espie D, Zhang Y, Chiang YH, Xie W, Rodriguez JL, Harris J, Devi P, Afolayan-Oloye OI, Xu J, Sussman JH, Elghawy O, Yang AG, Barsouk A, Cho JH, Shaw CE, Singh EB, Ugwuanyi O, Paruzzo L, Stella F MD, Liu S, Nason S, Imparato A, Rotolo A, Lemoine J, Barrett DM, Posey AD Jr, Rook AH, Pillai V, Bagg A, Pileri SA, Liu D, Tan K, Schuster SJ, Teachey DT, Porazzi P, Ruella M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490267"},{"title01":"Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germline ERCC6L2 disease.","title02":"Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germline ERCC6L2 disease.","journal":"Blood","issue":"2026 January 5. doi: 10.1182\/blood.2025030230. Online ahead of print","author":"Schimmer R, Klemm N, Fullin J, Topcu E, Treacy M, Zielinska K, Doerdelmann C, Devesa-Serrano D, Lock M, Caiado F, Koch C, Dietliker N, Schwotzer R, Buehler MM, Myllymaki M, Kurppa KJ, Manz MG, Lopes M, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41490322"},{"title01":"Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia.","title02":"Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.288587. Online ahead of print","author":"Jabbour E, Sandhu KS, Shaughnessy P, Logan AC, Abedi M, Shah BD, Bishop MR, Park JH, DeAngelo DJ, Tholouli E, Yallop D, Chaganti S, Hodby K, Barba P, Guerreiro M, Menne T, Shang J, Lao-Sirieix P, Brugger W, Roddie C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504229"},{"title01":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","title02":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.","journal":"Haematologica","issue":"2026 January 1; 111(1):122-134. doi: 10.3324\/haematol.2025.287456","author":"Balduzzi A, Glogova E, Peters C, Sedlacek P, Dalle JH, Locatelli F, Meisel R, Burkhardt B, Buechner J, Wachowiak J, Bierings M, Staciuk R, Graphakos S, Gungor T, Yesilipek A, Svec P, Palma J, Krivan G, Diaz-de-Heredia C, Limido F, Ansari M, Kalwak K, Bader P, Ifversen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820816"},{"title01":"Metallothionein 1 mediates growth and survival of Dnmt3a;Npm1-mutant acute myeloid leukemia.","title02":"Metallothionein 1 mediates growth and survival of Dnmt3a;Npm1-mutant acute myeloid leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):373-378. doi: 10.3324\/haematol.2025.287662","author":"Colom Diaz PA, Mistry JJ, Young KA, Chou CH, Boyer N, Levine RL, Salomonis N, Grimes HL, Trowbridge JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820834"},{"title01":"All patients with acute myeloid leukemia and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? &#8211; the CON.","title02":"All patients with acute myeloid leukemia and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? &#8211; the CON.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288786. Online ahead of print","author":"Russell NH, Lewis KD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537333"},{"title01":"QKI dysregulation induces extensive splicing changes in T-cell acute lymphoblastic leukemia.","title02":"QKI dysregulation induces extensive splicing changes in T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.287809. Online ahead of print","author":"Palhais B, Sharma ND, Fijalkowski I, Pieters T, Deforce D, Nieuwerburgh FV, Mestdagh P, Ntziachristos P, Matlawska-Wasowska K, Vlierberghe PV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537349"},{"title01":"Evaluation of acute myeloid leukemia using genomic proximity mapping-based next generation cytogenomics.","title02":"Evaluation of acute myeloid leukemia using genomic proximity mapping-based next generation cytogenomics.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288461. Online ahead of print","author":"Yeung CCS, Eacker SM, Sala-Torra O, Wood M, Beppu L, Woolston DW, Liachko I, Malig M, Stirewalt D, Muratov A, Fang M, Radich J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537347"},{"title01":"Toward chemotherapy-reduced cure for TCF3::HLF B-cell acute lymphoblastic leukemia using CD19-directed immunotherapy.","title02":"Toward chemotherapy-reduced cure for TCF3::HLF B-cell acute lymphoblastic leukemia using CD19-directed immunotherapy.","journal":"Haematologica","issue":"2026 January 1; 111(1):93-95. doi: 10.3324\/haematol.2025.288192","author":"Zeckanovic A, Baruchel A, Bourquin JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40836779"},{"title01":"All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? &#8211; the PRO.","title02":"All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? &#8211; the PRO.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288785. Online ahead of print","author":"Kayser S, Schlenk RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537334"},{"title01":"Real-life management of 476 older adults with Philadelphianegative acute lymphoblastic leukemia: a Campus ALL study.","title02":"Real-life management of 476 older adults with Philadelphianegative acute lymphoblastic leukemia: a Campus ALL study.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288555. Online ahead of print","author":"Cerrano M, Lazzarotto D, Boscaro E, Borlenghi E, Tanasi I, Chiusolo P, Minetto P, Grimaldi F, Giglio F, Dargenio M, Leoncin M, Trappolini S, Papayannidis C, Forghieri F, Gurrieri C, Zappasodi P, La Starza R, Fracchiolla N, Di Biase F, Del Principe MI, Defina M, Pasciolla C, Cambo B, Mosna F, Pietrasanta D, Mariani S, Mancini V, Guolo F, Lussana F, Todisco E, Annunziata M, Calafiore V, Ciccone M, Pasquini A, Dragani ME, Sani B, Mauro E, Basilico C, De Marco B, Antonacci M, Forlani L, Fumagalli M, Trastulli F, Lunghi M, Salutari P, Mastaglio S, Chiaretti S, Candoni A, Ferrara F, Pizzolo G, Foa R, Bonifacio M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537316"},{"title01":"ALK-positive histiocytosis and a clonally related chronic myelomonocytic leukemia.","title02":"ALK-positive histiocytosis and a clonally related chronic myelomonocytic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):423-426. doi: 10.3324\/haematol.2025.288275","author":"Breimer GE, Rozeman EA, Braunius WW, Daenen LGM, Kester LA, Leguit RJ, Mahieu R, Solleveld-Westerink N, Straatman L, Schutgens F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931869"},{"title01":"The age of fit-equity: ignoring age and fitness in treatment selection for chronic lymphocytic leukemia.","title02":"The age of fit-equity: ignoring age and fitness in treatment selection for chronic lymphocytic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):89-90. doi: 10.3324\/haematol.2025.288379","author":"Owen C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874327"},{"title01":"Common ancestral origin of indeterminate dendritic cell tumor and chronic myelomonocytic leukemia in clonal hematopoiesis.","title02":"Common ancestral origin of indeterminate dendritic cell tumor and chronic myelomonocytic leukemia in clonal hematopoiesis.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288974. Online ahead of print","author":"Sato A, Yusa N, Takamori H, Shimizu E, Jimbo K, Kato S, Konuma T, Yokoyama K, Imoto S, Takahashi S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537315"},{"title01":"Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel.","title02":"Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel.","journal":"Haematologica","issue":"2026 January 1; 111(1):98-107. doi: 10.3324\/haematol.2025.288228","author":"Wang SA, Arenillas L, Buccisano F, Bruggemann M, Kern W, Menes M, Plesa A, Stone L, Wellnitz D, Westerman DA, Wood BL, Freeman SD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40905082"},{"title01":"Accurate automated diagnosis of B-acute lymphoblastic leukemia using deep learning and flow cytometry.","title02":"Accurate automated diagnosis of B-acute lymphoblastic leukemia using deep learning and flow cytometry.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.288277. Online ahead of print","author":"Chalise S, Roshal M, Roshal S, Baik J, Gao Q, Li A, Dogan A, Veeraraghavan H, Zhu ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504225"},{"title01":"Metallothionein 1: the Achilles heel of Dnmt3a;Npm1-mutant acute myeloid leukemia.","title02":"Metallothionein 1: the Achilles heel of Dnmt3a;Npm1-mutant acute myeloid leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):96-97. doi: 10.3324\/haematol.2025.288820","author":"Yan B, Guryanova OA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40963388"},{"title01":"Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study.","title02":"Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study.","journal":"Br J Haematol","issue":"2026 January 11. doi: 10.1111\/bjh.70332. Online ahead of print","author":"Breccia M, Giai V, Rosso T, Pregno P, Castagnetti F, Bonifacio M, Capodanno I, Tiribelli M, Stagno F, Mulas O, Gozzini A, Patriarca A, Sora F, Loglisci G, Rossi AR, Coppi MR, Miggiano MC, Di Raimondo F, Rosti G, Pane F, Saglio G, Ciccone G, Specchia G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41521026"},{"title01":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","title02":"Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.","journal":"Br J Haematol","issue":"2026 January 4. doi: 10.1111\/bjh.70307. Online ahead of print","author":"Nakamura F, Ishiyama K, Suzuki R, Maruyama H, Onishi Y, Usuki K, Koh H, Takenaka K, Saiki R, Ogawa S, Matsumoto K, Takahashi T, Hosomichi K, Zaimoku Y, Yoshimura K, Matsumura I, Akashi K, Nakao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41485764"},{"title01":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","title02":"Equal outcomes after human leukocyte antigen-matched unrelated versus sibling donor transplants-Results of the AML SCT-BFM 2007 trial and consecutive &#8216;real-world routine&#8217;.","journal":"Br J Haematol","issue":"2026 January 7. doi: 10.1111\/bjh.70324. Online ahead of print","author":"Sauer MG, Lang PJ, Albert MH, Bader P, Eyrich M, Gruhn B, Klingebiel T, Mauz-Korholz C, Meisel R, Muller I, Niemeyer CM, Peters C, Burkhardt B, Reinhardt D, Sedlacek P, Strahm B, Woessmann W, Handgretinger R, Zimmermann M, Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41502109"},{"title01":"Clinical features and incidence of central nervous system involvement in patients with adult T-cell leukaemia\/lymphoma.","title02":"Clinical features and incidence of central nervous system involvement in patients with adult T-cell leukaemia\/lymphoma.","journal":"Br J Haematol","issue":"2026 January 5. doi: 10.1111\/bjh.70301. Online ahead of print","author":"Ueno T, Yoshimitsu M, Sameshima M, Nagano T, Akahoshi R, Takeshita Y, Shodai A, Shima K, Arima N, Kamada Y, Nakamura D, Ishitsuka K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41491883"},{"title01":"More than CLK bait? Rogocekib for MDS and AML.","title02":"More than CLK bait? Rogocekib for MDS and AML.","journal":"Blood advances","issue":"2026 January 13; 10(1):260-261. doi: 10.1182\/bloodadvances.2025018552","author":"Chen EC, Stahl M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41528737"},{"title01":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","title02":"MDS\/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.","journal":"Blood advances","issue":"2026 January 13. doi: 10.1182\/bloodadvances.2025018408. Online ahead of print","author":"Boertjes EL, Grob T, Al Hinai ASA, Beverloo BH, Versluis J, Kavelaars FG, Rijken M, Compagne KG, Erpelinck-Verschueren CAJ, Sanders MA, Stoetman ECG, Hanekamp D, Gradowska P, Ossenkoppele GJ, Biemond BJ, Manz MG, Pabst T, Jongen-Lavrencic M, Lowenberg B, Valk PJM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41529224"},{"title01":"Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review &#038; meta-analysis.","title02":"Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review &#038; meta-analysis.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025016879. Online ahead of print","author":"Oliveros MJ, Chowdhury SR, Roldan Y, Ibrahim S, Bravo-Soto G, Foucar CE, Bhogal G, Burgos-Mansilla B, Bagherianlemraski M, Movahed H, Gutierrez-Arias R, Taj TK, Chang Y, Hadeiy SK, Demichelis-Gomez R, Malcovati L, Loh KP, Platzbecker U, Gilberto L, Treitz J, Baer MR, Marini BL, Mattison RJ, Sekeres MA, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538293"},{"title01":"Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 Criteria.","title02":"Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 Criteria.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018032. Online ahead of print","author":"Shimony S, Wang Y, Cronin AM, Walsh TP, Charles A, Slopen N, Cho HL, Stahl MF, Bystrom RP, Luskin MR, Abel GA, DeAngelo DJ, Stone RM, Lindsley RC, Hantel A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538295"},{"title01":"Exercise-Mobilized Lymphocytes Enhance the Function of Cytokine-Induced Memory-like NK-cells Against Myeloid Leukemia.","title02":"Exercise-Mobilized Lymphocytes Enhance the Function of Cytokine-Induced Memory-like NK-cells Against Myeloid Leukemia.","journal":"Blood advances","issue":"2026 January 15. doi: 10.1182\/bloodadvances.2025018345. Online ahead of print","author":"Batatinha H, Valenzuela AM, Filioglou D, Wilde P, Leite G, Kistner TM, Baker FL, Katsanis E, Simpson RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41538301"},{"title01":"Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.","title02":"Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.","journal":"Blood advances","issue":"2026 January 7. doi: 10.1182\/bloodadvances.2025018757. Online ahead of print","author":"Martino EA, Pitino A, Vigna E, Pasquale R, Ferrarini I, Moia R, Visentin A, Sanna A, Motta M, Moratti M, Sportoletti P, Chiarenza A, Maggi A, Zammit V, Merli M, Innocenti I, Giordano C, Nocilli L, Postorino M, Stelitano C, Ferrario A, Frustaci AM, Riva M, Pepe S, Ibatici A, Scardino S, Anticoli Borza P, Ballotta L, Mancuso S, Malaspina F, Mele A, Galimberti S, Catania G, Giordano A, Angeletti I, Schiattone L, Pennese E, Miccolis RM, Fama A, Giordano G, Califano C, Bruzzese A, Caserta S, Farina G, Bulian P, Loseto G, Pocali B, Innao V, Galieni P, Fraticelli V Sr, Vitale C, Romeo A, Rossi M, Scortechini I, Vozella F, Malandruccolo L, Varettoni M, Morello L, Pietrantuono G, Conte E, Cantelli M, Murru R, Caracciolo D, Derenzini E, Di Martina V, Marasca R, Del Principe MI, Figuera A, Angotzi F, Coscia M, Di Renzo N, Laurenti L, Amodio N, Musto P, Di Raimondo F, Liso A, Tedeschi A, Trentin L, Gaidano G, Mauro FR, Tripepi G, Morabito F, Gattei V, Gentile M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41499776"},{"title01":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","title02":"NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02848-4. Online ahead of print","author":"Chonabayashi K, Iwasaki M, Kanda J, Takamori H, Yoda A, Kawata T, Mizuta S, Sakurada M, Kondo T, Hiramoto N, Ueda Y, Gotoh A, Watanabe M, Kasahara S, Ishikawa Y, Kiyoi H, Imada K, Mitani K, Kitano T, Arima N, Nakabo Y, Sezaki N, Kanemura N, Fukuda T, Ichikawa M, Miyazaki Y, Fuji S, Sakata-Yanagimoto M, Yoshida Y, Takaori-Kondo A, Ogawa S, Nannya Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501506"},{"title01":"Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.","title02":"Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia.","journal":"Leukemia","issue":"2026 January 8. doi: 10.1038\/s41375-025-02845-7. Online ahead of print","author":"Gonzales F, Schneider C, Alexe G, Lin S, Khalid D, Alvarez M, Basanthakumar A, Ellegast JM, Merickel L, Salhotra S, Taillon A, Giaimo M, Wunderlich M, Ansari M, Perry JA, Degar B, Pikman Y, Stegmaier K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41507381"},{"title01":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.","title02":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.","journal":"Leukemia","issue":"2026 January; 40(1):63-71. doi: 10.1038\/s41375-025-02781-6","author":"Bill M, Eckardt JN, Dohner K, Rohnert MA, Rausch C, Metzeler KH, Spiekermann K, Stasik S, Wurm AA, Sauer T, Scholl S, Schnetzke U, Hochhaus A, Crysandt M, Brummendorf TH, Krug U, Wormann B, Einsele H, Hiddemann W, Gorlich D, Sauerland C, Steffen B, Neubauer A, Burchert A, Schafer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hanel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Schetelig J, Middeke JM, Bullinger L, Heuser M, Thol F, Serve H, Baldus CD, Platzbecker U, Muller-Tidow C, Valka J, Sramek J, Weinbergerova B, Mayer J, Dumas PY, Bertoli S, Delabesse E, Recher C, Pigneux A, Herold T, Ganser A, Dohner H, Bornhauser M, Thiede C, Rollig C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145671"},{"title01":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","title02":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2026 January; 13(1):e8-e21. doi: 10.1016\/S2352-3026(25)00327-8","author":"Kater AP, Janssens A, Eradat H, Offner F, Sandoval-Sus JD, Shadman M, Poulsen CB, Christensen JH, Thompson MC, Guan M, Steele AJ, Rios M, Holst Morch M, Oki T, Valentin R, Bellido M, Eichhorst B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380698"},{"title01":"Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.","title02":"Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.","journal":"Lancet Haematol","issue":"2026 January 14. doi: 10.1016\/S2352-3026(25)00323-0. Online ahead of print","author":"Heitmann JS, Maringer Y, Jung S, Wacker M, Hackenbruch C, Polster M, Marconato M, Nelde A, Bauer J, Zwick M, Baur AS, Lehmann A, Krolla C, Andrieux G, Kohler N, Boerries M, Denk M, Zieschang L, Kammer C, Hoenisch-Gravel N, Richter M, Oezbek MT, Wirths S, Dengler A, Dubbelaar ML, Pumptow M, Martus P, Bruggemann M, Rammensee HG, Salih HR, Walz JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41547362"},{"title01":"Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","title02":"Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","issue":"2026 January 10; 44(2):134. doi: 10.1200\/JCO-25-02762","author":"Montesinos P, Rodriguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodriguez-Arboli E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, Lopez-Lopez JA, Vives S, Lopez-Lorenzo JL, Colorado M, Vidriales MB, Boyero RG, Olave MT, Herrera P, Arce O, Barrios M, Sayas MJ, Polo M, Gomez-Roncero MI, Barragan E, Ayala R, Chillon C, Calasanz MJ, Paiva B, Boluda B, Casas-Aviles I, Lloret P, Sanchez MJ, Rodriguez-Medina C, Cuevas L, Raposo-Puglia JA, Mateos MC, Olivares M, Martinez-Chamorro C, Alonso N, Suarez S, Sanchez-Vadillo I, Rodriguez MS, Gonzalez BJ, Martinez-Frances A, Cuello R, Fernandez A, Martinez-Cuadron D, Labrador J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41325561"},{"title01":"Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","title02":"Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","issue":"2026 January; 44(1):68-70. doi: 10.1200\/JCO-25-02252","author":"Marvin-Peek J, DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264889"},{"title01":"Ibrutinib versus acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy.","title02":"Ibrutinib versus acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy.","journal":"Haematologica","issue":"2026 January 1; 111(1):412-417. doi: 10.3324\/haematol.2025.288323","author":"Molica S, Shanafelt TD, Giannarelli D, Allsup D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605690"},{"title01":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","title02":"Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center.","journal":"Haematologica","issue":"2026 January 1; 111(1):149-157. doi: 10.3324\/haematol.2025.287628","author":"Oran B, Thall P, Alousi A, Al-Atrash G, Mehta R, Marin D, Kebriaei P, Popat U, Bassett R, Bashir Q, Im J, Olson A, Jewell J, Smallbone P, Shpall E, Champlin R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702903"},{"title01":"Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).","title02":"Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).","journal":"Haematologica","issue":"2026 January 1; 111(1):158-167. doi: 10.3324\/haematol.2025.288085","author":"Yates SJ, Weiss JJ, Sneider A, Geramita E, Murthy GSG, Badar T, Im A, Lin C, Cheng W, Abaza Y, Swaroop A, Winer ES, Litzow MR, Atallah EL, Patel AA, Shallis RM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702896"},{"title01":"Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment.","title02":"Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment.","journal":"Haematologica","issue":"2026 January 1; 111(1):401-404. doi: 10.3324\/haematol.2025.288105","author":"Alkabbani O, Jabban Y, He R, Viswanatha D, Bessonen K, Greipp P, Jevremovic D, Foran JM, Badar T, Yi CA, Kusne Y, Saliba AN, Hefazi M, Matin A, Hogan WJ, Mangaonkar A, Alkhateeb H, Patnaik M, Shah M, Begna K, Litzow MR, Al-Kali A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671498"},{"title01":"CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia.","title02":"CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):196-205. doi: 10.3324\/haematol.2025.287564","author":"Carrillo-Serradell L, Pineyroa JA, Bousquets-Munoz P, Planells-Romeo V, Aragon-Serrano L, Casado-Llombart S, Colomer D, Andres MV, Puente XS, Delgado J, Mozas P, Lozano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605694"},{"title01":"PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia.","title02":"PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):108-121. doi: 10.3324\/haematol.2024.287124","author":"Stanulovic VS, Binhassan S, Jaber BA, Alazmi S, Saleman FMB, Potluri S, Pratt G, Ludwig C, Ward DG, Hoogenkamp M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637766"},{"title01":"Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice.","title02":"Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice.","journal":"Haematologica","issue":"2026 January 1; 111(1):206-218. doi: 10.3324\/haematol.2025.287799","author":"Frustaci AM, Galitzia A, Lucignano M, Appio L, Olivieri J, Sanna A, Barate C, Pane F, Schiattone L, Casadei B, Ferrarini I, Figuera A, Sportoletti P, Loseto G, Stelitano C, Visentin A, Celli M, Mauro FR, Palombi M, Coscia M, Innao V, Moia R, Motta M, Russo F, Tani M, Arcari A, Boccellato E, Borella C, Capochiani E, Ferrari A, Gentile M, Giachetti R, Giordano A, Bullo M, Lista E, Malandruccolo L, Musso M, Varettoni M, Vozella F, Cibien F, Merli M, Nocilli L, Pasquini MC, Romeo AA, Rossi V, Turri G, Vanazzi A, Cavaliere M, Gozzetti A, Crucitti L, Lucesole M, Deodato M, Tomasso A, Zappaterra A, Murru R, Patti C, Laurenti L, Tedeschi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568727"},{"title01":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","title02":"Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.","journal":"Haematologica","issue":"2026 January 1; 111(1):168-176. doi: 10.3324\/haematol.2024.287205","author":"Prata PH, Eikema DJ, Piepenbroek B, Kulasekararaj A, Drexler B, Tjon JM, Vaht K, Aljurf M, Chevallier P, Gedde-Dahl T, Kaare A, Salmenniemi U, Schroeder T, Byrne J, Cornillon J, Barraco F, Maertens J, Tholouli E, Platzbecker U, Kroger N, Blaise D, Sica S, Zeiser R, Risitano AM, De Latour RP, Anemia Working Party ESA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605711"},{"title01":"IDH1-mutated B-cell acute lymphoblastic leukemia characterized by oncogenic reprogramming of lipid metabolism.","title02":"IDH1-mutated B-cell acute lymphoblastic leukemia characterized by oncogenic reprogramming of lipid metabolism.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.288472. Online ahead of print","author":"Qian Y, Shen D, Ling Q, Zhao S, Zhou Y, Zhao Y, Li X, Wang Y, Huang J, Wang J, Yu W, Tong H, Sun J, Zhang X, Jin J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504243"},{"title01":"NKX2-1 regulates cell survival, maturation, and DNA-damage responses as a cofactor of RUNX1 in T-cell acute lymphoblastic leukemia.","title02":"NKX2-1 regulates cell survival, maturation, and DNA-damage responses as a cofactor of RUNX1 in T-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 8. doi: 10.3324\/haematol.2025.287966. Online ahead of print","author":"Van Aerschot L, Demeyer S, Timcheva K, Heylen E, Verstraete P, De Groote D, Caruso M, Lauwereins L, Veloso A, Kampen KR, Pepe D, Boeckx N, Royaert J, Verbeeck J, Segers H, Cools J, De Keersmaecker K, Granados DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41504233"},{"title01":"The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia.","title02":"The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):135-148. doi: 10.3324\/haematol.2024.286228","author":"Zhao HG, Cruz-Rodriguez N, Johnson KC, Pomicter AD, Bates B, Bateman B, Haferlach T, Gu T, Ahmann J, Yan D, Lee GS, Zhu W, Bishop J, Odelberg SJ, Deininger MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637748"},{"title01":"Flow cytometric analysis of cerebrospinal fluid identifies patients with occult central nervous system involvement in relapsed pediatric acute lymphoblastic leukemia.","title02":"Flow cytometric analysis of cerebrospinal fluid identifies patients with occult central nervous system involvement in relapsed pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):355-360. doi: 10.3324\/haematol.2025.287392","author":"Thastrup M, Marquart HV, Levinsen M, Ulvmoen A, Albertsen BK, Pronk CJ, Olsen M, Wehner P, Taskinen M, Als-Nielsen B, Schmiegelow K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637739"},{"title01":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21.","title02":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21.","journal":"Haematologica","issue":"2026 January 1; 111(1):329-334. doi: 10.3324\/haematol.2024.286719","author":"Sakaguchi H, Sakaguchi K, Kato I, Noma H, Hiramatsu H, Ishida H, Yabe H, Goto H, Kawahara Y, Yamashita YI, Sanada M, Deguchi T, Takahashi Y, Saito AM, Takagi M, Okuno K, Taga T, Horibe K, Okamoto Y, Koh K, Manabe A, Umeda K, Of Japanese Children's Cancer Group TTACTC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40637726"},{"title01":"Mechanisms sensitive to different drugs mediate a proadhesive and pro-thrombotic platelet phenotype in antiphospholipid syndrome.","title02":"Mechanisms sensitive to different drugs mediate a proadhesive and pro-thrombotic platelet phenotype in antiphospholipid syndrome.","journal":"Haematologica","issue":"2026 January 1; 111(1):219-229. doi: 10.3324\/haematol.2024.287133","author":"Camera M, Brambilla M, Lonati PA, Becchetti A, Grossi C, Nallio K, Da Via A, Trespidi L, Borghi MO, Tedesco F, Meroni PL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605716"},{"title01":"Don&#8217;t forget about thrombosis in acute promyelocytic leukemia.","title02":"Don&#8217;t forget about thrombosis in acute promyelocytic leukemia.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.300189. Online ahead of print","author":"Tallman MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537346"},{"title01":"Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia.","title02":"Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemia.","journal":"Haematologica","issue":"2026 January 15. doi: 10.3324\/haematol.2025.288876. Online ahead of print","author":"Abraham IE, Rauscher GH, Luo J, Monick S, Burkart M, Doukas P, Aleem A, Raptis N, Dave A, Wilmington A, Debettencourt M, Nwachukwu M, Fatima J, Erra A, Shankar G, Tsai SB, Larson M, Zia M, Quigley J, Altman JK, Stock W, Patel A, Khan I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41537345"},{"title01":"Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial.","title02":"Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial.","journal":"Lancet Oncol","issue":"2026 January; 27(1):125-136. doi: 10.1016\/S1470-2045(25)00526-1","author":"Cheville AL, Herrin J, Pachman DR, Grzegorczyk V, Kroenke K, Ridgeway JL, Minteer SA, Austin JD, Griffin JM, Chlan L, Tofthagen C, Mitchell SA, Smith A, Ruddy KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41344348"},{"title01":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia &#8211; a HARMONY study.","title02":"Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia &#8211; a HARMONY study.","journal":"Leukemia","issue":"2026 January 14. doi: 10.1038\/s41375-025-02851-9. Online ahead of print","author":"Hernandez-Sanchez A, Villaverde Ramiro A, Strang E, Turki AT, Abaigar M, Versluis J, Thomas I, Sobas M, Martinez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martinez-Lopez J, Pratcorona M, Mills KI, Sanz G, Voso MT, Soren L, Rollig C, Thiede C, Metzeler KH, Dohner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernandez-Rivas JM, Huntly B, Ossenkoppele G, Dohner H, Bullinger L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41535568"},{"title01":"Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.","title02":"Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):3-24. doi: 10.1038\/s41375-025-02804-2","author":"Mikkelsen T, Helenius M, Ampatzidou M, Attarbaschi A, Andres-Jensen L, Borkhardt A, Conde Cuevas N, Escherich G, Hagleitner MM, Halsey C, Josephs-Spaulding J, Lundgren L, Pehn S, Polychronopoulou S, Stoltze U, Toksvang LN, Wahlberg A, Junk SV, Schmiegelow K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41361660"},{"title01":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","title02":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","journal":"Leukemia","issue":"2026 January; 40(1):261. doi: 10.1038\/s41375-025-02824-y","author":"Tedeschi A, Frustaci AM, Menna P, Minotti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41331358"},{"title01":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","title02":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","journal":"Leukemia","issue":"2026 January; 40(1):178-187. doi: 10.1038\/s41375-025-02814-0","author":"Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho G, Gondek L, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Versino F, Montoro MJ, Torres-Esquius S, Jerez Cayuela A, Lopez-Esteban M, Martinez-Laperche C, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski JP, Ogawa S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41339477"},{"title01":"40 years of LEUKEMIA.","title02":"40 years of LEUKEMIA.","journal":"Leukemia","issue":"2026 January; 40(1):1-2. doi: 10.1038\/s41375-025-02840-y","author":"Hochhaus A, Gale RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41361661"},{"title01":"Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE\/CML-IX).","title02":"Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE\/CML-IX).","journal":"Leukemia","issue":"2026 January 12. doi: 10.1038\/s41375-025-02859-1. Online ahead of print","author":"Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, Metzelder SK, Pauck K, Garn H, Raifer H, Huber M, Gattermann N, Crysandt M, Schafhausen P, Bormann M, Radsak MP, Guerci-Bresler A, Illmer T, Goebeler ME, Herhaus P, Teichmann LL, Franke GN, Lang F, Krause SW, Mohle R, Klausmann M, Stegelmann F, Lutz C, Etienne G, Stoltefuss A, Gothert JR, Ernst T, Abu-Samra M, Hoffkes HG, Neubauer A, Wang Y, Weiland P, Otto C, Kiessler L, Weber T, Kroning L, Nist A, Stiewe T, Hehlmann R, Aminossadati B, Wittenberg M, Winterstein K, Oellerich T, Lechner M, Pfirrmann M, Schade-Brittinger C, Klemm P, Michel C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41526617"},{"title01":"Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis.","title02":"Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis.","journal":"Leukemia","issue":"2026 January; 40(1):120-129. doi: 10.1038\/s41375-025-02753-w","author":"Geels J, van Rhenen A, Gradowska P, Asselbergs FW, Linschoten M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41073560"},{"title01":"REL overexpression and sustained NF-kappaB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.","title02":"REL overexpression and sustained NF-kappaB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):188-198. doi: 10.1038\/s41375-025-02818-w","author":"Dehgane L, Mallet E, Brasseur C, Krzisch D, Zeitouni W, Hitier C, Ayoub M, Dubois K, Perez Carretero C, Roos-Weil D, Choquet S, Maloum K, Bravetti C, Armand M, Garnier D, Hernandez-Rivas JM, Susin SA, Nguyen-Khac F, Chapiro E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41366531"},{"title01":"Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.","title02":"Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):262. doi: 10.1038\/s41375-025-02827-9","author":"DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41372600"},{"title01":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","title02":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","journal":"Leukemia","issue":"2026 January; 40(1):55-62. doi: 10.1038\/s41375-025-02820-2","author":"Truger M, Meggendorfer M, Walter W, Hutter S, Alsdorf W, Massenkeil G, Martens UM, Kern W, Horst K, Kuhn C, Reiter A, Hochhaus A, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419605"},{"title01":"Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.","title02":"Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.","journal":"Leukemia","issue":"2026 January; 40(1):29-36. doi: 10.1038\/s41375-025-02826-w","author":"Ernst P, Lohse C, Lauseker M, Geissler J, le Coutre P, Brummendorf TH, Saussele S, Burchert A, Franke GN, La Rosee P, Brioli A, Schenk T, Fabisch C, Ernst T, Mehlkop G, Hochhaus A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419606"},{"title01":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","title02":"Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02854-6. Online ahead of print","author":"Fujimoto A, Maeda T, Doki N, Fukuhara N, Iwaki N, Hiramoto N, Goto H, Miyazaki T, Shiki I, Miyazaki K, Yamaguchi M, Ishida F, Suzuki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501503"},{"title01":"Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.","title02":"Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02846-6. Online ahead of print","author":"Ayoub M, Hitier C, Dehgane L, Mallet E, Tannoury M, Nemazanyy I, Roos-Weil D, Maloum K, Ringshausen I, Chapiro E, Nguyen-Khac F, Garnier D, Lagouge M, Lerner LK, Susin SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501504"},{"title01":"Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.","title02":"Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis.","journal":"Leukemia","issue":"2026 January 7. doi: 10.1038\/s41375-025-02797-y. Online ahead of print","author":"Agathangelidis A, Iatrou A, Pechlivanis N, Karakatsoulis G, Zaragoza-Infante L, Galigalidou C, Maity PC, Ranghetti P, Almeida J, Fuentes-Herrero B, Navarro A, Alcoceba M, Rabbani L, Thorvaldsdottir B, Scarfo L, Orfao A, Psomopoulos F, Jumaa H, Rosenquist R, Chatzidimitriou A, Ghia P, Stamatopoulos K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41501505"},{"title01":"Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","title02":"Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","issue":"2026 January; 44(1):42-53. doi: 10.1200\/JCO-25-01841","author":"Montesinos P, Rodriguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodriguez-Arboli E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, Lopez-Lopez JA, Vives S, Lopez-Lorenzo JL, Colorado M, Vidriales MB, Garcia Boyero R, Olave MT, Herrera Puente P, Arce O, Barrios M, Jose Sayas M, Polo M, Gomez-Roncero MI, Barragan E, Ayala R, Chillon C, Calasanz MJ, Paiva B, Boluda B, Casas-Aviles I, Lloret-Madrid P, Sanchez MJ, Rodriguez-Medina C, Cuevas L, Raposo-Puglia JA, Mateos MC, Olivares M, Martinez-Chamorro C, Alonso N, Suarez S, Sanchez-Vadillo I, Sole Rodriguez M, Gonzalez BJ, Martinez-Frances A, Cuello R, Fernandez A, Martinez-Cuadron D, Labrador J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41082703"},{"title01":"Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","title02":"Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","issue":"2026 January; 44(1):68. doi: 10.1200\/JCO-25-01666","author":"Fuji S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264888"},{"title01":"Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.","title02":"Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","issue":"2026 January 8; JCO2501806. doi: 10.1200\/JCO-25-01806. Online ahead of print","author":"Vieira Martins M, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, Stary J, Ferster A, Brethon B, Locatelli F, Schrappe M, Scholte-van Houtem PE, Valsecchi MG, Huitema ADR, Pieters R, van der Sluis IM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41505662"},{"title01":"Durable remission achieved in pediatric patients with TCF3-HLF-positive relapsed\/refractory B-cell acute lymphoblastic leukemia by dual CD19- and CD22-targeted chimeric antigen receptor T-cell therapy.","title02":"Durable remission achieved in pediatric patients with TCF3-HLF-positive relapsed\/refractory B-cell acute lymphoblastic leukemia by dual CD19- and CD22-targeted chimeric antigen receptor T-cell therapy.","journal":"Haematologica","issue":"2026 January 1; 111(1):340-344. doi: 10.3324\/haematol.2024.287023","author":"Wan X, Wang T, Yang J, Yang X, Li W, Ding L, Yang L, Zhang J, Su M, An K, Zhou Z, Li Y, Wang X, Zhu H, Luo C, Gu L, Chen J, Song L, Tang Y, Li B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400462"},{"title01":"Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.","title02":"Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):350-354. doi: 10.3324\/haematol.2024.287253","author":"Rockwell B, Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica AR, Kornblum N, Shah N, Levitz D, Shapiro LC, Gupta R, Munoz A, Dhawan A, Fehn K, Comas M, Verceles J, Cooper DL, Konopleva M, Feldman EJ, Verma A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671491"},{"title01":"Asparaginase-associated pancreatitis during therapy for pediatric acute lymphoblastic leukemia.","title02":"Asparaginase-associated pancreatitis during therapy for pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2026 January 1; 111(1):335-339. doi: 10.3324\/haematol.2024.286803","author":"McCarville MB, Ashcraft E, Ribeiro RC, Rees M, Swanson HD, Inaba H, Jeha S, Cheng C, Pui CH, Karol SE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820809"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2026 January 8; 394(2):152-165. doi: 10.1056\/NEJMoa2505478","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study.","title02":"Intensive chemotherapy for high-risk acute lymphoblastic leukemia in first remission: results from the NOPHO ALL2008 study.","journal":"Leukemia","issue":"2026 January; 40(1):215-218. doi: 10.1038\/s41375-025-02789-y","author":"Nikkila A, Lohi O, Abrahamsson J, Griskevicius L, Hallbook H, Jonsson OG, Lund B, Marquart HV, Overgaard U, Palk K, Pruunsild K, Quist-Paulsen P, Toft N, Vaitkeviciene GE, Wartiovaara-Kautto U, Heyman M, Vettenranta K, Schmiegelow K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145672"},{"title01":"CRISPR\/Cas9-mediated t(4;11) translocation in human hematopoietic stem\/precursor cells demonstrates plasticity to differentiate into either the myeloid or lymphoid lineage.","title02":"CRISPR\/Cas9-mediated t(4;11) translocation in human hematopoietic stem\/precursor cells demonstrates plasticity to differentiate into either the myeloid or lymphoid lineage.","journal":"Leukemia","issue":"2026 January; 40(1):72-86. doi: 10.1038\/s41375-025-02791-4","author":"Benz T, Larghero P, Meyer C, Hanewald T, Bruggmann D, Hentrich AE, Louwen F, Marschalek R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145673"},{"title01":"Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.","title02":"Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):130-137. doi: 10.1038\/s41375-025-02764-7","author":"Greiner J, Schuler PJ, Schrezenmeier H, Weiss J, Bulach C, Goetz M, Guinn BA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41145674"},{"title01":"The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival.","title02":"The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival.","journal":"Leukemia","issue":"2026 January; 40(1):138-151. doi: 10.1038\/s41375-025-02799-w","author":"Dhir A, Ethell A, Watkins R, Lam C, Tur-Rodriguez K, Persinger J, Dobish KK, Panda S, Buckley SM, Swenson SA, Brahma S, Rowley MJ, Hyde RK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214140"},{"title01":"Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.","title02":"Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.","journal":"Leukemia","issue":"2026 January; 40(1):230-234. doi: 10.1038\/s41375-025-02800-6","author":"Locatelli F, Rizzari C, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Eckert C, Moricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, Desai R, Henry M, Zugmaier G, von Stackelberg A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41233549"},{"title01":"Oncogenic activation of EVC\/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.","title02":"Oncogenic activation of EVC\/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.","journal":"Leukemia","issue":"2026 January; 40(1):166-177. doi: 10.1038\/s41375-025-02803-3","author":"Sui P, Li Y, Hong J, Delma CR, Chen S, Wang J, Zhang P, Han S, Noor A, Yang H, Pang Y, Luan Y, Xu M, Lee J, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41249566"},{"title01":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.","title02":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.","journal":"Leukemia","issue":"2026 January; 40(1):47-54. doi: 10.1038\/s41375-025-02796-z","author":"Castagnetti F, Breccia M, Abruzzese E, Bassan R, Binotto G, Bonifacio M, Caocci G, Capodanno I, Cavazzini F, Cimino G, Fazi P, Gozzini A, Iurlo A, Janssen JJWM, Lunghi M, Marasca R, Martino B, Messina M, Muriano F, Paoloni F, Piciocchi A, Rosti G, Russo Rossi A, Saglio G, Sica S, Soverini S, Tafuri A, Vallisa D, Westerweel PE, Pane F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41254114"},{"title01":"Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody.","title02":"Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody.","journal":"Blood","issue":"2025 December 25; 146(26):3201-3212. doi: 10.1182\/blood.2025029836","author":"Newton NM, Agrawal K, Odell AV, Tracy T, Hackett C, Eldrup A, Whitfield M, Martyanov V, Girardi M, Sefik E, Flavell RA, Odell ID","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961242"},{"title01":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","title02":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","journal":"Blood advances","issue":"2025 December 23; 9(24):6314-6325. doi: 10.1182\/bloodadvances.2025017084","author":"Loschi M, Villy MC, Galimard JE, Auboiroux MM, Gachard N, Perani A, Duchmann M, Largeaud L, Nguyen S, Sicre de Fontbrune F, Robin M, Yakoub-Agha I, Daguindau E, Chantepie S, Charbonnier A, Lebon D, Maury S, Labussiere-Wallet H, Huynh A, Forcade E, Castilla-Llorente C, Cluzeau T, Ades L, D'aveni M, Devillier R, Maillard N, Benachour S, Dombret H, Recher C, Pigneux A, Clappier E, Delabesse E, Duployez N, Turlure P, Peffault de Latour R, Sebert M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924929"},{"title01":"Abatacept improves posttransplant survival and reduces endothelial injury syndromes in beta-thalassemia major.","title02":"Abatacept improves posttransplant survival and reduces endothelial injury syndromes in beta-thalassemia major.","journal":"Blood advances","issue":"2025 December 23; 9(24):6370-6379. doi: 10.1182\/bloodadvances.2025017197","author":"Khandelwal P, Ibrahimova A, Lane A, Grimley M, Davies SM, Jodele S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40938738"},{"title01":"Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation.","title02":"Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation.","journal":"Blood advances","issue":"2025 December 23; 9(24):6394-6401. doi: 10.1182\/bloodadvances.2025016655","author":"Bhasin-Chhabra B, Wang T, Levine JE, Shenoy S, Perales MA, Bashey A, Raff H, Saber W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991367"},{"title01":"In situ gene editing of hematopoietic stem cells via AAV-delivered CRISPR guide RNAs.","title02":"In situ gene editing of hematopoietic stem cells via AAV-delivered CRISPR guide RNAs.","journal":"Blood advances","issue":"2025 December 23; 9(24):6563-6574. doi: 10.1182\/bloodadvances.2025016775","author":"Karimzadeh A, Kim R, Garcia V, Florea M, Peacker BL, Kobayashi S, Watkins D, Messemer K, Zeng J, Bauer DE, Serwold T, Wagers AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991373"},{"title01":"Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.","title02":"Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.","journal":"Blood advances","issue":"2025 December 23; 9(24):6305-6313. doi: 10.1182\/bloodadvances.2025017097","author":"Rubinstein JD, Pham G, Sridharan A, Khoury R, Wang YM, Hudda Z, Wilhelm J, Lichtenstein DA, Heyenbruch D, Cancelas JA, Davies SM, Lutzko C, Grimley MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991376"},{"title01":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","title02":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","journal":"Blood advances","issue":"2025 December 23; 9(24):6524-6533. doi: 10.1182\/bloodadvances.2025016054","author":"Tanhehco YC, Thibodeaux S, Shi PA, Chou ST, Kelly SA, Monis GF, Newton C, West-Mitchell K, Zheng Y, Fernandez C, Anderson C, Ching K, Coleman-Cowger V, Shapiro A, Manis JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41396678"},{"title01":"A genome-wide screen identifies Runx2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment.","title02":"A genome-wide screen identifies Runx2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment.","journal":"Blood","issue":"2025 December 25; 146(26):3188-3200. doi: 10.1182\/blood.2025029115","author":"Meaker GA, Nicholls M, Chahrour C, Hsu I, Smith A, Bozhilov Y, Leung M, Vassort H, Olender L, Beaven O, Huang X, Brown EJ, Vanden Bempt M, Khoo HM, Bhadury J, Milne TA, Wilkinson AC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961240"},{"title01":"MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.","title02":"MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.","journal":"Blood","issue":"2025 December 18; 146(25):3098-3105. doi: 10.1182\/blood.2025028914","author":"Pastoors D, Havermans M, Mulet-Lazaro R, Smeenk L, Ottema S, Erpelinck-Verschueren C, van Herk S, Anthonissen M, Grob T, Subramanian S, Thoms JAI, Pimanda JE, Wouters BJ, Beverloo B, Haferlach T, Haferlach C, Zuber J, Bindels E, Delwel R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060369"},{"title01":"Runx2 takes center stage in regulating HSC expansion.","title02":"Runx2 takes center stage in regulating HSC expansion.","journal":"Blood","issue":"2025 December 25; 146(26):3135-3136. doi: 10.1182\/blood.2025031276","author":"Miles LA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41447456"},{"title01":"Enterococcus induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","title02":"Enterococcus induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","journal":"Blood","issue":"2025 December 29. doi: 10.1182\/blood.2024028248. Online ahead of print","author":"Nguyen C, Funes J, Ghale R, Duong N, Victor K, Gipson B, Zhang ZJ, Dai A, Li R, Armijo GK, Huang AS, Martinez M, Chen Y, Ghazarian DM, Docampo MD, Pathak KV, Pirrotte P, Markey KA, Peled JU, Paredes J, Burgos da Silva M, van den Brink MRM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460962"},{"title01":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","title02":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","journal":"Lancet","issue":"2025 December 21; 404(10471):2584-2592. doi: 10.1016\/S0140-6736(24)01880-4","author":"Rio P, Zubicaray J, Navarro S, Galvez E, Sanchez-Dominguez R, Nicoletti E, Sebastian E, Rothe M, Pujol R, Bogliolo M, John-Neek P, Bastone AL, Schambach A, Wang W, Schmidt M, Larcher L, Segovia JC, Yanez RM, Alberquilla O, Diez B, Fernandez-Garcia M, Garcia-Garcia L, Ramirez M, Galy A, Lefrere F, Cavazzana M, Leblanc T, Garcia de Andoin N, Lopez-Almaraz R, Catala A, Barquinero J, Rodriguez-Perales S, Rao G, Surralles J, Soulier J, Diaz-de-Heredia C, Schwartz JD, Sevilla J, Bueren JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39642902"},{"title01":"Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021.","title02":"Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021.","journal":"Lancet","issue":"2025 December 21; 404(10471):2543-2583. doi: 10.1016\/S0140-6736(24)01821-X","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39667386"},{"title01":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","title02":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","journal":"Blood advances","issue":"2025 December 23; 9(24):6524-6533. doi: 10.1182\/bloodadvances.2025016054","author":"Tanhehco YC, Thibodeaux S, Shi PA, Chou ST, Kelly SA, Monis GF, Newton C, West-Mitchell K, Zheng Y, Fernandez C, Anderson C, Ching K, Coleman-Cowger V, Shapiro A, Manis JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41396678"},{"title01":"Platelet Dysfunction in Chronic Kidney Disease Arises from Bone Marrow Remodeling and Megakaryocyte Reprogramming.","title02":"Platelet Dysfunction in Chronic Kidney Disease Arises from Bone Marrow Remodeling and Megakaryocyte Reprogramming.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025017625. Online ahead of print","author":"Carminita E, Camacho V, Branfield S, Walsey E, Barrachina MN, Tabang DN, Lee DH, Becker IC, Brodsky S, Issa SM, Gendron N, Machado S, Wolberg AS, Steen H, Kerlin BA, Machlus KR, Zarjou A, Italiano JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411491"},{"title01":"Epo and hypoxia accelerate a pattern of gradual cell cycle shortening in BFU-e and CFU-e erythroid progenitors in vivo.","title02":"Epo and hypoxia accelerate a pattern of gradual cell cycle shortening in BFU-e and CFU-e erythroid progenitors in vivo.","journal":"Blood advances","issue":"2025 December 24. doi: 10.1182\/bloodadvances.2025017907. Online ahead of print","author":"Winward A, Lalonde L, Nair D, Socolovsky M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441873"},{"title01":"Rbm38 deficiency impairs erythroid heme biosynthesis and induces porphyria via reduced ferrochelatase expression.","title02":"Rbm38 deficiency impairs erythroid heme biosynthesis and induces porphyria via reduced ferrochelatase expression.","journal":"Blood","issue":"2025 December 18; 146(25):3106-3123. doi: 10.1182\/blood.2025028783","author":"Xie X, Zou A, Zhang L, Ma X, He Y, Liu H, Lu Y, Yang Y, Ouyang J, Liu K, Zhong P, Li J, Xu S, Zhou L, Han B, Chen M, Lv K, Zhang D, Liu L, Mei Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40961234"},{"title01":"NMNAT3 deficiency: a novel red blood cell enzymopathy causing hemolysis by altering NAD levels and glycolysis.","title02":"NMNAT3 deficiency: a novel red blood cell enzymopathy causing hemolysis by altering NAD levels and glycolysis.","journal":"Blood","issue":"2025 December 25; 146(26):3246-3249. doi: 10.1182\/blood.2025030958","author":"Ruiter TJJ, van Oirschot BA, Waanders E, Koop K, van Solinge WW, van Wijk R, Jans JJM, Bartels M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100733"},{"title01":"Rbm38 binds Fech pre-mRNA to prevent anemia and porphyria.","title02":"Rbm38 binds Fech pre-mRNA to prevent anemia and porphyria.","journal":"Blood","issue":"2025 December 18; 146(25):3016-3017. doi: 10.1182\/blood.2025031227","author":"An X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410917"},{"title01":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","title02":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","journal":"Leukemia","issue":"2025 December 17. doi: 10.1038\/s41375-025-02839-5. Online ahead of print","author":"Fullin J, Topcu E, Zielinska KA, Schimmer RR, Klemm N, Koch C, Caiado F, Lock M, Doerdelmann C, Buhler MM, Tchinda J, Kurppa KJ, Borsig L, Jones PH, Lopes M, Manz MG, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41407825"},{"title01":"A novel GATA1 variant linking germline and somatic myelodysplastic syndrome in two patients.","title02":"A novel GATA1 variant linking germline and somatic myelodysplastic syndrome in two patients.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.289133. Online ahead of print","author":"Revilla N, Atance M, Grasa JM, Garcia-Ortego A, Soto C, Rodriguez-Pinilla SM, Arquero T, Perlado S, Ledesma S, Esquinas-Tarifa E, Serrano-Lopez J, Lopez-Lorenzo JL, Velasco-Rodriguez D, Alonso-Dominguez JM, Mata R, Llamas-Sillero P, Salgado RN, Rio-Machin A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437813"},{"title01":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","title02":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288906. Online ahead of print","author":"Wang SA, Ok CY, Tsai HK, Loayza N, Daneshpajouhnejad P, Seth N, Cantu MD, Bagg A, Tam W, Weinberg O, Barone PD, Geyer JT, Lindsley CR, Montalban-Bravo G, Simon CR, Arber DA, Bueso-Ramos CE, Hsi ED, Foucar K, Orazi A, Patnaik MM, Hasserjian RP, Reichard KK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437825"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2025 December 24. doi: 10.1111\/bjh.70303. Online ahead of print","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","title02":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","journal":"Blood advances","issue":"2025 December 23; 9(24):6314-6325. doi: 10.1182\/bloodadvances.2025017084","author":"Loschi M, Villy MC, Galimard JE, Auboiroux MM, Gachard N, Perani A, Duchmann M, Largeaud L, Nguyen S, Sicre de Fontbrune F, Robin M, Yakoub-Agha I, Daguindau E, Chantepie S, Charbonnier A, Lebon D, Maury S, Labussiere-Wallet H, Huynh A, Forcade E, Castilla-Llorente C, Cluzeau T, Ades L, D'aveni M, Devillier R, Maillard N, Benachour S, Dombret H, Recher C, Pigneux A, Clappier E, Delabesse E, Duployez N, Turlure P, Peffault de Latour R, Sebert M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924929"},{"title01":"Luspatercept for patients with lower-risk myelodysplastic syndromes\/neoplasms: a systematic review and meta-analysis.","title02":"Luspatercept for patients with lower-risk myelodysplastic syndromes\/neoplasms: a systematic review and meta-analysis.","journal":"Blood advances","issue":"2025 December 23; 9(24):6511-6523. doi: 10.1182\/bloodadvances.2025017611","author":"Alhajahjeh A, Woite NL, Rolles B, Stempel JM, Mina A, Mendez L, Kewan T, Podoltsev NA, Stahl M, Grimshaw AA, Zeidan AM, Bewersdorf JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966428"},{"title01":"Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.","title02":"Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.","journal":"Leukemia","issue":"2025 December 23. doi: 10.1038\/s41375-025-02836-8. Online ahead of print","author":"Guy A, Mansier O, Decilap M, Catherineau A, Garcia G, Labrouche-Colomer S, Bats ML, Boyer F, Ianotto JC, Lippert E, Roy L, Tavitian S, Slama B, Girault S, Etienne G, Parry A, Saint-Lezer A, Denis G, Mediavilla C, Viallard JF, Legros L, Ranta D, Wemeau M, Nicolini FE, Lifermann F, Cambier N, Darnige L, Girodon F, Soret-Dulphy J, Cayssials E, Vacheret F, Sureau L, Paz DL, Ugo V, Kiladjian JJ, Thiebaut R, James C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41436639"},{"title01":"Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22\/CD40.","title02":"Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22\/CD40.","journal":"Blood","issue":"2025 December 25; 146(26):3228-3233. doi: 10.1182\/blood.2025028489","author":"Tapper WJ, Dawoud AAZ, Score J, Chase AJ, Baxter EJ, Ewing J, Wallis L, Guglielmelli P, Colomer D, Bellosillo B, Gomez M, Hernandez-Boluda JC, Besses C, Cervantes F, Koschmieder S, Green AR, Reiter A, Vannucchi A, Harrison C, Cross NCP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026930"},{"title01":"The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms.","title02":"The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms.","journal":"Blood","issue":"2025 December 17. doi: 10.1182\/blood.2025028703. Online ahead of print","author":"Yan Y, Liu J, Zhao S, Li F, Yang L, Xu Z, Qin T, Zhu X, An W, Shi Z, Shen W, Zhang P, Huang G, Rampal RK, Xiao Z, Li B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405487"},{"title01":"MPN predisposition: shared roots, split branches.","title02":"MPN predisposition: shared roots, split branches.","journal":"Blood","issue":"2025 December 25; 146(26):3140-3141. doi: 10.1182\/blood.2025031510","author":"Agarwal G, Sankaran VG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41447454"},{"title01":"CSF1R modulates megakaryopoiesis by targeting RUNX1 in immune thrombocytopenia.","title02":"CSF1R modulates megakaryopoiesis by targeting RUNX1 in immune thrombocytopenia.","journal":"Haematologica","issue":"2025 December 18. doi: 10.3324\/haematol.2025.288511. Online ahead of print","author":"Han H, Zhou M, Qi J, Song X, Li X, Zhang Z, Pan T, Xu X, Guo M, Wu D, Han Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41414965"},{"title01":"Incidence of systemic lupus erythematosus in patients with immune thrombocytopenia: A nationwide study.","title02":"Incidence of systemic lupus erythematosus in patients with immune thrombocytopenia: A nationwide study.","journal":"Br J Haematol","issue":"2025 December 22. doi: 10.1111\/bjh.70299. Online ahead of print","author":"Rasmussen M, Mannering N, Frederiksen H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41431208"},{"title01":"Real world comparison of progression free survival and time to next therapy in 761 newly diagnosed multiple myeloma patients.","title02":"Real world comparison of progression free survival and time to next therapy in 761 newly diagnosed multiple myeloma patients.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025018655. Online ahead of print","author":"Mian H, Arribas M, Fonseca R, Mutterback E, Shahid O, Gouda R, Pond GR, Visram A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411522"},{"title01":"Plasma Cell Leukemia: Genomic Features and Their Potential Relevance for Exploring Clinical Actionability.","title02":"Plasma Cell Leukemia: Genomic Features and Their Potential Relevance for Exploring Clinical Actionability.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025018342. Online ahead of print","author":"Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan SV, Dhakal B, D'Souza A, Lin DI, Ho C, Kurzrock R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411484"},{"title01":"Dual anti-CD19\/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.","title02":"Dual anti-CD19\/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.","journal":"Blood advances","issue":"2025 December 23; 9(24):6340-6344. doi: 10.1182\/bloodadvances.2025017770","author":"Roerden M, Hensen L, Besemer B, Schwartz F, Reuss K, Weiss-Haug A, Harland L, Ginsberg F, Faul C, Bethge W, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026972"},{"title01":"Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma.","title02":"Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma.","journal":"Blood advances","issue":"2025 December 23; 9(24):6246-6251. doi: 10.1182\/bloodadvances.2025016659","author":"Bilotta MT, Solimando AG, Desantis V, Di Marzo L, Sabatini A, Forcelloni S, Andriano A, Morizio A, Argentiero A, Ria R, Quatrini L, Moretta L, Vacca P, Tumino N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924928"},{"title01":"Clinical applications of mass spectrometry in multiple myeloma.","title02":"Clinical applications of mass spectrometry in multiple myeloma.","journal":"Blood advances","issue":"2025 December 23; 9(24):6593-6603. doi: 10.1182\/bloodadvances.2024015685","author":"Derman BA, Yee AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40921003"},{"title01":"Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.","title02":"Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.","journal":"Blood","issue":"2025 December 18. doi: 10.1182\/blood.2025030083. Online ahead of print","author":"Fokkema C, Bertamini L, de Jong MME, Tahri S, Hofste Op Bruinink D, Kellermayer Z, Papazian N, den Hollander C, Vermeulen M, Stoetman ECG, van Beek G, Hoogenboezem R, van der Velden VHJ, Hulin C, Perrot A, Moreau P, Rowe M, Vieyra D, Carson R, van Duin M, Sanders MA, Broijl A, Sonneveld P, Cupedo T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411148"},{"title01":"Premaintenance PET in patients with myeloma.","title02":"Premaintenance PET in patients with myeloma.","journal":"Blood","issue":"2025 December 18; 146(25):3130. doi: 10.1182\/blood.2025032271","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410915"},{"title01":"Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs.","title02":"Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs.","journal":"Blood","issue":"2025 December 17. doi: 10.1182\/blood.2025029572. Online ahead of print","author":"Jelinek T, Zihala D, Zabaleta A, Kostopoulos IV, Soucek O, Venglar O, Moreno C, Fotiou D, Radova E, Tamariz-Amador LE, Theodorakakou F, Muronova L, Manubens A, Tsitsilonis O, Popkova T, Gonzalez C, Anilkumar Sithara A, Corrado F, Bidikian N, Guerrero C, Kapustova V, Bilek D, Hagner PR, Larrayoz M, Martinez-Climent JA, Broskevicova L, Mihalyova J, Merz M, Sevcikova T, Ghobrial IM, San-Miguel JF, Dimopoulos MA, Rodriguez-Otero P, Radocha J, Kastritis E, Paiva B, Hajek R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405507"},{"title01":"Prognostic value of premaintenance FDG PET\/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.","title02":"Prognostic value of premaintenance FDG PET\/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.","journal":"Blood","issue":"2025 December 18; 146(25):3050-3058. doi: 10.1182\/blood.2025030084","author":"Kraeber-Bodere F, Jamet B, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, Leleu X, Belhadj K, Itti E, Karlin L, Bailly C, Levin MD, Minnema MC, Bodet-Milin C, de Keizer B, Corre J, Sonneveld P, Moreau P, Carlier T, Touzeau C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991848"},{"title01":"Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.","title02":"Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.","journal":"Blood advances","issue":"2025 December 23; 9(24):6305-6313. doi: 10.1182\/bloodadvances.2025017097","author":"Rubinstein JD, Pham G, Sridharan A, Khoury R, Wang YM, Hudda Z, Wilhelm J, Lichtenstein DA, Heyenbruch D, Cancelas JA, Davies SM, Lutzko C, Grimley MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991376"},{"title01":"Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel.","title02":"Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel.","journal":"Blood advances","issue":"2025 December 23; 9(24):6481-6490. doi: 10.1182\/bloodadvances.2025016701","author":"Sharma A, Locatelli F, Bhatia M, Molinari L, Mapara MY, Liem RI, Dedeken L, Wall D, Eckrich MJ, Kuo KHM, Smith W, Imren S, Kohli P, Li N, Liu T, Rubin J, Hobbs W, Grupp SA, Frangoul H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857358"},{"title01":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","title02":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.","journal":"Blood advances","issue":"2025 December 23; 9(24):6524-6533. doi: 10.1182\/bloodadvances.2025016054","author":"Tanhehco YC, Thibodeaux S, Shi PA, Chou ST, Kelly SA, Monis GF, Newton C, West-Mitchell K, Zheng Y, Fernandez C, Anderson C, Ching K, Coleman-Cowger V, Shapiro A, Manis JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41396678"},{"title01":"Improvements in health-related quality of life in patients with transfusion-dependent beta-thalassemia after exagamglogene autotemcel.","title02":"Improvements in health-related quality of life in patients with transfusion-dependent beta-thalassemia after exagamglogene autotemcel.","journal":"Blood advances","issue":"2025 December 23; 9(24):6502-6510. doi: 10.1182\/bloodadvances.2025016702","author":"Fuente J, Frangoul H, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, Shah AJ, Carpenter B, Kwiatkowski JL, Mapara MY, Liem RI, Rupprecht J, Kuo KHM, Merkeley H, Algeri M, Smith W, Kohli P, Li N, Rubin J, Zhang S, Hobbs W, Locatelli F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40862696"},{"title01":"A Proposal for Expedited Stem Cell Transplantation for TP53-Mutant Myelodysplastic Neoplasms and Acute Myeloid Leukemia.","title02":"A Proposal for Expedited Stem Cell Transplantation for TP53-Mutant Myelodysplastic Neoplasms and Acute Myeloid Leukemia.","journal":"Blood advances","issue":"2025 December 24. doi: 10.1182\/bloodadvances.2025017795. Online ahead of print","author":"Patel SA, Devine SM, Cerny J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441875"},{"title01":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.","title02":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.","journal":"Blood","issue":"2025 December 25; 146(26):3163-3174. doi: 10.1182\/blood.2025029532","author":"Geyer MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B, McAvoy D, Katsamakis Z, Lorenc R, Lewis AM, Gipson B, Cuibus MA, Girotra NN, Wu K, Smith N, Burns ER, Um JS, Yoo S, Masouleh BK, Galera P, Hosszu K, Chaudhari J, Wang X, Lin Q, Curran KJ, Park JH, Scheinberg DA, van den Brink MRM, Abdel-Wahab O, Brentjens RJ, Daniyan AF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864984"},{"title01":"Posttransplant Cyclophosphamide in HLA-matched Peripheral Blood Transplantation: What&#8217;s next?","title02":"Posttransplant Cyclophosphamide in HLA-matched Peripheral Blood Transplantation: What&#8217;s next?","journal":"Blood","issue":"2025 December 18. doi: 10.1182\/blood.2025030416. Online ahead of print","author":"Curtis DJ, Hill GR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411147"},{"title01":"Enterococcus induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","title02":"Enterococcus induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.","journal":"Blood","issue":"2025 December 29. doi: 10.1182\/blood.2024028248. Online ahead of print","author":"Nguyen C, Funes J, Ghale R, Duong N, Victor K, Gipson B, Zhang ZJ, Dai A, Li R, Armijo GK, Huang AS, Martinez M, Chen Y, Ghazarian DM, Docampo MD, Pathak KV, Pirrotte P, Markey KA, Peled JU, Paredes J, Burgos da Silva M, van den Brink MRM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460962"},{"title01":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","title02":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","journal":"Lancet","issue":"2025 December 21; 404(10471):2584-2592. doi: 10.1016\/S0140-6736(24)01880-4","author":"Rio P, Zubicaray J, Navarro S, Galvez E, Sanchez-Dominguez R, Nicoletti E, Sebastian E, Rothe M, Pujol R, Bogliolo M, John-Neek P, Bastone AL, Schambach A, Wang W, Schmidt M, Larcher L, Segovia JC, Yanez RM, Alberquilla O, Diez B, Fernandez-Garcia M, Garcia-Garcia L, Ramirez M, Galy A, Lefrere F, Cavazzana M, Leblanc T, Garcia de Andoin N, Lopez-Almaraz R, Catala A, Barquinero J, Rodriguez-Perales S, Rao G, Surralles J, Soulier J, Diaz-de-Heredia C, Schwartz JD, Sevilla J, Bueren JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39642902"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2025 December 17; JCO2500889. doi: 10.1200\/JCO-25-00889. Online ahead of print","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Lipid dysregulation after hematopoietic stem cell transplant.","title02":"Lipid dysregulation after hematopoietic stem cell transplant.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288933. Online ahead of print","author":"Koo J, Langenberg L, Zhao X, Setchell KR, Lake KE, Luebbering N, Walter E, Lane A, Myers KC, Reynaud D, Sabulski A, Teusink-Cross A, Jodele S, Davies SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437821"},{"title01":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","title02":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","journal":"Br J Haematol","issue":"2025 December 19. doi: 10.1111\/bjh.70289. Online ahead of print","author":"Boudry A, Chevillon F, Marceau-Renaut A, Braun T, Boyer T, Helevaut N, Fournier E, Geffroy S, Boissel N, Clappier E, Preudhomme C, Duployez N, Poirot C, Fenwarth L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41416831"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2025 December 24. doi: 10.1111\/bjh.70303. Online ahead of print","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration.","title02":"Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration.","journal":"Blood advances","issue":"2025 December 23; 9(24):6575-6589. doi: 10.1182\/bloodadvances.2024015762","author":"Liu X, Wu J, Li X, Pan R, Liu L, Huang T, Ma L, Chen G, Wang Q, Zhang N, Tong X, Tan Y, Jiang H, Liang Y, Shen M, Li R, Yin W, Zhang X, Zhou F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920990"},{"title01":"Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed\/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib\/II Trial.","title02":"Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed\/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib\/II Trial.","journal":"J Clin Oncol","issue":"2025 December 20; 43(36):3788-3798. doi: 10.1200\/JCO-25-00992","author":"Hutchings M, Sureda A, Bosch F, Larsen TS, Corradini P, Avigdor A, Terol MJ, Dominguez AR, Pinto A, Skarbnik A, Cordoba R, Jorgensen JM, Zinzani PL, Leung W, Bottos A, Li D, Relf J, Tandon M, Sellam G, Gritti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41115257"},{"title01":"Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory\/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.","title02":"Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory\/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.","journal":"J Clin Oncol","issue":"2025 December 20; 43(36):3799-3811. doi: 10.1200\/JCO-25-01957","author":"Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Leao Cordeiro de Farias D, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41037766"},{"title01":"Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.","title02":"Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.","journal":"J Clin Oncol","issue":"2025 December 22; JCO2501587. doi: 10.1200\/JCO-25-01587. Online ahead of print","author":"Krupka JA, Moutsopoulos I, Cutmore NH, Trethewey CS, Dayimu A, Goodhew R, Kaji F, Raso-Barnett L, Cheow H, Elzubeir L, Smith J, Kamil A, Barbara RR, Price J, Elston K, Kolodziejczyk A, Tarantino S, Mariscotti F, Barry P, Frost S, Demiris N, Thomas MG, Hassane D, Munugalavadla V, Nagumantry SK, Karanth MJ, Ahearne M, Shah N, Fox CP, Anand S, Hodson DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428995"},{"title01":"Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysis.","title02":"Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysis.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288419. Online ahead of print","author":"Marcus R, Avigdor A, Greenbaum U, Brown S, Fried S, Golan-Accav N, Shem-Tov N, Yerushalmi R, Danylesko I, Jacoby E, Nagler A, Shimoni A, Itzhaki O, Esensten J, Valid OB, Ballweg A, Deschenes-Simard X, Luttwak E, Shah G, Scordo M, Dahi P, Perales MA, Zuckerman T, Devlin SM, Yehudai-Ofir D, Khatib H, Shibly N, Shouval R, Beyar-Katz O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437832"},{"title01":"Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.","title02":"Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.289294. Online ahead of print","author":"Lee D, Dahiya S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437826"},{"title01":"Secondary T-cell lymphoma arising from pre-existing clones in a patient with diffuse large B-cell lymphoma during epcoritamab treatment following CAR-T therapy.","title02":"Secondary T-cell lymphoma arising from pre-existing clones in a patient with diffuse large B-cell lymphoma during epcoritamab treatment following CAR-T therapy.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.289269. Online ahead of print","author":"Terakawa T, Fuji S, Shi H, Amemiya Y, Nakahara W, Matsuoka Y, Tada Y, Shingai Y, Yuda S, Ishikawa J, Satomi H, Murakami H, Suga M, Hosen N, Nannya Y, Ogawa S, Yokota T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437820"},{"title01":"The importance of assessing the fitness of older patients with newly diagnosed diffuse large B-cell lymphoma and classic Hodgkin lymphoma.","title02":"The importance of assessing the fitness of older patients with newly diagnosed diffuse large B-cell lymphoma and classic Hodgkin lymphoma.","journal":"Br J Haematol","issue":"2025 December 25. doi: 10.1111\/bjh.70290. Online ahead of print","author":"Zilioli VR, Tucci A, Spina M, Merli F, Arcari A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41449752"},{"title01":"T-cell\/histiocyte-rich large B-cell lymphoma in the era of novel immunotherapy: A focused review.","title02":"T-cell\/histiocyte-rich large B-cell lymphoma in the era of novel immunotherapy: A focused review.","journal":"Br J Haematol","issue":"2025 December 23. doi: 10.1111\/bjh.70294. Online ahead of print","author":"Choy JP, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41436860"},{"title01":"Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).","title02":"Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).","journal":"Br J Haematol","issue":"2025 December 18. doi: 10.1111\/bjh.70286. Online ahead of print","author":"Kirk A, James B, Feltbower RG, Mushtaq T, Whitehead E, Kraft J, Motwani J, Parkin H, Guest J, Gray J, Palmer J, Pelling J, Appleby J, Ledwich N, Dondo TB, Amin N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410159"},{"title01":"Dynamics of circulating tumour DNA in relapsed\/refractory diffuse large B-cell lymphoma patients.","title02":"Dynamics of circulating tumour DNA in relapsed\/refractory diffuse large B-cell lymphoma patients.","journal":"Br J Haematol","issue":"2025 December 18. doi: 10.1111\/bjh.70296. Online ahead of print","author":"Zhong Y, Bult J, Veltmaat N, de Jesus FM, Sillje L, Kluiver J, van den Berg A, Plattel W, Diepstra A, Nijland M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410192"},{"title01":"Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration.","title02":"Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration.","journal":"Blood advances","issue":"2025 December 23; 9(24):6425-6431. doi: 10.1182\/bloodadvances.2025017181","author":"Gao L, Kallam A, Shouse G, Baird JH, Pak S, Qin Y, Song JY, Marcucci G, Ghoda LY, Guillen C, Hyung SJ, Saad OM, Davis H, Dere R, Batlevi CL, Meinert J, Budde LE, Danilov AV, Herrera AF, Kwak LW, Forman SJ, Godfrey JK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061156"},{"title01":"Antibody-DNA nanostructure conjugates integrate doxorubicin and rituximab to enhance therapeutic efficacy for DLBCL.","title02":"Antibody-DNA nanostructure conjugates integrate doxorubicin and rituximab to enhance therapeutic efficacy for DLBCL.","journal":"Blood advances","issue":"2025 December 23; 9(24):6549-6562. doi: 10.1182\/bloodadvances.2025017118","author":"Xia Z, Cao J, Li Y, Wu J, Ren J, Sheng W, Li C, Li S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026974"},{"title01":"Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma.","title02":"Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma.","journal":"Blood advances","issue":"2025 December 23; 9(24):6443-6454. doi: 10.1182\/bloodadvances.2025016827","author":"Ramsower CA, Wright G, Li H, Cerhan JR, Maurer MJ, Mwangi R, Rosenthal AC, Novak AJ, Link BK, Witzig TE, Habermann TM, Kridel R, LeBlanc ML, Shadman M, Smith SM, Friedberg JW, Scott DW, Steidl C, Staudt LM, Rimsza LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966421"},{"title01":"SOX11 modulates BCR signaling through the PAX5\/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma.","title02":"SOX11 modulates BCR signaling through the PAX5\/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma.","journal":"Blood advances","issue":"2025 December 23; 9(24):6267-6278. doi: 10.1182\/bloodadvances.2025016801","author":"Dutta RP, Lee HH, Leshchenko VV, Shukla RP, Yan F, Liu Y, Kaniskan HU, Qiu X, Jin J, Alinari L, Wang M, Parekh S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845256"},{"title01":"Leukemic phase of hepatosplenic T-cell lymphoma.","title02":"Leukemic phase of hepatosplenic T-cell lymphoma.","journal":"Blood","issue":"2025 December 18; 146(25):3129. doi: 10.1182\/blood.2025031068","author":"Stalls JS, Park DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410916"},{"title01":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","title02":"PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.","journal":"Blood","issue":"2025 December 17. doi: 10.1182\/blood.2025030151. Online ahead of print","author":"Desai SH, Moskowitz AJ, Merryman RW, Shah HR, Pederson LD, Geyer S, Ganesan N, Chang T, Othman T, Falade AS, Shah GL, Durani U, Sumransub N, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Armand P, Iyengar S, Micallef IN, Stuver RN, Herrera AF, Mei MG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405496"},{"title01":"Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?","title02":"Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?","journal":"Blood","issue":"2025 December 25; 146(26):3145-3152. doi: 10.1182\/blood.2025029935","author":"Jaworek CP, Brockelmann PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175363"},{"title01":"Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiency.","title02":"Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiency.","journal":"Blood","issue":"2025 December 18; 146(25):3059-3071. doi: 10.1182\/blood.2024027763","author":"Myers JA, Huang RS, Phung SK, Chacon JM, Bendzick L, Weis A, Shetty M, DePauw TA, Khaw MJ, Abrahante JE, O'Flanagan SD, Ashby KM, Lozada JR, Jameson SC, Hwang JH, Cichocki F, Felices M, Miller JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857665"},{"title01":"Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.","title02":"Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.","journal":"Blood","issue":"2025 December 29. doi: 10.1182\/blood.2025030190. Online ahead of print","author":"Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo-Domenech E, Hess BT, Schuster SR, Linhares Y, Gandhi MD, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460964"},{"title01":"Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma.","title02":"Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma.","journal":"Blood","issue":"2025 December 23. doi: 10.1182\/blood.2025031476. Online ahead of print","author":"Luan D, Valid OB, Beyar-Katz O, Tix T, Golan-Accav N, Alhomoud M, Avigdor A, Bucklein VL, Cohen L, Dahi PB, Einarsdottir S, Elimelech J, Escribano Serrat S, Falchi L, Fei T, Giralt SA, Gomez-Llobell M, Goy A, Horesh N, Israeli S, Kruk L, Leslie LA, Lue JK, Marcus R, Nagler A, Palomba ML, Park JH, Raj SS, Reddy ST, Romancik JT, Rosenbaum E, Salles GA, Scordo M, Shah GL, Shimoni A, von Bergwelt-Baildon M, Perales MA, Subklewe M, Greenbaum U, Ip A, Ram R, Rejeski K, Shouval R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41489404"},{"title01":"Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed\/refractory multiple myeloma.","title02":"Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed\/refractory multiple myeloma.","journal":"Leukemia","issue":"2025 December 22. doi: 10.1038\/s41375-025-02834-w. Online ahead of print","author":"Grozinger M, Schlanke M, Grone J, Erdmann S, Hajiyianni M, Poos AM, Thierjung H, Mai EK, Sauer S, Kaudewitz D, Veelken K, Michel CS, Frenking JH, Sester LS, Weber TF, Sedaghat S, Wennmann M, Muller-Tidow C, Schlemmer HP, Delorme S, Raab MS, Goldschmidt H, Weinhold N, John L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41430398"},{"title01":"Prognostic value of serological and PET\/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.","title02":"Prognostic value of serological and PET\/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02819-9. Online ahead of print","author":"Gustine JN, Scaringi JA, Bauer F, Cirstea DD, Branagan AR, Puliafito BR, Maus MV, Frigault MJ, Yee AJ, Mahmood U, Raje NS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419604"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02823-z. Online ahead of print","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up &#8211; a case report.","title02":"t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up &#8211; a case report.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288950. Online ahead of print","author":"Decheiver S, Schavgoulidze A, Maheo S, Vion PA, Lucidarme O, Corre J, Garderet L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437828"},{"title01":"Translocation t(11;14) and BCL2-inhibition in multiple myeloma.","title02":"Translocation t(11;14) and BCL2-inhibition in multiple myeloma.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.289147. Online ahead of print","author":"Sim S, Dhakal B, Quach H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437818"},{"title01":"Impact of the plasma cell quantification method on the International Myeloma Working Group diagnostic criteria for MGUS\/SMM.","title02":"Impact of the plasma cell quantification method on the International Myeloma Working Group diagnostic criteria for MGUS\/SMM.","journal":"Haematologica","issue":"2025 December 18. doi: 10.3324\/haematol.2025.289176. Online ahead of print","author":"Uehara A, Sakuma H, Fujii F, Toho M, Tabata R, Narita K, Takeuchi M, Matsuda R, Isuge D, Ikeda D, Miyamoto T, Takamatsu H, Matsue K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41414966"},{"title01":"NEAT1: a multifaceted long non-coding RNA in multiple myeloma.","title02":"NEAT1: a multifaceted long non-coding RNA in multiple myeloma.","journal":"Haematologica","issue":"2025 December 18. doi: 10.3324\/haematol.2025.289258. Online ahead of print","author":"Benini G, Taranto S, Sciume M, Rigali F, Marcheselli R, Abate A, Mitola S, Sigala S, Sacco A, Roccaro AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41414960"},{"title01":"Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going.","title02":"Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going.","journal":"Blood advances","issue":"2025 December 23; 9(24):6252-6266. doi: 10.1182\/bloodadvances.2024015686","author":"Zamagni E, Talarico M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875592"},{"title01":"An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden.","title02":"An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden.","journal":"Blood","issue":"2025 December 18; 146(25):3072-3085. doi: 10.1182\/blood.2025029215","author":"Meermeier EW, Pfeffer K, Stein CK, Sharik ME, Du MT, Tafoya Alvarado Y, Shi CX, Zhu YX, Bergsagel PL, Chesi M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864972"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02823-z. Online ahead of print","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","title02":"Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1\/2 (FANCOLEN-1) and long-term clinical trials.","journal":"Lancet","issue":"2025 December 21; 404(10471):2584-2592. doi: 10.1016\/S0140-6736(24)01880-4","author":"Rio P, Zubicaray J, Navarro S, Galvez E, Sanchez-Dominguez R, Nicoletti E, Sebastian E, Rothe M, Pujol R, Bogliolo M, John-Neek P, Bastone AL, Schambach A, Wang W, Schmidt M, Larcher L, Segovia JC, Yanez RM, Alberquilla O, Diez B, Fernandez-Garcia M, Garcia-Garcia L, Ramirez M, Galy A, Lefrere F, Cavazzana M, Leblanc T, Garcia de Andoin N, Lopez-Almaraz R, Catala A, Barquinero J, Rodriguez-Perales S, Rao G, Surralles J, Soulier J, Diaz-de-Heredia C, Schwartz JD, Sevilla J, Bueren JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/39642902"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2025 December 17; JCO2500889. doi: 10.1200\/JCO-25-00889. Online ahead of print","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory\/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.","title02":"Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory\/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.","journal":"J Clin Oncol","issue":"2025 December 20; 43(36):3799-3811. doi: 10.1200\/JCO-25-01957","author":"Budde LE, Zhang H, Kim WS, Maruyama D, Rego EM, Norasetthada L, Hong H, Ozcan M, Jeon YW, Leao Cordeiro de Farias D, Fogliatto LM, Pavlovsky A, Goto H, Olszewski AJ, Shah N, Hu B, Yin S, Wu H, To I, Ead WS, Ashby J, Janousek M, Pham S, Wang J, Kwan A, Batlevi CL, Wei MC, Westin J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41037766"},{"title01":"Lipid dysregulation after hematopoietic stem cell transplant.","title02":"Lipid dysregulation after hematopoietic stem cell transplant.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288933. Online ahead of print","author":"Koo J, Langenberg L, Zhao X, Setchell KR, Lake KE, Luebbering N, Walter E, Lane A, Myers KC, Reynaud D, Sabulski A, Teusink-Cross A, Jodele S, Davies SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437821"},{"title01":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","title02":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","journal":"Br J Haematol","issue":"2025 December 19. doi: 10.1111\/bjh.70289. Online ahead of print","author":"Boudry A, Chevillon F, Marceau-Renaut A, Braun T, Boyer T, Helevaut N, Fournier E, Geffroy S, Boissel N, Clappier E, Preudhomme C, Duployez N, Poirot C, Fenwarth L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41416831"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2025 December 24. doi: 10.1111\/bjh.70303. Online ahead of print","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","title02":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","journal":"Blood advances","issue":"2025 December 23; 9(24):6314-6325. doi: 10.1182\/bloodadvances.2025017084","author":"Loschi M, Villy MC, Galimard JE, Auboiroux MM, Gachard N, Perani A, Duchmann M, Largeaud L, Nguyen S, Sicre de Fontbrune F, Robin M, Yakoub-Agha I, Daguindau E, Chantepie S, Charbonnier A, Lebon D, Maury S, Labussiere-Wallet H, Huynh A, Forcade E, Castilla-Llorente C, Cluzeau T, Ades L, D'aveni M, Devillier R, Maillard N, Benachour S, Dombret H, Recher C, Pigneux A, Clappier E, Delabesse E, Duployez N, Turlure P, Peffault de Latour R, Sebert M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924929"},{"title01":"Abatacept improves posttransplant survival and reduces endothelial injury syndromes in beta-thalassemia major.","title02":"Abatacept improves posttransplant survival and reduces endothelial injury syndromes in beta-thalassemia major.","journal":"Blood advances","issue":"2025 December 23; 9(24):6370-6379. doi: 10.1182\/bloodadvances.2025017197","author":"Khandelwal P, Ibrahimova A, Lane A, Grimley M, Davies SM, Jodele S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40938738"},{"title01":"Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation.","title02":"Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation.","journal":"Blood advances","issue":"2025 December 23; 9(24):6394-6401. doi: 10.1182\/bloodadvances.2025016655","author":"Bhasin-Chhabra B, Wang T, Levine JE, Shenoy S, Perales MA, Bashey A, Raff H, Saber W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991367"},{"title01":"Androgen receptor signaling as a new target for intervention in acute myeloid leukemia.","title02":"Androgen receptor signaling as a new target for intervention in acute myeloid leukemia.","journal":"Blood advances","issue":"2025 December 23; 9(24):6326-6339. doi: 10.1182\/bloodadvances.2024012639","author":"Qian F, Sarkar D, Arner BE, Peduzzi VM, Bai Y, Ruan B, Jia B, Zheng H, Paulson RF, Prabhu KS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991369"},{"title01":"A new sUSPect in T-ALL risk stratification.","title02":"A new sUSPect in T-ALL risk stratification.","journal":"Blood advances","issue":"2025 December 23; 9(24):6467-6468. doi: 10.1182\/bloodadvances.2025017870","author":"Si Lim SJ, Teachey DT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385206"},{"title01":"Combining drugs that bypass p53 to treat TP53-mutated leukemias.","title02":"Combining drugs that bypass p53 to treat TP53-mutated leukemias.","journal":"Blood advances","issue":"2025 December 23; 9(24):6410-6424. doi: 10.1182\/bloodadvances.2025016683","author":"Biswas S, Zahran ZAM, Gu X, Cardone L, Marti R, Mouannes N, Stich M, Jain A, Fedorov K, Tomlinson B, Goldfinger M, Verma A, Saunthararajah Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061202"},{"title01":"Challenges and opportunities for improvement in the practical management of adults with acute lymphoblastic leukemia.","title02":"Challenges and opportunities for improvement in the practical management of adults with acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2025 December 23; 9(24):6345-6353. doi: 10.1182\/bloodadvances.2025017584","author":"Cassaday RD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056518"},{"title01":"Dual anti-CD19\/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.","title02":"Dual anti-CD19\/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.","journal":"Blood advances","issue":"2025 December 23; 9(24):6340-6344. doi: 10.1182\/bloodadvances.2025017770","author":"Roerden M, Hensen L, Besemer B, Schwartz F, Reuss K, Weiss-Haug A, Harland L, Ginsberg F, Faul C, Bethge W, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026972"},{"title01":"Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.","title02":"Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.","journal":"Blood advances","issue":"2025 December 23; 9(24):6455-6466. doi: 10.1182\/bloodadvances.2025017244","author":"Russell N, Othman J, Cumming O, Thomas A, Tedjaseputra A, Potter N, Jovanovic J, Gilkes A, Batten L, Canham J, Hinson E, Runglall M, Aucken P, Kottaridis P, Cavenagh J, Arnold C, Freeman S, Dennis M, Knapper S, Dillon R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026969"},{"title01":"Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.","title02":"Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.","journal":"Blood advances","issue":"2025 December 23; 9(24):6279-6291. doi: 10.1182\/bloodadvances.2025017057","author":"Yan Y, Yuan B, Qiu T, Liu G, Chen W, Wang T, Yu Y, Xiong W, An G, Zou D, Li J, Wang L, Yi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902084"},{"title01":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","title02":"Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies.","journal":"Blood advances","issue":"2025 December 23; 9(24):6314-6325. doi: 10.1182\/bloodadvances.2025017084","author":"Loschi M, Villy MC, Galimard JE, Auboiroux MM, Gachard N, Perani A, Duchmann M, Largeaud L, Nguyen S, Sicre de Fontbrune F, Robin M, Yakoub-Agha I, Daguindau E, Chantepie S, Charbonnier A, Lebon D, Maury S, Labussiere-Wallet H, Huynh A, Forcade E, Castilla-Llorente C, Cluzeau T, Ades L, D'aveni M, Devillier R, Maillard N, Benachour S, Dombret H, Recher C, Pigneux A, Clappier E, Delabesse E, Duployez N, Turlure P, Peffault de Latour R, Sebert M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40924929"},{"title01":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.","title02":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.","journal":"Blood","issue":"2025 December 25; 146(26):3163-3174. doi: 10.1182\/blood.2025029532","author":"Geyer MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B, McAvoy D, Katsamakis Z, Lorenc R, Lewis AM, Gipson B, Cuibus MA, Girotra NN, Wu K, Smith N, Burns ER, Um JS, Yoo S, Masouleh BK, Galera P, Hosszu K, Chaudhari J, Wang X, Lin Q, Curran KJ, Park JH, Scheinberg DA, van den Brink MRM, Abdel-Wahab O, Brentjens RJ, Daniyan AF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864984"},{"title01":"LEF1 and CLL: a matter of quantity and quality.","title02":"LEF1 and CLL: a matter of quantity and quality.","journal":"Blood","issue":"2025 December 25; 146(26):3138-3140. doi: 10.1182\/blood.2025031187","author":"Deaglio S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41447459"},{"title01":"Armed and SAVVY: CAR T cells combat AML.","title02":"Armed and SAVVY: CAR T cells combat AML.","journal":"Blood","issue":"2025 December 25; 146(26):3133-3134. doi: 10.1182\/blood.2025031004","author":"Zinsky MT, Bonifant CL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41447455"},{"title01":"Acalabrutinib to assail CLL in the frail.","title02":"Acalabrutinib to assail CLL in the frail.","journal":"Blood","issue":"2025 December 25; 146(26):3131-3132. doi: 10.1182\/blood.2025030747","author":"Ryan CE, Davids MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41447452"},{"title01":"LEF1 intragenic deletions: is Wnt&#8217;er coming for T-ALL?","title02":"LEF1 intragenic deletions: is Wnt&#8217;er coming for T-ALL?","journal":"Blood","issue":"2025 December 18; 146(25):3005-3006. doi: 10.1182\/blood.2025030884","author":"Fragoso AR, Barata JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410923"},{"title01":"Increased LEF1 protein levels and isoform switching drive cell proliferation in chronic lymphocytic leukemia.","title02":"Increased LEF1 protein levels and isoform switching drive cell proliferation in chronic lymphocytic leukemia.","journal":"Blood","issue":"2025 December 25; 146(26):3213-3227. doi: 10.1182\/blood.2025030129","author":"Mateos-Jaimez J, Vidal-Crespo A, Charalampopoulou S, Perez RF, Chapaprieta V, Jimenez-Martinez V, Caviedes-Cardenas L, Duran-Ferrer M, Espadas G, Sabido E, Largeot A, Herbst SA, Dietrich S, Boente MB, Alcoceba M, Nadeu F, Ringshausen I, Paggetti J, Moussay E, Colomer D, Campo E, Maiques-Diaz A, Martin-Subero JI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983031"},{"title01":"Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiency.","title02":"Chronic NK cell activation results in a dysfunctional, tissue resident-like state mediated by KLF2 deficiency.","journal":"Blood","issue":"2025 December 18; 146(25):3059-3071. doi: 10.1182\/blood.2024027763","author":"Myers JA, Huang RS, Phung SK, Chacon JM, Bendzick L, Weis A, Shetty M, DePauw TA, Khaw MJ, Abrahante JE, O'Flanagan SD, Ashby KM, Lozada JR, Jameson SC, Hwang JH, Cichocki F, Felices M, Miller JS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857665"},{"title01":"CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.","title02":"CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.","journal":"Blood","issue":"2025 December 18; 146(25):3019-3035. doi: 10.1182\/blood.2025028954","author":"Fleming TJ, Antoszewski M, Lambo S, Gundry MC, Piussi R, Wahlster L, Shah S, Reed FE, Dong KD, Paulo JA, Gygi SP, Mimoso C, Goldman SR, Adelman K, Perry JA, Pikman Y, Stegmaier K, Barrachina MN, Machlus KR, Hovestadt V, Arruda A, Minden MD, Voit RA, Sankaran VG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991835"},{"title01":"MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.","title02":"MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.","journal":"Blood","issue":"2025 December 18; 146(25):3098-3105. doi: 10.1182\/blood.2025028914","author":"Pastoors D, Havermans M, Mulet-Lazaro R, Smeenk L, Ottema S, Erpelinck-Verschueren C, van Herk S, Anthonissen M, Grob T, Subramanian S, Thoms JAI, Pimanda JE, Wouters BJ, Beverloo B, Haferlach T, Haferlach C, Zuber J, Bindels E, Delwel R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41060369"},{"title01":"A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.","title02":"A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.","journal":"Blood","issue":"2025 December 17. doi: 10.1182\/blood.2025029971. Online ahead of print","author":"Itsara A, Rogness VM, Samples L, Yuan CM, Wang HW, Ahn IE, Farooqui MZH, Tian X, Sun C, Tomasulo E, Soto S, Superata J, Bezkorovaynaya L, Hughes TE, Nierman PK, Wiestner A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405491"},{"title01":"The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML.","title02":"The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML.","journal":"Blood","issue":"2025 December 17. doi: 10.1182\/blood.2024028147. Online ahead of print","author":"Mujollari J, Estruch Alrich M, Khadgawat P, Choudhary S, Gustavsson T, Dagil R, Redlinger N, Loppke C, Vidal Calvo E, Anemone Nordmaj M, Theander TG, Heidenreich O, Nguyen Y, Qin S, Tolboll Sorensen AL, Gronbaek K, Porse BT, Kircher B, Mueller J, Agerbaek M, Salanti A, Theilgaard-Monch K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41405498"},{"title01":"Breaking the silence: restoring CEBPA to fight leukemia.","title02":"Breaking the silence: restoring CEBPA to fight leukemia.","journal":"Blood","issue":"2025 December 18; 146(25):3014-3015. doi: 10.1182\/blood.2025031363","author":"Wilson NK, Gottgens B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410921"},{"title01":"The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia.","title02":"The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia.","journal":"Blood","issue":"2025 December 23. doi: 10.1182\/blood.2025029905. Online ahead of print","author":"Al-Sawaf O, Locher BN, Christen F, Hablesreiter R, Rajamani A, Robrecht S, Zhang C, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Kopp K, Mertz ME, Fustero-Torre C, Kleo K, Seymour JF, Blombery P, Bullinger L, Chyla B, Jin HY, Jiang Y, Stilgenbauer S, Hallek MJ, Eichhorst BF, Langerbeins P, Fischer K, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41528026"},{"title01":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","title02":"Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02823-z. Online ahead of print","author":"Stein CM, Hablesreiter R, Christen F, Lowe P, Fustero-Torre C, Kopp K, Locher BN, Nitsch L, Altwasser R, Kerschbaum JF, Bullinger L, Ludwig LS, Strzelecka PM, Damm F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419602"},{"title01":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","title02":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","journal":"Leukemia","issue":"2026 January; 40(1):55-62. doi: 10.1038\/s41375-025-02820-2","author":"Truger M, Meggendorfer M, Walter W, Hutter S, Alsdorf W, Massenkeil G, Martens UM, Kern W, Horst K, Kuhn C, Reiter A, Hochhaus A, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419605"},{"title01":"Sequencing T-cell therapy for relapsed or refractory large B-cell lymphoma.","title02":"Sequencing T-cell therapy for relapsed or refractory large B-cell lymphoma.","journal":"Lancet Haematol","issue":"2025 December 22. doi: 10.1016\/S2352-3026(25)00342-4. Online ahead of print","author":"Karmali R, Gordon LI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41448214"},{"title01":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.","title02":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis.","journal":"Lancet Haematol","issue":"2025 December 22. doi: 10.1016\/S2352-3026(25)00318-7. Online ahead of print","author":"Sorin M, Okde R, Goulet M, Ghaleb L, Pang R, Prosty C, Brailovski E, Assouline S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41448213"},{"title01":"Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene.","title02":"Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene.","journal":"J Clin Oncol","issue":"2025 December 20; 43(36):3833-3843. doi: 10.1200\/JCO-25-01114","author":"Oak N, Chen W, Blake A, Harrison L, O'Brien M, Previti C, Balasubramanian G, Maass K, Hirsch S, Penkert J, Jones BC, Schramm K, Nathrath M, Pajtler KW, Jones DTW, Witt O, Dirksen U, Li J, Sapkota Y, Ness KK, Guenther LM, Pfister SM, Kratz C, Wang Z, Armstrong GT, Hudson MM, Wu G, Autry RJ, Nichols KE, Sharma R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41066719"},{"title01":"Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.","title02":"Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.","journal":"J Clin Oncol","issue":"2025 December 20; 43(36):3775-3777. doi: 10.1200\/JCO-25-02200","author":"Dickinson MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41202195"},{"title01":"Validation of prognostic scores in patients with HIV-related diffuse large B-cell lymphoma: The value of peripheral blood parameters-A study from the Spanish Lymphoma Group GELTAMO.","title02":"Validation of prognostic scores in patients with HIV-related diffuse large B-cell lymphoma: The value of peripheral blood parameters-A study from the Spanish Lymphoma Group GELTAMO.","journal":"Br J Haematol","issue":"2025 December 23. doi: 10.1111\/bjh.70287. Online ahead of print","author":"Huguet M, Morgades M, Rivas-Delgado A, Bastos-Oreiro M, Cordoba R, Salar A, de la Cruz-Vicente F, Alcoceba M, Ferrer-Lores B, Jimenez-Ubieto A, Gutierrez A, Infante M, Huerga S, Abrisqueta P, Cruz D, Montalban C, Muntanola A, Villambrosia SG, Ribera JM, Navarro JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41431425"},{"title01":"Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: A multicentre real-world study.","title02":"Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: A multicentre real-world study.","journal":"Br J Haematol","issue":"2025 December 26. doi: 10.1111\/bjh.70280. Online ahead of print","author":"Terao T, Yoshida I, Kobayashi H, Urata T, Fujii F, Meguri Y, Sugiura H, Yoshioka T, Saeki K, Niiya D, Asakura S, Nishimori H, Ikeda D, Fujiwara H, Ennishi D, Maeda Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41451861"},{"title01":"Integrated Genetic Analyses Identified T-cell Neoplasms Other Than Adult T-cell Leukemia\/Lymphoma in HTLV-1 Carriers.","title02":"Integrated Genetic Analyses Identified T-cell Neoplasms Other Than Adult T-cell Leukemia\/Lymphoma in HTLV-1 Carriers.","journal":"Blood advances","issue":"2025 December 22. doi: 10.1182\/bloodadvances.2025018059. Online ahead of print","author":"Naito Y, Yasuda T, Sakihama S, Aiba M, Morichika K, Miyazaki K, Imai H, Masaki A, Tsuyuki T, Shimada S, Yoshimitsu M, Aoyama H, Nakada N, Miyagi T, Tamaki T, Chen BJ, Yuan CT, Fukushima T, Chuang SS, Karube K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428991"},{"title01":"Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.","title02":"Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.","journal":"Blood advances","issue":"2025 December 23; 9(24):6292-6304. doi: 10.1182\/bloodadvances.2024015787","author":"Tournilhac O, Bouabdallah K, Lecolant S, Hacini M, Laribi K, Bailly S, Belmondo T, Maerevoet M, Ysebaert L, Guidez S, Le Gouill S, Bonnet C, Andre M, Dupuis J, Thieblemont C, Bachy E, Daguindau N, Morschhauser F, Tricot S, Moulin C, Banos A, Houot R, Chauchet A, Gyan E, Cartron G, Farhat H, Camus V, Drenou B, Zerazhi H, Sibon D, Nicolas-Virelizier E, Delette C, Snauwaert S, Bailly S, Delarue R, Carras S, Ledoux-Pilon A, Parrens MC, Griolet S, Gaulard P, Delfau-Larue MH, de Leval L, Damaj GL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40758949"},{"title01":"Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.","title02":"Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma.","journal":"Blood advances","issue":"2025 December 22. doi: 10.1182\/bloodadvances.2025016765. Online ahead of print","author":"Li N, Liu Y, Zhang L, Guo S, Wu Z, Xu Y, Yang M, Kong J, Che Y, Shao K, Yang H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428986"},{"title01":"Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis.","title02":"Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis.","journal":"Blood advances","issue":"2025 December 23; 9(24):6491-6501. doi: 10.1182\/bloodadvances.2025016117","author":"Dodero A, Ceparano G, Casadei B, Angelillo P, Bramanti S, Tisi MC, Ljevar S, Stella F, Chiappella A, Botto B, Cutini I, Zanirato G, Chiusolo P, Barbui AM, Farina M, Di Rocco A, Grillo G, Olivieri J, Krampera M, Ladetto M, Guidetti A, Zinzani PL, Carniti C, Corradini P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763273"},{"title01":"Early CAR T-cell therapy in relapsed\/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.","title02":"Early CAR T-cell therapy in relapsed\/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025018353. Online ahead of print","author":"Zeremski V, Aydilek E, Behringer A, Brunner F, Haage TR, Haenel M, Kos IA, Krueger WH, Lenz G, Lesan V, Schneider J, Schultze-Florey CR, Shumilov E, Weber T, Wulf GG, Vucinic V, Mougiakakos D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411524"},{"title01":"Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia.","title02":"Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December 22. doi: 10.1038\/s41375-025-02829-7. Online ahead of print","author":"Dinh TTT, Lordo MR, Zhang AY, Goda C, Shilo N, Altynova E, Ruesch M, Kronen P, Broughton M, Jeremy E, Sellers VL, Zhang X, Larkin KT, Collins PL, Dorrance AM, Freud AG, Oakes CC, Mundy-Bosse BL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41430399"},{"title01":"BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","title02":"BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02842-w. Online ahead of print","author":"Birdwell CE, Fiskus W, Mill CP, Kadia TM, Daver N, DiNardo CD, Sasaki K, Davis JA, Das K, Hou H, Jain A, Malovannaya A, Flores LB, Pourebrahim R, Yuan S, Su X, Ceribelli M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419608"},{"title01":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","title02":"The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis.","journal":"Leukemia","issue":"2025 December 17. doi: 10.1038\/s41375-025-02839-5. Online ahead of print","author":"Fullin J, Topcu E, Zielinska KA, Schimmer RR, Klemm N, Koch C, Caiado F, Lock M, Doerdelmann C, Buhler MM, Tchinda J, Kurppa KJ, Borsig L, Jones PH, Lopes M, Manz MG, Boettcher S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41407825"},{"title01":"Etiology of TP53 mutated complex karyotype acute myeloid leukemia.","title02":"Etiology of TP53 mutated complex karyotype acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02835-9. Online ahead of print","author":"Fedenko A, Czapinska H, Kramer A, Stolzel F, Bochtler T, Bochtler M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419603"},{"title01":"In vivo expression of CD3\/CD19 bispecific T-cell engager and alpha-PD-L1-Fc enables effective and durable immunotherapy for CD19(+)\/PD-L1(+) leukemia.","title02":"In vivo expression of CD3\/CD19 bispecific T-cell engager and alpha-PD-L1-Fc enables effective and durable immunotherapy for CD19(+)\/PD-L1(+) leukemia.","journal":"Leukemia","issue":"2025 December 23. doi: 10.1038\/s41375-025-02832-y. Online ahead of print","author":"Yang Y, Liu X, Wei J, Qin J, Tan Q, Ji J, Guo F, Zheng Y, Bi F, Liu M, Wang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41436638"},{"title01":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","title02":"Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing.","journal":"Leukemia","issue":"2026 January; 40(1):55-62. doi: 10.1038\/s41375-025-02820-2","author":"Truger M, Meggendorfer M, Walter W, Hutter S, Alsdorf W, Massenkeil G, Martens UM, Kern W, Horst K, Kuhn C, Reiter A, Hochhaus A, Haferlach T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419605"},{"title01":"Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.","title02":"Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.","journal":"Leukemia","issue":"2026 January; 40(1):29-36. doi: 10.1038\/s41375-025-02826-w","author":"Ernst P, Lohse C, Lauseker M, Geissler J, le Coutre P, Brummendorf TH, Saussele S, Burchert A, Franke GN, La Rosee P, Brioli A, Schenk T, Fabisch C, Ernst T, Mehlkop G, Hochhaus A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419606"},{"title01":"Targeting IL-1\/IRAK1\/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.","title02":"Targeting IL-1\/IRAK1\/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.","journal":"Leukemia","issue":"2025 December 19. doi: 10.1038\/s41375-025-02816-y. Online ahead of print","author":"Ho TC, LaMere MW, Kawano H, Byun DK, LaMere EA, Chiu YC, Chen C, Wang LJ, Wang J, Ramdas B, Dokholyan NV, Calvi LM, Liesveld JL, Jordan CT, Singh RK, Kapur R, Becker MW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41419607"},{"title01":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","title02":"Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.","journal":"J Clin Oncol","issue":"2025 December 17; JCO2500889. doi: 10.1200\/JCO-25-00889. Online ahead of print","author":"Wingard JR, Lee JH, Li D, Al-Mansour Z, Farhadfar N, Hsu J, Hiemenz J, Dean EA, Brown R, Trikha G, Schulz JN, Cline CL, Leather H, Sugrue MW, Dahl WJ, McGee KH, Leggett A, Kelly DL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41406403"},{"title01":"Venetoclax with intensive induction chemotherapy in newly diagnosed adult acute myeloid leukemia: early outcomes from a real-world experience.","title02":"Venetoclax with intensive induction chemotherapy in newly diagnosed adult acute myeloid leukemia: early outcomes from a real-world experience.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.289048. Online ahead of print","author":"Naik A, Kataria B, Sharma V, Sharma A, Batra A, Bhatia K, Singh B, Chopra A, Rout D, Sagiraju H, Talukdar R, Tiwari S, Kumar A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437831"},{"title01":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","title02":"Isolated KRAS and NRAS mutations in adults with monocytosis and\/or cytopenia(s).","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288906. Online ahead of print","author":"Wang SA, Ok CY, Tsai HK, Loayza N, Daneshpajouhnejad P, Seth N, Cantu MD, Bagg A, Tam W, Weinberg O, Barone PD, Geyer JT, Lindsley CR, Montalban-Bravo G, Simon CR, Arber DA, Bueso-Ramos CE, Hsi ED, Foucar K, Orazi A, Patnaik MM, Hasserjian RP, Reichard KK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437825"},{"title01":"Two episodes of Ph+ acute leukemia with divergent Ig\/TCR rearrangements in two patients with persistent BCR::ABL1 positivity: a 17-year follow-up.","title02":"Two episodes of Ph+ acute leukemia with divergent Ig\/TCR rearrangements in two patients with persistent BCR::ABL1 positivity: a 17-year follow-up.","journal":"Haematologica","issue":"2025 December 24. doi: 10.3324\/haematol.2025.288671. Online ahead of print","author":"Rubio-San-Simon A, Salzer E, Luesink M, Sonneveld E, Van der Sluis I, Pieters R, Hoogerbrugge PM, Zwaan MC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437812"},{"title01":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","title02":"Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.","journal":"Br J Haematol","issue":"2025 December 19. doi: 10.1111\/bjh.70289. Online ahead of print","author":"Boudry A, Chevillon F, Marceau-Renaut A, Braun T, Boyer T, Helevaut N, Fournier E, Geffroy S, Boissel N, Clappier E, Preudhomme C, Duployez N, Poirot C, Fenwarth L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41416831"},{"title01":"Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).","title02":"Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).","journal":"Br J Haematol","issue":"2025 December 18. doi: 10.1111\/bjh.70286. Online ahead of print","author":"Kirk A, James B, Feltbower RG, Mushtaq T, Whitehead E, Kraft J, Motwani J, Parkin H, Guest J, Gray J, Palmer J, Pelling J, Appleby J, Ledwich N, Dondo TB, Amin N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41410159"},{"title01":"The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-alpha2b in newly diagnosed chronic phase chronic myeloid leukaemia.","title02":"The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-alpha2b in newly diagnosed chronic phase chronic myeloid leukaemia.","journal":"Br J Haematol","issue":"2025 December 22. doi: 10.1111\/bjh.70276. Online ahead of print","author":"Yeung DT, Grigg AP, Reynolds J, Branford S, Mazumdar D, Cunningham I, Shortt J, Rowlings P, Harrup R, Ross DM, Kipp D, Mills AK, Arthur CK, Schwarer A, Jackson K, Viiala N, Weinkove R, Yong ASM, Gazdar SG, White D, Shanmuganathan N, Hughes T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41431370"},{"title01":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","title02":"Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.","journal":"Br J Haematol","issue":"2025 December 24. doi: 10.1111\/bjh.70303. Online ahead of print","author":"Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, Kim I, Yoon SS, Hong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41437919"},{"title01":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challenge.","title02":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challenge.","journal":"Br J Haematol","issue":"2025 December 25. doi: 10.1111\/bjh.70288. Online ahead of print","author":"Balduzzi A, Valsecchi MG, Tran TH, Zuna J, Leoni V, Cario G, Fazio G, Gandemer V, Tasian SK, van der Sluis IM, Peccatori N, Parasole R, Monterisi S, Loh ML, Devidas M, Hunger SP, Kairalla JA, De Lorenzo P, Silverman LB, Biondi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41448829"},{"title01":"T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia.","title02":"T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemia.","journal":"Br J Haematol","issue":"2025 December 25. doi: 10.1111\/bjh.70293. Online ahead of print","author":"Andersson ML, Lind O, Heimersson K, Berglof A, Del Peso Santos T, Pena-Perez L, Wang Q, Mulder TA, Zain R, Mansson R, Rosenquist R, Smith CIE, Osterborg A, Palma M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41449785"},{"title01":"Integrated Genetic Analyses Identified T-cell Neoplasms Other Than Adult T-cell Leukemia\/Lymphoma in HTLV-1 Carriers.","title02":"Integrated Genetic Analyses Identified T-cell Neoplasms Other Than Adult T-cell Leukemia\/Lymphoma in HTLV-1 Carriers.","journal":"Blood advances","issue":"2025 December 22. doi: 10.1182\/bloodadvances.2025018059. Online ahead of print","author":"Naito Y, Yasuda T, Sakihama S, Aiba M, Morichika K, Miyazaki K, Imai H, Masaki A, Tsuyuki T, Shimada S, Yoshimitsu M, Aoyama H, Nakada N, Miyagi T, Tamaki T, Chen BJ, Yuan CT, Fukushima T, Chuang SS, Karube K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41428991"},{"title01":"10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemia.","title02":"10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025017753. Online ahead of print","author":"Dreyzin A, Yates B, Shalabi HN, Silbert SK, Wang HW, Yuan CM, Hoang CN, Culbert AA, Gava F, Nair MS, Giordani VM, Little L, Foley T, Nussenblatt V, Fry TJ, Stroncek DF, Highfill SL, Shah NN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411486"},{"title01":"A Proposal for Expedited Stem Cell Transplantation for TP53-Mutant Myelodysplastic Neoplasms and Acute Myeloid Leukemia.","title02":"A Proposal for Expedited Stem Cell Transplantation for TP53-Mutant Myelodysplastic Neoplasms and Acute Myeloid Leukemia.","journal":"Blood advances","issue":"2025 December 24. doi: 10.1182\/bloodadvances.2025017795. Online ahead of print","author":"Patel SA, Devine SM, Cerny J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41441875"},{"title01":"USP7 alterations are associated with a poor survival in pediatric T-cell acute lymphoblastic leukemia.","title02":"USP7 alterations are associated with a poor survival in pediatric T-cell acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2025 December 23; 9(24):6404-6409. doi: 10.1182\/bloodadvances.2025017219","author":"Illarregi U, Gutierrez-Camino A, Lopez-Almaraz R, Arzuaga-Mendez J, Ramirez-Orellana M, Ashcraft E, Sinnett D, Astigarraga I, Martin-Guerrero I, Lopez-Lopez E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845231"},{"title01":"Plasma Cell Leukemia: Genomic Features and Their Potential Relevance for Exploring Clinical Actionability.","title02":"Plasma Cell Leukemia: Genomic Features and Their Potential Relevance for Exploring Clinical Actionability.","journal":"Blood advances","issue":"2025 December 18. doi: 10.1182\/bloodadvances.2025018342. Online ahead of print","author":"Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan SV, Dhakal B, D'Souza A, Lin DI, Ho C, Kurzrock R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41411484"},{"title01":"Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration.","title02":"Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration.","journal":"Blood advances","issue":"2025 December 23; 9(24):6575-6589. doi: 10.1182\/bloodadvances.2024015762","author":"Liu X, Wu J, Li X, Pan R, Liu L, Huang T, Ma L, Chen G, Wang Q, Zhang N, Tong X, Tan Y, Jiang H, Liang Y, Shen M, Li R, Yin W, Zhang X, Zhou F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920990"},{"title01":"Acalabrutinib treatment for older (aged >\/=80 years) and\/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.","title02":"Acalabrutinib treatment for older (aged >\/=80 years) and\/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.","journal":"Blood","issue":"2025 December 25; 146(26):3153-3162. doi: 10.1182\/blood.2025028550","author":"Simon F, Ligtvoet R, Bohn JP, Nosslinger T, von Tresckow J, Liersch R, Gaska T, Jentsch-Ullrich K, Gartner M, Wolff T, Schwaner I, Wolf D, Schneider C, Vehling-Kaiser U, Ritgen M, Spoer C, Eckart M, Decker T, Chakupurakal G, Schottker B, Kisro J, Kreuzer KA, Tausch E, Stilgenbauer S, Robrecht S, Stumpf J, Fink AM, Furstenau M, Fischer K, Goede V, Hallek M, Eichhorst B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906922"},{"title01":"Comprehensive Molecular and Functional Analysis of NUTM1-Rearranged Leukemia.","title02":"Comprehensive Molecular and Functional Analysis of NUTM1-Rearranged Leukemia.","journal":"Blood","issue":"2025 December 29. doi: 10.1182\/blood.2024026928. Online ahead of print","author":"Nishimura K, Isobe T, Shigehiro T, Nomura M, Zang W, Xiao M, Liao W, Koike Y, Nishimura A, Sato-Otsubo A, Yamazaki H, Ito H, Okada S, Matsumoto N, Saika W, Zhang Y, Aoyama Y, Hasegawa C, Yamasaki T, Kubota Y, Oki K, Kiyokawa N, Nagae G, Yoshida K, Nannya Y, Ueno H, Fukuda S, Tatsuno K, Tsutsumi S, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Eguchi M, Arakawa Y, Koh K, Deguchi T, Tomizawa D, Miyamura T, Ishii E, Mizutani S, Miyano S, Aburatani H, Ogawa S, Takaori-Kondo A, Yokoyama A, Abdel-Wahab O, Ernst P, Takita J, Ikawa T, Takagi M, Inoue D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41460961"},{"title01":"LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt\/beta-catenin vulnerability in T-ALL.","title02":"LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt\/beta-catenin vulnerability in T-ALL.","journal":"Blood","issue":"2025 December 18; 146(25):3036-3049. doi: 10.1182\/blood.2025030161","author":"Delafoy M, Bonnet MF, Lengline E, Cieslak A, Touzart A, Balducci E, Simonin M, Lheritier V, Dourthe ME, Heid-Picard B, Latour S, Dombret H, Rousselot P, Baruchel A, Boissel N, Andrieu GP, Asnafi V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857670"},{"title01":"Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC.","title02":"Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC.","journal":"Br J Haematol","issue":"2025 December 14. doi: 10.1111\/bjh.70262. Online ahead of print","author":"Villaboni S, Stuart-Smith S, De Kreuk A, Rees DC, Brewin JN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41392388"},{"title01":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","title02":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","journal":"Br J Haematol","issue":"2025 December 3. doi: 10.1111\/bjh.70274. Online ahead of print","author":"Peters DT, Nicolet D, Madanat YF, Gonzalez-Lugo J, Ambinder A, Chan O, Foucar CE, Sahasrabudhe KD, Ameyi J, Mrozek K, Lin T, Al-Ali N, Lancet J, Barredo B, Banaszak LG, Hochman MJ, Ragon BK, McMahon CM, Haque T, Mims AS, Eisfeld AK, Zeidner JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41332326"},{"title01":"Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.","title02":"Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70284. Online ahead of print","author":"Jin H, Guo Z, Zhu L, Huang F, Wu Y, Qiu H, Wang Y, Gong Y, He G, Fan L, Shi Z, Shen W, Qiao C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41386566"},{"title01":"Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial.","title02":"Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70272. Online ahead of print","author":"Voso MT, de Botton S, Pfeilstocker M, Alvarez AF, Wang K, See WL, Guerrero MU, de Menezes DL, Petrlik E, Prebet T, Roboz GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387169"},{"title01":"Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience.","title02":"Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience.","journal":"Br J Haematol","issue":"2025 December 14. doi: 10.1111\/bjh.70285. Online ahead of print","author":"Bergonzi GM, Cozzo E, Tomelleri A, Piccolo C, Scorpio G, Gurnari C, Romano F, Matucci-Cerinic M, Dagna L, Bernardi M, Vago L, Ciceri F, Campochiaro C, Diral E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41392421"},{"title01":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","title02":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017089. Online ahead of print","author":"Palmieri R, Guolo F, Fianchi L, Ferrara F, Minetto P, Martelli MP, Riva C, Chiusolo P, Rondoni M, Capria S, Minotti C, Pilo F, Perrone S, Corbingi A, Grimaldi F, De Luca G, Fili C, Alati C, Mannelli F, Lessi F, Marchesi F, Brunetti L, Capelli D, Piccioni AL, Vetro C, Palumbo FE, Mazzone C, Sperotto A, Luzi G, Dargenio M, Mariani S, Cerrano M, Mule A, Di Veroli A, Meddi E, Moretti F, Papayannidis C, Isidori A, Ferrari A, Galimberti S, Cilloni D, Breccia M, Lanza F, Gottardi M, Cairoli R, Candoni A, Pagano L, Todisco E, Lemoli RM, Venditti A, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346286"},{"title01":"Vulnerability of SRSF2 mutated chronic myelomonocytic leukemia to perturbation of cGAS-STING pathway.","title02":"Vulnerability of SRSF2 mutated chronic myelomonocytic leukemia to perturbation of cGAS-STING pathway.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017005. Online ahead of print","author":"Chen Y, Chan KC, Sin CF, Zheng L, Wang D, Tu L, He F, Hui WHJ, Leung HK, Chan LKF, Tsui SP, Chan HY, Ma ACH, Leung AY, Sun X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346291"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","journal":"Blood advances","issue":"2025 December 5. doi: 10.1182\/bloodadvances.2025018631. Online ahead of print","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro RM, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan JA, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2025 December 8. doi: 10.1182\/blood.2025030816. Online ahead of print","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst RT, Wolf D, Baldus CD, Oelschlaegel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2025 December 12. doi: 10.1182\/blood.2025031313. Online ahead of print","author":"Meyer E, Salhotra A, Gandhi A, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand RG, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau JM, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian S, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"Challenges in predicting hydroxyurea resistance and reducing thrombotic risk in polycythemia vera patients: unmasking the limits of its machine learning study.","title02":"Challenges in predicting hydroxyurea resistance and reducing thrombotic risk in polycythemia vera patients: unmasking the limits of its machine learning study.","journal":"Leukemia","issue":"2025 December; 39(12):3052-3053. doi: 10.1038\/s41375-025-02807-z","author":"Xu F, Li Z, Fu H, Ma J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214138"},{"title01":"Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms.","title02":"Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms.","journal":"Blood advances","issue":"2025 December 9; 9(23):6189-6198. doi: 10.1182\/bloodadvances.2025017016","author":"Davidsen ID, Larsen MK, Loffler L, Skov V, Kjaer L, Knudsen TA, Sorensen AL, Christensen SF, Cordua S, Eickhardt-Dalboge CS, Kristiansen MH, Ellervik C, Wienecke T, Hasselbalch HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966426"},{"title01":"Towards New Therapy Endpoints in Polycythemia Vera: Targeting Clonal and Inflammatory Pathways.","title02":"Towards New Therapy Endpoints in Polycythemia Vera: Targeting Clonal and Inflammatory Pathways.","journal":"Blood advances","issue":"2025 December 10. doi: 10.1182\/bloodadvances.2025018011. Online ahead of print","author":"Barbui T, Scandura JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370203"},{"title01":"Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells.","title02":"Microenvironmental cell interactions are essential for sustaining functionality of myelofibrosis malignant stem cells.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025031454. Online ahead of print","author":"Lu M, Mia MB, Xia L, Mosoyan G, Hayat M, Schaniel C, Hoffman R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397284"},{"title01":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia.","title02":"Ianalumab plus Eltrombopag in Immune Thrombocytopenia.","journal":"N Engl J Med","issue":"2025 December 9. doi: 10.1056\/NEJMoa2515168. Online ahead of print","author":"Cuker A, Stauch T, Cooper N, Al-Samkari H, Michel M, Ghanima W, Urban P, Fronczek J, Foster M, Weill M, Zhang L, Hou M, Zander T, Sharif A, Sun J, Nath UK, Schutgens R, Rossi E, Deleu L, Cervinek L, Yoon JH, Chang H, Ruchutrakool T, Iino M, Goto T, Zaja F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363800"},{"title01":"Elevated 5-HTR7 deteriorates dysregulated megakaryocytopoiesis in immune thrombocytopenic purpura via upregulating the PKA\/Orai1\/ERK1\/2 pathway.","title02":"Elevated 5-HTR7 deteriorates dysregulated megakaryocytopoiesis in immune thrombocytopenic purpura via upregulating the PKA\/Orai1\/ERK1\/2 pathway.","journal":"Haematologica","issue":"2025 December 1; 110(12):2997-3008. doi: 10.3324\/haematol.2024.287287","author":"Zhou M, Han H, Qi J, Zhang Z, Song X, Li X, Chu T, Wu D, Han Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534501"},{"title01":"Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries.","title02":"Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries.","journal":"Haematologica","issue":"2025 December 1; 110(12):3094-3098. doi: 10.3324\/haematol.2025.287408","author":"Moulis G, Chen F, Carli G, Ghanima W, Trautmann-Grill K, Stauch T, Schifferli A, Miah H, Rueter M, Ghiotto L, Tomasello R, Georgi A, McDonald V, Zaja F, Pettersen HH, Kuhne T, Lozano ML, Gonzalez-Lopez TJ, Provan D, Michel M, Cooper N, Rodeghiero F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568720"},{"title01":"Differentiating pathogenic from bystander autoantibodies in immune thrombocytopenia using intact glycoprotein-deficient megakaryocytes.","title02":"Differentiating pathogenic from bystander autoantibodies in immune thrombocytopenia using intact glycoprotein-deficient megakaryocytes.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.288832. Online ahead of print","author":"Zhang N, Uzun G, Bakchoul T, Curtis BR, Newman PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376564"},{"title01":"Longitudinal plasma proteomics in romiplostim-treated patients with immune thrombocytopenia.","title02":"Longitudinal plasma proteomics in romiplostim-treated patients with immune thrombocytopenia.","journal":"Br J Haematol","issue":"2025 December 9. doi: 10.1111\/bjh.70279. Online ahead of print","author":"Nelson VS, Smit ER, de Haas M, Schipperus MR, van den Biggelaar M, Kapur R, Munoz Sandoval D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41362951"},{"title01":"Are there long-term effects of combination therapy for newly diagnosed adults with ITP?","title02":"Are there long-term effects of combination therapy for newly diagnosed adults with ITP?","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70255. Online ahead of print","author":"Peko GA, Bussel JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387255"},{"title01":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.","title02":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.","journal":"Blood","issue":"2025 December 8. doi: 10.1182\/blood.2025031449. Online ahead of print","author":"Leaf RK, Mones JV, Shenoy T, Warsame M, Beltrami-Moreira M, Panch S, Leavitt AD, Zon RL, Kendall EK, Shahamatdar S, Lim TL, Cui C, Jiang D, Kaunfer SA, Durai L, Hoge ST, Dias JA, Sha C, Holmes A, Easton N, Corley E, Zhao E, Li X, Spelman A, Amos CB, Soebbing DR, Shabih M, Jamison T, Liu B, Hussein G, Yadav SK, Elsaid MI, Owen DH, Mera A, Juras PK, Suresh A, Heskel MJ, Huang JJ, Glezerman I, Go RS, Reynolds K, Al-Samkari H, Kroll MH, Leaf DE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359796"},{"title01":"Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study.","title02":"Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e956-e965. doi: 10.1016\/S2352-3026(25)00293-5","author":"Scordo M, Perales MA, Mauguen A, Lin A, Kunvarjee B, Paes Pena M, Mcavoy D, Nguyen LK, Hogan M, Chapman N, Bieler J, Cho C, Gyurkocza B, Harris AC, Spitzer B, O'Reilly RJ, Jakubowski AA, Lin RJ, Papadopoulos EB, Politikos I, Ponce DM, Shaffer BC, Shah GL, Tamari R, Giralt SA, Boelens JJ, Curran KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338864"},{"title01":"Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.","title02":"Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.","journal":"J Clin Oncol","issue":"2025 December; 43(34):3639-3645. doi: 10.1200\/JCO-25-00809","author":"Mohty M, Socie G, Szer J, Niederwieser D, Butler J, Wagner-Drouet E, Or R, Rovenvald-Zuckerman T, Bozdag SC, Forcade E, Grillo G, Kroger N, Stolzel F, Russo D, Sanz J, Sarkar R, Stefanelli T, Wilke C, Zeiser R, von Bubnoff N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092247"},{"title01":"Loss of endothelial miR-126 drives age-related decline in hematopoiesis.","title02":"Loss of endothelial miR-126 drives age-related decline in hematopoiesis.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.288736. Online ahead of print","author":"Zhao D, Nguyen LXT, Gong X, Chen F, Zhao X, Chen MH, Marcucci G, Zhang B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342184"},{"title01":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children&#8217;s Oncology Group AALL1331 trial.","title02":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children&#8217;s Oncology Group AALL1331 trial.","journal":"Haematologica","issue":"2025 December 1; 110(12):2930-2941. doi: 10.3324\/haematol.2025.287386","author":"Hogan LE, Bhatla T, Xu X, Gore L, Raetz EA, Bhojwani D, Teachey DT, Hunger SP, Loh ML, Brown PA, Ji L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568722"},{"title01":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2025 December 1; 110(12):3088-3093. doi: 10.3324\/haematol.2025.287326","author":"Li L, Ye Y, Galimard JE, Labopin M, Wu D, Chen J, Kroger N, Passweg J, Salmenniemi U, Itala-Remes M, Poire X, Eder M, Maertens J, Burns D, Sengeloev H, Olesen G, Blaise D, Finke J, Gadisseur A, Bazarbachi A, Brissot E, Nagler A, Luo Y, Shi J, Mohty M, Huang H, Ciceri F, Claude Gorin N Sr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534491"},{"title01":"HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial.","title02":"HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.300013. Online ahead of print","author":"Dhedin N, Bruno B, Paillard C, Gounfle E, Buchbinder N, Chardin MO, Gaba M, Arlet JB, Arnaud C, Jung C, Pondarre C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376570"},{"title01":"Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to SLC29A3 mutations.","title02":"Allogeneic hematopoietic cell transplantation rescues congenital red cell aplasia in H syndrome due to SLC29A3 mutations.","journal":"Haematologica","issue":"2025 December 1; 110(12):3164-3167. doi: 10.3324\/haematol.2025.288098","author":"Quigg TC, Kurt BA, Seaver LH, Holsworth AR, Duffner UA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40874332"},{"title01":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-world data study.","title02":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-world data study.","journal":"Haematologica","issue":"2025 December 1; 110(12):3150-3153. doi: 10.3324\/haematol.2025.288067","author":"Masetti R, Barbara G, Muratore E, Marasco G, Cremon C, Marangoni A, Brigidi P, Putignani L, Angelino G, Quagliarella F, Galaverna F, Leardini D, Lazzarotto T, Gabelli M, Savarino E, Zecca M, Faraci M, Prete A, Biffi A, Locatelli F, Merli P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568731"},{"title01":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","title02":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","journal":"Br J Haematol","issue":"2025 December 3. doi: 10.1111\/bjh.70274. Online ahead of print","author":"Peters DT, Nicolet D, Madanat YF, Gonzalez-Lugo J, Ambinder A, Chan O, Foucar CE, Sahasrabudhe KD, Ameyi J, Mrozek K, Lin T, Al-Ali N, Lancet J, Barredo B, Banaszak LG, Hochman MJ, Ragon BK, McMahon CM, Haque T, Mims AS, Eisfeld AK, Zeidner JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41332326"},{"title01":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","title02":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70281. Online ahead of print","author":"Gu J, Wang J, Liu L, Zhang Y, Ghanad P, Goli MM, Bao C, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387940"},{"title01":"Impact of graft-versus-host disease prophylaxis strategies on GvHD-free\/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis.","title02":"Impact of graft-versus-host disease prophylaxis strategies on GvHD-free\/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis.","journal":"Br J Haematol","issue":"2025 December 5. doi: 10.1111\/bjh.70269. Online ahead of print","author":"Desai N, Rodriguez SR, Al-Shaibani E, Moya TA, Novitzky-Basso I, Law AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346275"},{"title01":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","title02":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","journal":"Blood advances","issue":"2025 December 10. doi: 10.1182\/bloodadvances.2025016338. Online ahead of print","author":"Arnold DE, Kaviany S, Aluri J, Calvo KR, Mehta SS, Tobin JM, Schuettpelz L, Saucier N, Schmitz EG, Murguia-Favela L, Wright NAM, De Ravin SS, Rao VK, Holland SM, Bleesing J, Loughran TP, Feith DJ, Powell J, Ratan A, Warren JT, Pai SY, Bednarski JJ, Connelly JA, Cooper MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370196"},{"title01":"Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients.","title02":"Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients.","journal":"Blood advances","issue":"2025 December 12. doi: 10.1182\/bloodadvances.2025017393. Online ahead of print","author":"Nishitani M, Graham RT, Wang T, DeVos JD, Lee SJ, Spellman SR, Kitko CL, MacMillan ML, DeFilipp Z, Gray AN, Williams KM, Takahashi T, Schoettler ML, Hashem H, Rangarajan HG, Prestidge T, Ringden O, Hamilton BK, Sharma A, Nusrat R, El Jurdi N, Bhatt NS, Duncan CN, Qayed M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385339"},{"title01":"Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates.","title02":"Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates.","journal":"Blood advances","issue":"2025 December 1. doi: 10.1182\/bloodadvances.2025017838. Online ahead of print","author":"Murray JD, Einhaus TK, Radtke S, Bar KJ, Peterson CW, Kiem HP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41324589"},{"title01":"Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group.","title02":"Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group.","journal":"Blood advances","issue":"2025 December 9; 9(23):6141-6157. doi: 10.1182\/bloodadvances.2025016915","author":"Hammoudi T, Nucera S, Troullioud Lucas AG, Ansari M, Balduzzi A, Bertaina A, Buechner J, Corbacioglu S, Dalle JH, Kalwak K, Lee D, Levine JE, Lindemans CA, Locatelli F, Meisel R, Nierkens S, Ottaviano G, Perez-Martinez A, Pichler H, Prockop SE, Pulsipher MA, Talano JM, Tewari S, Schultz KR, Shah NN, Verneris MR, Boelens JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902074"},{"title01":"Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.","title02":"Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.","journal":"Blood advances","issue":"2025 December 9; 9(23):5965-5975. doi: 10.1182\/bloodadvances.2024013727","author":"Djassemi N, Hanisch B, Motta C, Maghzian N, Vatsayan A, Durkee-Shock JR, Keller MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864193"},{"title01":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","title02":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","journal":"Blood advances","issue":"2025 December 9; 9(23):6205-6217. doi: 10.1182\/bloodadvances.2024015600","author":"Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor A, Townsend W, Andre M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811783"},{"title01":"CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways.","title02":"CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways.","journal":"Blood","issue":"2025 December 11; 146(24):2914-2930. doi: 10.1182\/blood.2024026815","author":"Martinez TC, Jotte MRM, Khan S, Stoddart A, Blaylock H, Malik A, McNerney ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920873"},{"title01":"Platelet factor 4 regulates hematopoietic stem cell aging.","title02":"Platelet factor 4 regulates hematopoietic stem cell aging.","journal":"Blood","issue":"2025 December 4; 146(23):2765-2778. doi: 10.1182\/blood.2024027432","author":"Zhang S, Ayemoba CE, Di Staulo AM, Joves K, Patel CM, Leung EHW, Bueno MLP, Du X, Poncz M, Ong SG, Nerlov C, Maryanovich M, Chronis C, Pinho S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920871"},{"title01":"Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.","title02":"Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.","journal":"Blood","issue":"2025 December 4; 146(23):2779-2793. doi: 10.1182\/blood.2024028194","author":"Venkatesh H, Granados Centeno E, Luo Q, Arroyo M, Heltemes-Harris L, Knutson TP, Qiu Y, Haaning A, Webber BR, Bachanova V, Farrar MA, Tracy SI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906918"},{"title01":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2025 December 12. doi: 10.1182\/blood.2025031313. Online ahead of print","author":"Meyer E, Salhotra A, Gandhi A, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand RG, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau JM, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian S, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.","title02":"2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025031480. Online ahead of print","author":"Cloos J, Valk PJM, Thiede C, Dohner K, Roboz GJ, Wood BL, Walter RB, Wang SA, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw DC, Kern W, Kim DDHDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bucklein VL, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon RJ, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397238"},{"title01":"Transient SP140 inhibition unlocks hematopoietic stem cell fate from human pluripotent stem cells.","title02":"Transient SP140 inhibition unlocks hematopoietic stem cell fate from human pluripotent stem cells.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025032084. Online ahead of print","author":"Liu X, Zhang Z, Cui X, Guo R, Ding X, Ma L, Liu P, Yu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397285"},{"title01":"Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.","title02":"Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.","journal":"Lancet Oncol","issue":"2025 December; 26(12):1626-1637. doi: 10.1016\/S1470-2045(25)00605-9","author":"Kim S, Boustani J, Iseas S, Vernerey D, Evesque L, Quero L, Ghiringhelli F, Coutzac C, Bouche O, Chibaudel B, Vernet C, Vienot A, Tougeron D, Nguyen T, Rebucci-Peixoto M, Meurisse A, Chennoufi S, Maritaz C, Borg C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41202834"},{"title01":"Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1\/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.","title02":"Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1\/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.","journal":"Lancet Oncol","issue":"2025 December; 26(12):1563-1574. doi: 10.1016\/S1470-2045(25)00523-6","author":"Li H, Liu J, Ouyang Q, Wang S, Liu Y, Teng Y, Wang X, Cheng J, Tong Z, Sun T, Yan M, Zhou X, Li F, Nie J, Shao ZM, Ye C, Wang Y, Wu X, Li Z, Wu Y, Xiong H, Li H, Gan L, Niu Z, Zhang J, Zhang Q, Pan Y, Wu X, Zhang Y, Xie W, Xiao Y, Gao J, Zhao H, Yin Y, Qian Z, Sun S, Zhang H, Wang K, Lu J, Li Y, Wang X, Yang X, Wang Y, Wang Q, Song E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41308673"},{"title01":"Menstrual blood loss reduction to control anaemia (and more).","title02":"Menstrual blood loss reduction to control anaemia (and more).","journal":"Lancet Haematol","issue":"2025 December; 12(12):e929-e930. doi: 10.1016\/S2352-3026(25)00317-5","author":"van Zutphen KG, Askari S, Verhoef H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338859"},{"title01":"Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.","title02":"Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial.","journal":"Lancet Haematol","issue":"2025 December 6. doi: 10.1016\/S2352-3026(25)00291-1. Online ahead of print","author":"Mahe I, Chapelle C, Girard P, Carrier M, Palomares LJ, Samama CM, Helfer H, Gerotziafas G, Laporte S, Vicaut E, Mismetti P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41365312"},{"title01":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.","title02":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.","journal":"J Clin Oncol","issue":"2025 December 10; 43(35):3714-3727. doi: 10.1200\/JCO-25-00872","author":"Hammel P, Metges JP, Macarulla Mercade T, Garcia-Carbonero R, Bouche O, Portales F, Pazo Cid RA, Mineur L, Cubillo Gracian A, Trouilloud I, Guimbaud R, Tougeron D, Reina JJ, Feliu J, Sauri T, Fountzilas C, Lecomte T, Molin Y, Ponz-Sarvise M, Forget F, Berardi R, Van Cutsem E, Gelsomino F, Tournigand C, Bockorny B, Bachet JB, Marin Vera M, Cuyle PJ, Wasan H, Noel M, Van Laethem JL, Kay R, Youssoufian H, El-Hariry I, Hidalgo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41187298"},{"title01":"Efficacy and safety of luspatercept in non-transfusion-dependent beta-thalassemia: long-term results from the BEYOND study.","title02":"Efficacy and safety of luspatercept in non-transfusion-dependent beta-thalassemia: long-term results from the BEYOND study.","journal":"Blood advances","issue":"2025 December 9; 9(23):6108-6119. doi: 10.1182\/bloodadvances.2025016554","author":"Taher AT, Viprakasit V, Kattamis A, Perrotta S, Ricchi P, Porter JB, Coates TD, Forni GL, Musallam KM, Esposito O, Pilot R, Kuo WL, Lai Y, Reverte M, Wei R, Bueno LM, Cappellini MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875596"},{"title01":"Regional Brain Age is Decreased in Children with Sickle Cell Anemia.","title02":"Regional Brain Age is Decreased in Children with Sickle Cell Anemia.","journal":"Blood advances","issue":"2025 December 1. doi: 10.1182\/bloodadvances.2025017172. Online ahead of print","author":"Mirro AE, Power LC, Wang J, Germino-Watnick P, Roberts H, Cam Y, Guilliams K, Fellah S, Chen Y, An H, Lee JM, Ford AL, Fields ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41324590"},{"title01":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","title02":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","journal":"Blood advances","issue":"2025 December 10. doi: 10.1182\/bloodadvances.2025016338. Online ahead of print","author":"Arnold DE, Kaviany S, Aluri J, Calvo KR, Mehta SS, Tobin JM, Schuettpelz L, Saucier N, Schmitz EG, Murguia-Favela L, Wright NAM, De Ravin SS, Rao VK, Holland SM, Bleesing J, Loughran TP, Feith DJ, Powell J, Ratan A, Warren JT, Pai SY, Bednarski JJ, Connelly JA, Cooper MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370196"},{"title01":"Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation.","title02":"Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation.","journal":"Blood","issue":"2025 December 11; 146(24):2863-2869. doi: 10.1182\/blood.2025028370","author":"Falabregue M, Aurrand C, Cazaulon L, Boussetta N, Zumerle S, Djebrani-Oussedik N, Poupon J, Guilmeau S, Karim Z, Dupe E, Aucouturier A, Langella P, Bermudez-Humaran LG, Vaulont S, Peyssonnaux C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40925095"},{"title01":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","title02":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","journal":"Leukemia","issue":"2025 December 3. doi: 10.1038\/s41375-025-02814-0. Online ahead of print","author":"Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho G, Gondek L, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Versino F, Montoro MJ, Torres-Esquius S, Jerez Cayuela A, Lopez-Esteban M, Martinez-Laperche C, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski JP, Ogawa S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41339477"},{"title01":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.","title02":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.","journal":"Leukemia","issue":"2025 December; 39(12):2907-2915. doi: 10.1038\/s41375-025-02767-4","author":"Pollyea D, Kerre T, Deeren D, Beguin Y, Lin TL, Sallman DA, Anguille S, Blum WG, Flament A, Breman E, Lonez C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954213"},{"title01":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","title02":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","journal":"Leukemia","issue":"2025 December; 39(12):3015-3025. doi: 10.1038\/s41375-025-02771-8","author":"Romero-Moya D, Torralba-Sales E, Calvo C, Marin-Bejar O, Magallon-Mosella M, Distefano M, Pera J, Castano J, De Giorgio F, Gonzalez J, Iglesias A, Berenguer-Balaguer C, Schilling M, Plass M, Pasquali L, Catala A, Molina O, Wlodarski MW, Bigas A, Giorgetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954215"},{"title01":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling.","title02":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling.","journal":"Leukemia","issue":"2025 December; 39(12):3026-3036. doi: 10.1038\/s41375-025-02756-7","author":"Mazzeo P, Penir SM, Shumilov E, Wolf S, Haupl B, Markus K, Shirneshan K, Rittscher K, Brzuszkiewicz E, Aydilek E, Treiber H, Oellerich T, Ganster C, Haase D, Koch R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973765"},{"title01":"Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.","title02":"Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.","journal":"Leukemia","issue":"2025 December; 39(12):2872-2880. doi: 10.1038\/s41375-025-02775-4","author":"Sakuma M, Wang AK, Magaziner SJ, Keane SP, Meggendorfer M, Kern W, Haferlach C, Haferlach T, Beck DB, Walter W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41068485"},{"title01":"US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.","title02":"US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.","journal":"J Clin Oncol","issue":"2025 December 10; 43(35):3760-3768. doi: 10.1200\/JCO-25-01369","author":"Kim N, Pulte ED, Ehrlich LA, Ionan AC, Haupert S, Vallejo J, Green F, Zheng N, Wang Y, Liu J, Blanco JG, Dorff SE, Booth B, Choe M, Gehrke B, Bhatnagar V, Theoret M, Pazdur R, De Claro RA, Norsworthy KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41135032"},{"title01":"PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes.","title02":"PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes.","journal":"Haematologica","issue":"2025 December 1; 110(12):3125-3128. doi: 10.3324\/haematol.2025.287874","author":"Bazinet A, Bataller A, Montalban-Bravo G, Chien K, Sasaki K, Jen WY, Swaminathan M, Kadia T, DiNardo C, Ravandi F, Garcia-Manero G, Kantarjian H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605709"},{"title01":"Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-beta1-driven macrophage polarization in myeloid leukemias.","title02":"Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-beta1-driven macrophage polarization in myeloid leukemias.","journal":"Haematologica","issue":"2025 December 1; 110(12):3009-3021. doi: 10.3324\/haematol.2024.287091","author":"Feng J, Gou J, Wang Y, Wei W, Ma Y, Ren X, Zhao C, Cheng X, Lei L, Tan Z, Guan F, Li X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400458"},{"title01":"Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.","title02":"Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.","journal":"Blood advances","issue":"2025 December 9; 9(23):6009-6018. doi: 10.1182\/bloodadvances.2025016966","author":"Galarza Fortuna GM, Peres L, Nazarenko E, De Menezes Silva Corraes A, Hovanky VN, Shune L, McGuirk J, De Avilla G, Khouri J, Dima D, Gaballa M, Dhakal B, Forsberg P, Godara A, Afrough A, Anderson L, Herr MM, Davis JA, Mann H, Purvey S, Clark W, Htut M, Beitinjaneh A, Pereira DL, Kocoglu MH, Ferreri CJ, Atrash S, Voorhees PM, Rossi A, Shambavi R, Hashmi H, Patel K, Sidana S, Lin Y, Hansen DK, Sborov DW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875887"},{"title01":"mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow.","title02":"mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow.","journal":"Blood advances","issue":"2025 December 9; 9(23):6175-6188. doi: 10.1182\/bloodadvances.2025016439","author":"Fulton-Ward T, Gudgeon N, Thirlwell I, Bishop EL, Marzullo B, Giles H, McIlroy G, Ferguson P, Kishore B, Rogers K, Alfasi N, Wong T, Aytain S, Tennant DA, Pratt G, Dimeloe S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40938732"},{"title01":"Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiple myeloma.","title02":"Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiple myeloma.","journal":"Blood","issue":"2025 December 11; 146(24):2931-2944. doi: 10.1182\/blood.2024027496","author":"Navarro F, Lozano T, Fuentes-Garcia A, Sanchez-Moreno I, Larrayoz M, Justicia P, Perucha B, Martinez-Tabar M, Martinez-Turrillas R, Casares N, Martin-Otal C, Gorraiz M, Meermeier EW, Chesi M, Lake D, Bergsagel PL, Santamaria E, Calleja-Cervantes ME, San Martin-Uriz P, Jordana-Urriza L, Agirre X, Hervas-Stubbs S, Rodriguez-Madoz JR, Martinez-Climent JA, Prosper F, Lasarte JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971494"},{"title01":"Glu(tamine)ing together myeloma metabolism and CAR T efficacy.","title02":"Glu(tamine)ing together myeloma metabolism and CAR T efficacy.","journal":"Blood","issue":"2025 December 11; 146(24):2854-2855. doi: 10.1182\/blood.2025031096","author":"Wiita AP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41379496"},{"title01":"Evolution of Multiple Myeloma from a Genomic Perspective.","title02":"Evolution of Multiple Myeloma from a Genomic Perspective.","journal":"Blood","issue":"2025 December 8. doi: 10.1182\/blood.2024026313. Online ahead of print","author":"Maura F, Samur MK, Munshi NC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359792"},{"title01":"Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy.","title02":"Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy.","journal":"Blood","issue":"2025 December 11; 146(24):2945-2962. doi: 10.1182\/blood.2025028441","author":"Bruno T, Cappelletto MC, Cortile C, Di Giovenale S, Amadio B, De Nicola F, Falcone I, Giuliani S, Palermo B, Catena V, Ciuffreda L, Cerruti F, Cascio P, Merola R, Masi S, De Pascale V, Annibali O, Ferraro S, Gumenyuk S, Pisani F, Marchesi F, Mengarelli A, Fanciulli M, Corleone G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920573"},{"title01":"Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma.","title02":"Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma.","journal":"Blood","issue":"2025 December 4. doi: 10.1182\/blood.2025031629. Online ahead of print","author":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Kanellias N, Migkou M Dr, Theodorakakou F, Spiliopoulou V, Solia I, Eleutherakis-Papaiakovou E, Psarros G, Kastritis E, Dimopoulos MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346230"},{"title01":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.","title02":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.","journal":"Blood","issue":"2025 December 11; 146(24):2902-2913. doi: 10.1182\/blood.2025029360","author":"Chari A, van de Donk NWCJ, Dholaria B, Weisel K, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodriguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosinol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi K, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit MD, Wasch R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40983036"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2025 December 8. doi: 10.1056\/NEJMoa2505478. Online ahead of print","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","title02":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","journal":"Leukemia","issue":"2025 December; 39(12):3015-3025. doi: 10.1038\/s41375-025-02771-8","author":"Romero-Moya D, Torralba-Sales E, Calvo C, Marin-Bejar O, Magallon-Mosella M, Distefano M, Pera J, Castano J, De Giorgio F, Gonzalez J, Iglesias A, Berenguer-Balaguer C, Schilling M, Plass M, Pasquali L, Catala A, Molina O, Wlodarski MW, Bigas A, Giorgetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954215"},{"title01":"Base edited &#8220;universal&#8221; donor CAR T-cell strategies for acute myeloid leukaemia.","title02":"Base edited &#8220;universal&#8221; donor CAR T-cell strategies for acute myeloid leukaemia.","journal":"Leukemia","issue":"2025 December; 39(12):2978-2987. doi: 10.1038\/s41375-025-02720-5","author":"Kadirkamanathan R, Georgiadis C, Kloos A, Joshi A, Etuk A, Preece R, Gough O, Schambach A, Sauer M, Heuser M, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41034424"},{"title01":"OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure.","title02":"OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure.","journal":"Leukemia","issue":"2025 December; 39(12):3037-3041. doi: 10.1038\/s41375-025-02783-4","author":"Saul D, Lischer C, Bruns H, Ziegler N, Kannt A, Michel M, Mougiakakos D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41094011"},{"title01":"HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial.","title02":"HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.300013. Online ahead of print","author":"Dhedin N, Bruno B, Paillard C, Gounfle E, Buchbinder N, Chardin MO, Gaba M, Arlet JB, Arnaud C, Jung C, Pondarre C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376570"},{"title01":"Randomized trial of anti-thymocyte globulin plus lowdose post-transplant cyclophosphamide to prevent graft-versus- host disease in haploidentical transplantation.","title02":"Randomized trial of anti-thymocyte globulin plus lowdose post-transplant cyclophosphamide to prevent graft-versus- host disease in haploidentical transplantation.","journal":"Haematologica","issue":"2025 December 1; 110(12):2965-2973. doi: 10.3324\/haematol.2025.287504","author":"Xu ZL, Han TT, Zhu XL, Liu J, Lv M, Sun YQ, Mo XD, Cheng YF, Xu LP, Zhang XH, Huang XJ, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534493"},{"title01":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","title02":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","journal":"Br J Haematol","issue":"2025 December 3. doi: 10.1111\/bjh.70274. Online ahead of print","author":"Peters DT, Nicolet D, Madanat YF, Gonzalez-Lugo J, Ambinder A, Chan O, Foucar CE, Sahasrabudhe KD, Ameyi J, Mrozek K, Lin T, Al-Ali N, Lancet J, Barredo B, Banaszak LG, Hochman MJ, Ragon BK, McMahon CM, Haque T, Mims AS, Eisfeld AK, Zeidner JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41332326"},{"title01":"Impact of graft-versus-host disease prophylaxis strategies on GvHD-free\/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis.","title02":"Impact of graft-versus-host disease prophylaxis strategies on GvHD-free\/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis.","journal":"Br J Haematol","issue":"2025 December 5. doi: 10.1111\/bjh.70269. Online ahead of print","author":"Desai N, Rodriguez SR, Al-Shaibani E, Moya TA, Novitzky-Basso I, Law AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346275"},{"title01":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","title02":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70281. Online ahead of print","author":"Gu J, Wang J, Liu L, Zhang Y, Ghanad P, Goli MM, Bao C, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387940"},{"title01":"Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group.","title02":"Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group.","journal":"Blood advances","issue":"2025 December 9; 9(23):6141-6157. doi: 10.1182\/bloodadvances.2025016915","author":"Hammoudi T, Nucera S, Troullioud Lucas AG, Ansari M, Balduzzi A, Bertaina A, Buechner J, Corbacioglu S, Dalle JH, Kalwak K, Lee D, Levine JE, Lindemans CA, Locatelli F, Meisel R, Nierkens S, Ottaviano G, Perez-Martinez A, Pichler H, Prockop SE, Pulsipher MA, Talano JM, Tewari S, Schultz KR, Shah NN, Verneris MR, Boelens JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902074"},{"title01":"Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.","title02":"Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.","journal":"Blood advances","issue":"2025 December 9; 9(23):5965-5975. doi: 10.1182\/bloodadvances.2024013727","author":"Djassemi N, Hanisch B, Motta C, Maghzian N, Vatsayan A, Durkee-Shock JR, Keller MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864193"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","journal":"Blood advances","issue":"2025 December 5. doi: 10.1182\/bloodadvances.2025018631. Online ahead of print","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro RM, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan JA, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","title02":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","journal":"Blood advances","issue":"2025 December 6. doi: 10.1182\/bloodadvances.2025018178. Online ahead of print","author":"Chin KK, Ball BJ, Abaza Y, Altman JK, Thakur RK, Ali M, Derkach A, Geyer MB, Goldberg AD, Haque T, Thompson MC, Park JH, Tallman MS, Cai SF, Wang ES, Aldoss I, Stein EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351513"},{"title01":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","title02":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","journal":"Blood advances","issue":"2025 December 9; 9(23):6205-6217. doi: 10.1182\/bloodadvances.2024015600","author":"Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor A, Townsend W, Andre M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811783"},{"title01":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","title02":"Clinical Characteristics, Management, and Hematopoietic Cell Transplantation of Patients with TLR8 Gain-of-Function.","journal":"Blood advances","issue":"2025 December 10. doi: 10.1182\/bloodadvances.2025016338. Online ahead of print","author":"Arnold DE, Kaviany S, Aluri J, Calvo KR, Mehta SS, Tobin JM, Schuettpelz L, Saucier N, Schmitz EG, Murguia-Favela L, Wright NAM, De Ravin SS, Rao VK, Holland SM, Bleesing J, Loughran TP, Feith DJ, Powell J, Ratan A, Warren JT, Pai SY, Bednarski JJ, Connelly JA, Cooper MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370196"},{"title01":"Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients.","title02":"Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients.","journal":"Blood advances","issue":"2025 December 12. doi: 10.1182\/bloodadvances.2025017393. Online ahead of print","author":"Nishitani M, Graham RT, Wang T, DeVos JD, Lee SJ, Spellman SR, Kitko CL, MacMillan ML, DeFilipp Z, Gray AN, Williams KM, Takahashi T, Schoettler ML, Hashem H, Rangarajan HG, Prestidge T, Ringden O, Hamilton BK, Sharma A, Nusrat R, El Jurdi N, Bhatt NS, Duncan CN, Qayed M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385339"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2025 December 8. doi: 10.1182\/blood.2025030816. Online ahead of print","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst RT, Wolf D, Baldus CD, Oelschlaegel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","title02":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","journal":"Blood","issue":"2025 December 4; 146(23):2745-2757. doi: 10.1182\/blood.2025029299","author":"Pan J, Zhao L, Zhang Y, Seery S, Tan Y, Deng B, Shan L, Ling Z, Wu F, Wang Z, Wang Q, Yu X, Zheng Q, Xu X, Yuan Y, Tian Z, Zhang Y, Peng S, Chang AH, Feng X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40712157"},{"title01":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2025 December 12. doi: 10.1182\/blood.2025031313. Online ahead of print","author":"Meyer E, Salhotra A, Gandhi A, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand RG, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau JM, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian S, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"How I Treat Advanced Phases of CML.","title02":"How I Treat Advanced Phases of CML.","journal":"Blood","issue":"2025 December 2. doi: 10.1182\/blood.2024026510. Online ahead of print","author":"Mauro MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329950"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2025 December 8. doi: 10.1056\/NEJMoa2505478. Online ahead of print","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"Prime Editing for p47(phox)-Deficient Chronic Granulomatous Disease.","title02":"Prime Editing for p47(phox)-Deficient Chronic Granulomatous Disease.","journal":"N Engl J Med","issue":"2025 December 7. doi: 10.1056\/NEJMoa2509807. Online ahead of print","author":"Gori JL, Haddad E, Frangoul H, Kohn DB, Morris EC, Martin BN, Deary BA, Nickerson M, Scholz RL, Fernandez I, Leveille K, De Ravin SS, Kang EM, Pierzynski M, Estwick T, Littel P, Kuhns DB, Long Priel DA, Teira P, Turvey S, Arnold J, Evans MD, McManus M, Carpenter B, Waterman DP, Anzalone AV, Petrusich A, Osuna CE, O'Malley TT, Stewart-Ornstein J, Heath JM, Nehilla BJ, Asmal M, Malech HL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358590"},{"title01":"Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.","title02":"Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.","journal":"Leukemia","issue":"2025 December; 39(12):2916-2925. doi: 10.1038\/s41375-025-02745-w","author":"Karakaslar EO, Argiro EM, Struckman NE, Shirali Hz R, Severens JF, Honders MW, Kloet SL, Veelken H, Reinders MJ, Griffioen M, van den Akker EB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954214"},{"title01":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","title02":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","journal":"Leukemia","issue":"2025 December; 39(12):3015-3025. doi: 10.1038\/s41375-025-02771-8","author":"Romero-Moya D, Torralba-Sales E, Calvo C, Marin-Bejar O, Magallon-Mosella M, Distefano M, Pera J, Castano J, De Giorgio F, Gonzalez J, Iglesias A, Berenguer-Balaguer C, Schilling M, Plass M, Pasquali L, Catala A, Molina O, Wlodarski MW, Bigas A, Giorgetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954215"},{"title01":"Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus.","title02":"Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus.","journal":"Leukemia","issue":"2025 December; 39(12):2862-2865. doi: 10.1038\/s41375-025-02754-9","author":"Salit RB, Hexner EO, Gagelmann N, Kroger N, McLornan DP, Jain T, Gupta V, Hobbs GS, Tamari R, Robin M, Scott B, Saber W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41083679"},{"title01":"Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","title02":"Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","journal":"Leukemia","issue":"2025 December; 39(12):2935-2945. doi: 10.1038\/s41375-025-02768-3","author":"Setiawan T, Muhammad JA, Marcellina N, Wirawan LM, Jun N, Sari IN, Oehler VG, Kim DW, Kwon HY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41034423"},{"title01":"Medical tourism for cellular therapy: a clinical perspective.","title02":"Medical tourism for cellular therapy: a clinical perspective.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e978-e985. doi: 10.1016\/S2352-3026(25)00294-7","author":"Esther CHL, Fan EB, Hew YY, Poon LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338866"},{"title01":"Hematopoietic Cell Transplantation for Wiskott-Aldrich syndrome: A PIDTC Report.","title02":"Hematopoietic Cell Transplantation for Wiskott-Aldrich syndrome: A PIDTC Report.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017662. Online ahead of print","author":"Alexander JL, Davila Saldana BJ, Brazauskas R, Dammalapati SG, Griffith LM, Shah AJ, Shimano KA, Ochs HD, Bleesing J, Ebens CL, Kapadia M, Bauchat A, Kapoor N, Oved JH, Eissa H, Lust H, Keller MD, Haines H, Chandrakasan S, Talano JM, Rayes A, Madden LM, Shereck EB, Miller HK, Forbes Satter LR, Martinez CA, Rozmus J, Bednarski JJ, Yu LC, Chellapandian D, Aquino VM, Knutsen AP, Chong H, Chopek A, Gillio AP, Joshi A, Rangarajan HG, Moore TB, Andolina JR, DeSantes K, Vander Lugt MT, Prockop SE, Shyr D, Sullivan KE, Parikh SH, Weinacht KG, Torgerson TR, Marsh RA, Dvorak CC, Chan AY, Haddad E, Heimall J, Pulsipher MA, Leiding JW, Kohn DB, Puck JM, Notarangelo LD, Rawlings DJ, Cowan MJ, Petrovic A, Pai SY, Burroughs LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346295"},{"title01":"Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.","title02":"Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.","journal":"Blood advances","issue":"2025 December 3. doi: 10.1182\/bloodadvances.2025018079. Online ahead of print","author":"Merryman RW, Rutherford SC, Ansell SM, Armand P, Leonard JP, Nastoupil L, Smith SM, Timmerman JM, Zelenetz AD, Gutierrez M, Beguelin W, Casulo C, Cerhan JR, Green MR, Kahl BS, Kridel R, Link BK, Maurer MJ, Nadel B, Radtke A, Luttwak E, Salles GA, Sehn LH, Pasqualucci L, LaCasce AS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337699"},{"title01":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","title02":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.","journal":"Blood advances","issue":"2025 December 9; 9(23):6205-6217. doi: 10.1182\/bloodadvances.2024015600","author":"Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor A, Townsend W, Andre M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811783"},{"title01":"Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.","title02":"Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.","journal":"Blood advances","issue":"2025 December 9; 9(23):5976-5987. doi: 10.1182\/bloodadvances.2024015282","author":"Iyer S, Mehta-Shah N, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Alpdogan O, Feldman TA, Camus V, Gritti G, Zinzani PL, Belada D, Mayer J, Choi I, Cheong JW, Rustia E, Fenton K, Fanale M, Savage KJ, Horwitz SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829107"},{"title01":"Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R\/R follicular lymphoma: phase 1\/2 BRUIN study.","title02":"Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R\/R follicular lymphoma: phase 1\/2 BRUIN study.","journal":"Blood advances","issue":"2025 December 9; 9(23):5954-5964. doi: 10.1182\/bloodadvances.2024014975","author":"Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845254"},{"title01":"Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOP.","title02":"Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOP.","journal":"Blood advances","issue":"2025 December 8. doi: 10.1182\/bloodadvances.2025016931. Online ahead of print","author":"Cetin O, Kos IA, Regitz E, Bewarder M, Rixecker TM, Tausch E, Schwarz EC, Jansky J, Lesan V, Schormann C, Neumann F, Loeffler M, Hallek MJ, Fischer K, Zophel S, Staiger AM, Ott G, Christofyllakis K, Bittenbring JT, Poeschel V, Kaddu-Mulindwa D, Staber PB, Ligtvoet R, Robrecht S, Ziepert M, Schmitz N, Hoth M, Kessel C, Stilgenbauer S, Altmann B, Thurner L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358738"},{"title01":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","title02":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","journal":"Blood","issue":"2025 December 4; 146(23):2745-2757. doi: 10.1182\/blood.2025029299","author":"Pan J, Zhao L, Zhang Y, Seery S, Tan Y, Deng B, Shan L, Ling Z, Wu F, Wang Z, Wang Q, Yu X, Zheng Q, Xu X, Yuan Y, Tian Z, Zhang Y, Peng S, Chang AH, Feng X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40712157"},{"title01":"Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.","title02":"Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.","journal":"Blood","issue":"2025 December 4; 146(23):2758-2764. doi: 10.1182\/blood.2025028823","author":"Zucca E, Ceriani L, Ciccone G, Di Rocco A, Pirosa MC, Kriachok I, Botto B, Balzarotti M, Tucci A, Usai SV, Zilioli VR, Pennese E, Arcaini L, Dabrowska-Iwanicka A, Ferreri AJM, Merli F, Zhao W, Rigacci L, Cellini C, Hodgson D, Ionescu C, Minoia C, Lucchini E, Spina M, Fossa A, Janikova A, Cwynarski K, Mikhaeel NG, Jerkeman M, Stathis A, Cozens K, Ielmini N, De Martino I, Walewski J, Trneny M, Cavalli F, Ricardi U, Johnson PWM, Davies A, Martelli M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40939190"},{"title01":"Sweet stuff is dangerous in DLBCL.","title02":"Sweet stuff is dangerous in DLBCL.","journal":"Blood","issue":"2025 December 4; 146(23):2739-2741. doi: 10.1182\/blood.2025031082","author":"Fend F, Quintanilla-Martinez L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41343169"},{"title01":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.","title02":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.","journal":"N Engl J Med","issue":"2025 December 9. doi: 10.1056\/NEJMoa2514663. Online ahead of print","author":"Costa LJ, Bahlis NJ, Perrot A, Nooka AK, Lu J, Pawlyn C, Mina R, Caeiro G, Kentos A, Hungria V, Reece D, Niu T, Mylin AK, Hansen CT, Teipel R, Besemer B, Dimopoulos MA, Zamagni E, Yoshihara S, Kim K, Min CK, Geerts P, Van Leeuwen-Segarceanu E, Tyczynska A, Reguera JL, Johansson M, Hansson M, Turgut M, Grey M, Sidana S, Rodriguez-Otero P, Martinez-Lopez J, Hashmi H, Carson R, Kobos R, Sun W, Lantz K, Seifert A, Briseno-Toomey D, O'Rourke L, Rubin M, Vieyra D, Kang L, Mateos MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363801"},{"title01":"Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.","title02":"Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.","journal":"N Engl J Med","issue":"2025 December 7. doi: 10.1056\/NEJMoa2514752. Online ahead of print","author":"Kumar S, Mateos MV, Ye JC, Atrash S, Magen H, Quach H, Chu MP, Trudel S, Richter J, Rodriguez-Otero P, Chuah H, Gatt M, Medvedova E, Raza S, Yoon DH, Ishida T, Matous JV, Rosinol L, Onodera K, Scott E, Heuck C, Zhang J, Henninger T, O'Rourke L, Thakkar P, Festa M, Huang L, Zhou J, Takamoto M, Pei L, Lu J, Au N, Krevvata M, Usmani SZ, Cohen YC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358582"},{"title01":"Measurable residual disease assessment in multiple myeloma.","title02":"Measurable residual disease assessment in multiple myeloma.","journal":"Leukemia","issue":"2025 December 5. doi: 10.1038\/s41375-025-02830-0. Online ahead of print","author":"Zanwar S, Rajkumar SV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41350429"},{"title01":"Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study.","title02":"Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study.","journal":"Leukemia","issue":"2025 December; 39(12):2997-3003. doi: 10.1038\/s41375-025-02762-9","author":"Andersen LS, Navarro RB, Ekberg S, Rognvaldsson S, Levy MR, Sverrisdottir IS, Vietharsson B, Onundarson PT, Agnarsson BA, Sigurethardottir M, Thornorsteinsdottir I, Olafsson I, Thornorethardottir AR, Eythornorsson E, Jonsson A, Olafsson A, Durie BGM, Harding S, Landgren O, Love TJ, Kristinsson SY, Thorsteinsdottir S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40940581"},{"title01":"The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma.","title02":"The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma.","journal":"Leukemia","issue":"2025 December; 39(12):3004-3014. doi: 10.1038\/s41375-025-02766-5","author":"Frede J, Poller JC, Shi K, Stuart H, Sotudeh N, Havig C, Lim K, Wiggers CRM, Cho EY, Vijaykumar T, Liu J, Waldschmidt JM, Nair MS, Anand P, Dimitrova V, Montanaro A, Yee AJ, Munshi NC, Anderson KC, Martin N, Kaiser SM, Raab MS, Raje NS, Knoechel B, Lohr JG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973768"},{"title01":"Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis.","title02":"Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis.","journal":"Leukemia","issue":"2025 December; 39(12):2866-2871. doi: 10.1038\/s41375-025-02776-3","author":"Zanwar S, Belge Bilgin G, Broski SM, Thorpe M, Bilgin C, Gonsalves W, Kapoor P, Kourelis T, Hayman S, Abdallah N, Binder M, Cook J, Dispenzieri A, Dingli D, Gertz MA, Leung N, Lin Y, Muchtar E, Warsame R, Kyle RA, Rajkumar SV, Kumar S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41016943"},{"title01":"Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics.","title02":"Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics.","journal":"J Clin Oncol","issue":"2025 December 12; JCO2502305. doi: 10.1200\/JCO-25-02305. Online ahead of print","author":"Saldarriaga MM, Bellman P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385751"},{"title01":"Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.","title02":"Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.","journal":"J Clin Oncol","issue":"2025 December 11; JCO2500289. doi: 10.1200\/JCO-25-00289. Online ahead of print","author":"Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, Fan Y, Dakiki Korucu B, Szalat R, Fulciniti M, Anderson KC, Sperling A, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380103"},{"title01":"Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed\/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.","title02":"Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed\/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.","journal":"J Clin Oncol","issue":"2025 December 10; JCO2500924. doi: 10.1200\/JCO-25-00924. Online ahead of print","author":"Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, Kapoor P, Katodritou E, Kortum KM, Ling S, Nagarajan C, Suzuki K, Qiu L, Onishi M, Ku G, Dail M, Mukherjee N, Ross JA, Badawi MA, Fusco MJ, Dobkowska E, Arriola E, Bueno OF, Bahlis NJ, Iida S, Moreau P, Valent J, Mateos MV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370738"},{"title01":"A Fighter Bigger Than Myeloma.","title02":"A Fighter Bigger Than Myeloma.","journal":"J Clin Oncol","issue":"2025 December; 43(34):3684-3685. doi: 10.1200\/JCO-25-00932","author":"Khan AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41086373"},{"title01":"Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.","title02":"Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.289245. Online ahead of print","author":"Besse A, Kraus M, Totu T, Buljan M, Janssen APA, Van der Stelt M, Matisikova K, Veprkova J, Sedlarikova L, Jurinakova T, Truger M, Haferlach C, Lopez MM, Kortum MK, Rasche L, Driessen C, Besse L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376558"},{"title01":"Genetic alterations of SENP6 in multiple myeloma disrupt genome and proteome stability, sensitizing to proteasome inhibition.","title02":"Genetic alterations of SENP6 in multiple myeloma disrupt genome and proteome stability, sensitizing to proteasome inhibition.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.288863. Online ahead of print","author":"Herzberg F, Korenkov M, Isaakidis K, Zang C, Wirth M, Muller S, Keller U, Demel UM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342169"},{"title01":"Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myeloma.","title02":"Radiopsy: a prospective observational study on quantitative multiparametric whole-body magnetic resonance imaging to discriminate between smoldering and multiple myeloma.","journal":"Haematologica","issue":"2025 December 1; 110(12):3104-3108. doi: 10.3324\/haematol.2025.287563","author":"Feliciani G, Loi E, Amadori E, Antognoni E, Iamurri AP, Diano D, Bruno D, Cattabriga A, Caroli P, Marchesini M, Bezzi D, Cangini D, Matteucci F, Barone D, Nappi D, Musuraca G, Ceccolini M, Ronconi S, Azzali I, Martinelli G, Maffioli LS, Normanno N, Sarnelli A, Rossi A, Cerchione C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534490"},{"title01":"Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era.","title02":"Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era.","journal":"Haematologica","issue":"2025 December 1; 110(12):3053-3064. doi: 10.3324\/haematol.2025.287545","author":"Broughton M, Bhatta S, Sonali D, Bumma N, Khan AM, Devarakonda S, Umyarova E, Benson D, Rosko A, Cottini F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501390"},{"title01":"Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies.","title02":"Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies.","journal":"Haematologica","issue":"2025 December 1; 110(12):3168-3170. doi: 10.3324\/haematol.2025.288359","author":"Rees MJ, Quach H, Jardine D, Thompson A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820805"},{"title01":"Optical genome mapping reveals complex cytogenetic abnormalities in multiple myeloma.","title02":"Optical genome mapping reveals complex cytogenetic abnormalities in multiple myeloma.","journal":"Haematologica","issue":"2025 December 1; 110(12):3133-3139. doi: 10.3324\/haematol.2025.288008","author":"Palacios JA, Bernal M, Vilchez JR, Garrido P, Jimenez P, Gutierrez-Bautista JF, Barrera-Aguilera MC, Ballesta L, Rodriguez T, Olivares-Duran MJ, Ruiz-Cabello F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534500"},{"title01":"Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma.","title02":"Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma.","journal":"Haematologica","issue":"2025 December 1; 110(12):3065-3077. doi: 10.3324\/haematol.2025.287985","author":"Portuguese AJ, Liang EC, Huang JJ, Jeon Y, Dima D, Banerjee R, Kwok M, Cicero KI, Hirayama AV, Basom R, Khouderchah C, Shadman M, Fong L, Cowan AJ, Gauthier J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534492"},{"title01":"Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing.","title02":"Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing.","journal":"Blood advances","issue":"2025 December 12. doi: 10.1182\/bloodadvances.2025018133. Online ahead of print","author":"Fang B, Zhu Z, Chang Y, He X, Li S, Li M, Yan S, Zhu D, Li Z, Mao M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385406"},{"title01":"Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed\/Refractory Multiple Myeloma.","title02":"Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed\/Refractory Multiple Myeloma.","journal":"Blood advances","issue":"2025 December 12. doi: 10.1182\/bloodadvances.2025017939. Online ahead of print","author":"Patel H, Hubbeling H, Yu KL, Carpenter M, LaRiviere MJ, Plastaras JP, Cohen AD, Kapur S, Vogl DT, Waxman AJ, Stadtmauer EA, Garfall AL, Susanibar-Adaniya SP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385343"},{"title01":"Prognosis and patterns of progression in smoldering multiple myeloma.","title02":"Prognosis and patterns of progression in smoldering multiple myeloma.","journal":"Blood advances","issue":"2025 December 11. doi: 10.1182\/bloodadvances.2025018021. Online ahead of print","author":"Akhlaghi T, Maclachlan KH, Wiggins A, Usmani SZ, Derkach A, Hultcrantz ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380108"},{"title01":"Real-world evidence of measurable residual disease assessment in multiple myeloma.","title02":"Real-world evidence of measurable residual disease assessment in multiple myeloma.","journal":"Blood advances","issue":"2025 December 11. doi: 10.1182\/bloodadvances.2025018454. Online ahead of print","author":"Cedena MT, Puig N, Paiva B, de la Puerta Rueda JE, Perez-Montana A, Casanova M, Brena Atienza J, Garcia A, de Arriba F, Martinez-Chamorro C, Sirvent M, Blanchard MJ, Alonso Fernandez R, Alvarez Rivas MA, Capote FJ, Garcia-Sanchez R, Perez JJ Sr, Rodriguez-Otero P, Lahuerta JJ, Martinez-Lopez J, Mateos MV, San-Miguel JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380099"},{"title01":"Bioenergetic diversity and nutrient auxotrophy shape the metabolic landscape of Multiple Myeloma.","title02":"Bioenergetic diversity and nutrient auxotrophy shape the metabolic landscape of Multiple Myeloma.","journal":"Blood advances","issue":"2025 December 1. doi: 10.1182\/bloodadvances.2025017676. Online ahead of print","author":"Chong PS, Lim SJ, Tan TZ, Kong LR, De Mel S, Yong ALC, Gim Seng EY, Chng WJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41324599"},{"title01":"Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide.","title02":"Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide.","journal":"Blood advances","issue":"2025 December 9; 9(23):6001-6008. doi: 10.1182\/bloodadvances.2025016625","author":"Systchenko T, Nsiala L, Bobin A, Gardeney H, Motard C, Olivier G, Borde F, Corby A, Roul C, Fleck E, Denis G, Dieval C, Mottaz P, Boscagli A, Defossez G, Leleu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864187"},{"title01":"Medical tourism for cellular therapy: a clinical perspective.","title02":"Medical tourism for cellular therapy: a clinical perspective.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e978-e985. doi: 10.1016\/S2352-3026(25)00294-7","author":"Esther CHL, Fan EB, Hew YY, Poon LM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338866"},{"title01":"Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study.","title02":"Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e956-e965. doi: 10.1016\/S2352-3026(25)00293-5","author":"Scordo M, Perales MA, Mauguen A, Lin A, Kunvarjee B, Paes Pena M, Mcavoy D, Nguyen LK, Hogan M, Chapman N, Bieler J, Cho C, Gyurkocza B, Harris AC, Spitzer B, O'Reilly RJ, Jakubowski AA, Lin RJ, Papadopoulos EB, Politikos I, Ponce DM, Shaffer BC, Shah GL, Tamari R, Giralt SA, Boelens JJ, Curran KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338864"},{"title01":"Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.","title02":"Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.","journal":"J Clin Oncol","issue":"2025 December; 43(34):3639-3645. doi: 10.1200\/JCO-25-00809","author":"Mohty M, Socie G, Szer J, Niederwieser D, Butler J, Wagner-Drouet E, Or R, Rovenvald-Zuckerman T, Bozdag SC, Forcade E, Grillo G, Kroger N, Stolzel F, Russo D, Sanz J, Sarkar R, Stefanelli T, Wilke C, Zeiser R, von Bubnoff N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41092247"},{"title01":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2025 December 1; 110(12):3088-3093. doi: 10.3324\/haematol.2025.287326","author":"Li L, Ye Y, Galimard JE, Labopin M, Wu D, Chen J, Kroger N, Passweg J, Salmenniemi U, Itala-Remes M, Poire X, Eder M, Maertens J, Burns D, Sengeloev H, Olesen G, Blaise D, Finke J, Gadisseur A, Bazarbachi A, Brissot E, Nagler A, Luo Y, Shi J, Mohty M, Huang H, Ciceri F, Claude Gorin N Sr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534491"},{"title01":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children&#8217;s Oncology Group AALL1331 trial.","title02":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children&#8217;s Oncology Group AALL1331 trial.","journal":"Haematologica","issue":"2025 December 1; 110(12):2930-2941. doi: 10.3324\/haematol.2025.287386","author":"Hogan LE, Bhatla T, Xu X, Gore L, Raetz EA, Bhojwani D, Teachey DT, Hunger SP, Loh ML, Brown PA, Ji L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568722"},{"title01":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-world data study.","title02":"Fecal microbiota transplantation for decolonization from multidrug-resistant bacteria in pediatric allogeneic hematopoietic stem cell transplantation recipients: a retrospective real-world data study.","journal":"Haematologica","issue":"2025 December 1; 110(12):3150-3153. doi: 10.3324\/haematol.2025.288067","author":"Masetti R, Barbara G, Muratore E, Marasco G, Cremon C, Marangoni A, Brigidi P, Putignani L, Angelino G, Quagliarella F, Galaverna F, Leardini D, Lazzarotto T, Gabelli M, Savarino E, Zecca M, Faraci M, Prete A, Biffi A, Locatelli F, Merli P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568731"},{"title01":"A new standard for relapsed or refractory follicular lymphoma.","title02":"A new standard for relapsed or refractory follicular lymphoma.","journal":"Lancet","issue":"2025 December 5. doi: 10.1016\/S0140-6736(25)01965-8. Online ahead of print","author":"Harel R, Cohen JB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41360063"},{"title01":"FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.","title02":"FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 2; JCO2500892. doi: 10.1200\/JCO-25-00892. Online ahead of print","author":"Maurer MJ, Prochazka VK, El-Galaly TC, Flowers CR, Villa D, Bachy E, Cahn EJ, Fournier M, Larson MC, Dietrich CE, Jakobsen LH, Ghesquieres H, Kridel R, Gandhi MK, Cheah CY, Hawkes EA, Seymour JF, Freeman CL, Clausen MR, Wahlin BE, Friedberg JW, Casulo C, Habermann TM, Wang Y, Nastoupil LJ, de Nully Brown P, Belada D, Janikova A, Mocikova H, Furst T, Feugier P, Tilly H, Haioun C, Davies AJ, Cartron G, Burack R, Chihara D, Martin P, Cohen JB, Lossos IS, Kahl BS, Sehn LH, Smedby KE, Salles G, Trneny M, Link BK, Morschhauser F, Cerhan JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329901"},{"title01":"Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity.","title02":"Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity.","journal":"J Clin Oncol","issue":"2025 December 10; JCO2502323. doi: 10.1200\/JCO-25-02323. Online ahead of print","author":"Pophali PA, Kenkre VP, Hayes CA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41370745"},{"title01":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 9; JCO2502380. doi: 10.1200\/JCO-25-02380. Online ahead of print","author":"Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363773"},{"title01":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 7; JCO2502477. doi: 10.1200\/JCO-25-02477. Online ahead of print","author":"Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovska A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Ozcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41353787"},{"title01":"Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?","title02":"Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?","journal":"J Clin Oncol","issue":"2025 December; 43(34):3631-3635. doi: 10.1200\/JCO-25-01932","author":"Rossi D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41056509"},{"title01":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","title02":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 10; 43(35):3698-3705. doi: 10.1200\/JCO-25-00925","author":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trneny M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Batlevi CL, Tilly H, Flowers CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991874"},{"title01":"Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.","title02":"Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 12; JCO2501712. doi: 10.1200\/JCO-25-01712. Online ahead of print","author":"Wang S, Nijland M, Strobbe L, Oosterveld M, Boersma R, Koene H, Klerk C, de Jongh E, Koster A, Pruijt H, van der Poel M, van Werkhoven E, Zanders H, Dinmohamed A, Pegtel M, Meek S, Stowell SL, Warinske H, Alizadeh AA, Kurtz DM, Chamuleau MED","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385760"},{"title01":"Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.","title02":"Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2025 December; 43(34):3652-3661. doi: 10.1200\/JCO-25-01534","author":"Roschewski M, Kurtz DM, Westin JR, Lynch RC, Gopal AK, Alig SK, Sworder BJ, Cherng HJ, Kuffer C, Blair D, Brown K, Goldstein JS, Schultz A, Close S, Chabon JJ, Diehn M, Wilson WH, Alizadeh AA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40802906"},{"title01":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma.","title02":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma.","journal":"Haematologica","issue":"2025 December 1; 110(12):2895-2901. doi: 10.3324\/haematol.2025.288114","author":"Ghione P, Zinzani PL, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702895"},{"title01":"Recognition, prevention, and management of adverse events associated with asparaginase\/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel.","title02":"Recognition, prevention, and management of adverse events associated with asparaginase\/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel.","journal":"Haematologica","issue":"2025 December 1; 110(12):2913-2929. doi: 10.3324\/haematol.2024.286744","author":"Curran E, Luskin MR, Alachkar H, Aldoss I, Burke PW, Cassaday RD, Karol SE, Perissinotti AJ, Rank CU, Schmiegelow K, Webster J, Douer D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40109190"},{"title01":"Erratum to: &#8220;Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance&#8221;.","title02":"Erratum to: &#8220;Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance&#8221;.","journal":"Haematologica","issue":"2025 December 1; 110(12):3180-3181. doi: 10.3324\/haematol.2025.288659","author":"Schmidt C, Scheubeck G, Jurinovic V, Sokler M, Forstpointner R, Buske C, Viardot A, Keller U, Graeven U, Marks R, Hanel M, Liersch R, Durig J, Pott C, Hoster E, Unterhalt M, Hiddemann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41321264"},{"title01":"Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma &#8211; a retrospective multicentre clinical study.","title02":"Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma &#8211; a retrospective multicentre clinical study.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.287982. Online ahead of print","author":"Kama K, Treiber H, Kutilina A, Trefz S, Wollnitza S, Shumilov E, Finke J, Lenz G, Wulf G, Isbell LK, Aksoy A, Jensch A, Illerhaus G, Wendler J, Schorb E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376557"},{"title01":"Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.","title02":"Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance.","journal":"Haematologica","issue":"2025 December 1; 110(12):3022-3031. doi: 10.3324\/haematol.2024.287162","author":"Schmidt C, Scheubeck G, Jurinovic V, Sokler M, Forstpointner R, Buske C, Viardot A, Keller U, Graeven U, Marks R, Hanel M, Liersch R, Durig J, Pott C, Hoster E, Unterhalt M, Hiddemann W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501414"},{"title01":"The progression at 24 months (POD24) induces a high risk of transformation of follicular lymphoma: A systematic biopsy verification.","title02":"The progression at 24 months (POD24) induces a high risk of transformation of follicular lymphoma: A systematic biopsy verification.","journal":"Br J Haematol","issue":"2025 December 3. doi: 10.1111\/bjh.70277. Online ahead of print","author":"Picardi M, Vincenzi A, Pugliese N, Giordano C, Mascolo M, Vigliar E, Troncone G, Zeppa P, Pane F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41332285"},{"title01":"A high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHL.","title02":"A high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHL.","journal":"Br J Haematol","issue":"2025 December 8. doi: 10.1111\/bjh.70273. Online ahead of print","author":"Zadro A, Arribas A, Colombo MV, Cannas E, Spriano F, Cascione L, Mensah AA, Simonetta F, Petta D, Candrian C, Arrigoni C, Bertoni F, Moretti M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41362022"},{"title01":"Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.","title02":"Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.","journal":"Blood advances","issue":"2025 December 11. doi: 10.1182\/bloodadvances.2025018527. Online ahead of print","author":"Wang Y, Larson MC, Hwang SR, Villa D, Kugathasan L, Kumar A, Joseph A, Brooks TR, Hill BT, Bond DA, Maddocks KJ, Nizamuddin IA, Kahl BS, Danilov AV, Argao C, Ruan J, Ryan CE, Merryman RW, Grover NS, Khan NB, Ouchveridze E, Tun A, Ayyappan SR, Mou E, Pongas GN, Lossos IS, Harris ZI, Munoz J, Young P, Portell CA, Baidoun F, Alhaj Moustafa M, Reagan PM, Banaszak LG, Pophali PA, Velayati A, Greenwell IB, Gerber D, Jain P, Wang ML, Narkhede MS, Mehta AN, Stack AC, Messmer MR, Bhansali RS, Barta SK, Moyo TK, Ghosh N, Kamdar M, Anna JL, Stanisic A, Karmali R, Maurer MJ, Cerhan JR, Cohen JB, Martin P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380101"},{"title01":"Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.","title02":"Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.","journal":"Blood advances","issue":"2025 December 9; 9(23):6063-6075. doi: 10.1182\/bloodadvances.2025016291","author":"van Besien H, Easwar N, Demetres M, Pasciolla M, Shore T, Leonard J, Barker J, Martin P, Yamshon S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40590871"},{"title01":"Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.","title02":"Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.","journal":"Blood advances","issue":"2025 December 11. doi: 10.1182\/bloodadvances.2025016646. Online ahead of print","author":"Handunnetti SM, Khot A, Blombery P, Burbury K, Thompson PA, Ritchie D, Hicks RJ, Burke G, Koldej RM, Bressel M, Di Iulio JL, Westerman DA, Lade S, Roberts AW, Seymour JF, Tam CS, Anderson MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380113"},{"title01":"Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed\/refractory diffuse large B cell lymphoma.","title02":"Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed\/refractory diffuse large B cell lymphoma.","journal":"Blood advances","issue":"2025 December 9. doi: 10.1182\/bloodadvances.2025016858. Online ahead of print","author":"Yoon SE, Kang W, Cho J, Cho HJ, Chalita M, Oh HS, Hyun DW, Han S, Kim H, Sung H, Lee JY, Park B, Ryu KJ, Kim HY, Cho D, Kim WS, Kim SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41364878"},{"title01":"Pharma steps back from Hodgkin lymphoma: now what?","title02":"Pharma steps back from Hodgkin lymphoma: now what?","journal":"Blood advances","issue":"2025 December 9; 9(23):6218-6219. doi: 10.1182\/bloodadvances.2025017650","author":"Lynch RC, Gopal AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41364449"},{"title01":"Early clearance of circulating tumor DNA and association with odronextamab response in relapsed\/refractory FL and DLBCL.","title02":"Early clearance of circulating tumor DNA and association with odronextamab response in relapsed\/refractory FL and DLBCL.","journal":"Blood advances","issue":"2025 December 9; 9(23):6130-6140. doi: 10.1182\/bloodadvances.2025016332","author":"Arnason JE, Matasar M, Luminari S, Tucker D, Sun D, Tao W, Zhu YO, Kundu K, Gupta NT, Leary A, Jankovic V, Ambati S, Mohamed H, Chaudhry A, Brouwer-Visser J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902079"},{"title01":"Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion.","title02":"Cutaneous diffuse large B-cell lymphoma induces a macrophage immunosuppressive phenotype through IL-10 secretion.","journal":"Blood advances","issue":"2025 December 8. doi: 10.1182\/bloodadvances.2025016492. Online ahead of print","author":"Galtier J, Peanne R, Le Morvan V, Blondy T, Melane M, Bidon A, Chopin A, Prochazkova-Carlotti M, Poglio S, Merlio JP, Chevret E, Gros A, Pham-Ledard A, Beylot-Barry M, Bresson-Bepoldin L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358745"},{"title01":"NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed\/refractory large B-cell lymphoma.","title02":"NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed\/refractory large B-cell lymphoma.","journal":"Blood advances","issue":"2025 December 9; 9(23):6092-6095. doi: 10.1182\/bloodadvances.2025016423","author":"Ahmed S, DiPersio J, Essell J, Diefenbach C, Perales MA, Castilla-Llorente C, Dahiya S, Liu Y, Xu H, Fanton C, Chaudhry S, Lee ZH, Marcondes AMQ, Tagliaferri MA, Zalevsky J, Miklos D, Turtle CJ, McGuirk J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40779552"},{"title01":"Inclusion, characteristics and reporting of older patients in recent registration trials for DLBCL: A systematic review.","title02":"Inclusion, characteristics and reporting of older patients in recent registration trials for DLBCL: A systematic review.","journal":"Blood advances","issue":"2025 December 6. doi: 10.1182\/bloodadvances.2025017530. Online ahead of print","author":"Neuendorff NR, Pugh K, Juthani R, Soudant C, Eochagain CM, Torka P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351516"},{"title01":"Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.","title02":"Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017643. Online ahead of print","author":"Kong X, Xu-Monette ZY, Xu Z, Hsi E, Zhao X, Yan H, Nunns H, Au K, Visco C, Tzankov A, Dybkaer K, Yao S, Wu D, Wang C, Xu AM, Pan Z, Parsons BM, Chiu A, Tam W, Montes-Moreno S, Zhan F, Bernal-Mizrachi L, Zu Y, Zhang S, Moller MB, Chen W, Au Q, Merchant AA, Bhagat G, Li Y, Young KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346287"},{"title01":"Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.","title02":"Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.","journal":"Blood","issue":"2025 December 4; 146(23):2794-2807. doi: 10.1182\/blood.2024027997","author":"Pal I, Illendula A, Joyner A, Manavalan JS, Deddens TM, Sabzevari A, Damera DP, Zuberi S, Marchi E, Fox TE, Dunlap-Brown ME, Jayappa KD, Khalife J, Craig JW, Loughran TP Jr, Feith DJ, O'Connor OA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40896830"},{"title01":"The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma.","title02":"The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma.","journal":"Blood","issue":"2025 December 4; 146(23):2808-2820. doi: 10.1182\/blood.2025029163","author":"Tatterton DJ, Newby ML, Allen JD, Sale B, Chiodin G, Duriez PJ, Butler J, McCann KJ, Scott DW, Morin RD, Dreval K, Davies AJ, Bryant DJ, Crispin M, Forconi F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40896832"},{"title01":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","title02":"Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.","journal":"Blood advances","issue":"2025 December 6. doi: 10.1182\/bloodadvances.2025018178. Online ahead of print","author":"Chin KK, Ball BJ, Abaza Y, Altman JK, Thakur RK, Ali M, Derkach A, Geyer MB, Goldberg AD, Haque T, Thompson MC, Park JH, Tallman MS, Cai SF, Wang ES, Aldoss I, Stein EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351513"},{"title01":"Vulnerability of SRSF2 mutated chronic myelomonocytic leukemia to perturbation of cGAS-STING pathway.","title02":"Vulnerability of SRSF2 mutated chronic myelomonocytic leukemia to perturbation of cGAS-STING pathway.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017005. Online ahead of print","author":"Chen Y, Chan KC, Sin CF, Zheng L, Wang D, Tu L, He F, Hui WHJ, Leung HK, Chan LKF, Tsui SP, Chan HY, Ma ACH, Leung AY, Sun X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346291"},{"title01":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","title02":"Venetoclax\/FluBu2 RIC transplant followed by all-oral venetoclax\/decitabine maintenance for poor risk MDS\/AML.","journal":"Blood advances","issue":"2025 December 5. doi: 10.1182\/bloodadvances.2025018631. Online ahead of print","author":"Garcia JS, Kim HT, Murdock HM, Bosch-Vilaseca A, Panaro KM, Lim F, Fiorilla J, Auriemma E, Brock J, Gooptu M, Ho VT, Cutler CS, Shapiro RM, Kelkar AH, Abel GA, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan JA, Fell G, Letai A, Ritz J, Lindsley RC, Antin JH, Soiffer RJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41348911"},{"title01":"Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress.","title02":"Studying clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress.","journal":"Blood advances","issue":"2025 December 6. doi: 10.1182\/bloodadvances.2025016618. Online ahead of print","author":"Mayerhofer C, Crompton E, Mayerhofer E, Kristiansen TA, Fukushima T, Keyes S, Sharda A, Li D, Da Silva C, Shrestha D, Kiem A, Feuchtinger T, Scadden DT, Miller PG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41351481"},{"title01":"Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.","title02":"Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.","journal":"Blood advances","issue":"2025 December 9; 9(23):6009-6018. doi: 10.1182\/bloodadvances.2025016966","author":"Galarza Fortuna GM, Peres L, Nazarenko E, De Menezes Silva Corraes A, Hovanky VN, Shune L, McGuirk J, De Avilla G, Khouri J, Dima D, Gaballa M, Dhakal B, Forsberg P, Godara A, Afrough A, Anderson L, Herr MM, Davis JA, Mann H, Purvey S, Clark W, Htut M, Beitinjaneh A, Pereira DL, Kocoglu MH, Ferreri CJ, Atrash S, Voorhees PM, Rossi A, Shambavi R, Hashmi H, Patel K, Sidana S, Lin Y, Hansen DK, Sborov DW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875887"},{"title01":"International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.","title02":"International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.","journal":"Blood advances","issue":"2025 December 9; 9(23):6047-6058. doi: 10.1182\/bloodadvances.2025017011","author":"Naik S, Aplenc R, Baumeister SHC, Becilli M, Bhagwat AS, Bonifant CL, Budde LE, Chien CD, Curran KJ, Daniyan AF, Dreyzin A, Gardner RA, Ghorashian S, Gottschalk S, Hill LC, Kohler ME, Lamble A, Locatelli F, Mamonkin M, Omer B, Park JH, Quintarelli C, Rambaldi B, Richards RM, Sallman DA, Sauer T, Shah NN, Subklewe M, Summers C, Tasian SK, Taylor N, Tettamanti S, Verneris MR, Velasquez MP, Gill SI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829117"},{"title01":"How can we chop CML with an ASXL1?","title02":"How can we chop CML with an ASXL1?","journal":"Blood","issue":"2025 December 4; 146(23):2741-2742. doi: 10.1182\/blood.2025031031","author":"Cortes J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41343167"},{"title01":"Donor-derived CD7 CAR-T in T-ALL\/LBL: promise and pitfalls.","title02":"Donor-derived CD7 CAR-T in T-ALL\/LBL: promise and pitfalls.","journal":"Blood","issue":"2025 December 4; 146(23):2731-2732. doi: 10.1182\/blood.2025030672","author":"Aldoss I, Muffly L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41343165"},{"title01":"Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.","title02":"Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.","journal":"Blood","issue":"2025 December 4; 146(23):2821-2832. doi: 10.1182\/blood.2025030259","author":"Shanmuganathan N, Yeung DT, Wadham C, Fernandes A, Maqsood M, Shahrin N, Saunders V, Kenyon RR, Lin M, Toubia J, McConnell J, Kaczorowski D, Ross DM, Yong ASM, Chee L, Shortt J, Viiala N, Braley J, Kok CH, Hughes TP, Branford S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40896831"},{"title01":"Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.","title02":"Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.","journal":"Blood","issue":"2025 December 4; 146(23):2779-2793. doi: 10.1182\/blood.2024028194","author":"Venkatesh H, Granados Centeno E, Luo Q, Arroyo M, Heltemes-Harris L, Knutson TP, Qiu Y, Haaning A, Webber BR, Bachanova V, Farrar MA, Tracy SI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906918"},{"title01":"CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways.","title02":"CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways.","journal":"Blood","issue":"2025 December 11; 146(24):2914-2930. doi: 10.1182\/blood.2024026815","author":"Martinez TC, Jotte MRM, Khan S, Stoddart A, Blaylock H, Malik A, McNerney ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920873"},{"title01":"Fusion gene depletion eliminates stemness and induces bidirectional differentiation of acute myeloid leukemia.","title02":"Fusion gene depletion eliminates stemness and induces bidirectional differentiation of acute myeloid leukemia.","journal":"Blood","issue":"2025 December 11; 146(24):2963-2978. doi: 10.1182\/blood.2025028988","author":"Derevyanko PK, Swart LE, Mata Casimiro LD, van Oort A, du Plessis M, van den Brink L, Ashtiani M, Zwaan CM, Krippner-Heidenreich A, Bonifer C, Schiffelers R, Vormoor J, Kellaway SG, Heidenreich O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40991849"},{"title01":"How I Treat Advanced Phases of CML.","title02":"How I Treat Advanced Phases of CML.","journal":"Blood","issue":"2025 December 2. doi: 10.1182\/blood.2024026510. Online ahead of print","author":"Mauro MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41329950"},{"title01":"Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.","title02":"Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025029210. Online ahead of print","author":"Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Etienne G, Kim I, Andorsky D, Bombaci F, Issa GC, Takahashi N, Kapoor S, Jinwal R, Malek K, McCulloch T, Yau L, Larson RA, Hochhaus A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397287"},{"title01":"Key regulatory roles of PRDM1 in human NK-cell differentiation and activation.","title02":"Key regulatory roles of PRDM1 in human NK-cell differentiation and activation.","journal":"Leukemia","issue":"2025 December 9. doi: 10.1038\/s41375-025-02815-z. Online ahead of print","author":"Liu X, Shi Y, Zhang J, Shetty K, Chew K, Kucuk C, Gong Q, Esmeray E, Li H, Chen R, Pan S, Dabrowska K, Moore RE, Garcia-Mansfield K, Pirrotte P, Wang J, Li Y, Dong G, Lee L, McKeithan TW, Iqbal J, Chan WC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41366532"},{"title01":"Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.","title02":"Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.","journal":"Leukemia","issue":"2025 December; 39(12):3061. doi: 10.1038\/s41375-025-02811-3","author":"Suto K, Takei N, Yokoyama K, Chiba M, Ishio T, Maeda M, Goto H, Endo T, Teshima T, Yang Y, Nakagawa M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214141"},{"title01":"Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving concept.","title02":"Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving concept.","journal":"Leukemia","issue":"2025 December; 39(12):2988-2996. doi: 10.1038\/s41375-025-02794-1","author":"Kurz KS, Zamo A, Drewes C, Madej E, Laurent C, Burroni B, Donzel M, Xerri L, Mescam L, Plank L, Gjerdrum LMR, Geyer J, Richter J, Oschlies I, Klapper W, Gramlich S, Doll J, Roth S, Maurus K, Staiger AM, Siebert R, Du MQ, Rosenwald A, Ott G, Horn H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41204003"},{"title01":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","title02":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2025 December 8. doi: 10.1016\/S2352-3026(25)00327-8. Online ahead of print","author":"Kater AP, Janssens A, Eradat H, Offner F, Sandoval-Sus JD, Shadman M, Poulsen CB, Christensen JH, Thompson MC, Guan M, Steele AJ, Rios M, Holst Morch M, Oki T, Valentin R, Bellido M, Eichhorst B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380698"},{"title01":"Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158\/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.","title02":"Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158\/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e935-e945. doi: 10.1016\/S2352-3026(25)00288-1","author":"Kater AP, Kersting S, Dubois JM, van der Holt B, da Cunha-Bang C, Te Raa D, Idink C, de Boer F, Droogendijk J, de Heer K, van der Burg L, Nijziel MR, Tick L, Levenga H, Silbermann M, Ludwig I, Beeker A, Bellido M, Dobber JA, Evers LM, van der Kevie-Kersemaekers AM, Mellink C, Meulendijks I, Cunha S, Abrahamse-Testroote M, Zwezerijnen G, Zijlstra J, Niemann CU, Levin MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338862"},{"title01":"A step forward in the treatment of relapsed or refractory follicular lymphoma.","title02":"A step forward in the treatment of relapsed or refractory follicular lymphoma.","journal":"Lancet","issue":"2025 December 7. doi: 10.1016\/S0140-6736(25)02436-5. Online ahead of print","author":"Magnano L, Rivero A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41371239"},{"title01":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.","title02":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.","journal":"Lancet","issue":"2025 December 7. doi: 10.1016\/S0140-6736(25)02360-8. Online ahead of print","author":"Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jimenez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41371238"},{"title01":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.","title02":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.","journal":"Lancet","issue":"2025 December 5. doi: 10.1016\/S0140-6736(25)01778-7. Online ahead of print","author":"Sehn LH, Hubel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jimenez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41360064"},{"title01":"B-cell lymphoblastic leukemia\/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.","title02":"B-cell lymphoblastic leukemia\/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.","journal":"Haematologica","issue":"2025 December 1; 110(12):3078-3082. doi: 10.3324\/haematol.2024.286626","author":"Alvey EN, Yap KL, Rathbun P, Fitzpatrick C, Gong S, Richardson AI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40013396"},{"title01":"Novel PI3kdelta inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.","title02":"Novel PI3kdelta inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.","journal":"Haematologica","issue":"2025 December 1; 110(12):2974-2985. doi: 10.3324\/haematol.2024.287180","author":"Sasi BK, Tarantelli C, Martindale S, Civanelli E, Cannas E, Sartori G, Arribas AJ, Fernandes SM, Shupe SJ, Machado JH, Tyekucheva S, Ren Y, Lahn M, Van der Veen L, Di Conza G, Bertoni F, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534489"},{"title01":"Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemoimmunotherapy on the SWOG S0016 trial.","title02":"Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemoimmunotherapy on the SWOG S0016 trial.","journal":"Haematologica","issue":"2025 December 1; 110(12):3145-3149. doi: 10.3324\/haematol.2025.288057","author":"Danilov AV, Li H, Shadman M, Rimsza L, Zebari A, Smith SM, LeBlanc M, Friedberg JW, Carlson C, Song JY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605713"},{"title01":"BTKi + humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?","title02":"BTKi + humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?","journal":"Haematologica","issue":"2025 December 1; 110(12):2890-2892. doi: 10.3324\/haematol.2025.288196","author":"Dogliotti I, Federico M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605702"},{"title01":"Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single-institution retrospective study of 66 patients.","title02":"Treatment approaches and clinical outcomes in primary colorectal MALT lymphoma: a single-institution retrospective study of 66 patients.","journal":"Haematologica","issue":"2025 December 1; 110(12):3154-3158. doi: 10.3324\/haematol.2025.288145","author":"Atallah-Yunes SA, Rees MJ, Habermann TM, Wang Y, Munoz J, Iqbal M, Villasboas JC, McPhail ED, Witzig TE, Ansell SM, Nowakowski GS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534511"},{"title01":"Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine.","title02":"Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine.","journal":"Br J Haematol","issue":"2025 December 8. doi: 10.1111\/bjh.70268. Online ahead of print","author":"Ortega-Francisco S, Prudente de Aquino MT, La Rosa C, Chiuppesi F, Gutierrez MA, Miller J, Li J, Mack-Onyeike J, Zhou Y, Zhou Q, Kaltcheva T, Patterson A, Dempsey S, Thomas S, Tiemann K, Yang D, Rida W, Wussow F, McKee K, Taplitz R, Raiden E, Siddiqi T, Rosen S, Diamond DJ, Danilov A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41360730"},{"title01":"Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.","title02":"Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70284. Online ahead of print","author":"Jin H, Guo Z, Zhu L, Huang F, Wu Y, Qiu H, Wang Y, Gong Y, He G, Fan L, Shi Z, Shen W, Qiao C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41386566"},{"title01":"Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis.","title02":"Real-world experience with CPX-351 for secondary acute myeloid leukaemia: Comparison with FLAG-IDA in a propensity score matching analysis.","journal":"Br J Haematol","issue":"2025 December 4. doi: 10.1111\/bjh.70275. Online ahead of print","author":"Perusini MA, Patino AF, Andrews C, Assouline SE, Brandwein JM, Chow S, Popradi G, Sanford D, Savoie L, Saini L, Nadia B, Khalaf D, Schuh AC, Yee K, Gupta V, Maze D, Chan SM, Schimmer AD, Sabry W, Sibai H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41344892"},{"title01":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","title02":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.","journal":"Br J Haematol","issue":"2025 December 3. doi: 10.1111\/bjh.70274. Online ahead of print","author":"Peters DT, Nicolet D, Madanat YF, Gonzalez-Lugo J, Ambinder A, Chan O, Foucar CE, Sahasrabudhe KD, Ameyi J, Mrozek K, Lin T, Al-Ali N, Lancet J, Barredo B, Banaszak LG, Hochman MJ, Ragon BK, McMahon CM, Haque T, Mims AS, Eisfeld AK, Zeidner JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41332326"},{"title01":"Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial.","title02":"Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70272. Online ahead of print","author":"Voso MT, de Botton S, Pfeilstocker M, Alvarez AF, Wang K, See WL, Guerrero MU, de Menezes DL, Petrlik E, Prebet T, Roboz GJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387169"},{"title01":"Elevated Lactate in AML Bone Marrow Contributes to Macrophage Polarization via GPR81 Signaling.","title02":"Elevated Lactate in AML Bone Marrow Contributes to Macrophage Polarization via GPR81 Signaling.","journal":"Blood advances","issue":"2025 December 9. doi: 10.1182\/bloodadvances.2025016400. Online ahead of print","author":"Soto CA, Lesch ML, Becker JL, Sharipol A, Khan A, Schafer XL, Li Z, Streeter AR, Becker MW, Munger JC, Frisch BJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41364872"},{"title01":"Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.","title02":"Reduced PRC2 function causes asparaginase resistance in T-ALL by decreasing WNT pathway activity.","journal":"Blood advances","issue":"2025 December 3. doi: 10.1182\/bloodadvances.2024015408. Online ahead of print","author":"Lefeivre T, Grosu TI, Tudose C, Jones L, Leon TE, Wynne K, Oliviero G, Smith O Professor, Trinquand A, Mansour MR, Ryan CJ, Bond J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337688"},{"title01":"Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations.","title02":"Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations.","journal":"Blood advances","issue":"2025 December 11. doi: 10.1182\/bloodadvances.2025017243. Online ahead of print","author":"Kuehn HS, Gil Silva AA, Klangkalya N, Esteve-Sole A, Goel S, Niemela JE, Stoddard JL, Chong H, Williams KW, Ip W, Framil Seoane M, Loganathan SK, Anantharachagan A, Garcia-Soidan A, Shaffren SB, Bindernagel C, Mendez P, Miller RZ, Abolhassani H, Hoytema van Konijnenburg DP, Geerlinks AV, Cabanillas D, Zonneveld-Huijssoon E, Rutgers A, Tangye SG, Ma CS, Grey A, O'Young P, Aldave Becerra JC, Lyons JJ, White A, Claiborne M, Doroudchi A, Modena BD, Milner JD, Solanich X, Farela Neves J, Platt C, Hammarstrom L, Routes J, Verbsky J, Butte M, Lesmana H, Griffiths WJ, Kumararatne DS, Hauck F, Allende LM, Rodriguez-Gallego C, Elfeky R, Rubin TS, Boztug K, Fleisher TA, Rosenzweig SD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380100"},{"title01":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","title02":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.","journal":"Blood advances","issue":"2025 December 4. doi: 10.1182\/bloodadvances.2025017089. Online ahead of print","author":"Palmieri R, Guolo F, Fianchi L, Ferrara F, Minetto P, Martelli MP, Riva C, Chiusolo P, Rondoni M, Capria S, Minotti C, Pilo F, Perrone S, Corbingi A, Grimaldi F, De Luca G, Fili C, Alati C, Mannelli F, Lessi F, Marchesi F, Brunetti L, Capelli D, Piccioni AL, Vetro C, Palumbo FE, Mazzone C, Sperotto A, Luzi G, Dargenio M, Mariani S, Cerrano M, Mule A, Di Veroli A, Meddi E, Moretti F, Papayannidis C, Isidori A, Ferrari A, Galimberti S, Cilloni D, Breccia M, Lanza F, Gottardi M, Cairoli R, Candoni A, Pagano L, Todisco E, Lemoli RM, Venditti A, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41346286"},{"title01":"FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion.","title02":"FLT3-directed BiTE Molecules versus CAR T Cells in AML: Co-stimulatory Signals Mitigate T-Cell Exhaustion.","journal":"Blood advances","issue":"2025 December 1. doi: 10.1182\/bloodadvances.2025018168. Online ahead of print","author":"Rohrbacher L, Nixdorf D, Stadler H, Brauchle B, Markl F, Gottschlich A, Hoffmann GV, Philipp N, Hanel G, Kirmaier ME, Marcinek A, Kazerani M, Richter D, Magno G, Goldstein RL, Theurich S, Straub T, Kobold S, Arvedson T, Bucklein VL, Subklewe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41324594"},{"title01":"The lncRNA ELDR suppresses tumorigenicity of AML by interfering with DNA replication and chromatin accessibility.","title02":"The lncRNA ELDR suppresses tumorigenicity of AML by interfering with DNA replication and chromatin accessibility.","journal":"Blood advances","issue":"2025 December 9; 9(23):6158-6174. doi: 10.1182\/bloodadvances.2024015427","author":"Arman K, Ross J, Piskor EM, Lazzari L, Calderon V, Reulet G, Vera M, St-Hilaire E, Wurtele H, Wilhelm BT, Moroy T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40921006"},{"title01":"Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series.","title02":"Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series.","journal":"Blood advances","issue":"2025 December 9; 9(23):6042-6046. doi: 10.1182\/bloodadvances.2025017109","author":"Goergen E, Robrecht S, Ligtvoet R, Fischer K, Eichhorst B, Langerbeins P, Hallek M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40921002"},{"title01":"Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia.","title02":"Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia.","journal":"Blood advances","issue":"2025 December 9; 9(23):6076-6089. doi: 10.1182\/bloodadvances.2025017345","author":"Cabrera-Serrano AJ, Sanchez-Maldonado JM, Rodriguez-Sevilla JJ, Reyes-Zurita FJ, Collado R, Puiggros A, Cornejo-Calvo E, Garcia-Martin P, Ter Horst R, Benavente Y, Jerez A, Landi S, Espinet B, Maffei R, Lopez-Nevot MA, Ramos-Campoy S, Gonzalez-Olmedo C, Chen-Liang TH, Moreno V, Jannus F, Marcos-Gragera R, Carretero-Fernandez M, Sampaio-Marques B, Gamez I, Garcia-Alvarez M, Camp NJ, Dierssen-Sotos T, Kamaso J, Perez EM, Norman AD, Luppi M, Li Y, Alcoceba M, Campa D, de San Jose S, Marasca R, Ludovico P, Clay-Gilmour A, Canzian F, Ibanez M, Netea MG, McKay J, Casabonne D, Berndt SI, Slager SL, Sainz J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902075"},{"title01":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","title02":"Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.","journal":"Blood","issue":"2025 December 12. doi: 10.1182\/blood.2025031313. Online ahead of print","author":"Meyer E, Salhotra A, Gandhi A, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand RG, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau JM, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian S, Li A, Negrin RS, Oliai C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41385341"},{"title01":"Promyelocyte maturation arrest after rituximab-induced late-onset neutropenia mimicking acute promyelocytic leukemia.","title02":"Promyelocyte maturation arrest after rituximab-induced late-onset neutropenia mimicking acute promyelocytic leukemia.","journal":"Blood","issue":"2025 December 11; 146(24):3003. doi: 10.1182\/blood.2025031015","author":"Souto Filho JTD, Paulo AB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41379492"},{"title01":"2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.","title02":"2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025031480. Online ahead of print","author":"Cloos J, Valk PJM, Thiede C, Dohner K, Roboz GJ, Wood BL, Walter RB, Wang SA, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw DC, Kern W, Kim DDHDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bucklein VL, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon RJ, Heuser M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397238"},{"title01":"Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia.","title02":"Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia.","journal":"Blood","issue":"2025 December 15. doi: 10.1182\/blood.2025029875. Online ahead of print","author":"Zhang L, Kang H, Valerio M, Hoang DH, Pathak KV, Garcia-Mansfield K, Lu X, Guo W, Fu YH, He X, Chen YC, Chen Z, Ghoda LY, Buettner R, Li Z, Blackmon A, Li L, Zhang B, Pirrotte P, Marcucci G, Kuo YH, Nguyen LXT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41397241"},{"title01":"Defusing AML: targeting t(8;21) forces myeloid maturation.","title02":"Defusing AML: targeting t(8;21) forces myeloid maturation.","journal":"Blood","issue":"2025 December 11; 146(24):2857-2859. doi: 10.1182\/blood.2025031252","author":"Obeng EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41379499"},{"title01":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","title02":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial.","journal":"Blood","issue":"2025 December 4; 146(23):2745-2757. doi: 10.1182\/blood.2025029299","author":"Pan J, Zhao L, Zhang Y, Seery S, Tan Y, Deng B, Shan L, Ling Z, Wu F, Wang Z, Wang Q, Yu X, Zheng Q, Xu X, Yuan Y, Tian Z, Zhang Y, Peng S, Chang AH, Feng X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40712157"},{"title01":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","title02":"Azacitidine to treat measurable residual disease in patients with MDS\/AML: final long-term results of the RELAZA2 trial.","journal":"Blood","issue":"2025 December 8. doi: 10.1182\/blood.2025030816. Online ahead of print","author":"Platzbecker AS, Georgi JA, Middeke JM, Sockel K, Wehner R, Herbst RT, Wolf D, Baldus CD, Oelschlaegel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Esseling E, Stolzel F, von Bonin M, Serve H, Hanel M, Duhrsen U, Harig A, Muller-Tidow C, Schetelig J, Stasik S, Rollig C, Ehninger G, Kramer M, Schmitz M, Bornhauser M, Platzbecker U, Thiede C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359791"},{"title01":"Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.","title02":"Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma.","journal":"Blood","issue":"2025 December 4; 146(23):2794-2807. doi: 10.1182\/blood.2024027997","author":"Pal I, Illendula A, Joyner A, Manavalan JS, Deddens TM, Sabzevari A, Damera DP, Zuberi S, Marchi E, Fox TE, Dunlap-Brown ME, Jayappa KD, Khalife J, Craig JW, Loughran TP Jr, Feith DJ, O'Connor OA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40896830"},{"title01":"Hijacked helpers: Tr1 cells fuel immune escape in B-ALL.","title02":"Hijacked helpers: Tr1 cells fuel immune escape in B-ALL.","journal":"Blood","issue":"2025 December 4; 146(23):2736-2737. doi: 10.1182\/blood.2025030985","author":"Seiffert M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41343168"},{"title01":"Potent synergy of DHODH and SREBP inhibition in acute myeloid leukemia via disruption of cholesterol and lipid metabolism.","title02":"Potent synergy of DHODH and SREBP inhibition in acute myeloid leukemia via disruption of cholesterol and lipid metabolism.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.287918. Online ahead of print","author":"Hogeling SM, Sternadt D, La Rose N, Geugien M, Pereira-Martins D, Van den Heuvel FAJ, Kuchnio A, Pietsch CE, Philippar U, Huls G, Schuringa JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376547"},{"title01":"Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia.","title02":"Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.289085. Online ahead of print","author":"Cheng F, Li W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376545"},{"title01":"Rapid and accurate identification of acute promyelocytic leukemia with a novel multiparametric flow cytometric scoring system.","title02":"Rapid and accurate identification of acute promyelocytic leukemia with a novel multiparametric flow cytometric scoring system.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.289104. Online ahead of print","author":"Lagana A, Fanciullo D, Kasmi D, Germano CA, Nardacci MG, Scalzulli E, Carmosino I, Bisegna ML, Minotti C, Nostro F, Milani ML, Buffolino S, Limongi MZ, Ielo C, Diverio D, Martelli M, Breccia M, De Propris MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342176"},{"title01":"The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia.","title02":"The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.288928. Online ahead of print","author":"Sandhu M, Konopleva M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342189"},{"title01":"Silver bullets for the golden age: treating IDH-mutated acute myeloid leukemia in older patients.","title02":"Silver bullets for the golden age: treating IDH-mutated acute myeloid leukemia in older patients.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.300191. Online ahead of print","author":"Wolach O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376578"},{"title01":"Allopurinol increases DNA-thioguanine nucleotides during maintenance therapy in pediatric acute lymphoblastic leukemia.","title02":"Allopurinol increases DNA-thioguanine nucleotides during maintenance therapy in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.288872. Online ahead of print","author":"Kallstrom J, Niinimaki R, Fredlund J, Vogt H, Korhonen LS, Castor A, Schmiegelow K, Thastrup M, Ek T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342181"},{"title01":"CPX-351 in secondary\/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3200 patients.","title02":"CPX-351 in secondary\/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3200 patients.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.300076. Online ahead of print","author":"Molica M, Giannarelli D, De Fazio L, Rossi M, Perrone S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376581"},{"title01":"Olverembatinib in chronic myeloid leukemia: is less actually better?","title02":"Olverembatinib in chronic myeloid leukemia: is less actually better?","journal":"Haematologica","issue":"2025 December 1; 110(12):2884-2886. doi: 10.3324\/haematol.2025.288065","author":"Perusini MA, Kim DDH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534512"},{"title01":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma.","title02":"Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma.","journal":"Haematologica","issue":"2025 December 1; 110(12):2895-2901. doi: 10.3324\/haematol.2025.288114","author":"Ghione P, Zinzani PL, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702895"},{"title01":"Leukemia stem cells in acute myeloid leukemia &#8211; mimicking the &#8220;space and time continuum&#8221;?","title02":"Leukemia stem cells in acute myeloid leukemia &#8211; mimicking the &#8220;space and time continuum&#8221;?","journal":"Haematologica","issue":"2025 December 1; 110(12):2877-2880. doi: 10.3324\/haematol.2025.288003","author":"Plesa A, Roumier C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40671495"},{"title01":"Relapsed acute lymphoblastic leukemia: back to the drawing board.","title02":"Relapsed acute lymphoblastic leukemia: back to the drawing board.","journal":"Haematologica","issue":"2025 December 1; 110(12):2875-2876. doi: 10.3324\/haematol.2025.288191","author":"Jacoby E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40605705"},{"title01":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children&#8217;s Oncology Group AALL1331 trial.","title02":"Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children&#8217;s Oncology Group AALL1331 trial.","journal":"Haematologica","issue":"2025 December 1; 110(12):2930-2941. doi: 10.3324\/haematol.2025.287386","author":"Hogan LE, Bhatla T, Xu X, Gore L, Raetz EA, Bhojwani D, Teachey DT, Hunger SP, Loh ML, Brown PA, Ji L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568722"},{"title01":"Sugar-free transforming growth factor beta1 increases the fitness of myelodysplastic neoplasm\/acute myeloid leukemia cells.","title02":"Sugar-free transforming growth factor beta1 increases the fitness of myelodysplastic neoplasm\/acute myeloid leukemia cells.","journal":"Haematologica","issue":"2025 December 1; 110(12):2887-2889. doi: 10.3324\/haematol.2025.288156","author":"Solary E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568718"},{"title01":"Comment on &#8220;Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report&#8221;.","title02":"Comment on &#8220;Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report&#8221;.","journal":"Haematologica","issue":"2025 December 1; 110(12):3178-3179. doi: 10.3324\/haematol.2025.288110","author":"Borkhardt A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371896"},{"title01":"Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell\/myeloid mixed phenotype acute leukemia.","title02":"Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell\/myeloid mixed phenotype acute leukemia.","journal":"Haematologica","issue":"2025 December 1; 110(12):3129-3132. doi: 10.3324\/haematol.2025.287932","author":"Azevedo RS, Jen WY, Hammond D, Haddad FG, Geppner A, Issa GC, Sasaki K, Senapati J, Jabbour E, Ravandi F, Kantarjian H, Kadia TM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40568715"},{"title01":"Recurrence of minimal residual disease in acute myeloid leukemia: a window of opportunity for intervention.","title02":"Recurrence of minimal residual disease in acute myeloid leukemia: a window of opportunity for intervention.","journal":"Haematologica","issue":"2025 December 1; 110(12):2881-2883. doi: 10.3324\/haematol.2025.288227","author":"Bankar A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40820796"},{"title01":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.","title02":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.","journal":"Haematologica","issue":"2025 December 1; 110(12):2942-2953. doi: 10.3324\/haematol.2024.287090","author":"Ngai LL, Reuvekamp T, Hanekamp D, Janssen F, Marsbergen LO, Carbaat-Ham J, Hofland MAM, Fayed MMHE, Kelder A, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Griskevicius L, Juliusson G, Van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Lowenberg B, Ossenkoppele GJ, De Leeuw DC, Cloos J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304060"},{"title01":"Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia.","title02":"Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia.","journal":"Haematologica","issue":"2025 December 1; 110(12):2986-2996. doi: 10.3324\/haematol.2024.287116","author":"Zhang X, Yang Y, Liu B, Du X, Wang X, Zhu H, Yu L, Li Z, Zhao S, Yang L, Ma Y, Meng L, Zhang Y, Li G, Yang L, Wang B, Ran X, Huang J, Gao N, Wen Q, Wen Y, Zhao Y, Zhu Y, Han Y, Liu Z, Du X, Weng J, Gale RP, Zhou L, Zhang Y, Jiang Q","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40304058"},{"title01":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","title02":"TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.","journal":"Haematologica","issue":"2025 December 1; 110(12):3088-3093. doi: 10.3324\/haematol.2025.287326","author":"Li L, Ye Y, Galimard JE, Labopin M, Wu D, Chen J, Kroger N, Passweg J, Salmenniemi U, Itala-Remes M, Poire X, Eder M, Maertens J, Burns D, Sengeloev H, Olesen G, Blaise D, Finke J, Gadisseur A, Bazarbachi A, Brissot E, Nagler A, Luo Y, Shi J, Mohty M, Huang H, Ciceri F, Claude Gorin N Sr","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534491"},{"title01":"Novel PI3kdelta inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.","title02":"Novel PI3kdelta inhibitor roginolisib synergizes with venetoclax in hematologic malignancies.","journal":"Haematologica","issue":"2025 December 1; 110(12):2974-2985. doi: 10.3324\/haematol.2024.287180","author":"Sasi BK, Tarantelli C, Martindale S, Civanelli E, Cannas E, Sartori G, Arribas AJ, Fernandes SM, Shupe SJ, Machado JH, Tyekucheva S, Ren Y, Lahn M, Van der Veen L, Di Conza G, Bertoni F, Brown JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40534489"},{"title01":"Atypical acute promyelocytic leukemia with tripartite fusion gene PML::RARG::LINE-L2a is resistant to ATRA but sensitive to arsenic-based therapy.","title02":"Atypical acute promyelocytic leukemia with tripartite fusion gene PML::RARG::LINE-L2a is resistant to ATRA but sensitive to arsenic-based therapy.","journal":"Haematologica","issue":"2025 December 1; 110(12):3083-3087. doi: 10.3324\/haematol.2025.287318","author":"Wu S, Yu Y, Lin X, Zhou X, Zhou Y, Luo P, Shen H, He J, Liu L, Liu X, Zhang DL, Liu Y, Xiao H, Zhou F, Liu H, Zhang Z","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501402"},{"title01":"Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia.","title02":"Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia.","journal":"Haematologica","issue":"2025 December 1; 110(12):2954-2964. doi: 10.3324\/haematol.2024.287119","author":"Gong B, Yang M, Qiu S, Liu B, Wang Y, Mi Y, Wei H, Wang J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501400"},{"title01":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","title02":"Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70281. Online ahead of print","author":"Gu J, Wang J, Liu L, Zhang Y, Ghanad P, Goli MM, Bao C, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387940"},{"title01":"Benchmarking the paediatric T-cell ALL subtype classifier, TALLSorts.","title02":"Benchmarking the paediatric T-cell ALL subtype classifier, TALLSorts.","journal":"Br J Haematol","issue":"2025 December 12. doi: 10.1111\/bjh.70263. Online ahead of print","author":"Gulbey O, James T, Cranston RE, Furmanczyk D, Schwab C, Lawson A, Kearns P, Vora A, Roels J, Van Vlierberghe P, Harrison CJ, Ross MT, Enshaei A, van Delft FW, Moorman AV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41387177"},{"title01":"DNA methylation alterations in acute lymphoblastic leukemia survivors with late neurocognitive deficits.","title02":"DNA methylation alterations in acute lymphoblastic leukemia survivors with late neurocognitive deficits.","journal":"Leukemia","issue":"2025 December; 39(12):3042-3046. doi: 10.1038\/s41375-025-02779-0","author":"Goodman SJ, Butcher DT, Guger SL, Diehl E, Brzezinski J, Spiegler B, Nieman BJ, Kallurkar P, Boulet Craig A, Krajinovic M, Laniel J, Laverdiere C, Sinnett D, Lippe S, Turinsky A, Shago M, Strug LJ, Ito S, Hitzler JK, Schachar R, Weksberg R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41107616"},{"title01":"Correction: miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.","title02":"Correction: miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December; 39(12):3059. doi: 10.1038\/s41375-025-02788-z","author":"Vu TT, Stolzel F, Wang KW, Rollig C, Tursky ML, Molloy TJ, Ma DD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41107617"},{"title01":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","title02":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","journal":"Leukemia","issue":"2025 December; 39(12):3060. doi: 10.1038\/s41375-025-02793-2","author":"Tedeschi A, Frustaci AM, Menna P, Minotti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41184635"},{"title01":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","title02":"Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","journal":"Leukemia","issue":"2025 December 2. doi: 10.1038\/s41375-025-02824-y. Online ahead of print","author":"Tedeschi A, Frustaci AM, Menna P, Minotti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41331358"},{"title01":"Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158\/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.","title02":"Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158\/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e935-e945. doi: 10.1016\/S2352-3026(25)00288-1","author":"Kater AP, Kersting S, Dubois JM, van der Holt B, da Cunha-Bang C, Te Raa D, Idink C, de Boer F, Droogendijk J, de Heer K, van der Burg L, Nijziel MR, Tick L, Levenga H, Silbermann M, Ludwig I, Beeker A, Bellido M, Dobber JA, Evers LM, van der Kevie-Kersemaekers AM, Mellink C, Meulendijks I, Cunha S, Abrahamse-Testroote M, Zwezerijnen G, Zijlstra J, Niemann CU, Levin MD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338862"},{"title01":"Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial.","title02":"Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e946-e955. doi: 10.1016\/S2352-3026(25)00284-4","author":"Cao HY, Zhang H, Zhang Y, Hu XH, Yang L, Yang YL, Zhang YM, Wu B, Huang ZQ, Huang R, Wang RJ, Wan CL, Wu DP, Dai HP, Xue SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338863"},{"title01":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","title02":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2025 December 8. doi: 10.1016\/S2352-3026(25)00327-8. Online ahead of print","author":"Kater AP, Janssens A, Eradat H, Offner F, Sandoval-Sus JD, Shadman M, Poulsen CB, Christensen JH, Thompson MC, Guan M, Steele AJ, Rios M, Holst Morch M, Oki T, Valentin R, Bellido M, Eichhorst B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41380698"},{"title01":"Acute myeloid leukaemia at the extremes.","title02":"Acute myeloid leukaemia at the extremes.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e927. doi: 10.1016\/S2352-3026(25)00326-6","author":"The Lancet Haematology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338856"},{"title01":"Leprosy and leukaemia: an unexpected interaction.","title02":"Leprosy and leukaemia: an unexpected interaction.","journal":"Lancet Haematol","issue":"2025 December; 12(12):e986. doi: 10.1016\/S2352-3026(25)00261-3","author":"Zhou N, Peng P, Xu G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41338867"},{"title01":"B-cell targeted therapies in acute lymphocytic leukaemia.","title02":"B-cell targeted therapies in acute lymphocytic leukaemia.","journal":"Lancet","issue":"2025 December 13; 406(10521):2751-2752. doi: 10.1016\/S0140-6736(25)02220-2","author":"Lunia A, Misbah SA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41390204"},{"title01":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 7; JCO2502477. doi: 10.1200\/JCO-25-02477. Online ahead of print","author":"Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, Yi S, Eom KS, Panovska A, Jurczak W, Laribi K, Jacobasch L, Baker R, Agajanian R, Berkovits A, Ozcan M, Lepretre S, Coombs CC, Cramer P, Lewis KL, Hill M, Bao K, Bian Y, De Batista Ribeiro SR, Bhandari NR, Ruppert AS, Leow CC, Wierda WG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41353787"},{"title01":"BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.","title02":"BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.","journal":"J Clin Oncol","issue":"2025 December 9; JCO2502691. doi: 10.1200\/JCO-25-02691. Online ahead of print","author":"Davids MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363770"},{"title01":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","title02":"BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma.","journal":"J Clin Oncol","issue":"2025 December 9; JCO2502380. doi: 10.1200\/JCO-25-02380. Online ahead of print","author":"Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363773"},{"title01":"Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","title02":"Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.","journal":"J Clin Oncol","issue":"2025 December 1; JCO2502762. doi: 10.1200\/JCO-25-02762. Online ahead of print","author":"Montesinos P, Rodriguez-Veiga R, Bergua JM, Algarra Algarra JL, Botella C, Rodriguez-Arboli E, Bernal T, Tormo M, Calbacho M, Salamero O, Serrano J, Noriega V, Lopez-Lopez JA, Vives S, Lopez-Lorenzo JL, Colorado M, Vidriales MB, Boyero RG, Olave MT, Herrera P, Arce O, Barrios M, Sayas MJ, Polo M, Gomez-Roncero MI, Barragan E, Ayala R, Chillon C, Calasanz MJ, Paiva B, Boluda B, Casas-Aviles I, Lloret P, Sanchez MJ, Rodriguez-Medina C, Cuevas L, Raposo-Puglia JA, Mateos MC, Olivares M, Martinez-Chamorro C, Alonso N, Suarez S, Sanchez-Vadillo I, Rodriguez MS, Gonzalez BJ, Martinez-Frances A, Cuello R, Fernandez A, Martinez-Cuadron D, Labrador J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41325561"},{"title01":"Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.","title02":"Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.","journal":"J Clin Oncol","issue":"2025 December 10; 43(35):3739-3749. doi: 10.1200\/JCO-25-01357","author":"Gottschalk H, Moricke A, Conter V, Schrappe M, Stary J, Cario G, Dworzak M, Attarbaschi A, Barbaric D, Locatelli F, Bodmer N, Elitzur S, Silvestri D, Dalla-Pozza L, Bergmann AK, Flotho C, Buldini B, Stanulla M, Izraeli S, Rizzari C, Bourquin JP, Biondi A, Valsecchi MG, Zimmermann M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213101"},{"title01":"Is there a best frontline therapy in chronic myeloid leukemia?","title02":"Is there a best frontline therapy in chronic myeloid leukemia?","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.287813. Online ahead of print","author":"Jain AG, Dalgetty M, Cortes JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376561"},{"title01":"Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission.","title02":"Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.287766. Online ahead of print","author":"Flynn KE, Atallah E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376566"},{"title01":"Recognition, prevention, and management of adverse events associated with asparaginase\/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel.","title02":"Recognition, prevention, and management of adverse events associated with asparaginase\/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel.","journal":"Haematologica","issue":"2025 December 1; 110(12):2913-2929. doi: 10.3324\/haematol.2024.286744","author":"Curran E, Luskin MR, Alachkar H, Aldoss I, Burke PW, Cassaday RD, Karol SE, Perissinotti AJ, Rank CU, Schmiegelow K, Webster J, Douer D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40109190"},{"title01":"Prognostic factors in chronic myeloid leukemia: at diagnosis and for treatment-free remission.","title02":"Prognostic factors in chronic myeloid leukemia: at diagnosis and for treatment-free remission.","journal":"Haematologica","issue":"2025 December 4. doi: 10.3324\/haematol.2025.287756. Online ahead of print","author":"Rea D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41342177"},{"title01":"Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature.","title02":"Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature.","journal":"Haematologica","issue":"2025 December 11. doi: 10.3324\/haematol.2025.289116. Online ahead of print","author":"Fazio M, Elena C, Ferrari J, Camilotto V, Stella S, Leotta D, Palumbo GA, Di Raimondo F, Romano A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41376555"},{"title01":"B-cell lymphoblastic leukemia\/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.","title02":"B-cell lymphoblastic leukemia\/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity.","journal":"Haematologica","issue":"2025 December 1; 110(12):3078-3082. doi: 10.3324\/haematol.2024.286626","author":"Alvey EN, Yap KL, Rathbun P, Fitzpatrick C, Gong S, Richardson AI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40013396"},{"title01":"Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-beta1-driven macrophage polarization in myeloid leukemias.","title02":"Bisecting GlcNAc expression by bone marrow stromal cells modulates TGF-beta1-driven macrophage polarization in myeloid leukemias.","journal":"Haematologica","issue":"2025 December 1; 110(12):3009-3021. doi: 10.3324\/haematol.2024.287091","author":"Feng J, Gou J, Wang Y, Wei W, Ma Y, Ren X, Zhao C, Cheng X, Lei L, Tan Z, Guan F, Li X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400458"},{"title01":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.","title02":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.","journal":"N Engl J Med","issue":"2025 December 4; 393(22):2279. doi: 10.1056\/NEJMc2515262","author":"Fleischman RA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337729"},{"title01":"Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.","title02":"Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.","journal":"N Engl J Med","issue":"2025 December 6. doi: 10.1056\/NEJMoa2515458. Online ahead of print","author":"Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindstrom V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Bottcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfo L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41358601"},{"title01":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.","title02":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.","journal":"N Engl J Med","issue":"2025 December 4; 393(22):2279-2280. doi: 10.1056\/NEJMc2515262","author":"Wang Y, Zhu Z, Liang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337730"},{"title01":"Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.","title02":"Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.","journal":"Leukemia","issue":"2025 December; 39(12):2895-2906. doi: 10.1038\/s41375-025-02752-x","author":"Miraki-Moud F, Ariza-McNaughton L, KoKo T, Othman J, Stronge R, de Bono J, Russell N, Thomas I, Gilkes A, Burnett A, Santiago LR, Cafferty F, Taussig L, Thornhill A, O'Connor S, Bonnet D, Taussig DC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40935826"},{"title01":"Misclassification of TP53 germline variants: implications for survival analysis in AML transplant studies.","title02":"Misclassification of TP53 germline variants: implications for survival analysis in AML transplant studies.","journal":"Leukemia","issue":"2025 December; 39(12):3054-3055. doi: 10.1038\/s41375-025-02772-7","author":"Rodriguez L, Delhommeau F, Soussi T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41016942"},{"title01":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.","title02":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.","journal":"Leukemia","issue":"2025 December; 39(12):2907-2915. doi: 10.1038\/s41375-025-02767-4","author":"Pollyea D, Kerre T, Deeren D, Beguin Y, Lin TL, Sallman DA, Anguille S, Blum WG, Flament A, Breman E, Lonez C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954213"},{"title01":"Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.","title02":"Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.","journal":"Leukemia","issue":"2025 December; 39(12):2916-2925. doi: 10.1038\/s41375-025-02745-w","author":"Karakaslar EO, Argiro EM, Struckman NE, Shirali Hz R, Severens JF, Honders MW, Kloet SL, Veelken H, Reinders MJ, Griffioen M, van den Akker EB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954214"},{"title01":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","title02":"CRISPR-engineered human GATA2 deficiency model uncovers mitotic dysfunction and premature aging in HSPCs, impairing hematopoietic fitness.","journal":"Leukemia","issue":"2025 December; 39(12):3015-3025. doi: 10.1038\/s41375-025-02771-8","author":"Romero-Moya D, Torralba-Sales E, Calvo C, Marin-Bejar O, Magallon-Mosella M, Distefano M, Pera J, Castano J, De Giorgio F, Gonzalez J, Iglesias A, Berenguer-Balaguer C, Schilling M, Plass M, Pasquali L, Catala A, Molina O, Wlodarski MW, Bigas A, Giorgetti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40954215"},{"title01":"Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.","title02":"Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.","journal":"Leukemia","issue":"2025 December; 39(12):2968-2977. doi: 10.1038\/s41375-025-02769-2","author":"Purhonen M, Tatun M, Luukkainen K, Hung K, Sundquist H, Tafjord O, Soderlund S, Adnan-Awad S, Dohlen A, Heikkinen J, Koskenvesa P, Siitonen S, Mustjoki S, Shanmuganathan N, Bryce C, Danielsson S, Hjorth-Hansen H, Olsson-Stromberg U, Kumagai T, Kimura S, Ross DM, Bruck O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40958033"},{"title01":"Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group &#038; Alliance for Clinical Trials in Oncology).","title02":"Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group &#038; Alliance for Clinical Trials in Oncology).","journal":"Leukemia","issue":"2025 December; 39(12):2926-2934. doi: 10.1038\/s41375-025-02644-0","author":"Cusan M, Larkin K, Nicolet D, Jurinovic V, Mrozek K, Batcha AMN, Rothenberg-Thurley M, Schneider S, Sauerland C, Gorlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Spiekermann K, Greif PA, Blachly JS, Mims AS, Walker CJ, Walker MC, Oakes CC, Orwick S, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Stone RM, Byrd JC, Metzeler KH, Herold T, Eisfeld AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973764"},{"title01":"Base edited &#8220;universal&#8221; donor CAR T-cell strategies for acute myeloid leukaemia.","title02":"Base edited &#8220;universal&#8221; donor CAR T-cell strategies for acute myeloid leukaemia.","journal":"Leukemia","issue":"2025 December; 39(12):2978-2987. doi: 10.1038\/s41375-025-02720-5","author":"Kadirkamanathan R, Georgiadis C, Kloos A, Joshi A, Etuk A, Preece R, Gough O, Schambach A, Sauer M, Heuser M, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41034424"},{"title01":"Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.","title02":"Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.","journal":"Leukemia","issue":"2025 December; 39(12):2946-2956. doi: 10.1038\/s41375-025-02774-5","author":"Voss RK, Pastor Loyola VB, Cardenas MF, Kumar P, Maciaszek JL, Namwanje M, Ma J, Neary JL, Jin M, Umeda M, Wilkinson MR, Payne-Turner D, Eldomery MK, Ma J, Gu J, Dalton J, Melton S, Liu YC, Foy S, Rusch M, Wheeler DA, Zhang J, Nichols KE, Karol SE, Inaba H, Ribeiro R, Rubnitz JE, Klco JM, Wang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41057686"},{"title01":"Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?","title02":"Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?","journal":"Leukemia","issue":"2025 December; 39(12):2858-2861. doi: 10.1038\/s41375-025-02784-3","author":"Rodriguez-Arboli E, Gale RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41083680"},{"title01":"DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum.","title02":"DUX4-rearranged B-ALL: deciphering a biological and clinical conundrum.","journal":"Leukemia","issue":"2025 December; 39(12):2835-2847. doi: 10.1038\/s41375-025-02758-5","author":"Bakewell J, Moorman AV, Ryan SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40940582"},{"title01":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","title02":"DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.","journal":"Leukemia","issue":"2025 December 3. doi: 10.1038\/s41375-025-02814-0. Online ahead of print","author":"Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho G, Gondek L, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Versino F, Montoro MJ, Torres-Esquius S, Jerez Cayuela A, Lopez-Esteban M, Martinez-Laperche C, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski JP, Ogawa S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41339477"},{"title01":"Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.","title02":"Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.","journal":"Leukemia","issue":"2025 December 8. doi: 10.1038\/s41375-025-02804-2. Online ahead of print","author":"Mikkelsen T, Helenius M, Ampatzidou M, Attarbaschi A, Andres-Jensen L, Borkhardt A, Conde Cuevas N, Escherich G, Hagleitner MM, Halsey C, Josephs-Spaulding J, Lundgren L, Pehn S, Polychronopoulou S, Stoltze U, Toksvang LN, Wahlberg A, Junk SV, Schmiegelow K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41361660"},{"title01":"A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.","title02":"A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December 12. doi: 10.1038\/s41375-025-02817-x. Online ahead of print","author":"Struckman NE, Koutsoumpli G, de Jong RCM, van der Lee DI, Remst DFG, Smith SI, Honders MW, Hagedoorn RS, de Ru AH, Matsuda M, Ishikawa F, Tak T, Valk PJM, Heemskerk MHM, van Veelen PA, Falkenburg JHF, Griffioen M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41388195"},{"title01":"Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.","title02":"Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December 10. doi: 10.1038\/s41375-025-02827-9. Online ahead of print","author":"DiNardo CD, Jen WY, Takahashi K, Kadia TM, Loghavi S, Daver NG, Xiao L, Reville PK, Issa GC, Short NJ, Sasaki K, Wang SA, Mullin JK, Pierce S, Bradley C, Borthakur G, Maiti A, Alvarado Y, Pemmaraju N, Ferrajoli A, Swaminathan M, Ohanian M, Abbas HA, Hammond D, Burger J, Haddad F, Montalban-Bravo G, Chien K, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41372600"},{"title01":"Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.","title02":"Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.","journal":"Leukemia","issue":"2025 December 10. doi: 10.1038\/s41375-025-02825-x. Online ahead of print","author":"Haaksma LH, Palmieri R, Reuvekamp T, Tettero JM, Ngai LL, Bachas C, Kelder A, Scholten WJ, Gradowska P, Arena V, Joao Simione A, Maurillo L, Venditti A, Lowenberg B, Ossenkoppele GJ, de Leeuw DC, Ikoma-Colturato MRV, Buccisano F, Cloos J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41372597"},{"title01":"REL overexpression and sustained NF-kappaB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.","title02":"REL overexpression and sustained NF-kappaB signaling associated with 2p gain induce resistance to BTK inhibitors in Chronic Lymphocytic Leukemia.","journal":"Leukemia","issue":"2025 December 9. doi: 10.1038\/s41375-025-02818-w. Online ahead of print","author":"Dehgane L, Mallet E, Brasseur C, Krzisch D, Zeitouni W, Hitier C, Ayoub M, Dubois K, Perez Carretero C, Roos-Weil D, Choquet S, Maloum K, Bravetti C, Armand M, Garnier D, Hernandez-Rivas JM, Susin SA, Nguyen-Khac F, Chapiro E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41366531"},{"title01":"40 years of LEUKEMIA.","title02":"40 years of LEUKEMIA.","journal":"Leukemia","issue":"2025 December 8. doi: 10.1038\/s41375-025-02840-y. Online ahead of print","author":"Hochhaus A, Gale RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41361661"},{"title01":"Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial.","title02":"Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial.","journal":"Lancet Oncol","issue":"2025 December 1. doi: 10.1016\/S1470-2045(25)00526-1. Online ahead of print","author":"Cheville AL, Herrin J, Pachman DR, Grzegorczyk V, Kroenke K, Ridgeway JL, Minteer SA, Austin JD, Griffin JM, Chlan L, Tofthagen C, Mitchell SA, Smith A, Ruddy KJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41344348"},{"title01":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.","title02":"Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.","journal":"N Engl J Med","issue":"2025 December 4; 393(22):2280. doi: 10.1056\/NEJMc2515262","author":"Munir T, Cairns DA, Hillmen P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41337731"},{"title01":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","title02":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.","journal":"N Engl J Med","issue":"2025 December 8. doi: 10.1056\/NEJMoa2505478. Online ahead of print","author":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, Selvage J, Mishra A, Ahmed B, Adams S, Thomas R, Gilmour K, Etuk A, Yallop D, O'Connor D, Qasim W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41363805"},{"title01":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling.","title02":"Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling.","journal":"Leukemia","issue":"2025 December; 39(12):3026-3036. doi: 10.1038\/s41375-025-02756-7","author":"Mazzeo P, Penir SM, Shumilov E, Wolf S, Haupl B, Markus K, Shirneshan K, Rittscher K, Brzuszkiewicz E, Aydilek E, Treiber H, Oellerich T, Ganster C, Haase D, Koch R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973765"},{"title01":"Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.","title02":"Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.","journal":"Leukemia","issue":"2025 December; 39(12):2957-2967. doi: 10.1038\/s41375-025-02755-8","author":"Visentin A, Gaffo E, Furstenau M, Rogers KA, Panagiotis B, Cui C, Miller C, Haferlach C, Plevova K, Oscier D, Davis Z, Nguyen-Khac F, Roncaglia E, Rigolin GM, Athanasiadou A, Baran-Marszak F, Valiente A, Terol MJ, Abrisqueta P, Espinet B, Puiggros A, Martines A, Bonaldi L, Mauro FR, Scarfo L, Chatzikonstantinou T, Tausch E, Kreuzer KA, Kater A, Bosch F, Doubek M, Panagiotidis P, Kalashnikova O, Frezzato F, Calabretto G, Ruocco V, Orsi S, Cellini A, Angotzi F, Serafin A, Yi S, Eichhorst B, Woyach JA, Cuneo A, Ghia P, Stamatopoulos K, Trentin L, Bortoluzzi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973766"},{"title01":"Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","title02":"Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.","journal":"Leukemia","issue":"2025 December; 39(12):2935-2945. doi: 10.1038\/s41375-025-02768-3","author":"Setiawan T, Muhammad JA, Marcellina N, Wirawan LM, Jun N, Sari IN, Oehler VG, Kim DW, Kwon HY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41034423"},{"title01":"A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia.","title02":"A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2025 December; 39(12):2881-2894. doi: 10.1038\/s41375-025-02739-8","author":"Kanari M, Jimenez Garcia I, Steffen FD, Krattiger LA, Bataclan C, Liu W, Simona BR, Deplancke B, Naveiras O, Ehrbar M, Bornhauser B, Bourquin JP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931046"},{"title01":"Correction: Correspondence to &#8220;A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development&#8221;.","title02":"Correction: Correspondence to &#8220;A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development&#8221;.","journal":"Leukemia","issue":"2025 November 21. doi: 10.1038\/s41375-025-02813-1. Online ahead of print","author":"Wang X, Yao H, Chen J, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41272183"},{"title01":"Beyond platelet counts: assessing safety of postsplenectomy TPO-RA use in ITP.","title02":"Beyond platelet counts: assessing safety of postsplenectomy TPO-RA use in ITP.","journal":"Blood advances","issue":"2025 November 25; 9(22):5902-5912. doi: 10.1182\/bloodadvances.2025017902","author":"Alyamany R, Houghton DE, Sridharan M, Pruthi RK, Shah S, Godby RC, Wolanskyj-Spinner A, Go RS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875595"},{"title01":"Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence.","title02":"Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence.","journal":"Blood","issue":"2025 November 27; 146(22):2656-2669. doi: 10.1182\/blood.2025028504","author":"Tufa DM, Hoffmeyer E, Schaller KL, Kooiman B, Woods E, Wang D, Jones D, Hall S, Cruz JC, Verneris MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906917"},{"title01":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.","title02":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.","journal":"Blood","issue":"2025 November 27; 146(22):2670-2680. doi: 10.1182\/blood.2025029987","author":"Beer SA, Cairns DA, Pawlyn C, Holroyd A, Ferris E, Cook G, Drayson M, Boyd K, Proszek P, Davies FE, de Tute R, Jenner M, Morgan GJ, Owen R, Hubank M, Houlston R, Jackson G, Kaiser MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40834881"},{"title01":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","title02":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","journal":"Blood","issue":"2025 November 19. doi: 10.1182\/blood.2025030951. Online ahead of print","author":"Buechner J, Poetschger U, Bader P, Yesilipek MA, Pichler H, Palma J, Staciuk R, Riha P, Krivan G, Ifversen M, Gungor T, Goussetis E, Kalwak K, Toporski J, Gabriel M, Renard MM, Diaz-de-Heredia C, Matic T, Calkoen FG, Svec P, Meisel R, Balduzzi AC, Locatelli F, Peters C, Dalle JH, Stein J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259231"},{"title01":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation.","title02":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation.","journal":"J Clin Oncol","issue":"2025 November 20; 43(33):3600-3609. doi: 10.1200\/JCO-25-01238","author":"Ueda Oshima M, Vo PT, Boeckh M, Bouvier ME, Carpenter PA, Mielcarek M, Petersdorf EW, Storb R, Gooley T, Sandmaier BM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41043099"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288654. Online ahead of print","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era emerging humoral and cellular players.","title02":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era emerging humoral and cellular players.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288237. Online ahead of print","author":"Lauruschkat CD, Gorge H, Knies K, Weissbrich B, Dolken L, Kochel C, Imhof N, Huber M, Hengel H, Einsele H, Wurster S, Kraus S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307128"},{"title01":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","title02":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288303. Online ahead of print","author":"Myers RM, Li Y, Liu H, Mumanachit S, Wang L, Leahy AB, Cain LE, DiNofia AM, Diorio C, Freedman JL, Hunger SP, Maude SL, McClory SE, Rheingold SR, Tasian SK, Wray L, Olson TS, Grupp SA, Bunin NJ, Seif AE, Elgarten CW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307125"},{"title01":"Lusutrombopag or hetrombopag supports in vitro megakaryopoiesis better than other thrombopoietin receptor agonists.","title02":"Lusutrombopag or hetrombopag supports in vitro megakaryopoiesis better than other thrombopoietin receptor agonists.","journal":"Br J Haematol","issue":"2025 November 28. doi: 10.1111\/bjh.70267. Online ahead of print","author":"He Y, Hu J, Zhai J, Wang L, Cheng X, Wang J, Dong F, Zhao X, Zhang F, Ema H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41315050"},{"title01":"Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.","title02":"Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017908. Online ahead of print","author":"Schroder J, Schwartz F, Metzdorf J, Barensteiner N, Mix L, Necke LM, Fehn A, Riedel A, Jentzsch L, Faustmann P, Vogel W, Bethge WA, Schroeder T, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289166"},{"title01":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","title02":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017742. Online ahead of print","author":"Sallman DA, McLemore AF, Komrokji RS, Elmariah H, Kuykendall AT, Bejanyan N, Chan O, Faramand R, Pidala JA, Yoder SJ, Perez LE, Nishihori T, Padron E, Fernandez H, Lancet JE, Mishra A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289162"},{"title01":"Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC.","title02":"Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025016812. Online ahead of print","author":"Rayes A, Logan BR, Liu X, Dara J, Buckley RH, Oved JH, Kapoor N, Kapadia M, Chandra S, Martinez CA, Bunin N, Chandrakasan S, Chen K, Bednarski JJ, Haines HL, Eissa H, Talano JM, Keller MD, Ebens CL, Chaudhury S, Shereck EB, Aquino VM, Knutsen AP, Alexander JL, Gillio AP, Chellapandian D, Shah AJ, Miller HK, Vander Lugt MT, Seroogy CM, Dorsey MJ, Mousallem T, Parrott RE, O'Reilly RJ, Aguayo-Hiraldo PI, Prockop SE, Davila Saldana BJ, Thakar MS, Burroughs LM, Torgerson TR, Leiding JW, Marsh RA, Griffith LM, Pulsipher MA, Kohn DB, Notarangelo LD, Cowan MJ, Puck JM, Cuvelier GDE, Heimall J, Haddad E, Pai SY, Dvorak CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289158"},{"title01":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","title02":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017934. Online ahead of print","author":"Sekeres MA, Mattison RJ, Artz AS, Baer MR, Chua CC, Demichelis-Gomez R, Egan PC, Fletcher L, Foucar CE, Garcia JS, Gilberto L, Gomez-De Leon A, Lancet JE, Loh KP, Malcovati L, Marini BL, Platzbecker U, Sorror ML, Tinsley-Vance S, Treitz J, Oliveros MJ, Ibrahim S, Roldan Y, Guyatt GH, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41321225"},{"title01":"CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.","title02":"CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.","journal":"Blood advances","issue":"2025 November 21. doi: 10.1182\/bloodadvances.2025018340. Online ahead of print","author":"Artz AS, Logan BR, Saber W, Geller N, Bellach A, Kou J, Wood WA, McCarty J, Knight TG, Runaas L, Johnston L, Walston JD, Nakamura R, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE Jr, Imus P, Hogan WJ, Nadiminti KV, Bhatt VR, Olin RL, Maakaron JE, Sobecks RM, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Sorror ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269781"},{"title01":"Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease.","title02":"Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease.","journal":"Blood advances","issue":"2025 November 25; 9(22):5811-5813. doi: 10.1182\/bloodadvances.2025017353","author":"Mejias-Figueroa JA, Saraf SL, Takemoto CM, Rodeghier M, DeBaun MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811819"},{"title01":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","title02":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","journal":"Blood advances","issue":"2025 November 19. doi: 10.1182\/bloodadvances.2025017217. Online ahead of print","author":"Liu L, Glaser A, Isiaku AI, Fairfax K, Casolari DA, Ristovski A, Murphy VJ, van Twest S, Henrikus SS, Heraud-Farlow J, Granger E, Novakovic S, Monks O'Byrne SF, Tsui V, Conyers R, Gonda TJ, Crismani W, D'Andrea RJ, Heierhorst J, Deans AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259745"},{"title01":"RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids.","title02":"RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids.","journal":"Blood advances","issue":"2025 November 25; 9(22):5920-5934. doi: 10.1182\/bloodadvances.2025016970","author":"Meng X, Melsen JE, van der Holst R, de Mooij B, Vloemans S, van Eggermond M, Berghuis D, Lankester AC, de Kivit S, Pike-Overzet K, Langerak AW, Staal FJT, Ott de Bruin LM, Cante-Barrett K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829114"},{"title01":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","title02":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","journal":"Blood","issue":"2025 November 19. doi: 10.1182\/blood.2025030951. Online ahead of print","author":"Buechner J, Poetschger U, Bader P, Yesilipek MA, Pichler H, Palma J, Staciuk R, Riha P, Krivan G, Ifversen M, Gungor T, Goussetis E, Kalwak K, Toporski J, Gabriel M, Renard MM, Diaz-de-Heredia C, Matic T, Calkoen FG, Svec P, Meisel R, Balduzzi AC, Locatelli F, Peters C, Dalle JH, Stein J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259231"},{"title01":"Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence.","title02":"Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence.","journal":"Blood","issue":"2025 November 27; 146(22):2656-2669. doi: 10.1182\/blood.2025028504","author":"Tufa DM, Hoffmeyer E, Schaller KL, Kooiman B, Woods E, Wang D, Jones D, Hall S, Cruz JC, Verneris MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40906917"},{"title01":"A prime editing strategy to rewrite the gamma-globin promoters and reactivate fetal hemoglobin for sickle cell disease.","title02":"A prime editing strategy to rewrite the gamma-globin promoters and reactivate fetal hemoglobin for sickle cell disease.","journal":"Blood","issue":"2025 November 27; 146(22):2641-2655. doi: 10.1182\/blood.2024028166","author":"Chalumeau A, Bou Dames M, Fontana L, Amistadi S, Antoniou P, Loganathan P, Mombled M, Corre G, Peterka M, Amendola M, Giovannangeli C, Maresca M, Miccio A, Brusson M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857666"},{"title01":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","title02":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","journal":"Blood","issue":"2025 November 27; 146(22):2710-2727. doi: 10.1182\/blood.2025028418","author":"McManus D, Copsel SN, Pfeiffer BJ, Wolf D, Barreras H, Ma S, Khodor A, Komai S, Burgos da Silva M, Hazime H, Gallardo M, Lime SG, van den Brink MRM, Park JH, Abreu MT, Hill GR, Perez VL, Levy RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749165"},{"title01":"Belzutifan for Advanced Pheochromocytoma or Paraganglioma.","title02":"Belzutifan for Advanced Pheochromocytoma or Paraganglioma.","journal":"N Engl J Med","issue":"2025 November 20; 393(20):2012-2022. doi: 10.1056\/NEJMoa2504964","author":"Jimenez C, Andreassen M, Durand A, Moog S, Hendifar A, Welin S, Spada F, Sharma R, Wolin E, Ruether J, Garcia-Carbonero R, Fassnacht M, Capdevila J, Del Rivero J, Iliopoulos O, Huillard O, Jang R, Mai K, Artamonova E, Hallqvist A, Else T, Odeleye-Ajakaye A, Gozman A, Naik GS, Berruti A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124218"},{"title01":"Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia.","title02":"Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia.","journal":"N Engl J Med","issue":"2025 November 27; 393(21):2131-2141. doi: 10.1056\/NEJMoa2504411","author":"Al-Samkari H, Hessels J, Riera-Mestre A, Dupuis-Girod S, Van Zele T, Gomez Del Olmo V, Hodges PG, Torres-Iglesias R, Berte R, Saint-Mezard P, Lazar H, Benedict N, Barker D, Bernasconi C, Picard D, Buscarini E, Mager HJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41297007"},{"title01":"Efficacy and safety of REGN9933(A2) and REGN7508(Cat) for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.","title02":"Efficacy and safety of REGN9933(A2) and REGN7508(Cat) for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.","journal":"Lancet","issue":"2025 November 29; 406(10519):2551-2563. doi: 10.1016\/S0140-6736(25)02097-5","author":"Weitz JI, Kithcart AP, O'Brien MP, Levy O, Marin E, Onisko M, Mohammadi KA, Li D, Meagher KA, Chang HH, Olenchock BA, Gutstein DE, Segers A, Roberts RS, Bonaca MP, Raskob GE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41218619"},{"title01":"Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia.","title02":"Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia.","journal":"Blood advances","issue":"2025 November 25; 9(22):5732-5735. doi: 10.1182\/bloodadvances.2024014855","author":"Lee JW, Jang JH, Yamazaki H, Sawa M, Kizaki M, Tomiyama Y, Nagafuji K, Usuki K, Gau JP, Morita Y, Tang JL, Chang H, Noshiro M, Matsuda A, Ozawa K, Mitani K, Kanda Y, Nakao S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40758947"},{"title01":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","title02":"Fancl-mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing.","journal":"Blood advances","issue":"2025 November 19. doi: 10.1182\/bloodadvances.2025017217. Online ahead of print","author":"Liu L, Glaser A, Isiaku AI, Fairfax K, Casolari DA, Ristovski A, Murphy VJ, van Twest S, Henrikus SS, Heraud-Farlow J, Granger E, Novakovic S, Monks O'Byrne SF, Tsui V, Conyers R, Gonda TJ, Crismani W, D'Andrea RJ, Heierhorst J, Deans AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259745"},{"title01":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","title02":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017433. Online ahead of print","author":"van der Meulen SA, Roemhild K, Driessen M, van den Akker E, Nethe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289157"},{"title01":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","title02":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","journal":"Blood advances","issue":"2025 November 26. doi: 10.1182\/bloodadvances.2024015776. Online ahead of print","author":"Liu QW, Fang F, Xue H, Wasterlid T, Smedby KE, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296017"},{"title01":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","title02":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288526. Online ahead of print","author":"Zhou X, Lin Y, Gao Y, Ge Z, Huang L, Zhang J, Cheng H, Ouyang G, Meng F, Tian Y, Kuang Y, Zhou F, Sheng L, Jin W, Xu G, Ma L, Ye L, Mei C, Li J, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262042"},{"title01":"Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.","title02":"Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial.","journal":"Br J Haematol","issue":"2025 November 30. doi: 10.1111\/bjh.70266. Online ahead of print","author":"Komrokji RS, Santini V, Platzbecker U, Van Eygen K, Diez-Campelo M, de Paz R, Santillana GS, Thepot S, Kazmierczak M, Oliva EN, Sekeres MA, Fenaux P, Madanat YF, Savona MR, Riggs J, Shah S, Lennox AL, Xia Q, Sun L, Berry T, Zeidan AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41320720"},{"title01":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","title02":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017742. Online ahead of print","author":"Sallman DA, McLemore AF, Komrokji RS, Elmariah H, Kuykendall AT, Bejanyan N, Chan O, Faramand R, Pidala JA, Yoder SJ, Perez LE, Nishihori T, Padron E, Fernandez H, Lancet JE, Mishra A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289162"},{"title01":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","title02":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","journal":"Blood","issue":"2025 November 20; 146(21):2574-2588. doi: 10.1182\/blood.2025028935","author":"Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine A, Andreeff M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40608889"},{"title01":"Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.","title02":"Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.","journal":"Blood","issue":"2025 November 27; 146(22):2681-2695. doi: 10.1182\/blood.2024027692","author":"Cheng WY, Yi X, Wang ZY, Li JF, Zhang JY, Zhang RH, Zhang QQ, Weng XQ, Huang T, Zhu YM, Wang C, Yin W, Zhang JN, Wu HY, Li JM, Zhu HM, Chen L, Wang WF, Dai YT, Gao CX, Liu X, Wang S, Wang SY, Jiao B, Chen Z, Fang H, Yin T, Shen Y, Chen SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829168"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288654. Online ahead of print","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.","title02":"Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288681. Online ahead of print","author":"Barosi G, Rosti V, Campanelli R, Massa M, Abba C, Carolei A, Catarsi P, Inzoli A, Pergola L, Barbui T, Tatarelli C, Finazzi MC, Condorelli A, Salmoiraghi S, Rambaldi A, Gianatti A, De Stefano V, Galli A, Gandossini M, Bardelli M, Gale RP, Malcovati L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262049"},{"title01":"Myeloproliferative neoplasms with clinically relevant paroxysmal nocturnal hemoglobinuria: clinical correlations and outcomes.","title02":"Myeloproliferative neoplasms with clinically relevant paroxysmal nocturnal hemoglobinuria: clinical correlations and outcomes.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.289078. Online ahead of print","author":"Faldu P, Abdelaziz R, Yousuf M, Pardanani A, Patnaik M, Tefferi A, Gangat N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307118"},{"title01":"Metformin alleviates side effects and supports the resumption of interferon therapy in polycythemia vera and essential thrombocythemia.","title02":"Metformin alleviates side effects and supports the resumption of interferon therapy in polycythemia vera and essential thrombocythemia.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288404. Online ahead of print","author":"Reeves BN, Song J, Leier A, Smith A, Kim SJ, Chen SL, Tashi T, Prchal JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307126"},{"title01":"Bcl-xL inhibition potentiates interferon-induced apoptosis in MPN stem cells.","title02":"Bcl-xL inhibition potentiates interferon-induced apoptosis in MPN stem cells.","journal":"Blood advances","issue":"2025 November 25; 9(22):5915-5919. doi: 10.1182\/bloodadvances.2025017242","author":"Bywater MJ, Haldar R, Janardhanan Y, Cooper E, Cooper L, Chan SHN, Hayes N, Ling V, Straube J, Lane SW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864222"},{"title01":"Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.","title02":"Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma.","journal":"Blood","issue":"2025 November 27; 146(22):2629-2640. doi: 10.1182\/blood.2025029909","author":"Falchi L, Sureda A, Leppa S, Vermaat JSP, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton KM, Sunkersett G, Hoehn D, Rana A, Abbas A, Marek J, Hao Y, Steele AJ, Morehouse C, Hutchings M, Belada D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40920572"},{"title01":"A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.","title02":"A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma.","journal":"Blood","issue":"2025 November 20; 146(21):2561-2573. doi: 10.1182\/blood.2025028649","author":"Xu PP, Zhu Y, Shi ZY, Wang L, Cheng S, Qian Y, Zhao Y, He Y, Yi HM, Ou-Yang BS, Jiang XF, Li B, Song Q, Mu RJ, Zhao WL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829156"},{"title01":"Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.","title02":"Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases.","journal":"Leukemia","issue":"2025 November 18. doi: 10.1038\/s41375-025-02802-4. Online ahead of print","author":"Pertesi M, Demangel D, Niroula A, Perrial E, Mahecha Escobar ML, Vallee M, Liacos C, Samur MK, Sperling AS, Munshi NC, Kastritis E, Dimopoulos MA, McKay JD, Mellqvist UH, Hansson M, Dumontet C, Nilsson B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41254116"},{"title01":"Return to employment outcomes in patients with multiple myeloma.","title02":"Return to employment outcomes in patients with multiple myeloma.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70257. Online ahead of print","author":"Lilli NL, Pequin M, Dulondel L, Blin N, Gastinne T, Tessoulin B, Dubruille V, Antier C, Roquelaure Y, Moreau P, Porro B, Touzeau C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41250906"},{"title01":"Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.","title02":"Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.","journal":"Blood advances","issue":"2025 November 25; 9(22):5708-5719. doi: 10.1182\/bloodadvances.2025016949","author":"Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelinek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763276"},{"title01":"Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis.","title02":"Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis.","journal":"Blood advances","issue":"2025 November 25; 9(22):5814-5827. doi: 10.1182\/bloodadvances.2025017214","author":"Spencer A, Gavriatopoulou M, Coriu D, Lysen A, Gutierrez NC, Escalante F, Eugenia Fantl DB, Hajek R, Seguro F, Kaur G, Bittencourt R, Kinda SB, Chu MP, Safah H, Martinez-Lopez J, de Queiroz Crusoe E, Cordeiro de Farias DL, Offidani M, Askari E, Sevindik OG, Maisnar V, Teng CL, Hughes O, Taylor R, Lehn K, Feng D, Thiebaut-Millot R, Li X, Murray L, Jung P, Rossi EL, Kongpachith S, Nichol A, Ross JA, Hader C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829119"},{"title01":"Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.","title02":"Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.","journal":"Blood advances","issue":"2025 November 25; 9(22):5828-5836. doi: 10.1182\/bloodadvances.2025017394","author":"Smits F, Groen K, Levin MD, Stege CAM, van Kampen R, van der Spek E, Nijhof I, Bilgin YM, Thielen N, Ludwig I, de Waal EGM, Sandberg Y, Kentos A, Timmers GJ, Regelink JC, Westerman M, de Heer K, Vekemans MC, Durdu-Rayman N, de Graauw NCHP, Seefat MR, van de Donk NWCJ, Ypma PF, Nasserinejad K, Zweegman S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845265"},{"title01":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1.","title02":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1.","journal":"Blood advances","issue":"2025 November 25; 9(22):5752-5762. doi: 10.1182\/bloodadvances.2025016613","author":"Schinke C, Rodriguez-Otero P, van de Donk NWCJ, Lipe B, Lavi N, Rasche L, Parekh S, Van Oekelen O, Vishwamitra D, Skerget S, Cortes-Selva D, Verona R, Hilder B, Masterson T, Campagna M, Khedkar S, Renaud T, Tolbert J, Kane C, Gray KS, Saber I, Heuck C, Chari A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864183"},{"title01":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","title02":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288654. Online ahead of print","author":"Vachhani P, Mesa R, Mascarenhas J, Rampal R, Oh ST, Vannucchi AM, Fox ML, Palandri F, Passamonti F, Kiladjian JJ, Azimi M, Harrison C, Bose P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262043"},{"title01":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","title02":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288303. Online ahead of print","author":"Myers RM, Li Y, Liu H, Mumanachit S, Wang L, Leahy AB, Cain LE, DiNofia AM, Diorio C, Freedman JL, Hunger SP, Maude SL, McClory SE, Rheingold SR, Tasian SK, Wray L, Olson TS, Grupp SA, Bunin NJ, Seif AE, Elgarten CW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307125"},{"title01":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era emerging humoral and cellular players.","title02":"Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era emerging humoral and cellular players.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288237. Online ahead of print","author":"Lauruschkat CD, Gorge H, Knies K, Weissbrich B, Dolken L, Kochel C, Imhof N, Huber M, Hengel H, Einsele H, Wurster S, Kraus S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307128"},{"title01":"Lusutrombopag or hetrombopag supports in vitro megakaryopoiesis better than other thrombopoietin receptor agonists.","title02":"Lusutrombopag or hetrombopag supports in vitro megakaryopoiesis better than other thrombopoietin receptor agonists.","journal":"Br J Haematol","issue":"2025 November 28. doi: 10.1111\/bjh.70267. Online ahead of print","author":"He Y, Hu J, Zhai J, Wang L, Cheng X, Wang J, Dong F, Zhao X, Zhang F, Ema H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41315050"},{"title01":"Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub-Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy.","title02":"Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub-Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy.","journal":"Br J Haematol","issue":"2025 November 17. doi: 10.1111\/bjh.70230. Online ahead of print","author":"Elfeky R, Broderick V, Ewins AM, Rivers E, Roberts W, Slatter M, Guest J, Hill A, Samrin L, Mclelland V, Holden V, Gardiner B, Sealy L, Waller L, Betteridge C, Tholouli E, Lee J, Broome H, Blundell Jones J, Prescott N, Hudson N, Hurrell R, Rao K, Gibson B, James B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41246914"},{"title01":"Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation.","title02":"Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70259. Online ahead of print","author":"Zhu X, Fu H, Liu J, Xu Z, Sun Y, Lv M, Mo X, Cheng Y, Xu L, Zhang XH, Huang XJ, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41250797"},{"title01":"Return to employment outcomes in patients with multiple myeloma.","title02":"Return to employment outcomes in patients with multiple myeloma.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70257. Online ahead of print","author":"Lilli NL, Pequin M, Dulondel L, Blin N, Gastinne T, Tessoulin B, Dubruille V, Antier C, Roquelaure Y, Moreau P, Porro B, Touzeau C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41250906"},{"title01":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","title02":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017934. Online ahead of print","author":"Sekeres MA, Mattison RJ, Artz AS, Baer MR, Chua CC, Demichelis-Gomez R, Egan PC, Fletcher L, Foucar CE, Garcia JS, Gilberto L, Gomez-De Leon A, Lancet JE, Loh KP, Malcovati L, Marini BL, Platzbecker U, Sorror ML, Tinsley-Vance S, Treitz J, Oliveros MJ, Ibrahim S, Roldan Y, Guyatt GH, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41321225"},{"title01":"RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids.","title02":"RAG1 lentiviral gene therapy restores T-cell development of RAG1-SCID patient cells in artificial thymic organoids.","journal":"Blood advances","issue":"2025 November 25; 9(22):5920-5934. doi: 10.1182\/bloodadvances.2025016970","author":"Meng X, Melsen JE, van der Holst R, de Mooij B, Vloemans S, van Eggermond M, Berghuis D, Lankester AC, de Kivit S, Pike-Overzet K, Langerak AW, Staal FJT, Ott de Bruin LM, Cante-Barrett K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829114"},{"title01":"Reproducibility and repeatability of the Myoton to quantify sclerotic chronic graft-versus-host disease.","title02":"Reproducibility and repeatability of the Myoton to quantify sclerotic chronic graft-versus-host disease.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025016648. Online ahead of print","author":"Farhadfar N, El Jurdi N, Baker K, Ghosh S, Bat-Erdene M MPH, Chen H, Sahu R, Weiss R, Mi J, Desatnik G, Williams LR, Tkaczyk ER, Lee SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191519"},{"title01":"The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.","title02":"The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.","journal":"Blood advances","issue":"2025 November 25; 9(22):5763-5773. doi: 10.1182\/bloodadvances.2025017116","author":"Akahoshi Y, Portelli J, Katsivelos N, Louloudis IE, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Hexner EO, Kitko CL, Kraus S, Merli P, Olson TS, Pasic I, Qayed M, Reshef R, Schechter T, Marx J, Ullrich E, Vasova I, Weber D, Wolfl M, Zeiser R, Baez J, Eng G, Gleich S, Kowalyk S, Morales G, Spyrou N, Young R, DeFilipp Z, Hogan WJ, Nakamura R, Levine JE, Ferrara JLM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40815797"},{"title01":"CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.","title02":"CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.","journal":"Blood advances","issue":"2025 November 21. doi: 10.1182\/bloodadvances.2025018340. Online ahead of print","author":"Artz AS, Logan BR, Saber W, Geller N, Bellach A, Kou J, Wood WA, McCarty J, Knight TG, Runaas L, Johnston L, Walston JD, Nakamura R, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE Jr, Imus P, Hogan WJ, Nadiminti KV, Bhatt VR, Olin RL, Maakaron JE, Sobecks RM, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Sorror ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269781"},{"title01":"Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC.","title02":"Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025016812. Online ahead of print","author":"Rayes A, Logan BR, Liu X, Dara J, Buckley RH, Oved JH, Kapoor N, Kapadia M, Chandra S, Martinez CA, Bunin N, Chandrakasan S, Chen K, Bednarski JJ, Haines HL, Eissa H, Talano JM, Keller MD, Ebens CL, Chaudhury S, Shereck EB, Aquino VM, Knutsen AP, Alexander JL, Gillio AP, Chellapandian D, Shah AJ, Miller HK, Vander Lugt MT, Seroogy CM, Dorsey MJ, Mousallem T, Parrott RE, O'Reilly RJ, Aguayo-Hiraldo PI, Prockop SE, Davila Saldana BJ, Thakar MS, Burroughs LM, Torgerson TR, Leiding JW, Marsh RA, Griffith LM, Pulsipher MA, Kohn DB, Notarangelo LD, Cowan MJ, Puck JM, Cuvelier GDE, Heimall J, Haddad E, Pai SY, Dvorak CC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289158"},{"title01":"Old but gold: ILC-induced T-cell senescence prevents GVHD.","title02":"Old but gold: ILC-induced T-cell senescence prevents GVHD.","journal":"Blood","issue":"2025 November 27; 146(22):2620-2621. doi: 10.1182\/blood.2025030805","author":"Chen S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307933"},{"title01":"Death receptor 3 gives life to Tregs in GVHD.","title02":"Death receptor 3 gives life to Tregs in GVHD.","journal":"Blood","issue":"2025 November 27; 146(22):2626-2627. doi: 10.1182\/blood.2025030671","author":"Shaikh H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307935"},{"title01":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","title02":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","journal":"Blood","issue":"2025 November 27; 146(22):2710-2727. doi: 10.1182\/blood.2025028418","author":"McManus D, Copsel SN, Pfeiffer BJ, Wolf D, Barreras H, Ma S, Khodor A, Komai S, Burgos da Silva M, Hazime H, Gallardo M, Lime SG, van den Brink MRM, Park JH, Abreu MT, Hill GR, Perez VL, Levy RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749165"},{"title01":"Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub-Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy.","title02":"Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub-Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy.","journal":"Br J Haematol","issue":"2025 November 17. doi: 10.1111\/bjh.70230. Online ahead of print","author":"Elfeky R, Broderick V, Ewins AM, Rivers E, Roberts W, Slatter M, Guest J, Hill A, Samrin L, Mclelland V, Holden V, Gardiner B, Sealy L, Waller L, Betteridge C, Tholouli E, Lee J, Broome H, Blundell Jones J, Prescott N, Hudson N, Hurrell R, Rao K, Gibson B, James B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41246914"},{"title01":"Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation.","title02":"Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70259. Online ahead of print","author":"Zhu X, Fu H, Liu J, Xu Z, Sun Y, Lv M, Mo X, Cheng Y, Xu L, Zhang XH, Huang XJ, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41250797"},{"title01":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","title02":"In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017433. Online ahead of print","author":"van der Meulen SA, Roemhild K, Driessen M, van den Akker E, Nethe M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289157"},{"title01":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","title02":"Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years.","journal":"Blood advances","issue":"2025 November 26. doi: 10.1182\/bloodadvances.2024015776. Online ahead of print","author":"Liu QW, Fang F, Xue H, Wasterlid T, Smedby KE, Liu X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296017"},{"title01":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","title02":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","journal":"Blood","issue":"2025 November 20; 146(21):2574-2588. doi: 10.1182\/blood.2025028935","author":"Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine A, Andreeff M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40608889"},{"title01":"Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","title02":"Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.","journal":"Leukemia","issue":"2025 November 20. doi: 10.1038\/s41375-025-02808-y. Online ahead of print","author":"Vallois D, Missiaglia E, Veloza L, Fischer A, Cavalieri D, Rattina V, Bisig B, Roh V, Wiehle L, Sarkis R, Bachy E, Bonnet C, Bruneau J, Cairoli A, De Wind R, Drieux F, Dubois R, Emile JF, Fataccioli V, Laribi K, Ledoux-Pilon A, Lemonnier F, Llamas-Gutierrez F, Morel P, Parrens M, Poullot E, Quintanilla-Martinez L, Sandrini J, Somja J, Xerri L, Tournilhac O, Gaulard P, Siebert R, de Leval L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41266881"},{"title01":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed\/Refractory Large B-Cell Lymphoma.","title02":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed\/Refractory Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2025 November 18; JCO2500507. doi: 10.1200\/JCO-25-00507. Online ahead of print","author":"Maziarz RT, Bishop MR, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu J, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Ma W, Han X, Nuortti M, Awasthi R, Mundt KE, Majdan M, Maier HJ, Jegerlehner A, Salles G, Schuster SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41252666"},{"title01":"Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma.","title02":"Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma.","journal":"J Clin Oncol","issue":"2025 November 20; 43(33):3573-3577. doi: 10.1200\/JCO-25-00668","author":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson ML, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt JD, Wulff J, Shen RR, Zhang W, Poddar S, Miao H, Nikolajeva O, Jacobson CA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41100801"},{"title01":"Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","title02":"Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.","journal":"J Clin Oncol","issue":"2025 November 20; JCO2502667. doi: 10.1200\/JCO-25-02667. Online ahead of print","author":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trneny M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Lee Batlevi C, Tilly H, Flowers CR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264903"},{"title01":"Complete remission of bronchus-associated lymphoid tissue lymphoma after antibiotic treatment for Tropheryma whipplei.","title02":"Complete remission of bronchus-associated lymphoid tissue lymphoma after antibiotic treatment for Tropheryma whipplei.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288045. Online ahead of print","author":"Kiener TA, Schweighofer-Zwink G, Rendl G, Kern JM, Baskova L, Neureiter D, Melchardt T, Raderer M, Greil R, Pirich C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307123"},{"title01":"Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma.","title02":"Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288946. Online ahead of print","author":"Olszewski AJ, Ollila TA, Chihara D, Shouse G, Grover N, Karmali R, Torka P, Thomas C, Geethakumari PR, Barta SK, Bartlett NL, Epperla N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307133"},{"title01":"Combinatorial targeting of MYC\/BCL2-associated vulnerabilities in high-grade B-cell lymphoma.","title02":"Combinatorial targeting of MYC\/BCL2-associated vulnerabilities in high-grade B-cell lymphoma.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70249. Online ahead of print","author":"Donati G, Nicoli P, Miele F, Podini P, Dina G, Quattrini A, Amati B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41255023"},{"title01":"Repurposing pacritinib to target MYD88-mutated Waldenstrom macroglobulinaemia.","title02":"Repurposing pacritinib to target MYD88-mutated Waldenstrom macroglobulinaemia.","journal":"Br J Haematol","issue":"2025 November 19. doi: 10.1111\/bjh.70254. Online ahead of print","author":"Liu S, Kofides A, Liu X, Hatcher JM, Sun H, Tsakmaklis N, Guijosa A, Guerrera ML, Pizzarella D, Peachey AL, Patterson CJ, Hunter ZR, Meid K, Castillo JJ, Sarosiek SR, Treon SP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41255253"},{"title01":"Hairy Cell Leukemia: a chronic B-lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","title02":"Hairy Cell Leukemia: a chronic B-lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","journal":"Blood advances","issue":"2025 November 26. doi: 10.1182\/bloodadvances.2025017165. Online ahead of print","author":"Zhang G, Hu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296002"},{"title01":"Real-World Comparative Effectiveness of Bruton Tyrosine Kinase Inhibitors in Relapsed\/Refractory Mantle Cell Lymphoma.","title02":"Real-World Comparative Effectiveness of Bruton Tyrosine Kinase Inhibitors in Relapsed\/Refractory Mantle Cell Lymphoma.","journal":"Blood advances","issue":"2025 November 21. doi: 10.1182\/bloodadvances.2025017160. Online ahead of print","author":"Phillips TJ, Di M, Miller T, Wang J, Pierre A, Maglinte GA, Seymour EK, Wang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269777"},{"title01":"Han JX, Koh MJ, Boussi L, et al. Global outcomes and prognosis for relapsed\/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium. Blood Adv. 2025;9(3):583-602.","title02":"Han JX, Koh MJ, Boussi L, et al. Global outcomes and prognosis for relapsed\/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium. Blood Adv. 2025;9(3):583-602.","journal":"Blood advances","issue":"2025 November 25; 9(22):5936. doi: 10.1182\/bloodadvances.2025018400","author":"No authors listed","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41288992"},{"title01":"MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma.","title02":"MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017760. Online ahead of print","author":"Ruan J, Bond DA, Shah BD, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D, Xiang JZ, Hobbie B, Harbhajan M, Sahni TK, Chen GZ, Sigouros M, Inghirami GG, Chen-Kiang S, Elemento O, Maddocks KJ, Leonard JP, Martin P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289154"},{"title01":"Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders.","title02":"Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders.","journal":"Blood advances","issue":"2025 November 25; 9(22):5880-5887. doi: 10.1182\/bloodadvances.2025016424","author":"Mauvieux L, Herbrecht R, Eischen A, Galoisy AC, Rolland D, Gervais C, Mayeur-Rousse C, Hueber-Bonnot S, Nicolae A, Fornecker LM, Goetsch T, Severac F, Bizoi R, Fabacher T, Miguet L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41236721"},{"title01":"An AI model classifies risks of early relapse post-CAR T-cell therapy in a multicenter real-world population with DLBCL.","title02":"An AI model classifies risks of early relapse post-CAR T-cell therapy in a multicenter real-world population with DLBCL.","journal":"Blood advances","issue":"2025 November 25; 9(22):5837-5852. doi: 10.1182\/bloodadvances.2025016375","author":"Wang M, Komanduri KV, Datta D, Patel A, Whitaker B, Belov A, Rubin B, Vashist R, Rodriguez-Monguio R, Cinar P, Anderson S, Butte AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40902085"},{"title01":"Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies.","title02":"Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies.","journal":"Blood advances","issue":"2025 November 25; 9(22):5792-5801. doi: 10.1182\/bloodadvances.2025016930","author":"Atallah-Yunes SA, Khurana A, Habermann TM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811832"},{"title01":"Characteristics and outcomes of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome.","title02":"Characteristics and outcomes of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome.","journal":"Blood advances","issue":"2025 November 25; 9(22):5720-5731. doi: 10.1182\/bloodadvances.2025016685","author":"Ramaswami R, Lurain K, Polizzotto MN, Widell A, Ekwede I, Tassi E, Rupert A, Marshall VA, Roth MJ, Filie AC, Pittaluga S, Jaffe ES, Wang HW, Whitby D, Uldrick TS, Yarchoan R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763275"},{"title01":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","title02":"Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.","journal":"Blood","issue":"2025 November 20; 146(21):2574-2588. doi: 10.1182\/blood.2025028935","author":"Carter BZ, Mak PY, Ayoub E, Wu X, Ke B, Nishida Y, Futreal A, Ostermann LB, Bedoy AD, Boettcher S, DiNardo CD, Puzio-Kuter A, Poyurovsky MV, Levine A, Andreeff M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40608889"},{"title01":"Big cells, bigger BTK resistance in mantle cell lymphoma.","title02":"Big cells, bigger BTK resistance in mantle cell lymphoma.","journal":"Blood","issue":"2025 November 20; 146(21):2500-2501. doi: 10.1182\/blood.2025029937","author":"Taylor J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264326"},{"title01":"Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine.","title02":"Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine.","journal":"Blood","issue":"2025 November 25. doi: 10.1182\/blood.2025031423. Online ahead of print","author":"Hosoya H, Bastidas Torres AN, Fernandez-Pol S, Gubatan JM, Najidh S, Duran GE, Dong F, Ehlinger Z, Lohman C, Wright C 3rd, Sahaf B, Mackall CL, Miklos DB, Sidana S, Kurtz DM, Khodadoust MS, Mikkilineni L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41288531"},{"title01":"Old problems, new tools: ZR2 in older patients with DLBCL.","title02":"Old problems, new tools: ZR2 in older patients with DLBCL.","journal":"Blood","issue":"2025 November 20; 146(21):2501-2502. doi: 10.1182\/blood.2025030855","author":"de Jonge AV, Chamuleau MED","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264332"},{"title01":"TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.","title02":"TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma.","journal":"Blood","issue":"2025 November 20; 146(21):2544-2560. doi: 10.1182\/blood.2024026919","author":"Wang W, Cai Q, Liu Y, Nie L, Lee HH, Yan F, Fei Y, Yao Y, Li Y, Tan L, Lorenzi PL, Wang YN, Yao J, Chen Z, McIntosh JM, Yu CT, Jain P, Jiang VC, Vargas J, Li X, Zhang T, Li S, Santos D, Thirumurthi S, Seeley EH, Simon LM, Flowers C, Ok CY, Wang M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700581"},{"title01":"Dreaming of a Better Future: Drug Development in Myeloma.","title02":"Dreaming of a Better Future: Drug Development in Myeloma.","journal":"Blood advances","issue":"2025 November 21. doi: 10.1182\/bloodadvances.2024015740. Online ahead of print","author":"Lonial S, Parikh R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269780"},{"title01":"A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.","title02":"A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.","journal":"Blood","issue":"2025 November 20; 146(21):2517-2530. doi: 10.1182\/blood.2025028587","author":"Bruins WSC, Smits F, Duetz C, Groen K, Korst CLBM, de Jonge AV, Verkleij CPM, Rentenaar R, Cosovic M, Eken M, Twickler I, Homan-Weert PM, Sonneveld P, Moreau P, Claesen J, van de Donk NWCJ, Zweegman S, Mutis T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829164"},{"title01":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.","title02":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.","journal":"Blood","issue":"2025 November 27; 146(22):2670-2680. doi: 10.1182\/blood.2025029987","author":"Beer SA, Cairns DA, Pawlyn C, Holroyd A, Ferris E, Cook G, Drayson M, Boyd K, Proszek P, Davies FE, de Tute R, Jenner M, Morgan GJ, Owen R, Hubank M, Houlston R, Jackson G, Kaiser MF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40834881"},{"title01":"Isatuximab for relapsed and\/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702).","title02":"Isatuximab for relapsed and\/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702).","journal":"Blood","issue":"2025 November 20; 146(21):2507-2516. doi: 10.1182\/blood.2024027962","author":"Parker TL, Rosenthal A, Sanchorawala V, Landau HJ, Campagnaro EL, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott EC, Hoering A, Durie BGM, Orlowski RZ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40925099"},{"title01":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","title02":"Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.","journal":"Blood","issue":"2025 November 24. doi: 10.1182\/blood.2025031426. Online ahead of print","author":"Banerjee R, Khouderchah C, Akhtar OS, Liang EC, Gauthier J, Dhodapkar MV, Portuguese AJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41284631"},{"title01":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation.","title02":"Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation.","journal":"J Clin Oncol","issue":"2025 November 20; 43(33):3600-3609. doi: 10.1200\/JCO-25-01238","author":"Ueda Oshima M, Vo PT, Boeckh M, Bouvier ME, Carpenter PA, Mielcarek M, Petersdorf EW, Storb R, Gooley T, Sandmaier BM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41043099"},{"title01":"Deletion mutations of the ABL1 gene in Philadelphia chromosome-positive acute lymphoblastic leukemia: high prevalence with limited clinical impact.","title02":"Deletion mutations of the ABL1 gene in Philadelphia chromosome-positive acute lymphoblastic leukemia: high prevalence with limited clinical impact.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288739. Online ahead of print","author":"Takano H, Takagi S, Kato K, Watanabe O, Yamaguchi K, Kageyama K, Kaji D, Taya Y, Nishida A, Ishiwata K, Yamamoto H, Asano-Mori Y, Yamamoto G, Wake A, Taniguchi S, Uchida N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262038"},{"title01":"Acute myeloid leukemia with t(10;17)(p15;q21)\/ZMYND11::MBTD1: a subtype with minimal differentiation, CD7\/CD56 expression, and generally poor outcomes in adults.","title02":"Acute myeloid leukemia with t(10;17)(p15;q21)\/ZMYND11::MBTD1: a subtype with minimal differentiation, CD7\/CD56 expression, and generally poor outcomes in adults.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288752. Online ahead of print","author":"Wei Q, Pemmaraju N, Wang SA, Hu S, DiNardo C, Issa GC, Bueso-Ramos CE, Xu J, Li S, Medeiros JL, Tang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262054"},{"title01":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","title02":"Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288303. Online ahead of print","author":"Myers RM, Li Y, Liu H, Mumanachit S, Wang L, Leahy AB, Cain LE, DiNofia AM, Diorio C, Freedman JL, Hunger SP, Maude SL, McClory SE, Rheingold SR, Tasian SK, Wray L, Olson TS, Grupp SA, Bunin NJ, Seif AE, Elgarten CW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307125"},{"title01":"A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity.","title02":"A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288221. Online ahead of print","author":"Jaiswal AK, Scherer GM, Thaxton ML, Sorrentino JP, Yuen C, Mehta MM, Sharma G, Lin TL, Tran TM, Cohen A, Ritter AJ, Kotecha RS, Sanford JR, Damoiseaux RD, Garg NK, Rao DS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307127"},{"title01":"Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter study.","title02":"Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter study.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288377. Online ahead of print","author":"Shu M, Ding W, Wang L, Wang Z, Wang L, Zhu M, Liu D, Shen H, Wang Y, Dou X, Ma X, Zhang Y, Xu Y, Wang Y, Xue S, Fu J, Qiu H, Tang X, Han Y, Huang J, Wu D, Dai H, Wen L, Chen S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307138"},{"title01":"A comparative analysis between real-time polymerase chain reaction and next-generation sequencing for the simultaneous detection of key fusions in acute myeloid leukaemia.","title02":"A comparative analysis between real-time polymerase chain reaction and next-generation sequencing for the simultaneous detection of key fusions in acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2025 November 17. doi: 10.1111\/bjh.70250. Online ahead of print","author":"Vieira AF, Erazo FAH, Lamas AMR, de Sousa CF, Souza GLB, Costa YA, da Silva Lira N, Pitaluga EM, da Silva SDB, de Sousa Misael NC, Bastos FQ, de Carvalho Pereira G, Xavier FD, Velasco LFR, Furtado FM, Barra GB, de Souza Andrade M, Amato AA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41243548"},{"title01":"Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study.","title02":"Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study.","journal":"Br J Haematol","issue":"2025 November 25. doi: 10.1111\/bjh.70264. Online ahead of print","author":"Kynning MK, Westerberg E, Forsell L, Creignou M, Berggren DM, Tesi B, Bernard E, Papaemmanuil E, Nannya Y, Franco LC, Valentini D, Lindberg EH, Ogawa S, Ejerblad E, Ungerstedt J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41287892"},{"title01":"Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.","title02":"Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.","journal":"Blood advances","issue":"2025 November 21. doi: 10.1182\/bloodadvances.2025017083. Online ahead of print","author":"Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V MD, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J MD, Ting SB, Hou JZ Hematology Oncology, Yamauchi T, Wang J, Strickland SA, Savona MR, Lin TL, Enjeti AK, Tiong IS, Lee S, Roboz GJ, Popovic R, Jiang Q, Liu Z, Sun Y, Mendes WL, Chyla B, DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41269778"},{"title01":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","title02":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017934. Online ahead of print","author":"Sekeres MA, Mattison RJ, Artz AS, Baer MR, Chua CC, Demichelis-Gomez R, Egan PC, Fletcher L, Foucar CE, Garcia JS, Gilberto L, Gomez-De Leon A, Lancet JE, Loh KP, Malcovati L, Marini BL, Platzbecker U, Sorror ML, Tinsley-Vance S, Treitz J, Oliveros MJ, Ibrahim S, Roldan Y, Guyatt GH, Brignardello-Petersen R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41321225"},{"title01":"TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells.","title02":"TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells.","journal":"Blood advances","issue":"2025 November 25; 9(22):5888-5901. doi: 10.1182\/bloodadvances.2025017018","author":"Lawler ME, Romer-Seibert JS, Bowman MS, Mitra R, Eischen CM, Bowman RL, Meyer SE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40833891"},{"title01":"Reflecting on 30 years of miRNA biology in malignant hematology: current challenges and future directions.","title02":"Reflecting on 30 years of miRNA biology in malignant hematology: current challenges and future directions.","journal":"Blood advances","issue":"2025 November 25; 9(22):5937-5944. doi: 10.1182\/bloodadvances.2024015611","author":"MacPhee L, Rouhi A, Vu LP, Kuchenbauer F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845247"},{"title01":"Role of race and ethnicity in survival among children\/young adults with relapsed ALL: a Children&#8217;s Oncology Group report.","title02":"Role of race and ethnicity in survival among children\/young adults with relapsed ALL: a Children&#8217;s Oncology Group report.","journal":"Blood advances","issue":"2025 November 25; 9(22):5738-5751. doi: 10.1182\/bloodadvances.2025016670","author":"Ligon JA, Ji L, Dang A, Xu X, Rheingold SR, Bhojwani D, Devidas M, Kairalla JA, Shago M, Heerema NA, Carroll AJ, Borowitz M, Wood BL, Winick NJ, Carroll WL, Hunger SP, Raetz EA, Loh ML, Gupta S, Winestone LE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40815811"},{"title01":"Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation.","title02":"Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation.","journal":"Blood advances","issue":"2025 November 19. doi: 10.1182\/bloodadvances.2025018090. Online ahead of print","author":"Aquilanti EA, Kageler L, Bozinov V, Meyerson ML","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259746"},{"title01":"Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders.","title02":"Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders.","journal":"Blood advances","issue":"2025 November 25; 9(22):5880-5887. doi: 10.1182\/bloodadvances.2025016424","author":"Mauvieux L, Herbrecht R, Eischen A, Galoisy AC, Rolland D, Gervais C, Mayeur-Rousse C, Hueber-Bonnot S, Nicolae A, Fornecker LM, Goetsch T, Severac F, Bizoi R, Fabacher T, Miguet L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41236721"},{"title01":"An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy.","title02":"An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy.","journal":"Blood advances","issue":"2025 November 25; 9(22):5802-5810. doi: 10.1182\/bloodadvances.2025016978","author":"Mason EJ, Crain AM, Scheurer ME, Lupo PJ, Rabin KR, Taylor OA, Roberts M, Woodhouse JP, Chavana A, Ludwig K, Klesse L, Heym K, Griffin T, Erana R, Bernini JC, Gramatges MM, Yi JS, Pruitt SL, Bernhardt MB, Zhu H, Mittelman SD, Huynh V, Orgel E, Schraw JM, Brown AL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829116"},{"title01":"Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia.","title02":"Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia.","journal":"Blood advances","issue":"2025 November 25; 9(22):5861-5869. doi: 10.1182\/bloodadvances.2025017044","author":"Hoppmann AL, Hurley DM, Cramer S, Brown MJ, Ghosal R, Alberg AJ, Bhatia S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40845260"},{"title01":"Proteomics: the key to understanding AML hematopoietic aging.","title02":"Proteomics: the key to understanding AML hematopoietic aging.","journal":"Blood","issue":"2025 November 27; 146(22):2623-2624. doi: 10.1182\/blood.2025030883","author":"Gosline SJC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307939"},{"title01":"Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.","title02":"Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.","journal":"Blood","issue":"2025 November 27; 146(22):2681-2695. doi: 10.1182\/blood.2024027692","author":"Cheng WY, Yi X, Wang ZY, Li JF, Zhang JY, Zhang RH, Zhang QQ, Weng XQ, Huang T, Zhu YM, Wang C, Yin W, Zhang JN, Wu HY, Li JM, Zhu HM, Chen L, Wang WF, Dai YT, Gao CX, Liu X, Wang S, Wang SY, Jiao B, Chen Z, Fang H, Yin T, Shen Y, Chen SJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829168"},{"title01":"Confirmation by conformation: rescue of mutant p53 in AML.","title02":"Confirmation by conformation: rescue of mutant p53 in AML.","journal":"Blood","issue":"2025 November 20; 146(21):2503-2504. doi: 10.1182\/blood.2025030273","author":"Lane DP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264333"},{"title01":"NPM1-mutated acute myeloid leukemia with marked erythroid and megakaryocytic differentiation.","title02":"NPM1-mutated acute myeloid leukemia with marked erythroid and megakaryocytic differentiation.","journal":"Blood","issue":"2025 November 20; 146(21):2612. doi: 10.1182\/blood.2025030468","author":"Parisi X, Loghavi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264323"},{"title01":"Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.","title02":"Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.","journal":"Blood","issue":"2025 November 20; 146(21):2589-2596. doi: 10.1182\/blood.2025029132","author":"O'Brien C, Nursimulu N, Tyagi A, Culp-Hill R, Arruda A, Murphy T, Minden MD, Kent A, Stevens B, Pollyea DA, Hope K, Kumar S, Reisz JA, D'Alessandro A, Jones CL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40857673"},{"title01":"FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.","title02":"FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.","journal":"Blood","issue":"2025 November 20; 146(21):2608-2611. doi: 10.1182\/blood.2025029391","author":"Raj R, Catueno S, Gibson A, McCall D, Garcia MB, Nunez C, Roth M, Sasaki K, Tewari P, Issa GC, Farhat A, Connors J, Sheikh I, Nishida Y, Yi JS, Stevens AM, Bataller A, Bhalla K, Petropoulos D, Daver N, Kadia T, Cuglievan B, DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40971491"},{"title01":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","title02":"Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.","journal":"Blood","issue":"2025 November 19. doi: 10.1182\/blood.2025030951. Online ahead of print","author":"Buechner J, Poetschger U, Bader P, Yesilipek MA, Pichler H, Palma J, Staciuk R, Riha P, Krivan G, Ifversen M, Gungor T, Goussetis E, Kalwak K, Toporski J, Gabriel M, Renard MM, Diaz-de-Heredia C, Matic T, Calkoen FG, Svec P, Meisel R, Balduzzi AC, Locatelli F, Peters C, Dalle JH, Stein J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41259231"},{"title01":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","title02":"Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT.","journal":"Blood","issue":"2025 November 27; 146(22):2710-2727. doi: 10.1182\/blood.2025028418","author":"McManus D, Copsel SN, Pfeiffer BJ, Wolf D, Barreras H, Ma S, Khodor A, Komai S, Burgos da Silva M, Hazime H, Gallardo M, Lime SG, van den Brink MRM, Park JH, Abreu MT, Hill GR, Perez VL, Levy RB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749165"},{"title01":"Cumulative incidence and factors associated with subsequent myeloid neoplasms in patients with nodal T-follicular helper cell lymphomas.","title02":"Cumulative incidence and factors associated with subsequent myeloid neoplasms in patients with nodal T-follicular helper cell lymphomas.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2025.288615. Online ahead of print","author":"Lin KS, Yan M, Ganesan N, Chang T, Dogan A, Epstein-Peterson Z, Eren OC, Ghione P, Iyengar V, Johnson W, Ksanznak K, Moskowitz A, Sordi B, Horwitz S, Xiao W, Stuver R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307131"},{"title01":"Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.","title02":"Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.","journal":"Haematologica","issue":"2025 November 27. doi: 10.3324\/haematol.2024.286813. Online ahead of print","author":"Joffe E, Uppal M, Zheng S, Bantilan KS, Batlevi C, Epstein-Peterson Z, Ghione P, Hamlin P, Matasar M, Moskowitz A, Noy A, Palomba ML, Keudell GV, Falchi L, Yahalom J, Segodin V, Kotlov N, Egorov E, Degryse S, Bagaev A, Fowler N, Arcila M, Dogan A, Salles G, Kumar A, Zelenetz AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41307120"},{"title01":"A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed\/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor.","title02":"A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed\/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor.","journal":"Br J Haematol","issue":"2025 November 17. doi: 10.1111\/bjh.70237. Online ahead of print","author":"Hess G, Eyre TA, Jen MH, Zhang J, Goebel B, Abhyankar S, Dreyling M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41251068"},{"title01":"Mosunetuzumab is effective and well tolerated in older patients with relapsed\/refractory follicular lymphoma: Subgroup analysis of a phase I\/II study.","title02":"Mosunetuzumab is effective and well tolerated in older patients with relapsed\/refractory follicular lymphoma: Subgroup analysis of a phase I\/II study.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70212. Online ahead of print","author":"Thiruvengadam SK, Popplewell LL, Herrera AF, Mei M, Nikolaenko L, Zuo X, Yin S, Zhou M, Mun Y, Wu M, Wei MC, Budde LE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41254806"},{"title01":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.","title02":"Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.","journal":"Leukemia","issue":"2025 November 18. doi: 10.1038\/s41375-025-02796-z. Online ahead of print","author":"Castagnetti F, Breccia M, Abruzzese E, Bassan R, Binotto G, Bonifacio M, Caocci G, Capodanno I, Cavazzini F, Cimino G, Fazi P, Gozzini A, Iurlo A, Janssen JJWM, Lunghi M, Marasca R, Martino B, Messina M, Muriano F, Paoloni F, Piciocchi A, Rosti G, Russo Rossi A, Saglio G, Sica S, Soverini S, Tafuri A, Vallisa D, Westerweel PE, Pane F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41254114"},{"title01":"Oncogenic activation of EVC\/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.","title02":"Oncogenic activation of EVC\/EVC2 defines a therapeutically targetable subset of acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November 17. doi: 10.1038\/s41375-025-02803-3. Online ahead of print","author":"Sui P, Li Y, Hong J, Delma CR, Chen S, Wang J, Zhang P, Han S, Noor A, Yang H, Pang Y, Luan Y, Xu M, Lee J, Yang FC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41249566"},{"title01":"Catch-up growth after switch to asciminib in a twin with chronic myeloid leukaemia.","title02":"Catch-up growth after switch to asciminib in a twin with chronic myeloid leukaemia.","journal":"Lancet","issue":"2025 November 29; 406(10519):2533-2535. doi: 10.1016\/S0140-6736(25)01732-5","author":"Sembill S, Marx M, Eikelberg I, Hofs M, Fuhrmann T, Karow A, Imschweiler T, Niehues T, Wotschofsky Z, Krumbholz M, Reinhardt D, Suttorp M, Woelfle J, Metzler M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41274296"},{"title01":"Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","title02":"Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","journal":"J Clin Oncol","issue":"2025 November 20; JCO2501666. doi: 10.1200\/JCO-25-01666. Online ahead of print","author":"Fuji S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264888"},{"title01":"Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","title02":"Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML?","journal":"J Clin Oncol","issue":"2025 November 20; JCO2502252. doi: 10.1200\/JCO-25-02252. Online ahead of print","author":"Marvin-Peek J, DiNardo CD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41264889"},{"title01":"Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","title02":"Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","journal":"J Clin Oncol","issue":"2025 November 21; JCO2501695. doi: 10.1200\/JCO-25-01695. Online ahead of print","author":"Cliff ERS, Lew TE, Simon F, Hilal T, Anderson MA, Thompson PA, Seymour JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41270246"},{"title01":"Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","title02":"Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial.","journal":"J Clin Oncol","issue":"2025 November 21; JCO2502231. doi: 10.1200\/JCO-25-02231. Online ahead of print","author":"Sharman JP, Liu B, Wang DY, Leow CC, Barr PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41270260"},{"title01":"Identification of a novel MYO1F::MLLT10 fusion in adult acute monocytic leukemia.","title02":"Identification of a novel MYO1F::MLLT10 fusion in adult acute monocytic leukemia.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288255. Online ahead of print","author":"Shah B, Francis R, Pei J, Neumann-Domer R, Mackrides N, Testa JR, Nejati R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262051"},{"title01":"Single-cell profiling of CD19-directed CAR-T cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia.","title02":"Single-cell profiling of CD19-directed CAR-T cell phenotypes and immune system dynamics in pediatric B-cell acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288397. Online ahead of print","author":"Oszer A, Pawlik B, Cwilichowska-Puslecka N, Marschollek P, Richert-Przygonska M, Mielcarek-Siedziuk M, Crawford JC, Mazurek M, Koladiya A, Kalwak K, Styczynski J, Janczar S, Poreba M, Velasquez MP, Davis KL, Mlynarski W","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262045"},{"title01":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","title02":"Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288526. Online ahead of print","author":"Zhou X, Lin Y, Gao Y, Ge Z, Huang L, Zhang J, Cheng H, Ouyang G, Meng F, Tian Y, Kuang Y, Zhou F, Sheng L, Jin W, Xu G, Ma L, Ye L, Mei C, Li J, Jin J, Tong H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262042"},{"title01":"Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed\/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication.","title02":"Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed\/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication.","journal":"Haematologica","issue":"2025 November 20. doi: 10.3324\/haematol.2025.288362. Online ahead of print","author":"Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Kayser S, Schliemann C, Kaufmann M, Kieser M, Platzbecker U, Muller-Tidow C, Schlenk RF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41262039"},{"title01":"Burden of haematological malignancies among children, adolescents and young adults: Global and high-income region insights from the GBD 2021 study.","title02":"Burden of haematological malignancies among children, adolescents and young adults: Global and high-income region insights from the GBD 2021 study.","journal":"Br J Haematol","issue":"2025 November 25. doi: 10.1111\/bjh.70265. Online ahead of print","author":"Xu S, Yang B, Liu X, Xu Z, Weng P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41292110"},{"title01":"Decoding the molecular drivers of TP53-mutant acute myeloid leukaemia: Clinical implications and prognostic insights.","title02":"Decoding the molecular drivers of TP53-mutant acute myeloid leukaemia: Clinical implications and prognostic insights.","journal":"Br J Haematol","issue":"2025 November 30. doi: 10.1111\/bjh.70271. Online ahead of print","author":"Wang LY, Gao HT, Fu Q, Jiang Q, Jiang H, Wang Y, Xu LP, Zhang XH, Huang XJ, Tang FF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41320982"},{"title01":"Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited.","title02":"Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited.","journal":"Br J Haematol","issue":"2025 November 18. doi: 10.1111\/bjh.70252. Online ahead of print","author":"Yao CY, Hsu CL, Yang YT, Tien FM, Lin CC, Wang YH, Tsai XC, Lee WH, Liu JH, Hsu YC, Kao CJ, Peng YL, Yi YH, Yang LT, Chen CC, Hou HA, Tien HF, Chou WC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41250875"},{"title01":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","title02":"Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017742. Online ahead of print","author":"Sallman DA, McLemore AF, Komrokji RS, Elmariah H, Kuykendall AT, Bejanyan N, Chan O, Faramand R, Pidala JA, Yoder SJ, Perez LE, Nishihori T, Padron E, Fernandez H, Lancet JE, Mishra A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289162"},{"title01":"Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.","title02":"Predictive Capacity of Peri-Transplant Measurable Residual Disease Thresholds in NPM1-Mutant Acute Myeloid Leukemia.","journal":"Blood advances","issue":"2025 November 25. doi: 10.1182\/bloodadvances.2025017908. Online ahead of print","author":"Schroder J, Schwartz F, Metzdorf J, Barensteiner N, Mix L, Necke LM, Fehn A, Riedel A, Jentzsch L, Faustmann P, Vogel W, Bethge WA, Schroeder T, Lengerke C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41289166"},{"title01":"Hairy Cell Leukemia: a chronic B-lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","title02":"Hairy Cell Leukemia: a chronic B-lymphoma with unique clinicopathological features and unresolved molecular mechanisms.","journal":"Blood advances","issue":"2025 November 26. doi: 10.1182\/bloodadvances.2025017165. Online ahead of print","author":"Zhang G, Hu J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41296002"},{"title01":"Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome.","title02":"Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome.","journal":"Leukemia","issue":"2025 November; 39(11):2820-2824. doi: 10.1038\/s41375-025-02760-x","author":"Bazinet A, Montalban-Bravo G, Bataller A, Hammond D, Loghavi S, Chien K, Sasaki K, Bouligny I, Swaminathan M, Jen WY, Popat U, Kadia T, DiNardo C, Jabbour E, Short N, Daver N, Ravandi F, Garcia-Manero G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40913105"},{"title01":"Base editing platform to investigate pathogenic SAMD9 mutations in paediatric myelodysplastic syndromes.","title02":"Base editing platform to investigate pathogenic SAMD9 mutations in paediatric myelodysplastic syndromes.","journal":"Br J Haematol","issue":"2025 November; 207(5):2158-2160. doi: 10.1111\/bjh.70117","author":"Canciani G, Lecis M, Frati G, D'Agostino V, Gelosi M, Del Bufalo F, Palumbo G, Palma P, Locatelli F, Ceglie G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41251388"},{"title01":"UBE2O AS A KEY REGULATOR OF DRUG-INDUCED ERYTHROPOIESIS IN THE CONTEXT OF MYELODYSPLASTIC SYNDROMES.","title02":"UBE2O AS A KEY REGULATOR OF DRUG-INDUCED ERYTHROPOIESIS IN THE CONTEXT OF MYELODYSPLASTIC SYNDROMES.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2025017340. Online ahead of print","author":"Maffeo B, Panuzzo C, Savi A, Itri F, Piccioli S, Danzero AC, Maglione A, Marini S, Voso MT, Fava C, Bracco E, Pergolizzi B, Cilloni D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191526"},{"title01":"CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.","title02":"CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.","journal":"Blood","issue":"2025 November 14. doi: 10.1182\/blood.2025031006. Online ahead of print","author":"Knapper S, Dillon LW, Babu M, Thomas A, Thomas I, Hourigan CS, Andrew GM, Dillon RJ, Gilkes AF, Marquez-Almuina N, King S, McCarthy N, Bahr R, Al-Ali RW, Stone L, Coats T, Byrne JL, Green S, Overgaard UM, Sellar RS, Dennis M, Mehta P, Hills RK, Freeman SD, Russell NH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237344"},{"title01":"The conundrum of drug development in higher-risk MDS: Lessons learned from recently failed phase 3 clinical trials.","title02":"The conundrum of drug development in higher-risk MDS: Lessons learned from recently failed phase 3 clinical trials.","journal":"Blood","issue":"2025 November 1. doi: 10.1182\/blood.2025029727. Online ahead of print","author":"Stahl MF, Zeidan AM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175364"},{"title01":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","title02":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","journal":"Leukemia","issue":"2025 November; 39(11):2745-2757. doi: 10.1038\/s41375-025-02737-w","author":"Zimolova V, Burocziova M, Berkova L, Grusanovic S, Gursky J, Janotka L, Kasparek P, Pecinova A, Kundrat D, Hrckulak D, Onhajzer J, Jeziskova I, Nekvindova L, Weinbergerova B, Pospisilova S, Doubek M, Alberich-Jorda M, Korinek V, Divoky V, Lanikova L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40841769"},{"title01":"TGF-beta-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.","title02":"TGF-beta-specific T cells are frequent in peripheral blood and bone-marrow from patients with myeloproliferative neoplasms.","journal":"Leukemia","issue":"2025 November 10. doi: 10.1038\/s41375-025-02798-x. Online ahead of print","author":"Lisle TL, Holmstrom MO, Penco MP, Ruders JH, Riley CH, Grauslund JH, Jensen EB, Sorensen AL, Skov V, Kjaer L, Hasselbalch H, Andersen MH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214139"},{"title01":"Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL.","title02":"Loss of KDEL function from a calreticulin frameshift mutation drives expression of an immature, mutant calreticulin-dependent form of the thrombopoietin receptor MPL.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.287585. Online ahead of print","author":"Masubuchi N, Yang Y, Imai M, Kihara Y, Morishita S, Edahiro Y, Komatsu N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195513"},{"title01":"A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of JAK2V617F-induced polycythemia vera.","title02":"A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2<\/i>V617F-induced polycythemia vera.","journal":"Haematologica","issue":"2025 November 1; 110(11):2702-2713. doi: 10.3324\/haematol.2024.287186","author":"Shan Y, DeSouza N, Littman N, Qiu Q, Nguyen K, Yu Y, Mohi G, Li S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468940"},{"title01":"Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.","title02":"Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.","journal":"Haematologica","issue":"2025 November 1; 110(11):2691-701. doi: 10.3324\/haematol.2024.286123","author":"Yu D, Zhang H, Song Y, Tao Y, Zhou F, Wang Z, Fu R, Sun T, Dong H, Gu W, Yang R, Xiao Z, Sun Q, Zhang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501395"},{"title01":"Seeing something new or with new eyes?","title02":"Seeing something new or with new eyes?","journal":"Br J Haematol","issue":"2025 November; 207(5):2231-2232. doi: 10.1111\/bjh.70140","author":"Hills RK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916555"},{"title01":"Seeing something new or with new eyes?","title02":"Seeing something new or with new eyes?","journal":"Br J Haematol","issue":"2025 November; 207(5):2231-2232. doi: 10.1111\/bjh.70140","author":"Hills RK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916555"},{"title01":"Reconsidering &#8216;primary myelofibrosis with increased haemoglobin&#8217; within the myeloproliferative neoplasms biological continuum.","title02":"Reconsidering &#8216;primary myelofibrosis with increased haemoglobin&#8217; within the myeloproliferative neoplasms biological continuum.","journal":"Br J Haematol","issue":"2025 November; 207(5):2226-2227. doi: 10.1111\/bjh.70103","author":"Hasselbalch HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40856246"},{"title01":"Improved outcomes in primary myelofibrosis patients with increased haemoglobin concentration.","title02":"Improved outcomes in primary myelofibrosis patients with increased haemoglobin concentration.","journal":"Br J Haematol","issue":"2025 November; 207(5):2224-2225. doi: 10.1111\/bjh.70062","author":"Krecak I, Lucijanic M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40741924"},{"title01":"Primary myelofibrosis with increased haemoglobin concentration at presentation.","title02":"Primary myelofibrosis with increased haemoglobin concentration at presentation.","journal":"Br J Haematol","issue":"2025 November; 207(5):1930-1937. doi: 10.1111\/bjh.20233","author":"Barosi G, Campanelli R, Catarsi P, Abba C, Carolei A, Massa M, De Silvestri A, Gale RP, Rosti V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40551505"},{"title01":"Hypoxia-inducible Factors Contribute to Venous Thrombosis in a Mouse Model of Myeloproliferative Neoplasms.","title02":"Hypoxia-inducible Factors Contribute to Venous Thrombosis in a Mouse Model of Myeloproliferative Neoplasms.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2025016344. Online ahead of print","author":"Ghosh S, Miklosz J, Trebak F, Tourn J, Grover SP, Pawlinski R, Reeves BN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191539"},{"title01":"Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.","title02":"Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.","journal":"Blood advances","issue":"2025 November 11; 9(21):5598-5609. doi: 10.1182\/bloodadvances.2025016898","author":"Fiskus W, Masarova L, Mill CP, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Torngren M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829105"},{"title01":"HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology.","title02":"HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology.","journal":"Blood","issue":"2025 November 13; 146(20):2428-2442. doi: 10.1182\/blood.2024027125","author":"Bonal DM, Oakes A, Chorzalska A, Pardo M, Petersen M, Clarke MY, Lee SH, Olszewski AJ, Treaba DO, Reagan JL, Dooner M, Morgan J, Bertone P, Zhao TC, Yang W, Ventetuolo CE, Hobbs GS, Mills J, Dubielecka PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40729727"},{"title01":"Hijack the HiJAKer: rethinking therapy for JAK2-mutant MPN.","title02":"Hijack the HiJAKer: rethinking therapy for JAK2-mutant MPN.","journal":"Blood","issue":"2025 November 13; 146(20):2377-2378. doi: 10.1182\/blood.2025030551","author":"Zenke M, Koschmieder S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41231464"},{"title01":"Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome.","title02":"Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome.","journal":"Leukemia","issue":"2025 November; 39(11):2820-2824. doi: 10.1038\/s41375-025-02760-x","author":"Bazinet A, Montalban-Bravo G, Bataller A, Hammond D, Loghavi S, Chien K, Sasaki K, Bouligny I, Swaminathan M, Jen WY, Popat U, Kadia T, DiNardo C, Jabbour E, Short N, Daver N, Ravandi F, Garcia-Manero G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40913105"},{"title01":"SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.","title02":"SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.","journal":"Leukemia","issue":"2025 November; 39(11):2801-2811. doi: 10.1038\/s41375-025-02740-1","author":"Thier J, Hofmann S, Kirchhof KM, Todisco G, Mortera-Blanco T, Lilienthal I, Kanellis DC, Barbosa I, Bjorklund AC, Deslauriers AG, Bartek J, Herold N, Papaemmanuil E, Papapetrou EP, Hellstrom-Lindberg E, Moura PL, Lundin V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858805"},{"title01":"Unraveling the impact of crizotinib to promote megakaryopoiesis for alleviating thrombocytopenia in myelodysplastic neoplasms.","title02":"Unraveling the impact of crizotinib to promote megakaryopoiesis for alleviating thrombocytopenia in myelodysplastic neoplasms.","journal":"Leukemia","issue":"2025 November; 39(11):2789-2800. doi: 10.1038\/s41375-025-02729-w","author":"Kobayashi H, Komizo Y, Watanabe N, Miyata Y, Ohnuma Y, Kamimura-Aoyagi Y, Yuki K, Hayashi Y, Yoshida M, Harada Y, Harada H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40813622"},{"title01":"Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.","title02":"Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.","journal":"Leukemia","issue":"2025 November; 39(11):2767-2778. doi: 10.1038\/s41375-025-02727-y","author":"Ford BL, Jokinen E, Huuhtanen J, Forsten S, Klievink J, Antignani G, Bruck O, Cerullo V, Peltonen K, Mustjoki S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40847198"},{"title01":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","title02":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e887-e897. doi: 10.1016\/S2352-3026(25)00254-6","author":"Richard-Carpentier G, Gupta G, Koraksic C, Cathelin S, Wang L, Bankar A, Davidson M, Gupta V, Maze D, Minden MD, Murphy T, Schimmer AD, Schuh AC, Sibai H, Yee K, DiNardo CD, Brandwein J, McNamara CJ, Chan SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41075807"},{"title01":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","title02":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e887-e897. doi: 10.1016\/S2352-3026(25)00254-6","author":"Richard-Carpentier G, Gupta G, Koraksic C, Cathelin S, Wang L, Bankar A, Davidson M, Gupta V, Maze D, Minden MD, Murphy T, Schimmer AD, Schuh AC, Sibai H, Yee K, DiNardo CD, Brandwein J, McNamara CJ, Chan SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41075807"},{"title01":"New hope, old challenges in myelodysplastic syndromes.","title02":"New hope, old challenges in myelodysplastic syndromes.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e851. doi: 10.1016\/S2352-3026(25)00292-3","author":"The Lancet Haematology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201525"},{"title01":"New hope, old challenges in myelodysplastic syndromes.","title02":"New hope, old challenges in myelodysplastic syndromes.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e851. doi: 10.1016\/S2352-3026(25)00292-3","author":"The Lancet Haematology","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201525"},{"title01":"Correspondence to &#8220;Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis&#8221;.","title02":"Correspondence to &#8220;Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis&#8221;.","journal":"Leukemia","issue":"2025 November 12. doi: 10.1038\/s41375-025-02812-2. Online ahead of print","author":"Zheng H, Zhang L, Li L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41225181"},{"title01":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","title02":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","journal":"Haematologica","issue":"2025 November 1; 110(11):2871-2872. doi: 10.3324\/haematol.2025.288047","author":"Ince E, Galimard JE, Ifversen M, Dalissier A, Szmit Z, Mirci-Danicar O, Locatelli F, Sedlacek P, Styczynski J, Dalle JH, Renard C, Balduzzi A, Lankester A, Bierings M, Fagioli F, Kielsen K, Rialland F, Buechner J, Taskinen M, Wynn R, Jubert C, Michel G, Pichler H, Krivan G, Cesaro S, Corbacioglu S, Meisel R, Kalwak K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178440"},{"title01":"Response to Comment on: &#8220;A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma&#8221;.","title02":"Response to Comment on: &#8220;A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma&#8221;.","journal":"Haematologica","issue":"2025 November 1; 110(11):2866-2867. doi: 10.3324\/haematol.2025.288284","author":"Lia K, Jorgensen RRK, Wikman P, Wold BL, Overgaard N, Fluge O, Fagerli UM, Bersvendsen H, Bo IB, Bhargava S, Molin D, Fossa A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501391"},{"title01":"When &#8216;simplified&#8217; may be oversimplified: reassessing frailty scoring in elderly Hodgkin lymphoma. Comment on: &#8220;A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma&#8221;.","title02":"When &#8216;simplified&#8217; may be oversimplified: reassessing frailty scoring in elderly Hodgkin lymphoma. Comment on: &#8220;A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma&#8221;.","journal":"Haematologica","issue":"2025 November 1; 110(11):2864-2865. doi: 10.3324\/haematol.2025.288186","author":"Huang K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468946"},{"title01":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","title02":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","journal":"Haematologica","issue":"2025 November 1; 110(11):2871-2872. doi: 10.3324\/haematol.2025.288047","author":"Ince E, Galimard JE, Ifversen M, Dalissier A, Szmit Z, Mirci-Danicar O, Locatelli F, Sedlacek P, Styczynski J, Dalle JH, Renard C, Balduzzi A, Lankester A, Bierings M, Fagioli F, Kielsen K, Rialland F, Buechner J, Taskinen M, Wynn R, Jubert C, Michel G, Pichler H, Krivan G, Cesaro S, Corbacioglu S, Meisel R, Kalwak K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178440"},{"title01":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","title02":"Erratum to: &#8220;Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study&#8221;.","journal":"Haematologica","issue":"2025 November 1; 110(11):2871-2872. doi: 10.3324\/haematol.2025.288047","author":"Ince E, Galimard JE, Ifversen M, Dalissier A, Szmit Z, Mirci-Danicar O, Locatelli F, Sedlacek P, Styczynski J, Dalle JH, Renard C, Balduzzi A, Lankester A, Bierings M, Fagioli F, Kielsen K, Rialland F, Buechner J, Taskinen M, Wynn R, Jubert C, Michel G, Pichler H, Krivan G, Cesaro S, Corbacioglu S, Meisel R, Kalwak K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178440"},{"title01":"Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).","title02":"Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).","journal":"Br J Haematol","issue":"2025 November; 207(5):1815-1831. doi: 10.1111\/bjh.70074","author":"Tsai XC, Yao ZH, Chou SW, Hu HC, Liu YC, Chen CH, Yeh SP, Huang WC, Lin TL, Yang TM, Lai CH, Ko HK, Kuo YW, Hsu HH, Cheng SL, Li CC, Ko BS, Wang HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926299"},{"title01":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation.","title02":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2187-2191. doi: 10.1111\/bjh.70142","author":"Hino A, Kusakabe S, Oka K, Kudo H, Ariyoshi T, Hayashi A, Takahashi M, Onizuka M, Takeda K, Mori M, Hosen N, Fukushima K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916567"},{"title01":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","title02":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1938-1943. doi: 10.1111\/bjh.70106","author":"Meyer JA, Xirenayi S, Werner J, Turakulov R, Hechmer A, Abdullaev Z, Hamdy N, Olshen A, Stieglitz E, Hammad M, Elhaddad A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887320"},{"title01":"Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.","title02":"Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.","journal":"Br J Haematol","issue":"2025 November; 207(5):1874-1882. doi: 10.1111\/bjh.70146","author":"Rodriguez-Rodriguez S, Desai N, Chen C, Jamani K, Sohier-Poirier C, Lemieux C, White J, Elemary M, Kennah M, Alfaro Moya T, Al-Shaibani E, Novitzky-Basso I, Pasic I, Law AD, Michelis FV, Viswabandya A, Kumar R, Mattsson J, Kim DDH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947302"},{"title01":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation.","title02":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2017-2025. doi: 10.1111\/bjh.70105","author":"Pei XY, Yin XY, Sun HL, Zhao ZF, Ma L, Wei FF, Zhao XS, Zhang YY, Sun YQ, Mo XD, Wang Y, Xu LP, Zhang XH, Huang XJ, Lv M, Zhao XY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903398"},{"title01":"Phosphorylation at Y317 on Syk negatively regulates both ITAM- and hemITAM-mediated signaling and function in platelets.","title02":"Phosphorylation at Y317 on Syk negatively regulates both ITAM- and hemITAM-mediated signaling and function in platelets.","journal":"Blood advances","issue":"2025 November 11; 9(21):5626-5637. doi: 10.1182\/bloodadvances.2025016714","author":"Elzoheiry MA, Dangelmaier CA, Vajipayajula DN, Wright MN, Tsygankov AY, Kunapuli SP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40779559"},{"title01":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.","title02":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.","journal":"N Engl J Med","issue":"2025 November 13; 393(19):1912-1925. doi: 10.1056\/NEJMoa2511734","author":"Cortes J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, Tokunaga E, Brufsky A, Park YH, Xu B, Hegg R, Oliveira M, Fabi A, Vaksman N, Valdez T, Zhang X, Lai C, Tolaney SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41124233"},{"title01":"Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.","title02":"Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.","journal":"Lancet Oncol","issue":"2025 November 4. doi: 10.1016\/S1470-2045(25)00605-9. Online ahead of print","author":"Kim S, Boustani J, Iseas S, Vernerey D, Evesque L, Quero L, Ghiringhelli F, Coutzac C, Bouche O, Chibaudel B, Vernet C, Vienot A, Tougeron D, Nguyen T, Rebucci-Peixoto M, Meurisse A, Chennoufi S, Maritaz C, Borg C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41202834"},{"title01":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.","title02":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.","journal":"Lancet Oncol","issue":"2025 November; 26(11):1489-1500. doi: 10.1016\/S1470-2045(25)00475-9","author":"Smith M, Piulats J, Todenhofer T, Lee JL, Arija JA, Mazilu L, Azad A, Alonso-Gordoa T, McGovern U, Choudhury A, Horvath L, Ye D, Han W, Suzuki H, Uemura H, McKay R, Ades S, Flechon A, Pieczonka C, Fernandes MS, Hulstijn M, Lithio A, Nacerddine K, Agarwal N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41167216"},{"title01":"Lutetium-177 [(177)Lu]Lu-PSMA-I&#038;T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1\/2 trial.","title02":"Lutetium-177 [(177)Lu]Lu-PSMA-I&#038;T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1\/2 trial.","journal":"Lancet Oncol","issue":"2025 November; 26(11):1479-1488. doi: 10.1016\/S1470-2045(25)00559-5","author":"Kostos L, Buteau JP, Xie J, Cardin A, Akhurst T, Alipour R, Au L, Chan J, Chin KY, Emmerson B, Furic L, Garcia Q, Hamilton AJ, Haskali MB, Jackson PA, Kashyap RK, Kong G, MacFarlane L, Murphy DG, Parker BS, Ravi Kumar AS, Saghebi J, Wang Y, Tran B, Azad AA, Hofman MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41119954"},{"title01":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.","title02":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.","journal":"Lancet","issue":"2025 November 8; 406(10516):2235-2243. doi: 10.1016\/S0140-6736(25)01954-3","author":"Yang Y, Zhou H, Tang L, Qiu S, Han Y, Ji D, Chen X, Lei F, Qu S, Deng B, Chen L, Huang J, Guo Y, Liu Z, Chen D, Li J, Shu X, Qin Y, Fu Z, Li B, Zhang P, Chen S, Hong J, Wei Y, Qin X, Qu S, Yang K, Lin D, Wang J, Yang L, Xiao S, Zhu H, Zhu Y, Zhang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41125110"},{"title01":"Efficacy and safety of REGN9933(A2) and REGN7508(Cat) for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.","title02":"Efficacy and safety of REGN9933(A2) and REGN7508(Cat) for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.","journal":"Lancet","issue":"2025 November 8. doi: 10.1016\/S0140-6736(25)02097-5. Online ahead of print","author":"Weitz JI, Kithcart AP, O'Brien MP, Levy O, Marin E, Onisko M, Mohammadi KA, Li D, Meagher KA, Chang HH, Olenchock BA, Gutstein DE, Segers A, Roberts RS, Bonaca MP, Raskob GE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41218619"},{"title01":"Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.","title02":"Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.","journal":"J Clin Oncol","issue":"2025 November 10; 43(32):3505-3515. doi: 10.1200\/JCO-25-00109","author":"Bian X, Yang T, Yin H, Hu B, Yao K, Jiang S, Chen Y, Lin J, Cao M, Liu N, Fu B, Hu C, Sun Z, Qin Y, Wang X, Yu Z, Zhang Q, Zhang X, Zhu Y, Zhu H, Xiao S, Ye D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41061200"},{"title01":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.","title02":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.","journal":"J Clin Oncol","issue":"2025 November 4; JCO2500872. doi: 10.1200\/JCO-25-00872. Online ahead of print","author":"Hammel P, Metges JP, Macarulla Mercade T, Garcia-Carbonero R, Bouche O, Portales F, Pazo Cid RA, Mineur L, Cubillo Gracian A, Trouilloud I, Guimbaud R, Tougeron D, Reina JJ, Feliu J, Sauri T, Fountzilas C, Lecomte T, Molin Y, Ponz-Sarvise M, Forget F, Berardi R, Van Cutsem E, Gelsomino F, Tournigand C, Bockorny B, Bachet JB, Marin Vera M, Cuyle PJ, Wasan H, Noel M, Van Laethem JL, Kay R, Youssoufian H, El-Hariry I, Hidalgo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41187298"},{"title01":"Myopathy, lactic acidosis and sideroblastic anemia syndrome 1 (MLASA1): clinical hallmarks in a large pedigree with a novel PUS1 R144Q mutation, remarkable response to somatropin, and review of the literature.","title02":"Myopathy, lactic acidosis and sideroblastic anemia syndrome 1 (MLASA1): clinical hallmarks in a large pedigree with a novel PUS1 R144Q mutation, remarkable response to somatropin, and review of the literature.","journal":"Haematologica","issue":"2025 November 1; 110(11):2819-2822. doi: 10.3324\/haematol.2025.287393","author":"Parisi L, Escher R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438980"},{"title01":"Optimizing CRISPR methodology for precise gene editing in the erythroid cell line BEL-A with high efficiency generation of a sickle cell anemia model.","title02":"Optimizing CRISPR methodology for precise gene editing in the erythroid cell line BEL-A with high efficiency generation of a sickle cell anemia model.","journal":"Haematologica","issue":"2025 November 1; 110(11):2806-2811. doi: 10.3324\/haematol.2024.287221","author":"Daniels DE, Hawksworth J, El Hoss S, Oyawoye FO, Ferrer-Vicens I, Wilson MC, Frayne J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40207730"},{"title01":"Systematic point-of-care newborn screening for sickle cell disease in rural Mali, West Africa.","title02":"Systematic point-of-care newborn screening for sickle cell disease in rural Mali, West Africa.","journal":"Br J Haematol","issue":"2025 November; 207(5):2118-2122. doi: 10.1111\/bjh.70158","author":"Guindo A, Cablay K, Kamate J, MacLean B, Saye D, Dembele P, Anderson AR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41017254"},{"title01":"A structural deletion in the 3&#8217;UTR of SLC11A2 is associated with altered iron status: Evidence from two large Danish cohorts.","title02":"A structural deletion in the 3&#8217;UTR of SLC11A2 is associated with altered iron status: Evidence from two large Danish cohorts.","journal":"Br J Haematol","issue":"2025 November; 207(5):2123-2134. doi: 10.1111\/bjh.70210","author":"Brons N, Rigas AS, Kaspersen KA, Pedersen OB, Erikstrup C, Hansen TF, Sorensen E, Dowsett J, Mikkelsen C, Christoffersen LAN, Dinh KM, Bruun MT, Aagaard B, Frikke-Schmidt R, Bundgaard H, Ullum H, Glenthoj A, Ostrowski SR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41103144"},{"title01":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","title02":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):2059-2071. doi: 10.1111\/bjh.70133","author":"Wu L, Zhou M, Chen X, Mo W, Zhou R, Li Y, Wang C, Xu S, Yang F, Zhang Y, He X, Li X, Wang S, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947584"},{"title01":"&#8216;Raise the Bar&#8217;, a Canadian intervention to combat disparities in the recognition and management of iron deficiency: Development of the intervention, feasibility and implementation.","title02":"&#8216;Raise the Bar&#8217;, a Canadian intervention to combat disparities in the recognition and management of iron deficiency: Development of the intervention, feasibility and implementation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2219-2223. doi: 10.1111\/bjh.70150","author":"Tang GH, Phillips Z, Poutanen S, Yip P, Brinc D, Goh E, Cheung M, Pai M, Oleschuk C, Beriault D, Stefan C, Matukas L, Good D, Weyand A, Baker J, Crowther M, Cogan J, White-AlHabeeb N, Mohammed-Ali Z, Wozniak M, Nyholt D, Nagarajah S, Bekdache C, Li H, Ghaffar H, Veljkovic K, Uddayasankar U, Sepiashvili L, Catomeris P, Selby R, Sholzberg M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40936490"},{"title01":"Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study.","title02":"Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study.","journal":"Br J Haematol","issue":"2025 November; 207(5):2192-2195. doi: 10.1111\/bjh.70138","author":"Jiang D, Fogerty AE, Kuter DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40922594"},{"title01":"Short-term risks and benefits of hydroxyurea (hydroxycarbamide)-induced transfusion independence in patients with beta-thalassaemia syndromes.","title02":"Short-term risks and benefits of hydroxyurea (hydroxycarbamide)-induced transfusion independence in patients with beta-thalassaemia syndromes.","journal":"Br J Haematol","issue":"2025 November; 207(5):2196-2199. doi: 10.1111\/bjh.70109","author":"Sevanthini BR, Hegde S, Sridhar T, Trivedi D, Reddy M, Shah V, Panchamia VM, Geetha T, Vora D, Pushpa H, Agarwal RK, Faulkner L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40884002"},{"title01":"Inflammatory cytokine profile in patients with sickle cell anaemia and leg ulcers.","title02":"Inflammatory cytokine profile in patients with sickle cell anaemia and leg ulcers.","journal":"Br J Haematol","issue":"2025 November 3. doi: 10.1111\/bjh.70236. Online ahead of print","author":"Diniz MV, Silva AP, Arcanjo GS, Batista THC, Rodrigues JVS, Rego MJBM, Leao HI, Silva RC, Souto FO, Melo CML, Barros BRS, Anjos ACM, Araujo AS, Domingos IF, Saad STO, Costa FF, Lucena-Araujo AR, Bezerra MAC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178469"},{"title01":"Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion.","title02":"Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion.","journal":"Blood","issue":"2025 November 13; 146(20):2385-2391. doi: 10.1182\/blood.2025029964","author":"Wilks A, Steinberg MH, Frangoul H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40834880"},{"title01":"Risk of cancer in adults with primary immune thrombocytopenia: a binational population-based realworld cohort study from Denmark and France.","title02":"Risk of cancer in adults with primary immune thrombocytopenia: a binational population-based realworld cohort study from Denmark and France.","journal":"Haematologica","issue":"2025 November 1; 110(11):2764-2773. doi: 10.3324\/haematol.2025.287330","author":"Mannering N, Zadro Y, Hansen DL, Maquet J, Lafaurie M, Pottegard A, Moulis G, Frederiksen H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400464"},{"title01":"Predictors of response to emergent therapies in paediatric immune thrombocytopenia.","title02":"Predictors of response to emergent therapies in paediatric immune thrombocytopenia.","journal":"Br J Haematol","issue":"2025 November; 207(5):2091-2098. doi: 10.1111\/bjh.70064","author":"O'Farrell C, Luckie TM, Willis MJ, Kirk SE, Lucari BR, Scheurer ME, Gao X, Grimes AB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40762147"},{"title01":"Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study.","title02":"Evans syndrome in pregnancy and the postpartum period: A retrospective cohort study.","journal":"Br J Haematol","issue":"2025 November; 207(5):2192-2195. doi: 10.1111\/bjh.70138","author":"Jiang D, Fogerty AE, Kuter DJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40922594"},{"title01":"T cells in ITP: Focus on T follicular helper cells and cytotoxic T cells.","title02":"T cells in ITP: Focus on T follicular helper cells and cytotoxic T cells.","journal":"Br J Haematol","issue":"2025 November 4. doi: 10.1111\/bjh.70242. Online ahead of print","author":"Audia S, Cooper N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41187769"},{"title01":"Dysfunctional T cells due to the abnormal glucose metabolism in patients with primary immune thrombocytopenia.","title02":"Dysfunctional T cells due to the abnormal glucose metabolism in patients with primary immune thrombocytopenia.","journal":"Br J Haematol","issue":"2025 November 7. doi: 10.1111\/bjh.70229. Online ahead of print","author":"Tang M, Li B, Zhuang J, Zhan Y, Xie F, Ye H, Li Z, Pang W, Cheng Y, Ji L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201304"},{"title01":"Integrin alphavbeta8-mediated TGF-beta1 activation regulates sustained response in immune thrombocytopenia after TPO-RA withdrawal.","title02":"Integrin alphavbeta8-mediated TGF-beta1 activation regulates sustained response in immune thrombocytopenia after TPO-RA withdrawal.","journal":"Blood","issue":"2025 November 14. doi: 10.1182\/blood.2025029769. Online ahead of print","author":"Mei H, Xu M, Shu JJ, Tang L, Xie Q, Luo L, Wei Q, Jiang H, Ming Z, Hu Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237341"},{"title01":"Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.","title02":"Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.","journal":"Lancet Oncol","issue":"2025 November; 26(11):e586-e596. doi: 10.1016\/S1470-2045(25)00426-7","author":"Sanz J, Bug G, Ciceri F, Craddock C, Dillon R, Esteve J, Porta MGD, Heuser M, de Leeuw DC, Nagler A, Onida F, Roboz GJ, Ruggeri A, Sanchez-Ortega I, Srour M, Yakoub-Agha I, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41167226"},{"title01":"Perspectives of potential haematopoietic stem-cell donors on education TikToks.","title02":"Perspectives of potential haematopoietic stem-cell donors on education TikToks.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e859-e861. doi: 10.1016\/S2352-3026(25)00287-X","author":"Jian YC, Park B, Vijenthira S, Fingrut WB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41193115"},{"title01":"Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.","title02":"Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.","journal":"J Clin Oncol","issue":"2025 November; 43(31):3369-3380. doi: 10.1200\/JCO-25-00206","author":"Lee SJ, Logan B, Horowitz MM, Dehn JG, Pidala J, Grunwald MR, Westervelt P, Farhadfar N, Hogan WJ, Bashey A, Hayes-Lattin B, Hill L, Brunstein C, Arai S, Srour SA, Symons H, Uberti J, Vasu S, Pusic I, Juckett M, Leifer E, He N, Devine S, Shaw BE, Ciurea SO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966481"},{"title01":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","title02":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","journal":"Haematologica","issue":"2025 November 1; 110(11):2635-2646. doi: 10.3324\/haematol.2025.287433","author":"Webster JA, Reed M, Tsai HL, Imus PH, Smith DB, Ambinder AJ, Levis MJ, DeZern AE, Prince GT, Jain T, Bolanos-Meade J, Gondek LP, Ghiaur G, Dalton WB, Karantanos T, Paul S, Fuchs EJ, Sterling C, Swinnen LJ, Wagner-Johnston N, Ambinder RF, Gocke CB, Ali SA, Huff CA, Luznik L, Varadhan R, Jones RJ, Gojo I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336316"},{"title01":"Role of donor regulatory T cell adoptive immunotherapy in B cell immunity after hematopoietic cell transplantation.","title02":"Role of donor regulatory T cell adoptive immunotherapy in B cell immunity after hematopoietic cell transplantation.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2024.286905. Online ahead of print","author":"Piccinelli S, Limongello R, Viglione V, Hohxa E, Zei T, Ostini RI, Bigerna B, Tabarrini A, Sembenico R, Tricarico S, Zorutti F, Martelli MP, Carotti A, Martelli MF, Velardi A, Ruggeri L, Mancusi A, Pierini A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195519"},{"title01":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","title02":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.289076. Online ahead of print","author":"Koo J, Webster A, Lake KE, Luebbering N, Dandoy C, Jodele S, Ryan TD, Davies SM, Sabulski A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195509"},{"title01":"A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of JAK2V617F-induced polycythemia vera.","title02":"A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of <i>JAK2<\/i>V617F-induced polycythemia vera.","journal":"Haematologica","issue":"2025 November 1; 110(11):2702-2713. doi: 10.3324\/haematol.2024.287186","author":"Shan Y, DeSouza N, Littman N, Qiu Q, Nguyen K, Yu Y, Mohi G, Li S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468940"},{"title01":"Novel and emerging therapeutic strategies for clonal haematopoiesis.","title02":"Novel and emerging therapeutic strategies for clonal haematopoiesis.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.287443. Online ahead of print","author":"Hosseini M, Chan SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230698"},{"title01":"Contribution of genetics to hematopoietic stem cell mobilization: a genome-wide association study of 564 healthy donors mobilized with granulocyte colony-stimulating factor.","title02":"Contribution of genetics to hematopoietic stem cell mobilization: a genome-wide association study of 564 healthy donors mobilized with granulocyte colony-stimulating factor.","journal":"Haematologica","issue":"2025 November 1; 110(11):2683-2690. doi: 10.3324\/haematol.2025.287637","author":"Stenzinger M, Beck S, Ourailidis I, Volckmar AL, Paramasivam N, Ahadova A, Portilla ALL, La Yen P, Nilsson B, Bermejo JL, Bonig H, Budczies J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468967"},{"title01":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease.","title02":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease.","journal":"Br J Haematol","issue":"2025 November; 207(5):2183-2186. doi: 10.1111\/bjh.70119","author":"Iversen PO, Gedde-Dahl T, Tjonnfjord GE, Ali MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875520"},{"title01":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","title02":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70248. Online ahead of print","author":"Petracci E, Pavesi F, Castagna L, Zappasodi P, Papayannidis C, Vetro C, Federico V, Cignetti A, Borlenghi E, Fracchiolla N, Facchini L, Maurillo L, Audisio E, Bernardi M, Ferrara F, Lanza F, Selleri C, Manfra I, Cerchione C, Nanni J, Romagnoli AD, Marconi G, Zingaretti C, Lotesoriere I, Gigli F, Martinelli G, Todisco E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224500"},{"title01":"Chronic myelomonocytic leukaemia.","title02":"Chronic myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November 2. doi: 10.1111\/bjh.70226. Online ahead of print","author":"Tefferi A, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41177945"},{"title01":"A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.","title02":"A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2049-2058. doi: 10.1111\/bjh.70124","author":"Desai N, Rodriguez-Rodriguez S, Al-Shaibani E, Alfaro Moya T, Law AD, Novitzky-Basso I, Pasic I, Michelis FV, Kumar R, Kim DDH, Mattsson J, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40859738"},{"title01":"The epidemiological landscape of bloodstream infections in children undergoing chemotherapy or haematopoietic cell transplantation: A retrospective study by Infectious Diseases Working Group of Italian Association of Pediatric Hematology and Oncology (AIEOP).","title02":"The epidemiological landscape of bloodstream infections in children undergoing chemotherapy or haematopoietic cell transplantation: A retrospective study by Infectious Diseases Working Group of Italian Association of Pediatric Hematology and Oncology (AIEOP).","journal":"Br J Haematol","issue":"2025 November; 207(5):1982-1993. doi: 10.1111\/bjh.70036","author":"Baccelli F, Compagno F, Tridello G, Delle Cave F, Zama D, Masetti R, Petris MG, Chiusaroli L, Spadea M, Trevisan F, Colombini A, Conci S, Meazza C, Muggeo P, Micheletti MV, Pancaldi A, Mura R, Onofrillo D, De Santis R, La Spina M, Castagnola E, Perruccio K, Barone A, Giurici N, Petrone A, Mercolini F, Rinieri S, Cesaro S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40976850"},{"title01":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","title02":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","journal":"Br J Haematol","issue":"2025 November; 207(5):1912-1919. doi: 10.1111\/bjh.70085","author":"Rokkanen R, Aarnivala H, Huhtaniska S, Palmu S, Pokka T, Poyhonen T, Suo-Palosaari M, Utriainen P, Jarvela L, Niinimaki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781902"},{"title01":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI).","title02":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI).","journal":"Br J Haematol","issue":"2025 November; 207(5):1802-1814. doi: 10.1111\/bjh.70061","author":"Clark A, Clouston H, Rao K, Folarin N, De la Fuente J, Hamblin A, Olavarria E, Richardson D, Talley P, Potter V, Loke J, McVeigh T, Snowden J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926330"},{"title01":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","title02":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):2059-2071. doi: 10.1111\/bjh.70133","author":"Wu L, Zhou M, Chen X, Mo W, Zhou R, Li Y, Wang C, Xu S, Yang F, Zhang Y, He X, Li X, Wang S, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947584"},{"title01":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","title02":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2006-2016. doi: 10.1111\/bjh.70102","author":"Yu F, Yu X, Hu X, Jiang E, Zhou J, Lu Y, Zhu X, Wan J, Miao K, Fu Y, Niu J, Wan L, Zhou F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40856278"},{"title01":"Dynamic activity of Erg promotes maturation of the hematopoietic system.","title02":"Dynamic activity of Erg promotes maturation of the hematopoietic system.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2025017705. Online ahead of print","author":"Tanaka-Yano M, Sugden W, Wang D, Falchetti M, Badalamenti B, Cote P, Chin DH, Goldstein J, George S, Rodrigues-Luiz GF, Lummertz da Rocha E, Li H, North T, Gryder BE, Rowe RG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191516"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2024015191. Online ahead of print","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2024014831. Online ahead of print","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio LJ, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191542"},{"title01":"Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.","title02":"Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.","journal":"Blood advances","issue":"2025 November 11; 9(21):5528-5538. doi: 10.1182\/bloodadvances.2025016284","author":"Caballero-Velazquez T, Delgado Serrano J, Lopez-Corral L, Ferra-Coll C, Garcia-Calderon CB, Valcarcel D, Garcia-Cadenas I, Perez Lopez E, Jimenez Lorenzo MJ, Martin-Dominguez FM, Jimenez-Leon MLR, Orti G, Escamilla Gomez V, Blazquez-Goni C, Cabero Martinez A, Andrade Ruiz H, Menendez-Pedregal E, Sanchez-Guijo F, Perez Simon JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737543"},{"title01":"Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.","title02":"Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.","journal":"Blood advances","issue":"2025 November 11; 9(21):5489-5500. doi: 10.1182\/bloodadvances.2025016149","author":"Rangarajan HG, Satwani P, Herr MM, Chen M, Martens MJ, Wudhikarn K, John S, Fabrizio VA, Hsieh EM, Kelkar AH, Doherty E, Marks DI, Ringden O, Friend B, Kelly MS, Farhadfar N, Prestidge T, Hossain NM, Liu H, Hashmi S, Modi D, Winestone LE, El Boghdadly Z, Murthy HS, Perales MA, Chemaly RF, Dandoy CE, Hill JA, Huppler A, Riches M, Auletta JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737539"},{"title01":"Connexin the dots in hematopoietic stem cell potential.","title02":"Connexin the dots in hematopoietic stem cell potential.","journal":"Blood","issue":"2025 November 6; 146(19):2276-2277. doi: 10.1182\/blood.2025030225","author":"Luchsinger LL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41196622"},{"title01":"Dynamic rRNA Methylation Regulates Translation in the Hematopoietic System and is Essential for Stem Cell Fitness.","title02":"Dynamic rRNA Methylation Regulates Translation in the Hematopoietic System and is Essential for Stem Cell Fitness.","journal":"Blood","issue":"2025 November 5. doi: 10.1182\/blood.2024028300. Online ahead of print","author":"Rabany O, Ben Dror S, Arafat M, Aharoni Levitanus H, Halperin Y, Marchand V, Romanovski N, Ussishkin N, Livneh Golany M, Reches A, Wexler J, Mayorek N, Monderer-Rothkoff G, Shifman S, Mammer Bouhou W, VanInsberghe M, Pauli C, Muller-Tidow C, Karmi O, Livneh Y, van Oudenaarden A, Motorin Y, Nachmani D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191530"},{"title01":"Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy.","title02":"Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy.","journal":"Blood","issue":"2025 November 5. doi: 10.1182\/blood.2024027948. Online ahead of print","author":"Turkalj S, Radtke FA, Stoilova B, Mecklenbrauck R, Groom AJ, Jakobsen NA, Lachowiez CA, Metzner M, Usukhbayar B, Salazar MA, Zeng Z, Loghavi S, Marvin-Peek J, Korber V, Ravandi F, Issa GC, Kadia TM, Symeonidou V, de Groot AP, Kantarjian HM, Takahashi K, Konopleva M, DiNardo CD, Vyas P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191518"},{"title01":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.","title02":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.","journal":"Blood","issue":"2025 November 6; 146(19):2293-2305. doi: 10.1182\/blood.2025028730","author":"Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Muller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, Klein SA, Niederland J, Kaufmann M, Schafer-Eckart K, Baldauf H, Stolzel F, Trost S, Rollig C, von Bonin M, Egger-Heidrich K, Kunadt D, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Mikesch JH, Bornhauser M, Schetelig J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737595"},{"title01":"Metabolic adaptation of regenerative hematopoiesis depends on docking-independent mitochondrial connexin 43.","title02":"Metabolic adaptation of regenerative hematopoiesis depends on docking-independent mitochondrial connexin 43.","journal":"Blood","issue":"2025 November 6; 146(19):2306-2321. doi: 10.1182\/blood.2024028079","author":"Singh AK, D'Alessandro A, Wellendorf AM, Gonzalez-Nieto D, Kofron M, Dzieciatkowska M, Mejia L, Barrio LC, Filippi MD, Cancelas JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749168"},{"title01":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","title02":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2663-2672. doi: 10.1038\/s41375-025-02735-y","author":"Telzerow E, Gorlich D, Sauerland C, Rothenberg-Thurley M, Moret AS, Krauss SM, Mumm FHA, Amler S, Berdel WE, Wormann BJ, Krug U, Braess J, Heussner P, Hiddemann W, Spiekermann K, Metzeler KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40847197"},{"title01":"Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus Perdere.","title02":"Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus Perdere.","journal":"J Clin Oncol","issue":"2025 November; 43(31):3331-3333. doi: 10.1200\/JCO-25-01884","author":"Rambaldi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026968"},{"title01":"Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.","title02":"Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.","journal":"J Clin Oncol","issue":"2025 November; 43(31):3369-3380. doi: 10.1200\/JCO-25-00206","author":"Lee SJ, Logan B, Horowitz MM, Dehn JG, Pidala J, Grunwald MR, Westervelt P, Farhadfar N, Hogan WJ, Bashey A, Hayes-Lattin B, Hill L, Brunstein C, Arai S, Srour SA, Symons H, Uberti J, Vasu S, Pusic I, Juckett M, Leifer E, He N, Devine S, Shaw BE, Ciurea SO","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40966481"},{"title01":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","title02":"Proteomic analysis of pericardial effusions in hematopoietic stem cell transplant recipients.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.289076. Online ahead of print","author":"Koo J, Webster A, Lake KE, Luebbering N, Dandoy C, Jodele S, Ryan TD, Davies SM, Sabulski A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195509"},{"title01":"Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response.","title02":"Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response.","journal":"Haematologica","issue":"2025 November 1; 110(11):2752-2763. doi: 10.3324\/haematol.2025.287848","author":"Rees MJ, Geyer S, Yohannan B, Toumeh N, Atallah-Yunes SA, Gertz MA, Dispenzieri A, Hayman SR, Buadi F, Dingli D, Warsame R, Kapoor P, Grogan M, Cook J, Binder M, Leung N, Kourelis T, Gonsalves W, Rajkumar VS, Kumar S, Muchtar E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400470"},{"title01":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","title02":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","journal":"Haematologica","issue":"2025 November 1; 110(11):2635-2646. doi: 10.3324\/haematol.2025.287433","author":"Webster JA, Reed M, Tsai HL, Imus PH, Smith DB, Ambinder AJ, Levis MJ, DeZern AE, Prince GT, Jain T, Bolanos-Meade J, Gondek LP, Ghiaur G, Dalton WB, Karantanos T, Paul S, Fuchs EJ, Sterling C, Swinnen LJ, Wagner-Johnston N, Ambinder RF, Gocke CB, Ali SA, Huff CA, Luznik L, Varadhan R, Jones RJ, Gojo I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336316"},{"title01":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.","title02":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.","journal":"Haematologica","issue":"2025 November 1; 110(11):2827-2833. doi: 10.3324\/haematol.2025.287485","author":"De Groot FA, Stedema FG, Kret EJ, De Haan LM, Jansen PM, Bohringer S, Diepstra A, Van der Poel MWM, Hamid MA, Te Boome LCJ, Terpstra V, Brink M, Veelken H, De Groen RAL, Dekker TJA, Nijland M, Vermaat JSP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438976"},{"title01":"Contribution of genetics to hematopoietic stem cell mobilization: a genome-wide association study of 564 healthy donors mobilized with granulocyte colony-stimulating factor.","title02":"Contribution of genetics to hematopoietic stem cell mobilization: a genome-wide association study of 564 healthy donors mobilized with granulocyte colony-stimulating factor.","journal":"Haematologica","issue":"2025 November 1; 110(11):2683-2690. doi: 10.3324\/haematol.2025.287637","author":"Stenzinger M, Beck S, Ourailidis I, Volckmar AL, Paramasivam N, Ahadova A, Portilla ALL, La Yen P, Nilsson B, Bermejo JL, Bonig H, Budczies J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468967"},{"title01":"Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.","title02":"Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.","journal":"Haematologica","issue":"2025 November 1; 110(11):2691-701. doi: 10.3324\/haematol.2024.286123","author":"Yu D, Zhang H, Song Y, Tao Y, Zhou F, Wang Z, Fu R, Sun T, Dong H, Gu W, Yang R, Xiao Z, Sun Q, Zhang L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501395"},{"title01":"Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.","title02":"Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2041-2048. doi: 10.1111\/bjh.70101","author":"Shimoni A, Peczynski C, Labopin M, Dominietto A, Koc M, Arat M, Tischer J, Sica S, Gulbas Z, Socie G, Blaise D, Pioltelli P, Ozdogu H, Vydra J, Ciceri F, Nagler A, Mohty M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40810334"},{"title01":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","title02":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor\/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):2059-2071. doi: 10.1111\/bjh.70133","author":"Wu L, Zhou M, Chen X, Mo W, Zhou R, Li Y, Wang C, Xu S, Yang F, Zhang Y, He X, Li X, Wang S, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947584"},{"title01":"Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.","title02":"Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.","journal":"Br J Haematol","issue":"2025 November; 207(5):1874-1882. doi: 10.1111\/bjh.70146","author":"Rodriguez-Rodriguez S, Desai N, Chen C, Jamani K, Sohier-Poirier C, Lemieux C, White J, Elemary M, Kennah M, Alfaro Moya T, Al-Shaibani E, Novitzky-Basso I, Pasic I, Law AD, Michelis FV, Viswabandya A, Kumar R, Mattsson J, Kim DDH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40947302"},{"title01":"Adoptive transfer of third-party donor CMV-specific T cells for refractory cytomegalovirus infection following umbilical cord blood transplantation.","title02":"Adoptive transfer of third-party donor CMV-specific T cells for refractory cytomegalovirus infection following umbilical cord blood transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2072-2079. doi: 10.1111\/bjh.70136","author":"Sun G, Tu J, Tang B, Lu Z, Fang X, Liu H, Han Y, Sun Z, Zheng C, Zhu X, Tong J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931393"},{"title01":"Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan.","title02":"Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan.","journal":"Br J Haematol","issue":"2025 November; 207(5):2026-2040. doi: 10.1111\/bjh.70099","author":"Konuma T, Kanda J, Uchida N, Tanaka M, Kimura F, Nakasone H, Uehara Y, Tokunaga M, Toyosaki M, Miyakoshi S, Doki N, Ishiwata K, Kobayashi H, Onishi Y, Kozai Y, Kato K, Ishimaru F, Fukuda T, Atsuta Y, Takahashi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40817823"},{"title01":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI).","title02":"UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI).","journal":"Br J Haematol","issue":"2025 November; 207(5):1802-1814. doi: 10.1111\/bjh.70061","author":"Clark A, Clouston H, Rao K, Folarin N, De la Fuente J, Hamblin A, Olavarria E, Richardson D, Talley P, Potter V, Loke J, McVeigh T, Snowden J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926330"},{"title01":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation.","title02":"Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2187-2191. doi: 10.1111\/bjh.70142","author":"Hino A, Kusakabe S, Oka K, Kudo H, Ariyoshi T, Hayashi A, Takahashi M, Onizuka M, Takeda K, Mori M, Hosen N, Fukushima K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916567"},{"title01":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation.","title02":"The clinical features, risk factors and outcomes of polyomavirus encephalitis after allogeneic haematological stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2017-2025. doi: 10.1111\/bjh.70105","author":"Pei XY, Yin XY, Sun HL, Zhao ZF, Ma L, Wei FF, Zhao XS, Zhang YY, Sun YQ, Mo XD, Wang Y, Xu LP, Zhang XH, Huang XJ, Lv M, Zhao XY","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903398"},{"title01":"Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas.","title02":"Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas.","journal":"Br J Haematol","issue":"2025 November; 207(5):2178-2182. doi: 10.1111\/bjh.70132","author":"Montes L, Choquet S, Uzunov M, Morel V, Baron M, Roos-Weil D, Joris M, Delette C, Lebon D, Azar N, Metz C, Nichelli L, Le Garff-Tavernier M, Boccon-Gibod C, Lacan C, Souchet L, Hoang-Xuan K, Soussain C, Boussen I, Houillier C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887743"},{"title01":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","title02":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1938-1943. doi: 10.1111\/bjh.70106","author":"Meyer JA, Xirenayi S, Werner J, Turakulov R, Hechmer A, Abdullaev Z, Hamdy N, Olshen A, Stieglitz E, Hammad M, Elhaddad A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887320"},{"title01":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease.","title02":"Quality of life the first year after allogeneic haematopoietic stem cell transplantation-A randomized controlled trial examining extracorporeal photophoresis to prevent graft-versus-host disease.","journal":"Br J Haematol","issue":"2025 November; 207(5):2183-2186. doi: 10.1111\/bjh.70119","author":"Iversen PO, Gedde-Dahl T, Tjonnfjord GE, Ali MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40875520"},{"title01":"A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.","title02":"A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2049-2058. doi: 10.1111\/bjh.70124","author":"Desai N, Rodriguez-Rodriguez S, Al-Shaibani E, Alfaro Moya T, Law AD, Novitzky-Basso I, Pasic I, Michelis FV, Kumar R, Kim DDH, Mattsson J, Viswabandya A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40859738"},{"title01":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","title02":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2006-2016. doi: 10.1111\/bjh.70102","author":"Yu F, Yu X, Hu X, Jiang E, Zhou J, Lu Y, Zhu X, Wan J, Miao K, Fu Y, Niu J, Wan L, Zhou F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40856278"},{"title01":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","title02":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","journal":"Br J Haematol","issue":"2025 November; 207(5):1912-1919. doi: 10.1111\/bjh.70085","author":"Rokkanen R, Aarnivala H, Huhtaniska S, Palmu S, Pokka T, Poyhonen T, Suo-Palosaari M, Utriainen P, Jarvela L, Niinimaki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781902"},{"title01":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","title02":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70248. Online ahead of print","author":"Petracci E, Pavesi F, Castagna L, Zappasodi P, Papayannidis C, Vetro C, Federico V, Cignetti A, Borlenghi E, Fracchiolla N, Facchini L, Maurillo L, Audisio E, Bernardi M, Ferrara F, Lanza F, Selleri C, Manfra I, Cerchione C, Nanni J, Romagnoli AD, Marconi G, Zingaretti C, Lotesoriere I, Gigli F, Martinelli G, Todisco E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224500"},{"title01":"Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.","title02":"Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.","journal":"Blood advances","issue":"2025 November 11; 9(21):5528-5538. doi: 10.1182\/bloodadvances.2025016284","author":"Caballero-Velazquez T, Delgado Serrano J, Lopez-Corral L, Ferra-Coll C, Garcia-Calderon CB, Valcarcel D, Garcia-Cadenas I, Perez Lopez E, Jimenez Lorenzo MJ, Martin-Dominguez FM, Jimenez-Leon MLR, Orti G, Escamilla Gomez V, Blazquez-Goni C, Cabero Martinez A, Andrade Ruiz H, Menendez-Pedregal E, Sanchez-Guijo F, Perez Simon JA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737543"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2024014831. Online ahead of print","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio LJ, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191542"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2024015191. Online ahead of print","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology.","title02":"HiJAKing the hematopoietic system: a low-frequency JAK2V617F clone drives myeloproliferative neoplasm pathology.","journal":"Blood","issue":"2025 November 13; 146(20):2428-2442. doi: 10.1182\/blood.2024027125","author":"Bonal DM, Oakes A, Chorzalska A, Pardo M, Petersen M, Clarke MY, Lee SH, Olszewski AJ, Treaba DO, Reagan JL, Dooner M, Morgan J, Bertone P, Zhao TC, Yang W, Ventetuolo CE, Hobbs GS, Mills J, Dubielecka PM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40729727"},{"title01":"SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.","title02":"SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.","journal":"Leukemia","issue":"2025 November; 39(11):2801-2811. doi: 10.1038\/s41375-025-02740-1","author":"Thier J, Hofmann S, Kirchhof KM, Todisco G, Mortera-Blanco T, Lilienthal I, Kanellis DC, Barbosa I, Bjorklund AC, Deslauriers AG, Bartek J, Herold N, Papaemmanuil E, Papapetrou EP, Hellstrom-Lindberg E, Moura PL, Lundin V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858805"},{"title01":"Publisher Correction: Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission.","title02":"Publisher Correction: Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission.","journal":"Leukemia","issue":"2025 November; 39(11):2833. doi: 10.1038\/s41375-025-02786-1","author":"Wang X, Ramdas B, Kumar R, Zhang J, Kapur R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41083681"},{"title01":"Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission.","title02":"Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission.","journal":"Leukemia","issue":"2025 November; 39(11):2825-2829. doi: 10.1038\/s41375-025-02770-9","author":"Wang X, Ramdas B, Kumar R, Zhang J, Kapur R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40958034"},{"title01":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","title02":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","journal":"Leukemia","issue":"2025 November; 39(11):2745-2757. doi: 10.1038\/s41375-025-02737-w","author":"Zimolova V, Burocziova M, Berkova L, Grusanovic S, Gursky J, Janotka L, Kasparek P, Pecinova A, Kundrat D, Hrckulak D, Onhajzer J, Jeziskova I, Nekvindova L, Weinbergerova B, Pospisilova S, Doubek M, Alberich-Jorda M, Korinek V, Divoky V, Lanikova L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40841769"},{"title01":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","title02":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2663-2672. doi: 10.1038\/s41375-025-02735-y","author":"Telzerow E, Gorlich D, Sauerland C, Rothenberg-Thurley M, Moret AS, Krauss SM, Mumm FHA, Amler S, Berdel WE, Wormann BJ, Krug U, Braess J, Heussner P, Hiddemann W, Spiekermann K, Metzeler KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40847197"},{"title01":"Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan.","title02":"Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan.","journal":"Br J Haematol","issue":"2025 November; 207(5):2026-2040. doi: 10.1111\/bjh.70099","author":"Konuma T, Kanda J, Uchida N, Tanaka M, Kimura F, Nakasone H, Uehara Y, Tokunaga M, Toyosaki M, Miyakoshi S, Doki N, Ishiwata K, Kobayashi H, Onishi Y, Kozai Y, Kato K, Ishimaru F, Fukuda T, Atsuta Y, Takahashi S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40817823"},{"title01":"Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019.","title02":"Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2025017752. Online ahead of print","author":"Luo Z, Li M, Primeaux B, Shah R, Lin R, Iyer SP, Nastoupil LJ, Green MR, Westin JR, Flowers CR, Chihara D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201381"},{"title01":"Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.","title02":"Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.","journal":"Blood advances","issue":"2025 November 11; 9(21):5654-5662. doi: 10.1182\/bloodadvances.2025016315","author":"Epstein-Peterson ZD, Lionel AC, Joseph A, Drill E, Atallah-Yunes SA, Brooks TR, Chong EA, Chong ER, Dela Cruz J, Frank MJ, Ip A, Iqbal M, Jacobson CA, Kamdar MK, Karmali R, Beyar-Katz O, Maddocks KJ, Matasar MJ, McLoughlin D, Merryman RW, Munoz JL, Navalekar R, Rhodes J, Riedell PA, Ryan CE, Salles G, Sauter CS, Sawalha Y, Sharma S, Shouval R, Shukla N, Therwhanger D, van Besien H, Varon B, Wang Y, Yamshon S, Zelenetz AD, Palomba ML, Jain P, Kumar A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40763269"},{"title01":"Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study.","title02":"Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study.","journal":"Blood advances","issue":"2025 November 11; 9(21):5501-5509. doi: 10.1182\/bloodadvances.2025017378","author":"Galli E, Di Blasi R, Di Rocco A, Cristinelli C, Pansini I, Bommier C, Corrente A, De Bernardis I, Viscovo M, Hohaus S, Modoni A, Sora F, Chiusolo P, Martelli M, Sica S, Thieblemont C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40779573"},{"title01":"Overcoming venetoclax resistance through heme-mediated NOXA\/cyclin D1\/Mcl-1 axis with a novel artemisinin conjugate.","title02":"Overcoming venetoclax resistance through heme-mediated NOXA\/cyclin D1\/Mcl-1 axis with a novel artemisinin conjugate.","journal":"Blood advances","issue":"2025 November 11; 9(21):5473-5488. doi: 10.1182\/bloodadvances.2025015806","author":"Zhang J, Zhang Z, Liu J, Luan S, Qu J, Wu Z, Kuang Y, Gong P, Bao Y, Wang Y, Yan X, Waxman S, Zhao L, Jing Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40795245"},{"title01":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.","title02":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.","journal":"Blood advances","issue":"2025 November 11; 9(21):5571-5584. doi: 10.1182\/bloodadvances.2025016778","author":"Deschenes-Simard X, Bromberg M, Devlin SM, Gonen M, Beyar-Katz O, Ip A, Marcus R, Avigdor A, Ballweg A, Rabinovich E, Alhomoud M, Rivas Delgado A, Corona De Lapuerta M, Luna De Abia A, Palomba ML, Shah GL, Lin R, Boardman AP, Falchi L, Lue J, Salles G, Perales MA, Shouval R, Dahi PB, Scordo M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40815804"},{"title01":"TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity.","title02":"TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.288692. Online ahead of print","author":"Cheng SS, Jiang JG, Lin SC, Yu YH, Chang TW, Lim C, Yu YB, Chu HM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195521"},{"title01":"Prognostic impact of the immune microenvironment in multiple myeloma: a meta-analysis of current studies.","title02":"Prognostic impact of the immune microenvironment in multiple myeloma: a meta-analysis of current studies.","journal":"Haematologica","issue":"2025 November 1; 110(11):2774-2778. doi: 10.3324\/haematol.2024.286264","author":"Susca N, Borrelli P, Botta C, Solimando AG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40371907"},{"title01":"LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma.","title02":"LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma.","journal":"Haematologica","issue":"2025 November 1; 110(11):2779-2785. doi: 10.3324\/haematol.2024.286835","author":"Zuo L, Li Z, Cai L, Li Q, Fan F, Zhang B, Zhao F, Luo S, Zheng Y, Hu Y, Sun C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336322"},{"title01":"Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response.","title02":"Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response.","journal":"Haematologica","issue":"2025 November 1; 110(11):2752-2763. doi: 10.3324\/haematol.2025.287848","author":"Rees MJ, Geyer S, Yohannan B, Toumeh N, Atallah-Yunes SA, Gertz MA, Dispenzieri A, Hayman SR, Buadi F, Dingli D, Warsame R, Kapoor P, Grogan M, Cook J, Binder M, Leung N, Kourelis T, Gonsalves W, Rajkumar VS, Kumar S, Muchtar E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400470"},{"title01":"Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study.","title02":"Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study.","journal":"Haematologica","issue":"2025 November 1; 110(11):2839-2843. doi: 10.3324\/haematol.2025.287506","author":"Shan X, Kuiper R, Ding C, Munshi PN, Stadtmauer EA, Susanibar-Adaniya SP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438975"},{"title01":"Outcomes for unselected, newly diagnosed multiple myeloma patients.","title02":"Outcomes for unselected, newly diagnosed multiple myeloma patients.","journal":"Haematologica","issue":"2025 November 1; 110(11):2823-2826. doi: 10.3324\/haematol.2025.287458","author":"Moore JT, Mettias SM, Cheung J, Swift R, Eades B, Eshaghian S, Schwartz G, Berenson JR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468965"},{"title01":"Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice.","title02":"Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice.","journal":"Haematologica","issue":"2025 November 1; 110(11):2740-2751. doi: 10.3324\/haematol.2025.287717","author":"Ling W, Zangari M, Van Rhee F, Barlogie B, Yaccoby S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501401"},{"title01":"Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing.","title02":"Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing.","journal":"Haematologica","issue":"2025 November 1; 110(11):2726-2739. doi: 10.3324\/haematol.2025.287586","author":"Liu L, Sun H, Feng F, Sun X, Ma J, Lv R, Yu T, Ye L, Li X, Yu Z, Zhang X, Jing H, Yao Y, Ma F, Qiu L, Hao M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438979"},{"title01":"Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort.","title02":"Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort.","journal":"Br J Haematol","issue":"2025 November; 207(5):2161-2166. doi: 10.1111\/bjh.70108","author":"Noveihed A, Al Hadidi S, Mohan M, Shah MR","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41251392"},{"title01":"Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.","title02":"Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma.","journal":"Br J Haematol","issue":"2025 November 3. doi: 10.1111\/bjh.70239. Online ahead of print","author":"Seefat MR, Cucchi DGJ, van Boven L, Durdu-Rayman N, Groen K, Levin MD, de Heer K, de Valk B, Wester R, van der Spek E, Rentenaar R, Korst CLBM, Quik M, O'Neill CA, Tzortzi P, Smits F, Mathot R, Heerma van Voss MR, van de Donk NWCJ, Mutis T, Bartelink IH, Zweegman S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178491"},{"title01":"No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry.","title02":"No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry.","journal":"Br J Haematol","issue":"2025 November 8. doi: 10.1111\/bjh.70238. Online ahead of print","author":"Lim SL, Wellard C, Rajagopal R, Harrison SJ, Khot A, Quach H, Ho PJ, Moore E, Wood E, Spencer A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41204910"},{"title01":"Myeloma bone disease: A constant problem in the changing landscape of myeloma management.","title02":"Myeloma bone disease: A constant problem in the changing landscape of myeloma management.","journal":"Br J Haematol","issue":"2025 November 3. doi: 10.1111\/bjh.70240. Online ahead of print","author":"Swan D, Yong A, Vandyke K, Hocking J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41178408"},{"title01":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","title02":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70246. Online ahead of print","author":"Li L, Wang Z, Qian C, Xu J, Zhu Z, Chen G, Lu T, Wang Y, Chen J, Chen S, Tang X, Fu C, Wu D, Xue SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224498"},{"title01":"Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group.","title02":"Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group.","journal":"Br J Haematol","issue":"2025 November; 207(5):1789-1801. doi: 10.1111\/bjh.70041","author":"Moore S, Miller H, Parrish C, Seymour F, Miller L, Chandler T, Land J, Karpha I, Brearton G, Thompson S, Clayton L, Jones J, McMillan A, McCourt O, Pawlyn C, Mian H, Cook G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903837"},{"title01":"Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies.","title02":"Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies.","journal":"Br J Haematol","issue":"2025 November; 207(5):1765-1778. doi: 10.1111\/bjh.70116","author":"Wang X, Cui Y, Wang Y, Fang B","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40879107"},{"title01":"NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.","title02":"NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.","journal":"Br J Haematol","issue":"2025 November; 207(5):2167-2172. doi: 10.1111\/bjh.70111","author":"Agarwal G, Kazeroun M, Salazar M, McBean K, Kannan A, Larham J, Varghese S, Balik B, Browning J, Caulier A, Chan YLT, Giles H, Jenner M, Kishore B, Pratt G, Rabin N, Robinson R, Talbot A, van de Wyngaert Z, Xu K, Moore S, Boyle E, Ansari-Pour N, Ramasamy K, Hamblin A, Thakurta A, Gooding S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41251385"},{"title01":"Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression.","title02":"Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2025018078. Online ahead of print","author":"Vieira Dos Santos J, Melnekoff DT, Aleman A, Mouhieddine TH, Montes de Oca R, Wang F, Rajeeve S, Bhalla S, Van Oekelen O, Upadhyaya B, Ghodke-Puranik Y, Leshchenko VV, Kim-Schulze S, Rahman AH, Afik S, Lewinsky H, Plaks V, Thibaud S, Cho HJ, Richter J, Rodriguez C, Sanchez LJ, Rossi AC, Richard S, Chari A, Madduri D, Jagannath S, Parekh S, Lagana A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191534"},{"title01":"HLA-E[pHLA-G] complex-specific monoclonal antibody enhancing NK activity in multiple myeloma.","title02":"HLA-E[pHLA-G] complex-specific monoclonal antibody enhancing NK activity in multiple myeloma.","journal":"Blood advances","issue":"2025 November 11; 9(21):5436-5448. doi: 10.1182\/bloodadvances.2025016276","author":"Ahmad MA, Radinsky O, Kaufman B, Waidha K, Gharra E, Dim S, Manikandan DB, Ofir N, Jager D, Meyer M, Elkabets M, Campbell KS, Zektser M, Gazit R, Rouvio O, Momburg F, Porgador A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40706037"},{"title01":"Smoldering multiple myeloma in the United States: A population-based analysis.","title02":"Smoldering multiple myeloma in the United States: A population-based analysis.","journal":"Blood advances","issue":"2025 November 10. doi: 10.1182\/bloodadvances.2025017817. Online ahead of print","author":"Wang SY, Wang R, Schoen M, Huber JH, Feuer E, Ruhl J, Neparidze N, Ma X, Davidoff AJ, Chang SH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213002"},{"title01":"A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma.","title02":"A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma.","journal":"Blood","issue":"2025 November 6; 146(19):2322-2335. doi: 10.1182\/blood.2025028597","author":"Dutta D, Liu J, Wen K, Ray A, Salatino A, Liu X, Gulla A, Hideshima T, Song Y, Anderson KC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40700574"},{"title01":"Breaking T-cell tolerance to fight multiple myeloma.","title02":"Breaking T-cell tolerance to fight multiple myeloma.","journal":"Blood","issue":"2025 November 6; 146(19):2277-2278. doi: 10.1182\/blood.2025030552","author":"Luu M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41196620"},{"title01":"Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma.","title02":"Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma.","journal":"Blood","issue":"2025 November 13; 146(20):2392-2405. doi: 10.1182\/blood.2025028963","author":"Rivera J, Yan Q, Daneshmandi S, Lannes R, Katsuta E, Choi J, Singh P, Belal A, Alberico R, Lund I, Schaefer M, Hassan H, Parker S, Anderson KC, Munshi NC, Samur M, McCarthy PL, Hillengass J, Mohammadpour H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40758944"},{"title01":"PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolism.","title02":"PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolism.","journal":"Blood","issue":"2025 November 5. doi: 10.1182\/blood.2025030061. Online ahead of print","author":"Bonolo De Campos C, He R, Pelino TJ, Abelman DD, Li Z, Lee DKC, Wang DY, St Paul M, Bruce J, Simpson CD, Wybenga-Groot L, Moran MF, Tiedemann RE, Pugh T, Mak TW, Issakova O, Sepetov N, Trudel S, Stewart AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191517"},{"title01":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.","title02":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.","journal":"Leukemia","issue":"2025 November; 39(11):2686-2696. doi: 10.1038\/s41375-025-02744-x","author":"Alfonso-Pierola A, Martinez-Cuadron D, Rodriguez-Veiga R, Gil C, Martinez-Sanchez P, Bernal T, Benavente C, Romero-Riquelme MA, Serrano-Lopez J, Bergua JM, Garcia-Boyero R, Tormo M, Herrera P, Sossa-Melo CL, Perez-Simon JA, Rodriguez-Medina C, Bass-Maturana MF, Lopez-Lorenzo JL, Algarra-Algarra L, Vidriales-Vicente B, Perez-Encinas M, Barrios-Garcia M, Vives S, Sayas-Lloris MJ, Capurro M, Hidalgo S, Olave M, Cuervo-Lozada D, Lavilla-Rubira E, Casado F, Mena-Duran A, Valero-Nunez M, Casado-Calderon S, Balerdi A, Torres V, Fernandez R, Noriega V, Stevenazzi M, Labrador J, Leon-Maldonado P, de Rueda-Ciller B, Arce-Fernandez O, Amigo ML, Raposo-Puglia JA, Sole M, Boluda B, Ayala R, Barragan E, Montesinos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40890512"},{"title01":"Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).","title02":"Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).","journal":"Br J Haematol","issue":"2025 November; 207(5):1815-1831. doi: 10.1111\/bjh.70074","author":"Tsai XC, Yao ZH, Chou SW, Hu HC, Liu YC, Chen CH, Yeh SP, Huang WC, Lin TL, Yang TM, Lai CH, Ko HK, Kuo YW, Hsu HH, Cheng SL, Li CC, Ko BS, Wang HC","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40926299"},{"title01":"Chronic myelomonocytic leukaemia.","title02":"Chronic myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November 2. doi: 10.1111\/bjh.70226. Online ahead of print","author":"Tefferi A, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41177945"},{"title01":"Optimizing activation and culture conditions for the production of cord blood-derived CAR-T and natural killer cells.","title02":"Optimizing activation and culture conditions for the production of cord blood-derived CAR-T and natural killer cells.","journal":"Br J Haematol","issue":"2025 November; 207(5):1863-1873. doi: 10.1111\/bjh.70139","author":"Nakamura N, Liao J, Soda Y, Takahashi M, Kodera H, Kobari Y, Hirai Y, Takaori-Kondo A, Okada T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41030086"},{"title01":"Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer\/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.","title02":"Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer\/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized study.","journal":"Haematologica","issue":"2025 November 1; 110(11):2714-2725. doi: 10.3324\/haematol.2025.287513","author":"Zhong H, Cheng S, Xiong J, Chen J, Mu R, Yang H, Yi H, Song Q, Zhang H, Hu Y, Cui G, Wei J, Zhang X, Xu B, Qian W, Huang X, Hou M, Yan F, Wang X, Song Y, Liu Y, Ma X, Hu J, Li F, Wu C, Chen J, Yu L, Bai O, Xu J, Zhu Z, Liu L, Zhou X, Huang L, Tong Y, Niu T, Wu D, Jiang X, Wang C, Ouyang B, Cai G, Li B, Liu J, Li Z, Xiao R, Wang L, Jiang Y, Liu Y, Zheng X, Xu P, Wang L, Chen S, Zhao WL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40207715"},{"title01":"Persistent Epstein-Barr virus viremia in NK-\/T-cell lymphoma: bad boys for life!","title02":"Persistent Epstein-Barr virus viremia in NK-\/T-cell lymphoma: bad boys for life!","journal":"Haematologica","issue":"2025 November 1; 110(11):2562-2565. doi: 10.3324\/haematol.2025.287922","author":"Xavier AC, Liao Y, Cairo MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40468963"},{"title01":"CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.","title02":"CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.","journal":"Haematologica","issue":"2025 November 1; 110(11):2661-2672. doi: 10.3324\/haematol.2025.287528","author":"Magni M, Jonnalagadda S, Bonifazi F, Bonafe M, Ljevar S, Zanirato G, De Matteis S, Stella F, Barone A, Bertolini G, Bermema A, Chiappella A, Tisi MC, Cutini I, Novo M, Grillo G, Farina M, Martino M, Krampera M, Massaia M, Arcaini L, Bramanti S, Zinzani PL, Dodero A, Corradini P, Carniti C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438977"},{"title01":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.","title02":"MATRix and HD-MTX\/IFO\/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.","journal":"Haematologica","issue":"2025 November 1; 110(11):2827-2833. doi: 10.3324\/haematol.2025.287485","author":"De Groot FA, Stedema FG, Kret EJ, De Haan LM, Jansen PM, Bohringer S, Diepstra A, Van der Poel MWM, Hamid MA, Te Boome LCJ, Terpstra V, Brink M, Veelken H, De Groen RAL, Dekker TJA, Nijland M, Vermaat JSP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438976"},{"title01":"Old methods, lasting impact in relapsed\/refractory primary mediastinal B-cell lymphoma.","title02":"Old methods, lasting impact in relapsed\/refractory primary mediastinal B-cell lymphoma.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.289153. Online ahead of print","author":"Ringelstein-Harlev S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230691"},{"title01":"MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.","title02":"MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.","journal":"Br J Haematol","issue":"2025 November; 207(5):2173-2177. doi: 10.1111\/bjh.70137","author":"Kuhnl A, Bouziana S, Barrington SF, Galani S, Menne T, Northend M, Stevens L, Kamat S, Osborne W, Johnson R, Kumar E, Sanderson R, Patten PEM, Benjamin R, Frew J, Prestwich R, Brady JL, Mikhaeel NG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40936317"},{"title01":"Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas.","title02":"Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas.","journal":"Br J Haematol","issue":"2025 November; 207(5):2178-2182. doi: 10.1111\/bjh.70132","author":"Montes L, Choquet S, Uzunov M, Morel V, Baron M, Roos-Weil D, Joris M, Delette C, Lebon D, Azar N, Metz C, Nichelli L, Le Garff-Tavernier M, Boccon-Gibod C, Lacan C, Souchet L, Hoang-Xuan K, Soussain C, Boussen I, Houillier C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887743"},{"title01":"Towards a chemo-free approach for follicular lymphoma.","title02":"Towards a chemo-free approach for follicular lymphoma.","journal":"Br J Haematol","issue":"2025 November; 207(5):1755-1764. doi: 10.1111\/bjh.70126","author":"Luminari S, Barbieri E, Nizzoli ME","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40884311"},{"title01":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","title02":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2006-2016. doi: 10.1111\/bjh.70102","author":"Yu F, Yu X, Hu X, Jiang E, Zhou J, Lu Y, Zhu X, Wan J, Miao K, Fu Y, Niu J, Wan L, Zhou F, Song X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40856278"},{"title01":"Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models.","title02":"Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models.","journal":"Br J Haematol","issue":"2025 November; 207(5):1744-1754. doi: 10.1111\/bjh.70115","author":"Koca O, Eskazan AE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40843643"},{"title01":"European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.","title02":"European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.","journal":"Br J Haematol","issue":"2025 November; 207(5):1832-1841. doi: 10.1111\/bjh.70125","author":"Kleinstern G, Robinson DP, Abu Seir R, Perlman R, Liu J, Jebrini N, Elyan H, Ben Yehuda D, Slager SL, Paltiel O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887045"},{"title01":"A multicenter phase 1\/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.","title02":"A multicenter phase 1\/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.","journal":"Blood advances","issue":"2025 November 11; 9(21):5665-5675. doi: 10.1182\/bloodadvances.2025017092","author":"Cahill K, Godfrey J, Nabhan C, Kline J, Riedell PA, Cohen KS, Narula S, Karrison TG, Robertson J, Karmali R, Venugopal P, Kim SH, Rapoport AP, Lee ST, Law J, Fishkin PAS, Isufi I, Velasco M, Kaminer L, Smith SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40720747"},{"title01":"Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR.","title02":"Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR.","journal":"Blood advances","issue":"2025 November 11; 9(21):5460-5472. doi: 10.1182\/bloodadvances.2025016141","author":"Wudhikarn K, Herr MM, Chen M, Martens MJ, Baird JH, Gowda L, Rangarajan HG, Abid MB, Kharfan-Dabaja MA, Williams KM, Ganguly S, Young JH, Sharma A, Fatobene G, Jain T, Kanakry CG, Modi D, Grover NS, Salem B, Batista MV, Vergidis P, Yin DE, Beitinjaneh AM, Kelkar AH, Nishihori T, Holter Chakrabarty J, Gergis U, Smith M, El Boghdadly Z, Dandoy CE, Murthy HS, Huppler AR, Perales MA, Chemaly RF, Hill JA, Riches M, Auletta JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40435511"},{"title01":"Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R\/R LBCL.","title02":"Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R\/R LBCL.","journal":"Blood advances","issue":"2025 November 11; 9(21):5641-5650. doi: 10.1182\/bloodadvances.2025016689","author":"de Boer JW, Keijzer K, van Dorp S, Mutsaers PGNJ, Niezink AGH, van Doesum JA, Serroukh YIM, Muntendam LW, Pulles AE, Kret EJ, Sijs-Szabo A, Oomen J, Demandt AMP, Stevens WBC, Kuipers MT, Pennings ERA, Spanjaart AM, Kersten MJ, Jak M, van Dijk LV, van der Poel MWM, Vermaat JSP, van Meerten T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40668622"},{"title01":"High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.","title02":"High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.","journal":"Blood advances","issue":"2025 November 11; 9(21):5409-5422. doi: 10.1182\/bloodadvances.2025016651","author":"Collinge B, Hilton LK, Wong J, Alduaij W, Ben-Neriah S, Slack GW, Farinha P, Boyle M, Meissner B, Cook JR, Ott G, Rosenwald A, Campo E, Amador C, Greiner TC, Raess PW, Song JY, Inghirami G, Ondrejka SL, Jaffe ES, Weisenburger DD, Chan WC, Holte H, Beiske K, Fu K, Delabie J, Pittaluga S, Iqbal J, Wright G, Savage KJ, Mungall AJ, Staudt LM, Steidl C, Feldman AL, Morin RD, Rimsza LM, Scott DW","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40674706"},{"title01":"Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.","title02":"Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.","journal":"Blood advances","issue":"2025 November 11; 9(21):5556-5563. doi: 10.1182\/bloodadvances.2025016168","author":"Steiner R, Nikolaenko L, Nair R, Seshan V, Thiruvengadam SK, Khan N, Abramson JS, Horwitz S, Matasar M, Owens C, Rodriguez Rivera II, Straus DJ, Pardee TS, Luther S, Saboukoulou S, Thet WS, Vemuri S, Noy A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40674734"},{"title01":"Beyond the CAR-T horizon in mantle cell lymphoma.","title02":"Beyond the CAR-T horizon in mantle cell lymphoma.","journal":"Blood advances","issue":"2025 November 11; 9(21):5651-5653. doi: 10.1182\/bloodadvances.2025017583","author":"Lew TE, Seymour JF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41217750"},{"title01":"Double-Hit Lymphoma: Is Lenalidomide Just Right.","title02":"Double-Hit Lymphoma: Is Lenalidomide Just Right.","journal":"Blood advances","issue":"2025 November 11; 9(21):5663-5664. doi: 10.1182\/bloodadvances.2025017787","author":"Driml JK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41217749"},{"title01":"Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma.","title02":"Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma.","journal":"Blood advances","issue":"2025 November 11; 9(21):5539-5545. doi: 10.1182\/bloodadvances.2024015788","author":"Krasnow N, Maurer K, Song C, Rhoades J, Xiong K, Crnjac A, Blewett T, Gao L, Jacene H, Merryman R, Gohil SH, Duffy C, Guerrero LI, Dela Cruz J, McDonough M, Wolff JO, Redd R, Mattie M, Miles B, Makrigiorgos GM, Neuberg DS, Rodig SJ, Armand P, Jacobson C, Adalsteinsson VA, Wu CJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40706054"},{"title01":"A Phase I Study of Blinatumomab\/Lenalidomide in Relapsed\/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis.","title02":"A Phase I Study of Blinatumomab\/Lenalidomide in Relapsed\/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis.","journal":"Blood advances","issue":"2025 November 10. doi: 10.1182\/bloodadvances.2025016845. Online ahead of print","author":"Tuscano JM, Othman T, Frankel P PhD, Ruel C, Poh C, Herbert S, Maverakis E, Merleev AA, Luxardi G, Abedi M, Ranganathan R, Modi D, Zain J, Budde LEE, Mei M, Rosenberg AS, Hoeg RT, Costello CL, Foss FM, William B, Holland HK, Sharon E, Streicher H, Danilov AV, Newman EM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213001"},{"title01":"Nivolumab in combination with R-CHOP for treatment-naive diffuse large B-cell lymphoma: an evaluation of safety and efficacy.","title02":"Nivolumab in combination with R-CHOP for treatment-naive diffuse large B-cell lymphoma: an evaluation of safety and efficacy.","journal":"Blood advances","issue":"2025 November 11; 9(21):5616-5625. doi: 10.1182\/bloodadvances.2025016298","author":"Odetola O, Ma S, Winter J, Pro B, Roy I, Xie P, Zhang B, Chen Q, Koulogeorgas GP, Mi X, Chen R, Ma Y, Tang X, Bayer R, Eisner R, Nelson V, Shaikh H, Tsarwhas D, Saghir F, Venugopal P, Gordon LI, Karmali R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40706069"},{"title01":"Racial and Clinical Determinants of Response in 2,304 r\/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical Trials.","title02":"Racial and Clinical Determinants of Response in 2,304 r\/r BCL Treated with Anti-CD19 CAR T-Cells in Clinical Trials.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2025016361. Online ahead of print","author":"Kho SJ, Diamond SS, Lafeuille P, Schatz JH, Maura F, Aptekar J, Locke FL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201393"},{"title01":"Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium.","title02":"Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2025017120. Online ahead of print","author":"Wang JS, Ellsworth BL, Melody M, Epperla N, Stephens DM, Romancik JT, Cortese MJ, Bhansali RS, Moyo TK, Kenkre VP, Ollila TA, Hess BT, Fitzgerald LA, Shouse G, Matasar MJ, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Grover NS, Karmali R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201962"},{"title01":"Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell-type chronic active EBV infection.","title02":"Multiomics analysis reveals the genetic and epigenetic features of high-risk NK cell-type chronic active EBV infection.","journal":"Blood","issue":"2025 November 6; 146(19):2336-2349. doi: 10.1182\/blood.2024026805","author":"Akazawa R, Mikami T, Yamada M, Kato I, Kubota H, Saida S, Uchihara Y, Ishikawa Y, Kamitori T, Tasaka K, Isobe K, Isobe T, Izawa K, Umeda K, Hiramatsu H, Jinnouchi K, Hirata M, Fujimoto M, Daifu T, Ueno H, Nodomi S, Sawada M, Fujino H, Koh K, Hiwatari M, Kato M, Goto H, Katano I, Ito R, Ito M, Kakiuchi N, Nakagawa MM, Shiraishi Y, Honda Y, Yoshitomi H, Ueno H, Sato M, Miyano S, Haga H, Sawada A, Imadome KI, Ogawa S, Takita J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737598"},{"title01":"Methylation profiling: unmasking CAEBV&#8217;s lymphoma connection.","title02":"Methylation profiling: unmasking CAEBV&#8217;s lymphoma connection.","journal":"Blood","issue":"2025 November 6; 146(19):2279-2280. doi: 10.1182\/blood.2025030040","author":"Fournier B, Latour S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41196625"},{"title01":"Classic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma.","title02":"Classic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma.","journal":"Blood","issue":"2025 November 6; 146(19):2370. doi: 10.1182\/blood.2025029949","author":"Elsharawi I, Selegean S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41196619"},{"title01":"Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture?","title02":"Feasibility and Safety of Anti-PD1 First-Line Treatment of Classic Hodgkin Lymphoma: Do We See the Full Picture?","journal":"Blood","issue":"2025 November 1. doi: 10.1182\/blood.2025029935. Online ahead of print","author":"Jaworek CP, Brockelmann PJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41175363"},{"title01":"Mantle cell lymphoma with KMT2A rearrangement.","title02":"Mantle cell lymphoma with KMT2A rearrangement.","journal":"Blood","issue":"2025 November 13; 146(20):2491. doi: 10.1182\/blood.2025030135","author":"Hu S, Tang G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41231456"},{"title01":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders.","title02":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders.","journal":"Leukemia","issue":"2025 November; 39(11):2610-2617. doi: 10.1038\/s41375-025-02654-y","author":"Zanwar S, Rajkumar SV","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40702148"},{"title01":"The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma.","title02":"The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma.","journal":"Leukemia","issue":"2025 November; 39(11):2779-2788. doi: 10.1038\/s41375-025-02736-x","author":"Zocchi S, Trichet P, Guernalec P, Agdada M, Alonso Bartolome A, Ogor V, Choisy C, Vias C, Sabate-Cadenas X, Bories JC, Goodhardt M, Shkumatava A, Garrick D","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858807"},{"title01":"Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.","title02":"Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e876-e886. doi: 10.1016\/S2352-3026(25)00256-X","author":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Wilkes J, McNamara S, Phillips-Jones A, Morris K, Pompilus F, Purser M, Sule N, Kremer B, Loubert A, Bunod L, M'Hari M, Zhou XL, Fulci G, Mateos MV, Trudel S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41193117"},{"title01":"Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.","title02":"Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.","journal":"Blood advances","issue":"2025 November 11; 9(21):5489-5500. doi: 10.1182\/bloodadvances.2025016149","author":"Rangarajan HG, Satwani P, Herr MM, Chen M, Martens MJ, Wudhikarn K, John S, Fabrizio VA, Hsieh EM, Kelkar AH, Doherty E, Marks DI, Ringden O, Friend B, Kelly MS, Farhadfar N, Prestidge T, Hossain NM, Liu H, Hashmi S, Modi D, Winestone LE, El Boghdadly Z, Murthy HS, Perales MA, Chemaly RF, Dandoy CE, Hill JA, Huppler A, Riches M, Auletta JJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737539"},{"title01":"Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.","title02":"Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.","journal":"Blood advances","issue":"2025 November 11; 9(21):5598-5609. doi: 10.1182\/bloodadvances.2025016898","author":"Fiskus W, Masarova L, Mill CP, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Torngren M, Bhalla KN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40829105"},{"title01":"Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia.","title02":"Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia.","journal":"Blood advances","issue":"2025 November 11; 9(21):5585-5597. doi: 10.1182\/bloodadvances.2024015449","author":"Liegel J, Stroopinsky D, Cheloni G, Karagkouni D, Nahas M, Ma Y, Torres D, Saldarriaga I, Wang S, Arruda de Amaral A, Ploumakis A, Clohessy J, Abirached J, Bisharat L, Fraenkel P, Yildirim O, Bonnevaux H, Guerif S, Rallis K, Chedid G, Kufe D, Vlachos IS, Avigan D, Rosenblatt J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811786"},{"title01":"Overcoming venetoclax resistance through heme-mediated NOXA\/cyclin D1\/Mcl-1 axis with a novel artemisinin conjugate.","title02":"Overcoming venetoclax resistance through heme-mediated NOXA\/cyclin D1\/Mcl-1 axis with a novel artemisinin conjugate.","journal":"Blood advances","issue":"2025 November 11; 9(21):5473-5488. doi: 10.1182\/bloodadvances.2025015806","author":"Zhang J, Zhang Z, Liu J, Luan S, Qu J, Wu Z, Kuang Y, Gong P, Bao Y, Wang Y, Yan X, Waxman S, Zhao L, Jing Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40795245"},{"title01":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","title02":"Dietary animal fat disrupts gut microbiota and aggravates Scl-cGVHD after allogeneic hematopoietic stem cell transfer.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2024014831. Online ahead of print","author":"Millick DD, Ghosh S, Wu G, Krzyzanowska AK, Osorio LJ, Zhao L, Strair R, Sant'Angelo DB","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191542"},{"title01":"Diagnostic Criteria for NK-Cell Large Granular Lymphocyte Leukemia: Validation Through a Multicentric International Study.","title02":"Diagnostic Criteria for NK-Cell Large Granular Lymphocyte Leukemia: Validation Through a Multicentric International Study.","journal":"Blood advances","issue":"2025 November 5. doi: 10.1182\/bloodadvances.2025016509. Online ahead of print","author":"Pastoret C, Yang J, Feith DJ, Roussel M, Moignet A, Dighe S, Solga MD, Marchand T, Visser G, Gasparini VR, Teramo A, Zambello R, Loughran TP, Lamy T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191533"},{"title01":"Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.","title02":"Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.","journal":"Blood","issue":"2025 November 14. doi: 10.1182\/blood.2025028933. Online ahead of print","author":"Ling T, O'Brien C, St-Germain J, Rondeau V, Shi M, Berman JM, Cepa AK, Saez Raez P, Wunderlich M, Carter K, Stillwell C, Sexton CR, Culp-Hill R, Reisz JA, Adeel SA, Zeng AGX, Bansal S, Tsao E, Chen HTT, Dick JE, Minden MD, Arruda A, Amaya ML, Tikhonova AN, Hope K, D'Alessandro A, Raught B, Jones CL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237364"},{"title01":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.","title02":"Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.","journal":"Blood","issue":"2025 November 6; 146(19):2293-2305. doi: 10.1182\/blood.2025028730","author":"Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Muller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, Klein SA, Niederland J, Kaufmann M, Schafer-Eckart K, Baldauf H, Stolzel F, Trost S, Rollig C, von Bonin M, Egger-Heidrich K, Kunadt D, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Mikesch JH, Bornhauser M, Schetelig J","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40737595"},{"title01":"Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.","title02":"Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.","journal":"Blood","issue":"2025 November 5. doi: 10.1182\/blood.2025030209. Online ahead of print","author":"Kawano G, Ikeda R, Ishihara D, Shima T, Sakoda T, Yamamoto S, Kochi Y, Semba Y, Ashitani S, Mori Y, Kato K, Maeda T, Miyamoto T, Soga T, Akashi K, Kikushige Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41191529"},{"title01":"AML biology matters, so should we transplant ASAP?","title02":"AML biology matters, so should we transplant ASAP?","journal":"Blood","issue":"2025 November 6; 146(19):2275-2276. doi: 10.1182\/blood.2025030527","author":"Levine JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41196624"},{"title01":"Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL.","title02":"Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL.","journal":"Blood","issue":"2025 November 13; 146(20):2417-2427. doi: 10.1182\/blood.2025029785","author":"Chen C, Cai J, Wu X, Hu Q, Wu X, Guo X, Hu S, Zhai X, Qi B, Zhang W, Wang N, Xu F, Fang Y, Li CK, Liang C, Wang L, Zhu J, Deng W, Tian X, Ju X, Zhang G, Tang J, Cheng C, Yang J, Shen S, Pui CH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40789043"},{"title01":"Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.","title02":"Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.","journal":"Blood","issue":"2025 November 6; 146(19):2350-2356. doi: 10.1182\/blood.2025028985","author":"Montefiori LE, Iacobucci I, Gao Q, Moore J, Wright WC, Wei H, Baviskar P, Sona S, Jin H, Budhraja A, Lott J, Tatarata QZ, Cheng Z, Khan T, Backhaus Wagner EA, Johnson M, Mehr CM, Freeman B, Janke L, Haferlach T, Geeleher P, Mead PE, Konopleva M, Opferman JT, Mullighan CG","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40811853"},{"title01":"Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.","title02":"Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.","journal":"Blood","issue":"2025 November 13; 146(20):2443-2456. doi: 10.1182\/blood.2024027822","author":"Pauli C, Kienhofer M, Blank MF, Begik O, Rohde C, Zimmermann SMN, Werner L, Heid D, Xu F, Weidenauer K, Delaunay S, Krall N, Trunk K, Zhao D, Zhou F, Llovera L, Ollivier A, Heit-Mondrzyk A, Platzbecker U, Baldus C, Serve H, Bornhauser M, Vagbo CB, Benitah SA, Krijgsveld J, Novoa EM, Muller-Tidow C, Frye M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40749163"},{"title01":"The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.","title02":"The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.","journal":"Blood","issue":"2025 November 13; 146(20):2406-2416. doi: 10.1182\/blood.2025028899","author":"Al-Sawaf O, Furstenau M, Giza A, Robrecht S, von Tresckow J, Fink AM, Simon F, Tausch E, Schneider C, Sivcheva L, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Juliusson G, da Cunha-Bang C, Illmer T, Gregor M, Thornton P, Janssens A, Tadmor T, Lindstrom V, Staber P, Levin MD, Wendtner CM, Kreuzer KA, Ritgen M, Stilgenbauer S, Kater AP, Niemann C, Fischer K, Eichhorst B, Hallek M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40864973"},{"title01":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.","title02":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.","journal":"Leukemia","issue":"2025 November 7. doi: 10.1038\/s41375-025-02795-0. Online ahead of print","author":"Moia R, Ragaini S, Cascione L, Rinaldi A, Genuardi E, Talotta D, Almasri M, Bruscaggin A, Zaccaria GM, Evangelista A, Civita AM, Di Rocco A, Petrucci L, Cavallo F, Celli M, Luppi M, Stelitano C, Stefani PM, Visco C, Billio A, Casaroli I, Castellino C, Pavone E, Galimberti S, Plenteda C, Merli F, Mahmoud AM, Rossi D, Gaidano G, Ladetto M, Bertoni F, Ferrero S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41204002"},{"title01":"Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.","title02":"Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.","journal":"Leukemia","issue":"2025 November 3. doi: 10.1038\/s41375-025-02787-0. Online ahead of print","author":"Khouja M, Genuardi E, Ferrero S, Laqua A, Alessandria B, Verhagen OJHM, Homburg CHE, Sanz RG, Medina Herrera A, van der Velden VHJ, da Silva MG, Gameiro P, Doorduijn J, Gine E, Visco C, Bruggemann M, Baldus CD, Ladetto M, Schmidt C, Dreyling M, Jiang L, Hoster E, Darzentas N, Pal K, Chitadze G, Stewart JP, Gonzalez D, Pott C","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41184633"},{"title01":"The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.","title02":"The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma.","journal":"Leukemia","issue":"2025 November 12. doi: 10.1038\/s41375-025-02809-x. Online ahead of print","author":"Wei W, Song Z, Wang Y, Li S, Tan L, Lee J, Cai KQ, Nejati R, Kadin ME, Campbell KS, Nakagawa M, Yang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41225182"},{"title01":"Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography\/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL\/FIL HD 0607 Trial.","title02":"Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography\/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL\/FIL HD 0607 Trial.","journal":"J Clin Oncol","issue":"2025 November; 43(31):3426-3427. doi: 10.1200\/JCO-25-02137","author":"Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mule A, Picardi M, Romano A, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravalloti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41004689"},{"title01":"Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.","title02":"Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.","journal":"J Clin Oncol","issue":"2025 November 7; JCO2502200. doi: 10.1200\/JCO-25-02200. Online ahead of print","author":"Dickinson MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41202195"},{"title01":"CD19 directed CAR T therapy for intravascular large B-cell lymphoma.","title02":"CD19 directed CAR T therapy for intravascular large B-cell lymphoma.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.288838. Online ahead of print","author":"Patel J, Gopal A, Cherniawsky H, Ram R, Kamble R, Hamadani M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195517"},{"title01":"Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.","title02":"Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.288185. Online ahead of print","author":"Loh Z, Yeh P, Keane C, Hawkes EA","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195522"},{"title01":"COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK&#8217;s Haematological Malignancy Research Network.","title02":"COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK&#8217;s Haematological Malignancy Research Network.","journal":"Br J Haematol","issue":"2025 November 11. doi: 10.1111\/bjh.70244. Online ahead of print","author":"Smith A, Frobisher C, Varghese A, Rawstron A, Crouch S, Howell D, Fielding A, Eastick K, Cargo C, Burton C, Cook G, Easom N, Tooze R, Lillie P, Roman E, Patmore R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41220109"},{"title01":"Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.","title02":"Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.","journal":"Br J Haematol","issue":"2025 November 10. doi: 10.1111\/bjh.70243. Online ahead of print","author":"Fakhri B, Lattupally R, Sint K, Stehr H, Menke JR, Conte M, Shanafelt T, Lu SX","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41215498"},{"title01":"Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.","title02":"Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.","journal":"Br J Haematol","issue":"2025 November; 207(5):2135-2139. doi: 10.1111\/bjh.70128","author":"Vodicka P, Hamova I, Velasova A, Kupcova K, Zemankova P, Nehasil P, Tkachenko A, Lochovska K, Muzikova S, Hrabetova S, Dlouha J, Blahovcova P, Frouz T, Senavova J, Dlouha L, Polgarova K, Klanova M, Salkova J, Benesova K, Klener P, Trneny M, Havranek O","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916568"},{"title01":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","title02":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70246. Online ahead of print","author":"Li L, Wang Z, Qian C, Xu J, Zhu Z, Chen G, Lu T, Wang Y, Chen J, Chen S, Tang X, Fu C, Wu D, Xue SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224498"},{"title01":"Bispecific antibody combination therapies in diffuse large B-cell lymphoma.","title02":"Bispecific antibody combination therapies in diffuse large B-cell lymphoma.","journal":"Br J Haematol","issue":"2025 November 7. doi: 10.1111\/bjh.70228. Online ahead of print","author":"Harrop S, Minson A, Steiner TM, Neeson PJ, Dickinson MJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201275"},{"title01":"Reed-Sternberg-like cells in central nervous system relapse of diffuse large B-cell lymphoma.","title02":"Reed-Sternberg-like cells in central nervous system relapse of diffuse large B-cell lymphoma.","journal":"Br J Haematol","issue":"2025 November; 207(5):1742-1743. doi: 10.1111\/bjh.70174","author":"Chiriac R, Baseggio L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41039717"},{"title01":"Comprehensive analysis of (177)Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes.","title02":"Comprehensive analysis of (177)Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes.","journal":"Br J Haematol","issue":"2025 November; 207(5):1855-1862. doi: 10.1111\/bjh.70143","author":"Patzke S, Cascione L, Melhus KB, Munz N, Arribas AJ, Gaudio E, Generalov R, Repetto-Llamazares AHV, Dahle J, Bertoni F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40967736"},{"title01":"Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.","title02":"Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.","journal":"Br J Haematol","issue":"2025 November; 207(5):1994-2005. doi: 10.1111\/bjh.70097","author":"Li Y, Jin L, Liu W, Liu Y, Yang K, Jia Y, Yang X, Dai Y, Yang L, Liu R, Jiang L, Zheng M, Xu J, Liu A, Sun L, Gao H, Jin R, Zheng Q, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40958529"},{"title01":"Chronic lymphocytic leukemia and associated chronic lung diseases.","title02":"Chronic lymphocytic leukemia and associated chronic lung diseases.","journal":"Haematologica","issue":"2025 November 1; 110(11):2673-2682. doi: 10.3324\/haematol.2025.287533","author":"Tadmor T, Hardak E, Melamed G, Alapi H, Rokach L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40438985"},{"title01":"Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia.","title02":"Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia.","journal":"Haematologica","issue":"2025 November 1; 110(11):2647-2660. doi: 10.3324\/haematol.2024.287265","author":"Ikeda J, Kunimoto H, Saito Y, Tsujimoto SI, Takeuchi M, Miura A, Kurosawa T, Murakami K, Kato I, Funakoshi-Tago M, Yokoyama A, Shiba N, Adachi S, Tomizawa D, Tamura T, Ito S, Nakajima H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501394"},{"title01":"Metabolic epigenome targeting hits KMT2A-rearranged acute lymphoblastic leukemia.","title02":"Metabolic epigenome targeting hits KMT2A-rearranged acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 1; 110(11):2557-2559. doi: 10.3324\/haematol.2025.287881","author":"Heckl D, Rettinger E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40501411"},{"title01":"An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia.","title02":"An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1782-1788. doi: 10.1111\/bjh.70134","author":"Metzler M, Branford S, Hijiya N, Sakamoto K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40921705"},{"title01":"Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.","title02":"Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation.","journal":"Br J Haematol","issue":"2025 November; 207(5):2041-2048. doi: 10.1111\/bjh.70101","author":"Shimoni A, Peczynski C, Labopin M, Dominietto A, Koc M, Arat M, Tischer J, Sica S, Gulbas Z, Socie G, Blaise D, Pioltelli P, Ozdogu H, Vydra J, Ciceri F, Nagler A, Mohty M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40810334"},{"title01":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","title02":"Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed\/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70248. Online ahead of print","author":"Petracci E, Pavesi F, Castagna L, Zappasodi P, Papayannidis C, Vetro C, Federico V, Cignetti A, Borlenghi E, Fracchiolla N, Facchini L, Maurillo L, Audisio E, Bernardi M, Ferrara F, Lanza F, Selleri C, Manfra I, Cerchione C, Nanni J, Romagnoli AD, Marconi G, Zingaretti C, Lotesoriere I, Gigli F, Martinelli G, Todisco E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224500"},{"title01":"Chronic myelomonocytic leukaemia.","title02":"Chronic myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November 2. doi: 10.1111\/bjh.70226. Online ahead of print","author":"Tefferi A, Patnaik MM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41177945"},{"title01":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","title02":"Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.","journal":"Br J Haematol","issue":"2025 November; 207(5):1912-1919. doi: 10.1111\/bjh.70085","author":"Rokkanen R, Aarnivala H, Huhtaniska S, Palmu S, Pokka T, Poyhonen T, Suo-Palosaari M, Utriainen P, Jarvela L, Niinimaki R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40781902"},{"title01":"Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature.","title02":"Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature.","journal":"Br J Haematol","issue":"2025 November; 207(5):2147-2152. doi: 10.1111\/bjh.70118","author":"Lahera A, Vela-Martin L, Fernandez-Navarro P, Lopez-Lorenzo JL, Cornago J, Llamas P, Fresno M, Santos J, Villa-Morales M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40859815"},{"title01":"Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia.","title02":"Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):2143-2146. doi: 10.1111\/bjh.70113","author":"Poh C, Chen X, Voutsinas J, Naresh K, Dizon JJ, Shadman M, Lynch RC, Till BG, Ujjani CS, Di M, Raghunathan V, Warren EH, Smith SD, Wu QV, Cherian S, Gopal AK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931545"},{"title01":"Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study.","title02":"Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study.","journal":"Br J Haematol","issue":"2025 November; 207(5):1920-1929. doi: 10.1111\/bjh.70145","author":"Dam M, Centanni M, Centanni D, Friberg LE, Karlsson MO, Lynggaard LS, Johannsdottir IM, Lepik K, Vaitkeviciene GE, Griskevicius L, Poyhonen T, Pyorala M, Jonsson OG, Quist-Paulsen P, Schmiegelow K, Christoforaki T, Overgaard U, Hansen SN, Albertsen BK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916350"},{"title01":"Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia.","title02":"Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1953-1961. doi: 10.1111\/bjh.70135","author":"Boudry A, Goursaud L, Lebon D, Dumezy F, Harrivel V, Boue-Raguet A, Joudinaud R, Marceau-Renaut A, Geffroy S, Hauspie C, Brijs J, Fenwarth L, Berthon C, Marolleau JP, Figeac M, Preudhomme C, Duployez N","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40903763"},{"title01":"The role of CBFbeta::MYH11 fusion gene in acute lysis pneumopathy: A dual impact on risk and prognosis.","title02":"The role of CBFbeta::MYH11 fusion gene in acute lysis pneumopathy: A dual impact on risk and prognosis.","journal":"Br J Haematol","issue":"2025 November; 207(5):1944-1952. doi: 10.1111\/bjh.70129","author":"Ying S, Yang L, Zhang L, Hong R, Luo W, Shao Y, Sun J, Guo Q, Luo Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887822"},{"title01":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","title02":"Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1938-1943. doi: 10.1111\/bjh.70106","author":"Meyer JA, Xirenayi S, Werner J, Turakulov R, Hechmer A, Abdullaev Z, Hamdy N, Olshen A, Stieglitz E, Hammad M, Elhaddad A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40887320"},{"title01":"A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model.","title02":"A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model.","journal":"Br J Haematol","issue":"2025 November; 207(5):1842-1854. doi: 10.1111\/bjh.70130","author":"Tamai M, Komatsu C, Kagami K, Kasai S, Watanabe A, Akahane K, Goi K, Tomoyasu C, Imamura T, Oguri S, Iwasaki S, Teshima T, Yatabe Y, Inukai T","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40884014"},{"title01":"Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia.","title02":"Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November; 207(5):1893-1901. doi: 10.1111\/bjh.70131","author":"Hoang T, Cheung MC, Juurlink DN, Chan KKW, Lau C, Liu N, Abdel-Qadir H, Prica A, Hay AE, Vijenthira A, Mozessohn L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40878718"},{"title01":"ET occurring in NPM1-mutated AML during molecular complete remission: A further potential evolution of a complex disease.","title02":"ET occurring in NPM1-mutated AML during molecular complete remission: A further potential evolution of a complex disease.","journal":"Br J Haematol","issue":"2025 November; 207(5):2153-2157. doi: 10.1111\/bjh.70076","author":"Bertoli D, Giupponi C, Rossi G, D'Adda M, Cancelli V, Cattaneo C, Masina L, De Marco B, Peli A, Biasiotto G, Tucci A, Borlenghi E","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41251387"},{"title01":"Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.","title02":"Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study.","journal":"Blood advances","issue":"2025 November 11; 9(21):5399-5408. doi: 10.1182\/bloodadvances.2025016546","author":"Fresa A, Innocenti I, Tomasso A, Vitale C, Sanna A, Frustaci AM, Visentin A, Romeo A, Sportoletti P, Giordano A, Perutelli F, Murru R, Mauro FR, Mosca A, Morelli F, Laureana R, Galitzia A, Angeletti I, Conte E, Moia R, D'Arena G, Pasquale R, Autore F, Olivieri J, Stirparo L, Benintende G, Angotzi F, Vuono F, Corbingi A, Del Principe MI, Giannarelli D, Tedeschi A, Coscia M, Sangiorgi E, Efremov DG, Laurenti L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40505061"},{"title01":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","title02":"Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.","journal":"Blood advances","issue":"2025 November 7. doi: 10.1182\/bloodadvances.2024015191. Online ahead of print","author":"Sinha R, Patil RV, Romano R, Sharma D, Lee E, Perriman R, Takeda S, Lesch BJ, Yao Z, Liu YL, Cromer MK, Porteus MH, Bertaina A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41201956"},{"title01":"CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.","title02":"CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.","journal":"Blood","issue":"2025 November 14. doi: 10.1182\/blood.2025031006. Online ahead of print","author":"Knapper S, Dillon LW, Babu M, Thomas A, Thomas I, Hourigan CS, Andrew GM, Dillon RJ, Gilkes AF, Marquez-Almuina N, King S, McCarthy N, Bahr R, Al-Ali RW, Stone L, Coats T, Byrne JL, Green S, Overgaard UM, Sellar RS, Dennis M, Mehta P, Hills RK, Freeman SD, Russell NH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41237344"},{"title01":"Decoding RNA modifications to unlock new treatments for AML.","title02":"Decoding RNA modifications to unlock new treatments for AML.","journal":"Blood","issue":"2025 November 13; 146(20):2378-2379. doi: 10.1182\/blood.2025030290","author":"Lane SW, Bywater M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41231460"},{"title01":"Refitting fitness in CLL.","title02":"Refitting fitness in CLL.","journal":"Blood","issue":"2025 November 13; 146(20):2374-2375. doi: 10.1182\/blood.2025030837","author":"Brander DM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41231458"},{"title01":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.","title02":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.","journal":"Leukemia","issue":"2025 November; 39(11):2686-2696. doi: 10.1038\/s41375-025-02744-x","author":"Alfonso-Pierola A, Martinez-Cuadron D, Rodriguez-Veiga R, Gil C, Martinez-Sanchez P, Bernal T, Benavente C, Romero-Riquelme MA, Serrano-Lopez J, Bergua JM, Garcia-Boyero R, Tormo M, Herrera P, Sossa-Melo CL, Perez-Simon JA, Rodriguez-Medina C, Bass-Maturana MF, Lopez-Lorenzo JL, Algarra-Algarra L, Vidriales-Vicente B, Perez-Encinas M, Barrios-Garcia M, Vives S, Sayas-Lloris MJ, Capurro M, Hidalgo S, Olave M, Cuervo-Lozada D, Lavilla-Rubira E, Casado F, Mena-Duran A, Valero-Nunez M, Casado-Calderon S, Balerdi A, Torres V, Fernandez R, Noriega V, Stevenazzi M, Labrador J, Leon-Maldonado P, de Rueda-Ciller B, Arce-Fernandez O, Amigo ML, Raposo-Puglia JA, Sole M, Boluda B, Ayala R, Barragan E, Montesinos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40890512"},{"title01":"Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1alpha.","title02":"Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1alpha.","journal":"Leukemia","issue":"2025 November; 39(11):2640-2651. doi: 10.1038\/s41375-025-02749-6","author":"Xu G, Wang F, Chen M, Gao W, Liu Y, Zhu J, Wang C, Jiang H, Li Y, Zhang P, Yuan J, Zhang T, Zhao C, Wang L, Wang L, Jiang J, Cao W, Zhang Z, Fu H, Dong T, Hu J, Li K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40897850"},{"title01":"Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.","title02":"Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.","journal":"Lancet Oncol","issue":"2025 November; 26(11):e586-e596. doi: 10.1016\/S1470-2045(25)00426-7","author":"Sanz J, Bug G, Ciceri F, Craddock C, Dillon R, Esteve J, Porta MGD, Heuser M, de Leeuw DC, Nagler A, Onida F, Roboz GJ, Ruggeri A, Sanchez-Ortega I, Srour M, Yakoub-Agha I, Buccisano F","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41167226"},{"title01":"Cytokine-engineered CAR T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukaemia.","title02":"Cytokine-engineered CAR T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukaemia.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e853-e855. doi: 10.1016\/S2352-3026(25)00263-7","author":"Faramand RG, Muffly L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41110449"},{"title01":"IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study.","title02":"IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e898-e907. doi: 10.1016\/S2352-3026(25)00253-4","author":"Xu Q, Guo Y, Gao M, Xue L, Xu H, Li H, Zhang X, Liu C, Li Y, Chen Q, Ren J, Sathiyanadan K, Hu Y, Tang L, Huang H, Wang X","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41110448"},{"title01":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.","title02":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e862-e875. doi: 10.1016\/S2352-3026(25)00264-9","author":"Mesa R, Gill H, Zhang L, Jin J, Kirito K, Komatsu N, Qin A, Xiao Z, Tashi T, Shimoda K, Ohishi K, Chen S, Zuo X, Shirane S, Hu Y, Zhang S, Wang Y, Takenaka K, Ichii M, Xu N, Shih LY, Lim KH, Lee SE, Bae SH, Teo WZY, Maze D, Oh ST, Bose P, Sato T, Zagrijtschuk O, Lin S, Shih WJ, Mascarenhas J, Masarova L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41193116"},{"title01":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","title02":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b\/2 trial.","journal":"Lancet Haematol","issue":"2025 November; 12(11):e887-e897. doi: 10.1016\/S2352-3026(25)00254-6","author":"Richard-Carpentier G, Gupta G, Koraksic C, Cathelin S, Wang L, Bankar A, Davidson M, Gupta V, Maze D, Minden MD, Murphy T, Schimmer AD, Schuh AC, Sibai H, Yee K, DiNardo CD, Brandwein J, McNamara CJ, Chan SM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41075807"},{"title01":"Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.","title02":"Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009.","journal":"J Clin Oncol","issue":"2025 November 10; JCO2501357. doi: 10.1200\/JCO-25-01357. Online ahead of print","author":"Gottschalk H, Moricke A, Conter V, Schrappe M, Stary J, Cario G, Dworzak M, Attarbaschi A, Barbaric D, Locatelli F, Bodmer N, Elitzur S, Silvestri D, Dalla-Pozza L, Bergmann AK, Flotho C, Buldini B, Stanulla M, Izraeli S, Rizzari C, Bourquin JP, Biondi A, Valsecchi MG, Zimmermann M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41213101"},{"title01":"Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.","title02":"Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.","journal":"J Clin Oncol","issue":"2025 November; 43(31):3381-3390. doi: 10.1200\/JCO-25-01694","author":"Wang ES, Montesinos P, Foran J, Erba H, Rodriguez-Arboli E, Fedorov K, Heiblig M, Heidel FH, Altman JK, Baer MR, Ades L, Pettit K, Peterlin P, Papayannidis C, Berthon C, Walter RB, Shah MV, Balasubramanian S, Khawandanah M, Salamero Garcia O, Bergeron J, Madanat YF, Roboz GJ, Ulrickson M, Redner RL, McCloskey J, Pigneux A, de la Fuente Burguera A, Mitra A, Soifer HS, Tabachri M, Zhang Z, Riches M, Corum D, Leoni M, Issa GC, Fathi AT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40997296"},{"title01":"Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.","title02":"Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.","journal":"J Clin Oncol","issue":"2025 November 10; 43(32):3526-3535. doi: 10.1200\/JCO-25-00307","author":"Wieduwilt MJ, Yin J, Kour O, Teske R, Stock W, Escherich C, Yang J, Li Z, Byrd K, Doucette K, Mangan J, Hall S, Mims AS, Jamieson K, Dinner SN, Bseiso AW, Giordano G, Saygin C, Uy GL, Litzow MR, Stone RM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41026957"},{"title01":"IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.","title02":"IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.288743. Online ahead of print","author":"Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Zeidner JF, Olin RL, Smith CC, Schiller GJ, Curran EK, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195510"},{"title01":"Curing acute promyelocytic leukemia: no boost from immunity needed.","title02":"Curing acute promyelocytic leukemia: no boost from immunity needed.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2025.300055. Online ahead of print","author":"Tallman MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195516"},{"title01":"Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1.","title02":"Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1.","journal":"Haematologica","issue":"2025 November 6. doi: 10.3324\/haematol.2024.286833. Online ahead of print","author":"Ciaurro V, Sharlandjieva V, Skwarska A, Chahrour C, Baran N, Zeng Z, Ramage C, Daver N, Carter BZ, Chaundhry S, Thandapani P, Martelli MP, Milne TA, Konopleva M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41195508"},{"title01":"An emerging triplet option for newly diagnosed FLT3-mutated acute myeloid leukemia.","title02":"An emerging triplet option for newly diagnosed FLT3-mutated acute myeloid leukemia.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.289066. Online ahead of print","author":"Boussi L, Goldberg AD","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230690"},{"title01":"Chromosomal rearrangement-enhanced mRNA stability drives the oncogenic potential of fusion genes in pediatric leukemia.","title02":"Chromosomal rearrangement-enhanced mRNA stability drives the oncogenic potential of fusion genes in pediatric leukemia.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.288256. Online ahead of print","author":"Shao X, Xia Z, Cai M, Shao C, Bing S, Wang T, Du W, Liu J, Shen D, Cao J, Yang B, He Q, Xu X, Zhang J, Ying M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230692"},{"title01":"The comprehensive landscape of TTMV::RARA fusion-driven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","title02":"The comprehensive landscape of TTMV::RARA fusion-driven acute myeloid leukemia: from viral integration mechanisms to clinical outcomes.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.288721. Online ahead of print","author":"Sun S, Liu Y, Xu QY, Wang J, Chen L, Cheng Z, Gao W, Wang H, Yang B, Wang H, Wen L, Xiao J, Lou J, Yu H, Li N, Wang F, Xie Y, Wang J, Wang X, Xue H, Chen K, Wu Y, Zhang L, Li K, Shen S, Chen S, Wang HY, Wang K, Huang J, Zhu HH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230695"},{"title01":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","title02":"Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.","journal":"Haematologica","issue":"2025 November 1; 110(11):2635-2646. doi: 10.3324\/haematol.2025.287433","author":"Webster JA, Reed M, Tsai HL, Imus PH, Smith DB, Ambinder AJ, Levis MJ, DeZern AE, Prince GT, Jain T, Bolanos-Meade J, Gondek LP, Ghiaur G, Dalton WB, Karantanos T, Paul S, Fuchs EJ, Sterling C, Swinnen LJ, Wagner-Johnston N, Ambinder RF, Gocke CB, Ali SA, Huff CA, Luznik L, Varadhan R, Jones RJ, Gojo I","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40336316"},{"title01":"A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA\/PALG study.","title02":"A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA\/PALG study.","journal":"Haematologica","issue":"2025 November 13. doi: 10.3324\/haematol.2025.288112. Online ahead of print","author":"Rodriguez-Veiga R, Gil C, Sobas M, Torres-Minana L, Botella C, De la Serna J, Bernal T, Salamero O, Otero C, Navarro-Vicente I, De Miguel C, Garrido A, Vives S, Bergua J, Perez-Encinas M, Algarra L, Gonzalez-Campos J, Gomez MDMC, Prates MV, Benavente C, Tormo M, Cervera M, Fazio P, Amutio ME, Garcia R, Pomares H, Vidriales B, Serrano J, Amigo ML, Rubio V, Almela A, Barrios M, Sossa-Melo CL, Paluszewska M, Novo A, Gromek T, Rodriguez-Macias G, Oleksiuk J, Lloret-Madrid P, Montesinos P","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41230704"},{"title01":"S-adenosylmethionine addiction confers sensitivity to methionine restriction in KMT2A-rearranged acute lymphoblastic leukemia.","title02":"S-adenosylmethionine addiction confers sensitivity to methionine restriction in KMT2A-rearranged acute lymphoblastic leukemia.","journal":"Haematologica","issue":"2025 November 1; 110(11):2620-2634. doi: 10.3324\/haematol.2023.284869","author":"Tee T, Ruiter TJJ, Wu S, Zhang W, Schenau DVI, Rodionova M, Wajon D, Vervoort BMT, Grunewald KJT, Bosma M, Hagelaar R, Baker-Hernandez J, Dahaoui A, Schneider P, Verhoeven-Duif NM, Van der Meer LT, Van Leeuwen FN","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40270205"},{"title01":"Characteristics and outcomes of newly diagnosed pediatric acute myeloid leukemia patients who were removed from standard regimens and received alternative therapy.","title02":"Characteristics and outcomes of newly diagnosed pediatric acute myeloid leukemia patients who were removed from standard regimens and received alternative therapy.","journal":"Haematologica","issue":"2025 November 1; 110(11):2834-2838. doi: 10.3324\/haematol.2025.287487","author":"Wahba A, Catueno S, Na K, Dickson S, Stevens A, Cuglievan B, Redell MS","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40400478"},{"title01":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","title02":"The interleukin-6 connection: Understanding cytomegalovirus reactivation following CAR-T-cell therapy.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70246. Online ahead of print","author":"Li L, Wang Z, Qian C, Xu J, Zhu Z, Chen G, Lu T, Wang Y, Chen J, Chen S, Tang X, Fu C, Wu D, Xue SL","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224498"},{"title01":"Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.","title02":"Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.","journal":"Br J Haematol","issue":"2025 November 12. doi: 10.1111\/bjh.70253. Online ahead of print","author":"Lee BJ, Griffin SP, Doh J, Quach A, Sun Y, Chumnumsiriwath P, Ciurea SO, Ramos-Perez J, Bellman P, Jeyakumar D, Kongtim P, Naqvi K","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41224356"},{"title01":"COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK&#8217;s Haematological Malignancy Research Network.","title02":"COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK&#8217;s Haematological Malignancy Research Network.","journal":"Br J Haematol","issue":"2025 November 11. doi: 10.1111\/bjh.70244. Online ahead of print","author":"Smith A, Frobisher C, Varghese A, Rawstron A, Crouch S, Howell D, Fielding A, Eastick K, Cargo C, Burton C, Cook G, Easom N, Tooze R, Lillie P, Roman E, Patmore R","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41220109"},{"title01":"Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naive chronic lymphocytic leukaemia.","title02":"Matching-adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed-duration venetoclax and ibrutinib in patients with treatment-naive chronic lymphocytic leukaemia.","journal":"Br J Haematol","issue":"2025 November 11. doi: 10.1111\/bjh.70241. Online ahead of print","author":"Munir T, Mohseninejad L, Rakonczai P, Dobi B, Xu S, Yang K, Vezan R, Calle NM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41215737"},{"title01":"Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.","title02":"Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.","journal":"Br J Haematol","issue":"2025 November 10. doi: 10.1111\/bjh.70243. Online ahead of print","author":"Fakhri B, Lattupally R, Sint K, Stehr H, Menke JR, Conte M, Shanafelt T, Lu SX","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41215498"},{"title01":"Seeing something new or with new eyes?","title02":"Seeing something new or with new eyes?","journal":"Br J Haematol","issue":"2025 November; 207(5):2231-2232. doi: 10.1111\/bjh.70140","author":"Hills RK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40916555"},{"title01":"Correction: Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.","title02":"Correction: Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.","journal":"Leukemia","issue":"2025 November; 39(11):2832. doi: 10.1038\/s41375-025-02773-6","author":"Ohlstrom D, Bakhtiari M, Mumme H, Michaud M, De Janon Gutierrez A, DeRyckere D, Ferguson KE, Chien F, Pilcher W, Satpathy S, Jordan S, Graham D, Bhasin S, Bhasin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40973769"},{"title01":"Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","title02":"Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.","journal":"Leukemia","issue":"2025 November; 39(11):2618-2621. doi: 10.1038\/s41375-025-02778-1","author":"Tedeschi A, Frustaci AM, Menna P, Minotti G","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41038988"},{"title01":"Targeting p16(INK4a)-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven acute myeloid leukemia.","title02":"Targeting p16(INK4a)-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2652-2662. doi: 10.1038\/s41375-025-02743-y","author":"Zheng J, Jin L, Chen Y, Duan Y, Zong S, Wu P, Zhu X, Yang W, Hu T, Zhang Y","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40841767"},{"title01":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","title02":"Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.","journal":"Leukemia","issue":"2025 November; 39(11):2745-2757. doi: 10.1038\/s41375-025-02737-w","author":"Zimolova V, Burocziova M, Berkova L, Grusanovic S, Gursky J, Janotka L, Kasparek P, Pecinova A, Kundrat D, Hrckulak D, Onhajzer J, Jeziskova I, Nekvindova L, Weinbergerova B, Pospisilova S, Doubek M, Alberich-Jorda M, Korinek V, Divoky V, Lanikova L","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40841769"},{"title01":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","title02":"Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2663-2672. doi: 10.1038\/s41375-025-02735-y","author":"Telzerow E, Gorlich D, Sauerland C, Rothenberg-Thurley M, Moret AS, Krauss SM, Mumm FHA, Amler S, Berdel WE, Wormann BJ, Krug U, Braess J, Heussner P, Hiddemann W, Spiekermann K, Metzeler KH","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40847197"},{"title01":"Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.","title02":"Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.","journal":"Leukemia","issue":"2025 November; 39(11):2767-2778. doi: 10.1038\/s41375-025-02727-y","author":"Ford BL, Jokinen E, Huuhtanen J, Forsten S, Klievink J, Antignani G, Bruck O, Cerullo V, Peltonen K, Mustjoki S","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40847198"},{"title01":"Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.","title02":"Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.","journal":"Leukemia","issue":"2025 November; 39(11):2816-2819. doi: 10.1038\/s41375-025-02780-7","author":"Hund I, Hess ME, Andrieux G, Stomper J, Greve G, Niemoller C, Ma T, Uhl D, Grishina O, Thol F, Heuser M, Bug G, Crysandt M, Neubauer A, Duyster J, Dohner H, Boerries M, Lubbert M, Becker H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41057684"},{"title01":"Combined treatment with amlexanox and cytarabine induces apoptosis via the S100A6-Akt pathway in KMT2A::AFF1-positive acute lymphoblastic leukemia.","title02":"Combined treatment with amlexanox and cytarabine induces apoptosis via the S100A6-Akt pathway in KMT2A::AFF1-positive acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2812-2815. doi: 10.1038\/s41375-025-02782-5","author":"Tamai H, Miyake K, Miyake N, Asano J, Ohashi A, Arai A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41053511"},{"title01":"Retinoic acid disrupts an NPM1c\/ROS\/SENP3\/ARF oncogenic axis in acute myeloid leukemia.","title02":"Retinoic acid disrupts an NPM1c\/ROS\/SENP3\/ARF oncogenic axis in acute myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2673-2685. doi: 10.1038\/s41375-025-02731-2","author":"Hleihel R, Skayneh H, Wu HC, Hamie M, Kurdi A, Dakour J, Machaalani C, El-Sabban M, de The H, Bazarbachi A, El Hajj H","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858804"},{"title01":"Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.","title02":"Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2575-2589. doi: 10.1038\/s41375-025-02723-2","author":"Amaral P, Christie R, Gresham DOF, Lucas EJM, Xu LK, Behrmann L, Bond J, Degerman S, van Delft FW, Goossens S, Hagleitner M, Halsey C, Jones N, Lammens T, van Leeuwen FN, Mansour MR, Ntziachristos P, O'Connor D, Barata JT","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40813621"},{"title01":"The evolving nosology of myeloid neoplasms: the semi-centennial of the 1976 French-American-British classification.","title02":"The evolving nosology of myeloid neoplasms: the semi-centennial of the 1976 French-American-British classification.","journal":"Leukemia","issue":"2025 November; 39(11):2603-2609. doi: 10.1038\/s41375-025-02746-9","author":"Patel SA, Bennett JM","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40858808"},{"title01":"How do ionizing radiations from inter-planetary travel cause leukaemia?","title02":"How do ionizing radiations from inter-planetary travel cause leukaemia?","journal":"Leukemia","issue":"2025 November; 39(11):2830-2831. doi: 10.1038\/s41375-025-02761-w","author":"Badie C, Gale RP","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41023183"},{"title01":"Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.","title02":"Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.","journal":"Leukemia","issue":"2025 November; 39(11):2697-2707. doi: 10.1038\/s41375-025-02730-3","author":"Venditti A, Hou JZ, Fenaux P, Jonas BA, Vrhovac R, Montesinos P, Garcia JS, Rizzieri D, Thirman MJ, Zhang M, Potluri J, Miller C, Dhalla M, Pullarkat V","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40913104"},{"title01":"Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia.","title02":"Estimating the burden of chronic stress through allostatic load in patients with chronic myeloid leukemia.","journal":"Leukemia","issue":"2025 November; 39(11):2735-2744. doi: 10.1038\/s41375-025-02763-8","author":"Miranda-Galvis M, Tjioe KC, Sharara M, Maloney M, Keruakous AR, Jillella A, Kota V, Guha A, Cortes JE","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40935825"},{"title01":"PML::RARalpha+ myeloid cells display metabolic alterations that can be targeted to treat resistant\/relapse acute promyelocytic leukemias.","title02":"PML::RARalpha+ myeloid cells display metabolic alterations that can be targeted to treat resistant\/relapse acute promyelocytic leukemias.","journal":"Leukemia","issue":"2025 November; 39(11):2708-2720. doi: 10.1038\/s41375-025-02738-9","author":"Zaza A, Zardo G, Banella C, Tucci S, de Marinis E, Gentile M, Travaglini S, Divona M, Ottone T, Castelli G, Cerio AM, Angelini DF, Faraoni I, Palmieri R, Niscola P, Ammatuna E, Venditti A, Nervi C, Voso MT, Catalano G, Noguera NI","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931045"},{"title01":"Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment.","title02":"Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment.","journal":"Leukemia","issue":"2025 November; 39(11):2622-2639. doi: 10.1038\/s41375-025-02734-z","author":"Ferrao Blanco MN, Kazybay B, Belderbos M, Heidenreich O, Vormoor HJ","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40817406"},{"title01":"Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.","title02":"Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML.","journal":"Leukemia","issue":"2025 November; 39(11):2721-2734. doi: 10.1038\/s41375-025-02748-7","author":"Ohlstrom D, Bakhtiari M, Mumme H, Michaud M, De Janon Gutierrez A, DeRyckere D, Ferguson KE, Chien F, Pilcher W, Satpathy S, Jordan S, Graham D, Bhasin S, Bhasin M","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/40931047"},{"title01":"Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.","title02":"Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study.","journal":"Leukemia","issue":"2025 November 13. doi: 10.1038\/s41375-025-02800-6. Online ahead of print","author":"Locatelli F, Rizzari C, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Eckert C, Moricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, Desai R, Henry M, Zugmaier G, von Stackelberg A","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41233549"},{"title01":"The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival.","title02":"The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival.","journal":"Leukemia","issue":"2025 November 10. doi: 10.1038\/s41375-025-02799-w. Online ahead of print","author":"Dhir A, Ethell A, Watkins R, Lam C, Tur-Rodriguez K, Persinger J, Dobish KK, Panda S, Buckley SM, Swenson SA, Brahma S, Rowley MJ, Hyde RK","url":"https:\/\/pubmed.ncbi.nlm.nih.gov\/41214140"}]